OA18052A - Hepatitis B core protein allosteric modulators. - Google Patents
Hepatitis B core protein allosteric modulators. Download PDFInfo
- Publication number
- OA18052A OA18052A OA1201600348 OA18052A OA 18052 A OA18052 A OA 18052A OA 1201600348 OA1201600348 OA 1201600348 OA 18052 A OA18052 A OA 18052A
- Authority
- OA
- OAPI
- Prior art keywords
- compound
- group
- halogen
- hydroxyl
- optionally substituted
- Prior art date
Links
- 208000002672 Hepatitis B Diseases 0.000 title claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 title claims description 15
- 108090000623 proteins and genes Proteins 0.000 title claims description 15
- 230000000051 modifying Effects 0.000 title claims description 5
- 230000003281 allosteric Effects 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 541
- 230000015572 biosynthetic process Effects 0.000 claims description 250
- 229910052736 halogen Inorganic materials 0.000 claims description 147
- 150000002367 halogens Chemical group 0.000 claims description 147
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 136
- -1 NR'R” Chemical group 0.000 claims description 135
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 120
- 125000001424 substituent group Chemical group 0.000 claims description 112
- 229910052739 hydrogen Inorganic materials 0.000 claims description 111
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 83
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 82
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 71
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 47
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 44
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 42
- 229910052731 fluorine Inorganic materials 0.000 claims description 38
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 33
- 125000001072 heteroaryl group Chemical group 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
- 125000000623 heterocyclic group Chemical group 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- 239000003112 inhibitor Substances 0.000 claims description 20
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 239000011780 sodium chloride Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 15
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 15
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 230000003612 virological Effects 0.000 claims description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 11
- 125000005842 heteroatoms Chemical group 0.000 claims description 11
- 210000000234 Capsid Anatomy 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 239000000460 chlorine Substances 0.000 claims description 10
- 235000019000 fluorine Nutrition 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 230000000840 anti-viral Effects 0.000 claims description 7
- 238000005755 formation reaction Methods 0.000 claims description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 7
- 108009000423 Hepatitis B infection Proteins 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 229910052721 tungsten Inorganic materials 0.000 claims description 4
- 230000025458 RNA interference Effects 0.000 claims description 3
- 239000002777 nucleoside Substances 0.000 claims description 3
- 239000000546 pharmaceutic aid Substances 0.000 claims description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 3
- 229960005486 vaccines Drugs 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 102100013714 DIABLO Human genes 0.000 claims description 2
- 101710002761 DIABLO Proteins 0.000 claims description 2
- 229960001438 IMMUNOSTIMULANTS Drugs 0.000 claims description 2
- PMPVIKIVABFJJI-UHFFFAOYSA-N cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000134 cyclophilin inhibitor Substances 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 230000001973 epigenetic Effects 0.000 claims description 2
- 230000003344 immunostimulant Effects 0.000 claims description 2
- 239000003022 immunostimulating agent Substances 0.000 claims description 2
- 230000002452 interceptive Effects 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 abstract description 4
- 206010047461 Viral infection Diseases 0.000 abstract description 4
- 208000001756 Virus Disease Diseases 0.000 abstract description 4
- 230000017613 viral reproduction Effects 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 546
- 238000006243 chemical reaction Methods 0.000 description 429
- 235000019439 ethyl acetate Nutrition 0.000 description 273
- 238000003786 synthesis reaction Methods 0.000 description 243
- 230000002194 synthesizing Effects 0.000 description 243
- 239000000243 solution Substances 0.000 description 239
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 234
- 239000008079 hexane Substances 0.000 description 207
- 239000007787 solid Substances 0.000 description 203
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 200
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 184
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 153
- 229910001868 water Inorganic materials 0.000 description 153
- 239000011541 reaction mixture Substances 0.000 description 113
- 239000003039 volatile agent Substances 0.000 description 103
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 102
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 94
- 229910052786 argon Inorganic materials 0.000 description 92
- 229910052938 sodium sulfate Inorganic materials 0.000 description 91
- 235000011152 sodium sulphate Nutrition 0.000 description 91
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 90
- 239000000284 extract Substances 0.000 description 87
- 238000005160 1H NMR spectroscopy Methods 0.000 description 86
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 82
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 73
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 69
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 58
- 238000010898 silica gel chromatography Methods 0.000 description 57
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 42
- 239000006188 syrup Substances 0.000 description 38
- 235000020357 syrup Nutrition 0.000 description 38
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 30
- 239000000543 intermediate Substances 0.000 description 29
- 239000002253 acid Substances 0.000 description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 26
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 23
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 22
- 229940040692 Lithium Hydroxide Monohydrate Drugs 0.000 description 21
- 239000000706 filtrate Substances 0.000 description 20
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 16
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 16
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminum hydride Chemical compound [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 13
- 239000012267 brine Substances 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 13
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- CNJJSTPBUHAEFH-UHFFFAOYSA-N methyl 4-fluoro-3-nitrobenzoate Chemical compound COC(=O)C1=CC=C(F)C([N+]([O-])=O)=C1 CNJJSTPBUHAEFH-UHFFFAOYSA-N 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- PTDVPWWJRCOIIO-UHFFFAOYSA-N (4-methoxyphenyl)methanethiol Chemical compound COC1=CC=C(CS)C=C1 PTDVPWWJRCOIIO-UHFFFAOYSA-N 0.000 description 11
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 11
- 229940086542 triethylamine Drugs 0.000 description 11
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 229940002612 prodrugs Drugs 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 9
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 9
- BAQGCWNPCFABAY-UHFFFAOYSA-N methyl 2-sulfanylbenzoate Chemical compound COC(=O)C1=CC=CC=C1S BAQGCWNPCFABAY-UHFFFAOYSA-N 0.000 description 9
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 8
- NXQBKSFALYWOQX-UHFFFAOYSA-N NC=1C=C(C(=O)OC)C=C(C1SC1=C(C=CC=C1)C(=O)OC)C Chemical compound NC=1C=C(C(=O)OC)C=C(C1SC1=C(C=CC=C1)C(=O)OC)C NXQBKSFALYWOQX-UHFFFAOYSA-N 0.000 description 8
- 201000009910 diseases by infectious agent Diseases 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 8
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 8
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 7
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 7
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- IBZJPGGBZMXXCE-UHFFFAOYSA-N 4-fluoro-2-methyl-5-nitrobenzoic acid Chemical compound CC1=CC(F)=C([N+]([O-])=O)C=C1C(O)=O IBZJPGGBZMXXCE-UHFFFAOYSA-N 0.000 description 6
- WNAZYCXCUUJPGQ-UHFFFAOYSA-N COC(=O)C1=C(C=CC=C1)NC1=C(C=C(C(=O)OC)C=C1)[N+](=O)[O-] Chemical compound COC(=O)C1=C(C=CC=C1)NC1=C(C=C(C(=O)OC)C=C1)[N+](=O)[O-] WNAZYCXCUUJPGQ-UHFFFAOYSA-N 0.000 description 6
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 125000004432 carbon atoms Chemical group C* 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- MAQWCDYCXJXWQU-UHFFFAOYSA-N methyl 4-(2-methoxycarbonylphenyl)sulfanyl-3-nitrobenzoate Chemical compound [O-][N+](=O)C1=CC(C(=O)OC)=CC=C1SC1=CC=CC=C1C(=O)OC MAQWCDYCXJXWQU-UHFFFAOYSA-N 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 6
- JWUZBESCMDKWCP-UHFFFAOYSA-N (2-methoxy-1,3-thiazol-5-yl)methanamine Chemical compound COC1=NC=C(CN)S1 JWUZBESCMDKWCP-UHFFFAOYSA-N 0.000 description 5
- NCBZARPLANPKAU-UHFFFAOYSA-N 1,4-thiazepine-7-carboxylic acid Chemical compound OC(=O)C1=CC=NC=CS1 NCBZARPLANPKAU-UHFFFAOYSA-N 0.000 description 5
- TYCKPZWFWBNXST-UHFFFAOYSA-N 2-(4-fluorophenoxy)ethanamine;hydrochloride Chemical compound Cl.NCCOC1=CC=C(F)C=C1 TYCKPZWFWBNXST-UHFFFAOYSA-N 0.000 description 5
- RGALHAKSGIVDMI-UHFFFAOYSA-N 3-amino-4-(2-carboxy-5-fluorophenyl)sulfanylbenzoic acid Chemical compound NC1=CC(C(O)=O)=CC=C1SC1=CC(F)=CC=C1C(O)=O RGALHAKSGIVDMI-UHFFFAOYSA-N 0.000 description 5
- CLOYVCHXXWLKSL-UHFFFAOYSA-N 3-methoxy-3-methylbutan-1-amine Chemical compound COC(C)(C)CCN CLOYVCHXXWLKSL-UHFFFAOYSA-N 0.000 description 5
- BVQCRCHSFBBKIM-UHFFFAOYSA-N 4-chloro-2-sulfanylbenzonitrile Chemical compound SC1=CC(Cl)=CC=C1C#N BVQCRCHSFBBKIM-UHFFFAOYSA-N 0.000 description 5
- RAJVMVYZMSFNIC-UHFFFAOYSA-N 5-chloro-2-sulfanylbenzonitrile Chemical compound SC1=CC=C(Cl)C=C1C#N RAJVMVYZMSFNIC-UHFFFAOYSA-N 0.000 description 5
- HOIFBXIJFRVZCH-UHFFFAOYSA-N C(C)N(C1=C(C=C(C(=O)OC)C=C1)[N+](=O)[O-])C1=C(C=CC=C1)C(=O)OC Chemical compound C(C)N(C1=C(C=C(C(=O)OC)C=C1)[N+](=O)[O-])C1=C(C=CC=C1)C(=O)OC HOIFBXIJFRVZCH-UHFFFAOYSA-N 0.000 description 5
- HKIINHHEBJYVJN-UHFFFAOYSA-N Cl.C(C)(C)C=1SC(=CN1)CN Chemical compound Cl.C(C)(C)C=1SC(=CN1)CN HKIINHHEBJYVJN-UHFFFAOYSA-N 0.000 description 5
- OUBKMWYXTAZEER-UHFFFAOYSA-N Cl.C(C)C=1SC(=CN1)CN Chemical compound Cl.C(C)C=1SC(=CN1)CN OUBKMWYXTAZEER-UHFFFAOYSA-N 0.000 description 5
- GIRBQSSZHHGIMO-UHFFFAOYSA-N ClC1=CC(=C(C=C1)SC1=C(C=C(C(=O)OC)C=C1)[N+](=O)[O-])C#N Chemical compound ClC1=CC(=C(C=C1)SC1=C(C=C(C(=O)OC)C=C1)[N+](=O)[O-])C#N GIRBQSSZHHGIMO-UHFFFAOYSA-N 0.000 description 5
- KRPLVISYGXTMDA-UHFFFAOYSA-N ClC=1C=CC(=C(C#N)C1)SCC1=CC=C(C=C1)OC Chemical compound ClC=1C=CC(=C(C#N)C1)SCC1=CC=C(C=C1)OC KRPLVISYGXTMDA-UHFFFAOYSA-N 0.000 description 5
- AXGZFVZWXVRUPU-UHFFFAOYSA-N ClC=1C=CC(=C(C1)SC1=C(C=C(C(=O)OC)C=C1)[N+](=O)[O-])C#N Chemical compound ClC=1C=CC(=C(C1)SC1=C(C=C(C(=O)OC)C=C1)[N+](=O)[O-])C#N AXGZFVZWXVRUPU-UHFFFAOYSA-N 0.000 description 5
- VOXGTUHFTWIFMF-UHFFFAOYSA-N FC1=C(C(=O)OC)C(=CC=C1)S Chemical compound FC1=C(C(=O)OC)C(=CC=C1)S VOXGTUHFTWIFMF-UHFFFAOYSA-N 0.000 description 5
- BCINTSRUHYICRQ-UHFFFAOYSA-N NC1=C(C=CC(=C1)C(=O)OC)SC1=C(C(=O)OC)C(=CC=C1)F Chemical compound NC1=C(C=CC(=C1)C(=O)OC)SC1=C(C(=O)OC)C(=CC=C1)F BCINTSRUHYICRQ-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 125000002837 carbocyclic group Chemical group 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- DWXKSCKBUSAOKS-UHFFFAOYSA-N ethyl 2-chloro-3-oxopropanoate Chemical compound CCOC(=O)C(Cl)C=O DWXKSCKBUSAOKS-UHFFFAOYSA-N 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 5
- KTHZBRAXOLUNBN-UHFFFAOYSA-N oxetan-3-ylmethanamine Chemical compound NCC1COC1 KTHZBRAXOLUNBN-UHFFFAOYSA-N 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 5
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 5
- FJRFBJJNVQHNBM-UHFFFAOYSA-N (2-ethyl-1,3-thiazol-5-yl)methanol Chemical compound CCC1=NC=C(CO)S1 FJRFBJJNVQHNBM-UHFFFAOYSA-N 0.000 description 4
- FCKAJPDGXQGBMZ-UHFFFAOYSA-N (2-propan-2-yl-1,3-thiazol-5-yl)methanol Chemical compound CC(C)C1=NC=C(CO)S1 FCKAJPDGXQGBMZ-UHFFFAOYSA-N 0.000 description 4
- CRPXMLXYMBLZEP-UHFFFAOYSA-N 1,3-oxazol-5-ylmethanol Chemical compound OCC1=CN=CO1 CRPXMLXYMBLZEP-UHFFFAOYSA-N 0.000 description 4
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 4
- RAKVPUSCSTWAPO-UHFFFAOYSA-N 1,4-thiazepine-3-carboxylic acid Chemical compound OC(=O)C1=CSC=CC=N1 RAKVPUSCSTWAPO-UHFFFAOYSA-N 0.000 description 4
- CFEKBKCGPASOFI-UHFFFAOYSA-N 2,4-dichloro-1,3-thiazole-5-carbaldehyde Chemical compound ClC1=NC(Cl)=C(C=O)S1 CFEKBKCGPASOFI-UHFFFAOYSA-N 0.000 description 4
- XUDWLFWTSOMCNP-UHFFFAOYSA-N 2-(1,3-oxazol-5-yl)acetonitrile Chemical compound N#CCC1=CN=CO1 XUDWLFWTSOMCNP-UHFFFAOYSA-N 0.000 description 4
- NHWVXEVKCPDPFB-UHFFFAOYSA-N 2-(1,3-thiazol-5-yl)acetonitrile Chemical compound N#CCC1=CN=CS1 NHWVXEVKCPDPFB-UHFFFAOYSA-N 0.000 description 4
- NASUVNCIEHJZBK-UHFFFAOYSA-N 2-(4-fluorocyclohexyl)acetonitrile Chemical compound FC1CCC(CC#N)CC1 NASUVNCIEHJZBK-UHFFFAOYSA-N 0.000 description 4
- ODBGONFPCSVCCM-UHFFFAOYSA-N 2-(4-fluorophenoxy)acetonitrile Chemical compound FC1=CC=C(OCC#N)C=C1 ODBGONFPCSVCCM-UHFFFAOYSA-N 0.000 description 4
- YYPAYWPSPJDUBG-UHFFFAOYSA-N 3-(nitromethylidene)oxetane Chemical compound [O-][N+](=O)C=C1COC1 YYPAYWPSPJDUBG-UHFFFAOYSA-N 0.000 description 4
- WCFJUSRQHZPVKY-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCCC(O)=O WCFJUSRQHZPVKY-UHFFFAOYSA-N 0.000 description 4
- HRYDRHFZQCJURB-UHFFFAOYSA-N 3-phenyl-3-pyrrolidin-1-ylpropanenitrile Chemical compound C=1C=CC=CC=1C(CC#N)N1CCCC1 HRYDRHFZQCJURB-UHFFFAOYSA-N 0.000 description 4
- YBQAAEQJWSERKE-UHFFFAOYSA-N 4-(2-carboxy-5-fluorophenyl)sulfanyl-3-nitrobenzoic acid Chemical compound [O-][N+](=O)C1=CC(C(=O)O)=CC=C1SC1=CC(F)=CC=C1C(O)=O YBQAAEQJWSERKE-UHFFFAOYSA-N 0.000 description 4
- QCADDKZKPOWCOH-UHFFFAOYSA-N 4-amino-3-(2-carboxyphenyl)sulfanylbenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1SC1=CC=CC=C1C(O)=O QCADDKZKPOWCOH-UHFFFAOYSA-N 0.000 description 4
- GJTWEAFBOIYNLZ-UHFFFAOYSA-N 4-chloro-1,3-thiazole-5-carbaldehyde Chemical compound ClC=1N=CSC=1C=O GJTWEAFBOIYNLZ-UHFFFAOYSA-N 0.000 description 4
- ZXPGPXRTSHSBPA-UHFFFAOYSA-N 4-chloro-5-(1,3-dioxolan-2-yl)-1,3-thiazole Chemical compound N1=CSC(C2OCCO2)=C1Cl ZXPGPXRTSHSBPA-UHFFFAOYSA-N 0.000 description 4
- UZAOOCPKYMGRHG-UHFFFAOYSA-N 5-(chloromethyl)-1,3-thiazole Chemical compound ClCC1=CN=CS1 UZAOOCPKYMGRHG-UHFFFAOYSA-N 0.000 description 4
- OSMNJSLUFGQCRO-UHFFFAOYSA-N 5-(chloromethyl)-2-ethyl-1,3-thiazole Chemical compound CCC1=NC=C(CCl)S1 OSMNJSLUFGQCRO-UHFFFAOYSA-N 0.000 description 4
- WDCNCEYFHMCMQH-UHFFFAOYSA-N C(=O)(O)C1=C(C=CC=C1)SC=1C=C(C(=O)O)C=CC1[N+](=O)[O-] Chemical compound C(=O)(O)C1=C(C=CC=C1)SC=1C=C(C(=O)O)C=CC1[N+](=O)[O-] WDCNCEYFHMCMQH-UHFFFAOYSA-N 0.000 description 4
- UPYKRPHLOALCAO-UHFFFAOYSA-N C(C)N1C2=C(NC(C3=C1C=CC=C3)=O)C=C(C=C2)C(=O)OC Chemical compound C(C)N1C2=C(NC(C3=C1C=CC=C3)=O)C=C(C=C2)C(=O)OC UPYKRPHLOALCAO-UHFFFAOYSA-N 0.000 description 4
- WOXOACANVDRREP-UHFFFAOYSA-N C(C1=CC=CC=C1)N1C2=C(NC(C3=C1C=CC=C3)=O)C=C(C=C2)C(=O)OC Chemical compound C(C1=CC=CC=C1)N1C2=C(NC(C3=C1C=CC=C3)=O)C=C(C=C2)C(=O)OC WOXOACANVDRREP-UHFFFAOYSA-N 0.000 description 4
- GZMGBBBSCQRYHG-UHFFFAOYSA-N COC(=O)C1=C(C=CC=C1)SC1=C(C=C(C(=O)OC)C=C1[N+](=O)[O-])C Chemical compound COC(=O)C1=C(C=CC=C1)SC1=C(C=C(C(=O)OC)C=C1[N+](=O)[O-])C GZMGBBBSCQRYHG-UHFFFAOYSA-N 0.000 description 4
- KCHCMAWXOYNLAF-UHFFFAOYSA-N COC(=O)C1=C(C=CC=C1)SC1=CC(=C(C(=O)O)C=C1[N+](=O)[O-])C Chemical compound COC(=O)C1=C(C=CC=C1)SC1=CC(=C(C(=O)O)C=C1[N+](=O)[O-])C KCHCMAWXOYNLAF-UHFFFAOYSA-N 0.000 description 4
- ANHZQYSNRSNYLC-UHFFFAOYSA-N COC(=O)C1=C(C=CC=C1)SC=1C=C(C(=O)OC)C=CC1[N+](=O)[O-] Chemical compound COC(=O)C1=C(C=CC=C1)SC=1C=C(C(=O)OC)C=CC1[N+](=O)[O-] ANHZQYSNRSNYLC-UHFFFAOYSA-N 0.000 description 4
- DMFKHBRHYZXVDE-UHFFFAOYSA-N COC1=C(C(=O)OC)C=C(C(=C1)SC1=C(C=CC=C1)C(=O)OC)[N+](=O)[O-] Chemical compound COC1=C(C(=O)OC)C=C(C(=C1)SC1=C(C=CC=C1)C(=O)OC)[N+](=O)[O-] DMFKHBRHYZXVDE-UHFFFAOYSA-N 0.000 description 4
- CRZIXRMIYIFWDW-UHFFFAOYSA-N Cl.C(C)C=1N=CSC1CN Chemical compound Cl.C(C)C=1N=CSC1CN CRZIXRMIYIFWDW-UHFFFAOYSA-N 0.000 description 4
- MGWSLKYTSRCSIL-UHFFFAOYSA-N ClCC1=C(N=CS1)C(C)C Chemical compound ClCC1=C(N=CS1)C(C)C MGWSLKYTSRCSIL-UHFFFAOYSA-N 0.000 description 4
- UGWVEBDJAYWCHI-UHFFFAOYSA-N FC1=C(C(=O)O)C(=CC(=C1[N+](=O)[O-])F)F Chemical compound FC1=C(C(=O)O)C(=CC(=C1[N+](=O)[O-])F)F UGWVEBDJAYWCHI-UHFFFAOYSA-N 0.000 description 4
- XBZIDFOCYQIFNP-UHFFFAOYSA-N FC1=C(C(=O)OC)C(=CC(=C1[N+](=O)[O-])F)F Chemical compound FC1=C(C(=O)OC)C(=CC(=C1[N+](=O)[O-])F)F XBZIDFOCYQIFNP-UHFFFAOYSA-N 0.000 description 4
- PFFNLJAXNKZUQA-UHFFFAOYSA-N FC1=C(C(=O)OC)C(=CC(=C1[N+](=O)[O-])SC1=C(C=CC=C1)C(=O)OC)F Chemical compound FC1=C(C(=O)OC)C(=CC(=C1[N+](=O)[O-])SC1=C(C=CC=C1)C(=O)OC)F PFFNLJAXNKZUQA-UHFFFAOYSA-N 0.000 description 4
- XNQVPNNBXFVYDG-UHFFFAOYSA-N FC1=C(C(=O)OC)C=C(C(=C1)SC1=C(C=CC=C1)C(=O)OC)[N+](=O)[O-] Chemical compound FC1=C(C(=O)OC)C=C(C(=C1)SC1=C(C=CC=C1)C(=O)OC)[N+](=O)[O-] XNQVPNNBXFVYDG-UHFFFAOYSA-N 0.000 description 4
- AAGCKLOPJWCGJL-UHFFFAOYSA-N N(=[N+]=[N-])CC1=C(N=CS1)C(C)C Chemical compound N(=[N+]=[N-])CC1=C(N=CS1)C(C)C AAGCKLOPJWCGJL-UHFFFAOYSA-N 0.000 description 4
- LJJVGVDGARGOLB-UHFFFAOYSA-N N(=[N+]=[N-])CC1=CN=C(S1)C(C)C Chemical compound N(=[N+]=[N-])CC1=CN=C(S1)C(C)C LJJVGVDGARGOLB-UHFFFAOYSA-N 0.000 description 4
- FTECDEMQHBOMFK-UHFFFAOYSA-N N(=[N+]=[N-])CC1=CN=C(S1)CC Chemical compound N(=[N+]=[N-])CC1=CN=C(S1)CC FTECDEMQHBOMFK-UHFFFAOYSA-N 0.000 description 4
- YCQYFRUBXQAOKQ-UHFFFAOYSA-N NC1=C(C=CC(=C1)C(=O)O)SC1=C(C(=O)O)C(=CC=C1)F Chemical compound NC1=C(C=CC(=C1)C(=O)O)SC1=C(C(=O)O)C(=CC=C1)F YCQYFRUBXQAOKQ-UHFFFAOYSA-N 0.000 description 4
- NWKRZGGBASKNRH-UHFFFAOYSA-N NC1=C(C=CC(=C1)C(=O)O)SC1=C(C(=O)O)C=C(C=C1)OC Chemical compound NC1=C(C=CC(=C1)C(=O)O)SC1=C(C(=O)O)C=C(C=C1)OC NWKRZGGBASKNRH-UHFFFAOYSA-N 0.000 description 4
- TVQDWQHRCRHYBK-UHFFFAOYSA-N NC1=C(C=CC(=C1)C(=O)OC)SC1=C(C(=O)OC)C=C(C=C1)F Chemical compound NC1=C(C=CC(=C1)C(=O)OC)SC1=C(C(=O)OC)C=C(C=C1)F TVQDWQHRCRHYBK-UHFFFAOYSA-N 0.000 description 4
- ZLKPYQJUFCQDKV-UHFFFAOYSA-N NC1=C(C=CC(=C1)C(=O)OC)SC1=C(C(=O)OC)C=C(C=C1)OC Chemical compound NC1=C(C=CC(=C1)C(=O)OC)SC1=C(C(=O)OC)C=C(C=C1)OC ZLKPYQJUFCQDKV-UHFFFAOYSA-N 0.000 description 4
- WVXZMCZACUAQPN-UHFFFAOYSA-N NC1=C(C=CC(=C1)C(=O)OC)SC1=C(C(=O)OC)C=CC=C1F Chemical compound NC1=C(C=CC(=C1)C(=O)OC)SC1=C(C(=O)OC)C=CC=C1F WVXZMCZACUAQPN-UHFFFAOYSA-N 0.000 description 4
- JVKISWCQEMSLLR-UHFFFAOYSA-N NC1=CC(=C(C=C1)SC1=C(C(=O)O)C=CC=C1)[N+](=O)[O-] Chemical compound NC1=CC(=C(C=C1)SC1=C(C(=O)O)C=CC=C1)[N+](=O)[O-] JVKISWCQEMSLLR-UHFFFAOYSA-N 0.000 description 4
- YIMGNBDPJFVBRC-UHFFFAOYSA-N NC=1C(=C(C(=O)O)C(=CC1SC1=C(C=CC=C1)C(=O)O)F)F Chemical compound NC=1C(=C(C(=O)O)C(=CC1SC1=C(C=CC=C1)C(=O)O)F)F YIMGNBDPJFVBRC-UHFFFAOYSA-N 0.000 description 4
- ICUCRLCUJPOFGS-UHFFFAOYSA-N NC=1C(=C(C(=O)O)C=CC1SC1=C(C=CC=C1)C(=O)O)C Chemical compound NC=1C(=C(C(=O)O)C=CC1SC1=C(C=CC=C1)C(=O)O)C ICUCRLCUJPOFGS-UHFFFAOYSA-N 0.000 description 4
- HKERDGNQBUPISB-UHFFFAOYSA-N NC=1C(=C(C(=O)OC)C=CC1SC1=C(C=CC=C1)C(=O)OC)C Chemical compound NC=1C(=C(C(=O)OC)C=CC1SC1=C(C=CC=C1)C(=O)OC)C HKERDGNQBUPISB-UHFFFAOYSA-N 0.000 description 4
- JWEPZFFJPJEGNF-UHFFFAOYSA-N NC=1C(=CC(=C(C(=O)O)C1)OC)SC1=C(C=CC=C1)C(=O)O Chemical compound NC=1C(=CC(=C(C(=O)O)C1)OC)SC1=C(C=CC=C1)C(=O)O JWEPZFFJPJEGNF-UHFFFAOYSA-N 0.000 description 4
- XCKJRULBAMNWJE-UHFFFAOYSA-N NC=1C=C(C(=O)O)C=C(C1SC1=C(C=CC=C1)C(=O)O)C Chemical compound NC=1C=C(C(=O)O)C=C(C1SC1=C(C=CC=C1)C(=O)O)C XCKJRULBAMNWJE-UHFFFAOYSA-N 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N Potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- JEPCBTMGAAIBML-UHFFFAOYSA-N [N+](=O)([O-])CC1(COC1)O Chemical compound [N+](=O)([O-])CC1(COC1)O JEPCBTMGAAIBML-UHFFFAOYSA-N 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 4
- HHLQEQWHWROTMX-UHFFFAOYSA-N ethyl 2-propan-2-yl-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(C(C)C)S1 HHLQEQWHWROTMX-UHFFFAOYSA-N 0.000 description 4
- YDVJUPSKFKJIQN-UHFFFAOYSA-N ethyl 4-ethyl-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC=NC=1CC YDVJUPSKFKJIQN-UHFFFAOYSA-N 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- FMTHVBOWAILEFZ-UHFFFAOYSA-N methyl 2,3-difluorobenzoate Chemical compound COC(=O)C1=CC=CC(F)=C1F FMTHVBOWAILEFZ-UHFFFAOYSA-N 0.000 description 4
- SDGJHNRLPOEFDD-UHFFFAOYSA-N methyl 4-bromo-3-methyl-5-nitrobenzoate Chemical compound COC(=O)C1=CC(C)=C(Br)C([N+]([O-])=O)=C1 SDGJHNRLPOEFDD-UHFFFAOYSA-N 0.000 description 4
- LHAVJVZNGLTPCY-UHFFFAOYSA-N methyl 4-fluoro-2-methoxy-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=C(F)C=C1OC LHAVJVZNGLTPCY-UHFFFAOYSA-N 0.000 description 4
- JUCFNZJKUATDQS-UHFFFAOYSA-N methyl 4-fluoro-2-methyl-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=C(F)C=C1C JUCFNZJKUATDQS-UHFFFAOYSA-N 0.000 description 4
- CQVRIGKAFSNQHM-UHFFFAOYSA-N methyl 4-fluoro-2-sulfanylbenzoate Chemical compound COC(=O)C1=CC=C(F)C=C1S CQVRIGKAFSNQHM-UHFFFAOYSA-N 0.000 description 4
- LURYYKGKBIBXOY-UHFFFAOYSA-N methyl 5-fluoro-2-sulfanylbenzoate Chemical compound COC(=O)C1=CC(F)=CC=C1S LURYYKGKBIBXOY-UHFFFAOYSA-N 0.000 description 4
- HJUKDCWCVBWIIU-UHFFFAOYSA-N methyl 5-methoxy-2-sulfanylbenzoate Chemical compound COC(=O)C1=CC(OC)=CC=C1S HJUKDCWCVBWIIU-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000000707 stereoselective Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- VKMXHCGSFOBPGQ-UHFFFAOYSA-N 2-(1,3-thiazol-5-yl)ethanamine Chemical compound NCCC1=CN=CS1 VKMXHCGSFOBPGQ-UHFFFAOYSA-N 0.000 description 3
- UZNMRHPOSFFDLD-UHFFFAOYSA-N 2-cyclohexylethanamine;hydrochloride Chemical compound Cl.NCCC1CCCCC1 UZNMRHPOSFFDLD-UHFFFAOYSA-N 0.000 description 3
- IHHNZPGRBWIKFD-UHFFFAOYSA-N 3-phenyl-3-pyrrolidin-1-ylpropan-1-amine Chemical compound C=1C=CC=CC=1C(CCN)N1CCCC1 IHHNZPGRBWIKFD-UHFFFAOYSA-N 0.000 description 3
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- FSEPTCYRDLILPI-UHFFFAOYSA-N 5-(aminomethyl)-1,3-thiazol-2-amine;dihydrochloride Chemical compound Cl.Cl.NCC1=CN=C(N)S1 FSEPTCYRDLILPI-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- WMOBQSMUBZCTKF-UHFFFAOYSA-N C(N)(OCCC(=O)NNC(C)=O)=O Chemical compound C(N)(OCCC(=O)NNC(C)=O)=O WMOBQSMUBZCTKF-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- YURWGJQIOOLXIT-UHFFFAOYSA-N Cl.FC1CCC(CC1)CCN Chemical compound Cl.FC1CCC(CC1)CCN YURWGJQIOOLXIT-UHFFFAOYSA-N 0.000 description 3
- QDGZDCVAUDNJFG-FXQIFTODSA-N Entecavir Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)C1=C QDGZDCVAUDNJFG-FXQIFTODSA-N 0.000 description 3
- 102000001998 Viral Core Proteins Human genes 0.000 description 3
- 108010015780 Viral Core Proteins Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 229960000980 entecavir Drugs 0.000 description 3
- GEMFOQNVIPGLNR-UHFFFAOYSA-N ethyl 2-chloro-3-oxopentanoate Chemical compound CCOC(=O)C(Cl)C(=O)CC GEMFOQNVIPGLNR-UHFFFAOYSA-N 0.000 description 3
- AUWPEXCKPSIEIX-UHFFFAOYSA-N ethyl 2-chloro-4-methyl-3-oxopentanoate Chemical compound CCOC(=O)C(Cl)C(=O)C(C)C AUWPEXCKPSIEIX-UHFFFAOYSA-N 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 150000003254 radicals Chemical group 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- SVUJNSGGPUCLQZ-FQQAACOVSA-N (E)-but-2-enedioic acid;propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate Chemical compound OC(=O)\C=C\C(O)=O.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 SVUJNSGGPUCLQZ-FQQAACOVSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-Toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- MLCPINGKKONVKT-UHFFFAOYSA-N 4-fluoro-2-methyl-3-nitrobenzoic acid Chemical compound CC1=C(C(O)=O)C=CC(F)=C1[N+]([O-])=O MLCPINGKKONVKT-UHFFFAOYSA-N 0.000 description 2
- KDXOONIQRUZGSY-UHFFFAOYSA-N 4-fluoro-2-methylbenzoic acid Chemical compound CC1=CC(F)=CC=C1C(O)=O KDXOONIQRUZGSY-UHFFFAOYSA-N 0.000 description 2
- RAIPHJJURHTUIC-UHFFFAOYSA-N Aminothiazole Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L Barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N Benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 2
- JCRNUUOYPTVQPU-UHFFFAOYSA-N COC(=O)C1=C(C=CC=C1)SC1=C(C(=C(C(=O)OC)C=C1)C)[N+](=O)[O-] Chemical compound COC(=O)C1=C(C=CC=C1)SC1=C(C(=C(C(=O)OC)C=C1)C)[N+](=O)[O-] JCRNUUOYPTVQPU-UHFFFAOYSA-N 0.000 description 2
- UYTTWYWIQTXVOA-UHFFFAOYSA-N COC(=O)C1=C(C=CC=C1)SC1=CC(=C(C(=O)OC)C=C1[N+](=O)[O-])C Chemical compound COC(=O)C1=C(C=CC=C1)SC1=CC(=C(C(=O)OC)C=C1[N+](=O)[O-])C UYTTWYWIQTXVOA-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- XMPZTFVPEKAKFH-UHFFFAOYSA-P Ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 2
- 229920002759 Circular DNA Polymers 0.000 description 2
- 108020004638 Circular DNA Proteins 0.000 description 2
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N Clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 description 2
- 238000005361 D2 NMR spectroscopy Methods 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N Diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N N,N'-Diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- IMWVWDYPALCOBF-UHFFFAOYSA-N NC=1C(=CC(=C(C(=O)OC)C1)C)SC1=C(C=CC=C1)C(=O)OC Chemical compound NC=1C(=CC(=C(C(=O)OC)C1)C)SC1=C(C=CC=C1)C(=O)OC IMWVWDYPALCOBF-UHFFFAOYSA-N 0.000 description 2
- YQNQNVDNTFHQSW-UHFFFAOYSA-N Nitazoxanide Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- LJCNRYVRMXRIQR-UHFFFAOYSA-L Potassium sodium tartrate Chemical class [Na+].[K+].[O-]C(=O)C(O)C(O)C([O-])=O LJCNRYVRMXRIQR-UHFFFAOYSA-L 0.000 description 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N Preveon Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N Sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N Sulfuryl chloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N Thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 2
- 102000016350 Viral Proteins Human genes 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- JKEKMBGUVUKMQB-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JKEKMBGUVUKMQB-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229960003205 adefovir dipivoxil Drugs 0.000 description 2
- 231100000494 adverse effect Toxicity 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000005124 aminocycloalkyl group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000692 anti-sense Effects 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 125000004429 atoms Chemical group 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 229960000074 biopharmaceuticals Drugs 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000005102 carbonylalkoxy group Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 2
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 description 2
- WWECTNRZJYIRLT-UHFFFAOYSA-N methyl 4-fluoro-2-methyl-3-nitrobenzoate Chemical compound COC(=O)C1=CC=C(F)C([N+]([O-])=O)=C1C WWECTNRZJYIRLT-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- LAIZPRYFQUWUBN-UHFFFAOYSA-L nickel chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ni+2] LAIZPRYFQUWUBN-UHFFFAOYSA-L 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 229940005943 ophthalmologic Antivirals Drugs 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- NSETWVJZUWGCKE-UHFFFAOYSA-N propylphosphonic acid Chemical compound CCCP(O)(O)=O NSETWVJZUWGCKE-UHFFFAOYSA-N 0.000 description 2
- PAQZWJGSJMLPMG-UHFFFAOYSA-N propylphosphonic anhydride Substances CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 2
- 125000004963 sulfonylalkyl group Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 229960003560 tenofovir alafenamide fumarate Drugs 0.000 description 2
- 229960004231 thymalfasin Drugs 0.000 description 2
- 231100000730 tolerability Toxicity 0.000 description 2
- 229940026754 topical Antivirals Drugs 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- BEONHKYAZHIDOA-UHFFFAOYSA-N (2-chloro-1,3-thiazol-4-yl)methanamine Chemical compound NCC1=CSC(Cl)=N1 BEONHKYAZHIDOA-UHFFFAOYSA-N 0.000 description 1
- KCDQBIMJBRASQE-UHFFFAOYSA-N (2-chloro-1,3-thiazol-5-yl)methanamine Chemical compound NCC1=CN=C(Cl)S1 KCDQBIMJBRASQE-UHFFFAOYSA-N 0.000 description 1
- PKWRMUKBEYJEIX-DXXQBUJASA-N (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanam Chemical compound CN[C@@H](C)C(=O)N[C@@H](CC)C(=O)N1C[C@@H](O)C[C@H]1CC1=C(C2=C(C3=CC=C(F)C=C3N2)C[C@H]2N(C[C@@H](O)C2)C(=O)[C@H](CC)NC(=O)[C@H](C)NC)NC2=CC(F)=CC=C12 PKWRMUKBEYJEIX-DXXQBUJASA-N 0.000 description 1
- AQHMBDAHQGYLIU-XNFHFXFQSA-N (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-27-[2-(dimethylamino)ethylsulfanyl]-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10, Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@@H](SCCN(C)C)N(C)C1=O AQHMBDAHQGYLIU-XNFHFXFQSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- ZWKNLRXFUTWSOY-QPJJXVBHSA-N (E)-3-phenylprop-2-enenitrile Chemical compound N#C\C=C\C1=CC=CC=C1 ZWKNLRXFUTWSOY-QPJJXVBHSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- WKBQQWDVVHGWDB-UHFFFAOYSA-N 1,3-thiazol-5-ylmethanol Chemical compound OCC1=CN=CS1 WKBQQWDVVHGWDB-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-Dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- JLZVIWSFUPLSOR-UHFFFAOYSA-N 2,3-difluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1F JLZVIWSFUPLSOR-UHFFFAOYSA-N 0.000 description 1
- SJZATRRXUILGHH-UHFFFAOYSA-N 2,4,6-trifluorobenzoic acid Chemical compound OC(=O)C1=C(F)C=C(F)C=C1F SJZATRRXUILGHH-UHFFFAOYSA-N 0.000 description 1
- YFHHJMBGGMKSSE-UHFFFAOYSA-N 2-(4-oxocyclohexyl)acetonitrile Chemical compound O=C1CCC(CC#N)CC1 YFHHJMBGGMKSSE-UHFFFAOYSA-N 0.000 description 1
- IUDMXOOVKMKODN-UHFFFAOYSA-N 2-(cyclohexen-1-yl)ethanamine Chemical compound NCCC1=CCCCC1 IUDMXOOVKMKODN-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-Aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- DLGBEGBHXSAQOC-UHFFFAOYSA-N 2-hydroxy-5-methylbenzoic acid Chemical compound CC1=CC=C(O)C(C(O)=O)=C1 DLGBEGBHXSAQOC-UHFFFAOYSA-N 0.000 description 1
- TZFVGECPKMMFQA-UHFFFAOYSA-N 2-methanidylprop-2-enoxymethylidyneoxidanium Chemical group [CH2-]C(=C)COC#[O+] TZFVGECPKMMFQA-UHFFFAOYSA-N 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- NPCLRBQYESMUPD-UHFFFAOYSA-N 2-methylpropanethioamide Chemical compound CC(C)C(N)=S NPCLRBQYESMUPD-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-Aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 1
- ROADCYAOHVSOLQ-UHFFFAOYSA-N 3-Oxetanone Chemical compound O=C1COC1 ROADCYAOHVSOLQ-UHFFFAOYSA-N 0.000 description 1
- QWZHDKGQKYEBKK-UHFFFAOYSA-N 3-aminochromen-2-one Chemical compound C1=CC=C2OC(=O)C(N)=CC2=C1 QWZHDKGQKYEBKK-UHFFFAOYSA-N 0.000 description 1
- MFKRHJVUCZRDTF-UHFFFAOYSA-N 3-methoxy-3-methylbutan-1-ol Chemical compound COC(C)(C)CCO MFKRHJVUCZRDTF-UHFFFAOYSA-N 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- JRDMGVGCATYZPW-UHFFFAOYSA-N 4-chloro-2-fluorobenzonitrile Chemical compound FC1=CC(Cl)=CC=C1C#N JRDMGVGCATYZPW-UHFFFAOYSA-N 0.000 description 1
- CGOVTZGCKPMLMN-UHFFFAOYSA-N 4-ethyl-1,3-thiazole Chemical compound CCC1=CSC=N1 CGOVTZGCKPMLMN-UHFFFAOYSA-N 0.000 description 1
- LLIOADBCFIXIEU-UHFFFAOYSA-N 4-fluoro-3-nitroaniline Chemical compound NC1=CC=C(F)C([N+]([O-])=O)=C1 LLIOADBCFIXIEU-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- GJNJDELEHIGPKJ-UHFFFAOYSA-N 5-chloro-2-fluorobenzonitrile Chemical compound FC1=CC=C(Cl)C=C1C#N GJNJDELEHIGPKJ-UHFFFAOYSA-N 0.000 description 1
- 229960004308 ACETYLCYSTEINE Drugs 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 229940054685 Alinia Drugs 0.000 description 1
- OLROWHGDTNFZBH-XEMWPYQTSA-N Alisporivir Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O OLROWHGDTNFZBH-XEMWPYQTSA-N 0.000 description 1
- 229950004789 Alisporivir Drugs 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- KCFYEAOKVJSACF-UHFFFAOYSA-N Arbidol Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- BJDJEJIINKBPHY-UHFFFAOYSA-N BODIPY FL Chemical compound C1=C2C=CC(CCC(O)=O)=[N+]2[B-](F)(F)N2C(C)=CC(C)=C21 BJDJEJIINKBPHY-UHFFFAOYSA-N 0.000 description 1
- 229940002637 Baraclude Drugs 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 229950002782 Besifovir Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 229950004237 Birinapant Drugs 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 102000001805 Bromodomains Human genes 0.000 description 1
- 108050009021 Bromodomains Proteins 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M CHEMBL593252 Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- NITSROBONADFIS-UHFFFAOYSA-N COC(=O)C1=CC(=C(C=C1)SC1=C(C(=O)OC)C=C(C=C1)C)[N+](=O)[O-] Chemical compound COC(=O)C1=CC(=C(C=C1)SC1=C(C(=O)OC)C=C(C=C1)C)[N+](=O)[O-] NITSROBONADFIS-UHFFFAOYSA-N 0.000 description 1
- HVPYDDONERJFND-UHFFFAOYSA-N COC1=CC=C(CSC2=C(C(=O)OC)C=C(C=C2)C)C=C1 Chemical compound COC1=CC=C(CSC2=C(C(=O)OC)C=C(C=C2)C)C=C1 HVPYDDONERJFND-UHFFFAOYSA-N 0.000 description 1
- WFQMROSTCMSCOR-UHFFFAOYSA-N COC1=CC=C(CSC2=C(C(=O)OC)C=CC(=C2)C)C=C1 Chemical compound COC1=CC=C(CSC2=C(C(=O)OC)C=CC(=C2)C)C=C1 WFQMROSTCMSCOR-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N Chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 101700070526 DNMT1 Proteins 0.000 description 1
- 102100018208 DNMT1 Human genes 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 101700079760 EFCB Proteins 0.000 description 1
- 101710005090 ERVFC1-1 Proteins 0.000 description 1
- 101710013371 ERVS71-1 Proteins 0.000 description 1
- 101700017378 EZH1 Proteins 0.000 description 1
- 101700041849 EZH2 Proteins 0.000 description 1
- 102100016041 EZH2 Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 229940079360 Enema for Constipation Drugs 0.000 description 1
- 229940074057 Epivir HBV Drugs 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N Ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N Ethyl iodide Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 229940093912 Gynecological Sulfonamides Drugs 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 206010019641 Hepatic cirrhosis Diseases 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 229940097709 Hepsera Drugs 0.000 description 1
- LIIALPBMIOVAHH-UHFFFAOYSA-N Herniarin Chemical compound C1=CC(=O)OC2=CC(OC)=CC=C21 LIIALPBMIOVAHH-UHFFFAOYSA-N 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N Hexamethylphosphoramide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100008763 IFNA2 Human genes 0.000 description 1
- 229940090438 Infergen Drugs 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 229940100994 Interleukin-7 Drugs 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 229940065638 Intron A Drugs 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 101700018814 KDM1A Proteins 0.000 description 1
- 102100000513 KDM1A Human genes 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 101700047494 LDL1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 229960001627 Lamivudine Drugs 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 102000003959 Lymphotoxin-beta Human genes 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L Magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- VAMXMNNIEUEQDV-UHFFFAOYSA-N Methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- DJOVLOYCGXNVPI-UHFFFAOYSA-N N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1H-pyridine-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2C=C(CN3CCOCC3)C=CC=2)C=C1NC(=O)C1=CNC(=O)C=C1C(F)(F)F DJOVLOYCGXNVPI-UHFFFAOYSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N N-benzyl-1-phenylmethanamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- GNDXJCUBLSVLMQ-UHFFFAOYSA-N NC1=C(C=CC(=C1)C(=O)O)SC1=C(C(=O)O)C=C(C=C1)C Chemical compound NC1=C(C=CC(=C1)C(=O)O)SC1=C(C(=O)O)C=C(C=C1)C GNDXJCUBLSVLMQ-UHFFFAOYSA-N 0.000 description 1
- FLJAIFADKLQNDA-UHFFFAOYSA-N NC1=C(C=CC(=C1)C(=O)O)SC1=C(C(=O)O)C=CC(=C1)C Chemical compound NC1=C(C=CC(=C1)C(=O)O)SC1=C(C(=O)O)C=CC(=C1)C FLJAIFADKLQNDA-UHFFFAOYSA-N 0.000 description 1
- SPFWDNQXEXWGPP-UHFFFAOYSA-N NC1=C(C=CC(=C1)C(=O)O)SC1=C(C(=O)O)C=CC(=C1)OC Chemical compound NC1=C(C=CC(=C1)C(=O)O)SC1=C(C(=O)O)C=CC(=C1)OC SPFWDNQXEXWGPP-UHFFFAOYSA-N 0.000 description 1
- GANNIVLCPRWWKS-UHFFFAOYSA-N NC1=C(C=CC(=C1)C(=O)OC)SC1=C(C(=O)OC)C=C(C=C1)C Chemical compound NC1=C(C=CC(=C1)C(=O)OC)SC1=C(C(=O)OC)C=C(C=C1)C GANNIVLCPRWWKS-UHFFFAOYSA-N 0.000 description 1
- LRWUJVGBAQJADL-UHFFFAOYSA-N NC1=C(C=CC(=C1)C(=O)OC)SC1=C(C(=O)OC)C=CC(=C1)C Chemical compound NC1=C(C=CC(=C1)C(=O)OC)SC1=C(C(=O)OC)C=CC(=C1)C LRWUJVGBAQJADL-UHFFFAOYSA-N 0.000 description 1
- RQUFALNVAWOZGD-UHFFFAOYSA-N NC1=C(C=CC(=C1)C(=O)OC)SC1=C(C(=O)OC)C=CC(=C1)OC Chemical compound NC1=C(C=CC(=C1)C(=O)OC)SC1=C(C(=O)OC)C=CC(=C1)OC RQUFALNVAWOZGD-UHFFFAOYSA-N 0.000 description 1
- RPJPZDVUUKWPGT-FOIHOXPVSA-N NIM811 Chemical compound CC[C@H](C)[C@@H]1N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC1=O RPJPZDVUUKWPGT-FOIHOXPVSA-N 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L Nickel(II) chloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N Nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- YKWFCOYSKMZKRN-UHFFFAOYSA-N O=C1C2=C(NC3=C(N1)C=C(C=C3)C(=O)NC3=CC=NC=C3)C=CC=C2 Chemical compound O=C1C2=C(NC3=C(N1)C=C(C=C3)C(=O)NC3=CC=NC=C3)C=CC=C2 YKWFCOYSKMZKRN-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N Oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 101710043203 P23p89 Proteins 0.000 description 1
- 102100019436 PLK1 Human genes 0.000 description 1
- 101700062434 PLK1 Proteins 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940002988 Pegasys Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N Phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 240000006711 Pistacia vera Species 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 108010077560 Plasmodium falciparum surface anion channel protein Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N Propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- VIAFLMPQBHAMLI-UHFFFAOYSA-N PyBOP Chemical compound F[P-](F)(F)(F)(F)F.C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 VIAFLMPQBHAMLI-UHFFFAOYSA-N 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N Resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 229950010550 Resiquimod Drugs 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 229960000329 Ribavirin Drugs 0.000 description 1
- 108010090287 SCY-635 Proteins 0.000 description 1
- 102100004436 SETD7 Human genes 0.000 description 1
- 101700032835 SETD7 Proteins 0.000 description 1
- 101700032104 SKY1 Proteins 0.000 description 1
- 101700000967 SRPK Proteins 0.000 description 1
- 101700032951 SWM1 Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- LEDMRZGFZIAGGB-UHFFFAOYSA-L Strontium carbonate Chemical compound [Sr+2].[O-]C([O-])=O LEDMRZGFZIAGGB-UHFFFAOYSA-L 0.000 description 1
- 101710006827 Su(var)3-3 Proteins 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 101700033741 TKB1 Proteins 0.000 description 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N Telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 1
- 229960004556 Tenofovir Drugs 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N Thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N Thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- FDTZUTSGGSRHQF-UHFFFAOYSA-N Tizoxanide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 FDTZUTSGGSRHQF-UHFFFAOYSA-N 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N Tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 229940066528 Trichloroacetate Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N Triphenylphosphine oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 229960004626 Umifenovir Drugs 0.000 description 1
- 229940109657 Viread Drugs 0.000 description 1
- ZHHGTMQHUWDEJF-UHFFFAOYSA-N [(6-chlorobenzotriazol-1-yl)oxy-(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=C(Cl)C=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 ZHHGTMQHUWDEJF-UHFFFAOYSA-N 0.000 description 1
- KDNSSKPZBDNJDF-UHFFFAOYSA-N [1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethylphosphonic acid Chemical compound C12=NC(N)=NC=C2N=CN1CC1(OCP(O)(O)=O)CC1 KDNSSKPZBDNJDF-UHFFFAOYSA-N 0.000 description 1
- DBGROTRFYBSUTR-UHFFFAOYSA-N [4-(trifluoromethoxy)phenyl]methanamine Chemical compound NCC1=CC=C(OC(F)(F)F)C=C1 DBGROTRFYBSUTR-UHFFFAOYSA-N 0.000 description 1
- UQYZFNUUOSSNKT-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 UQYZFNUUOSSNKT-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazonic acid Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 108010058359 alisporivir Proteins 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000078 anti-malarial Effects 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 108010063132 birinapant Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- WPTMDNDUQTZHIC-UHFFFAOYSA-N but-1-yne Chemical group [CH2-]CC#[C+] WPTMDNDUQTZHIC-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical compound C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 229960005338 clevudine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- VUMPFOPENBVFOF-UHFFFAOYSA-N dimethyl 2-bromobenzene-1,4-dicarboxylate Chemical compound COC(=O)C1=CC=C(C(=O)OC)C(Br)=C1 VUMPFOPENBVFOF-UHFFFAOYSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- MRNJHNUEBDGNEL-UHFFFAOYSA-N dimethylphosphanylmethyl(dimethyl)phosphane Chemical compound CP(C)CP(C)C MRNJHNUEBDGNEL-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion media Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- KRMORCCAHXFIHF-UHFFFAOYSA-N ethyl 1,3-oxazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=CO1 KRMORCCAHXFIHF-UHFFFAOYSA-N 0.000 description 1
- NAEPNWOYOBQMBP-UHFFFAOYSA-N ethyl 2-amino-2-pyridin-2-ylacetate Chemical compound CCOC(=O)C(N)C1=CC=CC=N1 NAEPNWOYOBQMBP-UHFFFAOYSA-N 0.000 description 1
- UDRCONFHWYGWFI-UHFFFAOYSA-N ethyl 3-oxopentanoate Chemical compound CCOC(=O)CC(=O)CC UDRCONFHWYGWFI-UHFFFAOYSA-N 0.000 description 1
- FAASZJGSPHPJJY-UHFFFAOYSA-N ethyl 4-(2-bromo-4-fluorophenyl)-6-(morpholin-4-ylmethyl)-2-(3H-pyrrol-2-yl)-1,4-dihydropyrimidine-5-carboxylate Chemical compound N1C(C=2CC=CN=2)=NC(C=2C(=CC(F)=CC=2)Br)C(C(=O)OCC)=C1CN1CCOCC1 FAASZJGSPHPJJY-UHFFFAOYSA-N 0.000 description 1
- XCLDSQRVMMXWMS-UHFFFAOYSA-N ethyl 4-methyl-3-oxopentanoate Chemical compound CCOC(=O)CC(=O)C(C)C XCLDSQRVMMXWMS-UHFFFAOYSA-N 0.000 description 1
- QVDYYQXUNAQSNI-UHFFFAOYSA-N ethyl acetate;pentane Chemical compound CCCCC.CCOC(C)=O QVDYYQXUNAQSNI-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229940121360 farnesoid X receptor (FXR) agonists Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 102000034387 fluorescent proteins Human genes 0.000 description 1
- 108091006031 fluorescent proteins Proteins 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- WHGLQYBALPTZNJ-UHFFFAOYSA-N furan;oxolane Chemical compound C1CCOC1.C=1C=COC=1 WHGLQYBALPTZNJ-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000004044 liver cirrhosis Diseases 0.000 description 1
- 201000009673 liver disease Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 101700049451 lppL Proteins 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011776 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- KLMBOVOUTOBMLS-UHFFFAOYSA-N methyl 2,4-difluoro-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=C(F)C=C1F KLMBOVOUTOBMLS-UHFFFAOYSA-N 0.000 description 1
- UDBLTZWJCWPYBA-UHFFFAOYSA-N methyl 2,5-difluorobenzoate Chemical compound COC(=O)C1=CC(F)=CC=C1F UDBLTZWJCWPYBA-UHFFFAOYSA-N 0.000 description 1
- QNPFLTKQLFSKBY-UHFFFAOYSA-N methyl 2,6-difluorobenzoate Chemical compound COC(=O)C1=C(F)C=CC=C1F QNPFLTKQLFSKBY-UHFFFAOYSA-N 0.000 description 1
- JENBPOJAZCPSEW-UHFFFAOYSA-N methyl 2-bromo-4-fluorobenzoate Chemical compound COC(=O)C1=CC=C(F)C=C1Br JENBPOJAZCPSEW-UHFFFAOYSA-N 0.000 description 1
- ZICRWXFGZCVTBZ-UHFFFAOYSA-N methyl 2-hydroxy-4-methoxybenzoate Chemical compound COC(=O)C1=CC=C(OC)C=C1O ZICRWXFGZCVTBZ-UHFFFAOYSA-N 0.000 description 1
- UITFCFWKYAOJEJ-UHFFFAOYSA-N methyl 2-hydroxy-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C=C1O UITFCFWKYAOJEJ-UHFFFAOYSA-N 0.000 description 1
- DFNBGZODMHWKKK-UHFFFAOYSA-N methyl 2-hydroxy-5-methoxybenzoate Chemical compound COC(=O)C1=CC(OC)=CC=C1O DFNBGZODMHWKKK-UHFFFAOYSA-N 0.000 description 1
- JQYUQKRFSSSGJM-UHFFFAOYSA-N methyl 2-hydroxy-5-methylbenzoate Chemical compound COC(=O)C1=CC(C)=CC=C1O JQYUQKRFSSSGJM-UHFFFAOYSA-N 0.000 description 1
- FKMZNQQOPCCUTD-UHFFFAOYSA-N methyl 3-fluoro-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 FKMZNQQOPCCUTD-UHFFFAOYSA-N 0.000 description 1
- UVFSBMWXJBYDMA-UHFFFAOYSA-N methyl 4-(2-chloro-4-fluorophenyl)-6-methyl-2-pyridin-2-yl-1,4-dihydropyrimidine-5-carboxylate Chemical compound COC(=O)C1=C(C)NC(C=2N=CC=CC=2)=NC1C1=CC=C(F)C=C1Cl UVFSBMWXJBYDMA-UHFFFAOYSA-N 0.000 description 1
- GTZTYNPAPQKIIR-UHFFFAOYSA-N methyl 4-bromo-3-methylbenzoate Chemical compound COC(=O)C1=CC=C(Br)C(C)=C1 GTZTYNPAPQKIIR-UHFFFAOYSA-N 0.000 description 1
- KRYZSGFIWDXDCM-UHFFFAOYSA-N methyl 4-methoxy-2-sulfanylbenzoate Chemical compound COC(=O)C1=CC=C(OC)C=C1S KRYZSGFIWDXDCM-UHFFFAOYSA-N 0.000 description 1
- PSHWYCLXZVNVCI-UHFFFAOYSA-N methyl 4-methyl-2-sulfanylbenzoate Chemical compound COC(=O)C1=CC=C(C)C=C1S PSHWYCLXZVNVCI-UHFFFAOYSA-N 0.000 description 1
- KNYLKWCXKDPWDW-UHFFFAOYSA-N methyl 5-methyl-2-(trifluoromethylsulfonyloxy)benzoate Chemical compound COC(=O)C1=CC(C)=CC=C1OS(=O)(=O)C(F)(F)F KNYLKWCXKDPWDW-UHFFFAOYSA-N 0.000 description 1
- KNBBZGZVUYEUGI-UHFFFAOYSA-N methyl 5-methyl-2-sulfanylbenzoate Chemical compound COC(=O)C1=CC(C)=CC=C1S KNBBZGZVUYEUGI-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960002480 nitazoxanide Drugs 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 125000001736 nosyl group Chemical group S(=O)(=O)(C1=CC=C([N+](=O)[O-])C=C1)* 0.000 description 1
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 101700016463 pls Proteins 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- WPZSAUFQHYFIPG-UHFFFAOYSA-N propanethioamide Chemical compound CCC(N)=S WPZSAUFQHYFIPG-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910000026 rubidium carbonate Inorganic materials 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 229910000018 strontium carbonate Inorganic materials 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960001355 tenofovir disoproxil Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- PINIEAOMWQJGBW-FYZOBXCZSA-N tenofovir hydrate Chemical compound O.N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N PINIEAOMWQJGBW-FYZOBXCZSA-N 0.000 description 1
- QWDYAIDDFCNTKJ-UHFFFAOYSA-N tert-butyl 4-fluoro-3-nitrobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(F)C([N+]([O-])=O)=C1 QWDYAIDDFCNTKJ-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 229940026752 topical Sulfonamides Drugs 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- SBUXRMKDJWEXRL-ZWKOTPCHSA-N trans-body Chemical compound O=C([C@@H]1N(C2=O)[C@H](C3=C(C4=CC=CC=C4N3)C1)CC)N2C1=CC=C(F)C=C1 SBUXRMKDJWEXRL-ZWKOTPCHSA-N 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-M trichloroacetate Chemical compound [O-]C(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-M 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000000605 viral structures Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N β-Alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
Abstract
The present disclosure provides, in part,
compounds having allosteric effector properties
against Hepatitis B virus Cp. Also provided herein
are methods of treating viral infections, such as
hepatitis B, comprising administering to a patient
in need thereof a disclosed compound.
Description
HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS
STATEMENT OF GOVERNMENT SUPPORT
This invention was made with govemment support under AI067417 awarded by the National Institutes of Health. The govemment has certain rights in the invention.
RELATED APPLICATIONS
This application claims the benefit of and priority to United States Provisional Patent Applications serial nos. 61/952,467, filed March 13, 2014, and 62/010,025, fïled June 10, 2014, the contents of each of which are hereby incorporated by reference.
BACKGROUND
Hepatitis B (HBV) causes viral Hepatitis that can further lead to chronic liver disease and increase the risk of liver cirrhosis and liver cancer (hepatocellular carcinoma). Worldwide, about 2 billion people hâve been infected with HBV, around 360 million people are chronically infected, and every year HBV infection causes more than one half million deaths (2009; WHO, 2009). HBV can be spread by body fluids: from mother to child, by sex, and via blood products. Children bom to HBV positive mothers may also be infected, unless vaccinated at birth.
The virus particle is composed of a lipid enveloped studded with surface protein (HBsAg) that surrounds the viral core. The core is composed of a protein shell, or capsid, built of 120 core protein (Cp) dimers, which in tum contains the relaxed circular DNA (rcDNA) viral genome as well as viral and host proteins. In an infected cell, the genome is found as a covalently closed circular DNA (cccDNA) in the host cell nucléus. The cccDNA is the template for viral RNAs and thus viral proteins. In the cytoplasm, Cp assembles around a complex of full-length viral RNA (the so-called pregenomic RNA or pgRNA and viral polymerase (P). After assembly, P reverse transcribes the pgRNA to rcDNA within the confines of the capsid to generate the DNA-fïlled viral core. For convenience, we divide the assembly process at the point of capsid assembly and pgRNApackaging. Steps preceding this event are “upstream”; steps following RNA-packaging are “downstream”.
At présent, chronic HBV is primarily treated with nucleos(t)ide analogs (e.g. entecavir) that suppress the virus while the patient remains on treatment but do not eliminate the infection, even after many years of treatment. Once a patient starts taking nucléotide analogs most must continue taking them or risk the possibility of a life threatening immune response to viral rebound. Further, nucleos(t)ide therapy may lead to the emergence of antiviral drug résistance (Deres and RubsamenWaigmann, 1999; Tennant et al., 1998; Zhang et al., 2003) and - in rare patients- adverse events hâve been reported (Ayoub and Keeffe , 2011).
The only FDA approved alternative to nucleos(t)ide analogs is treatment with interferon a or pegylated interferon a. Unfortunately, the adverse event incidence and profile of interferon a can resuit in poor tolerability, and many patients are unable to complété therapy. Moreover, only a small percentage of patients are considered appropriate for interferon therapy, as only a small subset of patients are likely to hâve asustained clinical response to a course of interferon therapy. As a resuit, interferon based thérapies are used in only a small percentage of ail diagnosed patients who elect for treatment.
Thus, current HBV treatments can range from palliative to watchful waiting. Nucleos(t)ide analogs suppress virus production, treating the symptom, but leave the infection intact. Interferon a has severe side effects and less tolerability among patients and is successful as a fînite treatment strategy in only a small minority of patients. There is a clear on-going need for more effective treatments for HBV infections.
SUMMARY
Provided herein are compounds that can hâve properties such as those described below, where the compounds in some embodiments may be represented by:
R4 Ο r!
N-L-R2
I
Rl Formula 1 ’ wherein R2, R4, R5, R6, R7, R8, R9, R10, RL, Y, T, and L are defined herein. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient a disclosed compound.
For example, the présent disclosure is directed in part to compounds having allosteric effector properties against Hepatitis B virus Cp, a protein found as a dimer, a multimer, and as the protein shell of the HBV core. Without being bound by theory, disclosed compounds may ultimately target multimerization of viral core proteins, which is central to HBV infection, where the core protein multimerizes into shell, or capsid, and/or disclosed compounds may for example, ultimately target interaction of viral core proteins with other macromolecules, such as host or viral nucleic acid, host proteins, or other viral proteins. For example, disclosed compounds may be considered in some embodiments CpAM — core protein allosteric modifîers. CpAM interaction with core protein can allosterically favor an assembly-active form of Cp dimer and lead to viral capsid assembly at an inappropriate time or place or lead to non-standard intersubunit interactions, ail resulting in defective capsids. CpAMs may additionally or altematively affect steps of “upstream” of capsid assembly by altering the concentrations or nature of Cp available as dimer as compared to capsid or other multimeric forms. Disclosed compounds or CpAMs may, in some embodiments, noticeably affect functions upstream of viral assembly such as modulation of cccDNA transcription, RNA stability and/or protein-protein interactions.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 illustrâtes synthetic scheme 1.
Figure 2 illustrâtes synthetic scheme 2.
DETAILED DESCRIPTION
The features and other details of the disclosure will now be more particularly described. Before further description of the présent invention, certain ternis employed in the spécification, examples and appended claims are collected here. These définitions should be read in light of the remainder of the disclosure and as understood by a person of skill in the art. Unless defined otherwise, ail technical and scientific terms used herein hâve the same meaning as commonly understood by a person of ordinary skill in the art.
Définitions
As intended herein, the terms a and an include singular as well as plural references unless the context clearly dictâtes otherwise. For example, the term an assembly effector can include one or more such effectors.
The term “alkyl” as used herein refers to a saturated straight or branched hydrocarbon. Exemplary alkyl groups include, but are not limited to, straight or branched hydrocarbons of 1-6, 1-4, or 1-3 carbon atoms, referred to herein as Ci^alkyl, Cj^alkyl, and Ci^alkyl, respectively. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-l-butyl, 3-methyl2-butyl, 2-methyl-l-pentyl, 3-methyl-1-pentyl, 4-methyl-l-pentyl, 2-methyl-2-pentyl, 3-methyl-2pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l-butyl, 3,3-dimethyl-l-butyl, 2-ethyl-l-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, etc.
The term “alkenyl” as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond. Exemplary alkenyl groups include, but are not limited to, a straight or branched group of 2-6 or 3-4 carbon atoms, referred to herein as C2-6alkenyl, and C3. 4alkenyl, respectively. Exemplary alkenyl groups include, but are not limited to, vinyl, allyl, butenyl, pentenyl, etc.
The term “alkoxy” as used herein refers to a straight or branched alkyl group attached to oxygen (alkyl-O-). Exemplary alkoxy groups include, but are not limited to, alkoxy groups of 1-6 or 2-6 carbon atoms, referred to herein as Ci.6alkoxy, and C2-6alkoxy, respectively. Exemplary alkoxy groups include, but are not limited to methoxy, ethoxy, isopropoxy, etc.
The term “alkynyl” as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond. Exemplary alkynyl groups include, but are not limited to, straight or branched groups of 2-6, or 3-6 carbon atoms, referred to herein as C2-6alkynyl, and C3. ôalkynyl, respectively. Exemplary alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, etc.
The ternis “cycloalkyl” or a “carbocyclic group” as used herein refers to a saturated or partially unsaturated hydrocarbon group of, for example, 3-6, or 4-6 carbons, referred to herein as C3. ôcycloalkyl or C^cycloalkyl, respectively. Exemplary cycloalkyl groups include, but are not limited to, cyclohexyl, cyclopentyl, cyclopentenyl, cyclobutyl or cyclopropyl.
The tenus “halo” or “halogen” as used herein refer to F, Cl, Br, or I.
The terms “heteroaryl” or “heteroaromatic group” as used herein refers to a monocyclic aromatic 56 membered ring system containing one or more heteroatoms, for example one to three heteroatoms, such as nitrogen, oxygen, and sulfur. Where possible, said heteroaryl ring may be linked to the adjacent radical though carbon or nitrogen. Examples of heteroaryl rings include but are not limited to furan, thiophene, pyrrole, thiazole, oxazole, isothiazole, isoxazole, imidazole, pyrazole, triazole, pyridine or pyrimidine etc.
The terms “heterocyclyl” or “heterocyclic group” are art-recognized and refer to saturated or partially unsaturated 4-7 membered ring structures, whose ring structures include one to three heteroatoms, such as nitrogen, oxygen, and sulfur. Where possible, heterocyclyl rings may be linked to the adjacent radical through carbon or nitrogen. Examples of heterocyclyl groups include, but are not limited to, pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, oxetane, azetidine, tetrahydrofuran or dihydrofuran etc
The terms “hydroxy” and “hydroxyl” as used herein refers to the radical -OH.
Treatment as used herein includes the alleviation, prévention, reversai, amelioration or control of a pathology, disease, disorder, process, condition or event, including viral infection. In this context, the term treatment is further to be understood as embracing the use of a drug to inhibit, block, reverse, restrict or control progression of viral infection.
As used herein, the terni “pharmaceutical composition” refers to compositions of matter comprising at least one pharmaceutical compound and optionally a pharmaceutically acceptable carrier.
As used herein, the term “pharmaceutical compound” or “drug” refers to a free compound, its therapeutically suitable salts, solvatés such as hydrates, spécifie crystal forms of the compound or its salts, or therapeutically suitable prodrugs of the compound.
Pharmaceutically or pharmacologically acceptable” include molecular entities and compositions that do not produce an adverse, allergie or other untoward reaction when administered to an animal, or a human, as appropriate. For human administration, préparations should meet sterility, pyrogenicity, and general safety and purity standards as required by FDA Office of Biologics standards.
The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” as used herein refers to any and ail solvents, dispersion media, coatings, isotonie and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The compositions may also contain other active compounds providing supplémentai, additional, or enhanced therapeutic functions.
The compounds of the disclosure may contain one or more chiral centers and, therefore, exist as stereoisomers. The term “stereoisomers” when used herein consist of ail enantiomers or diastereomers. These compounds may be designated by the symbols “(+),” “R” or “S,” depending on the configuration of substituents around the stereogenic carbon atom, but the skilled artisan will recognize that a structure may dénoté a chiral center implicitly. The présent invention encompasses various stereoisomers of these compounds and mixtures thereof. Mixtures of enantiomers or diastereomers may be designated “(±)” in nomenclature, but the skilled artisan will recognize that a structure may dénoté a chiral center implicitly.
The compounds of the disclosure may contain one or more double bonds and, therefore, exist as géométrie isomers resulting from the arrangement of substituents around a carbon-carbon double bond. The symbol = dénotés a bond that may be a single, double or triple bond as described herein. Substituents around a carbon-carbon double bond are designated as being in the “Z” or configuration wherein the terms “Z” and are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the and “Z” isomers.
Substituents around a carbon-carbon double bond altematively can be referred to as “cis” or “trans,” where “cis” represents substituents on the same side of the double bond and “trans” represents substituents on opposite sides of the double bond.
Compounds of the disclosure may contain a carbocyclic or heterocyclic ring and therefore, exist as géométrie isomers resulting from the arrangement of substituents around the ring. The arrangement of substituents around a carbocyclic or heterocyclic ring are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUP AC standards. Unless otherwise specified, structures depicting carbocyclic or heterocyclic rings encompass both “Z” and “E” isomers. Substituents around a carbocyclic or heterocyclic ring may also be referred to as “cis” or “trans”, where the term “cis” represents substituents on the same side of the plane of the ring and the term “trans” represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated “cis/trans.”
Individual enantiomers and diasteriomers of compounds of the présent invention can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by préparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, séparation of the resulting mixture of diastereomers by recrystallization or chromatography and libération of the optically pure product from the auxiliary, (2) sait formation employing an optically active resolving agent, (3) direct séparation of the mixture of optical enantiomers on chiral liquid chromatographie columns or (4) kinetic resolution using stereoselective chemical or enzymatic reagents. Racemic mixtures can also be resolved into their component enantiomers by well known methods, such as chiral-phase liquid chromatography or crystallizing the compound in a chiral solvent. Stereoselective synthèses, a chemical or enzymatic reaction in which a single reactant forms an unequal mixture of stereoisomers during the création of a new stereocenter or during the transformation of a pre-existing one, are well known in the art. Stereoselective synthèses encompass both enantio- and diastereoselective transformations, and may involve the use of chiral auxiliaries. For examples, see Carreira and Kvaemo, Classics in Stereoselective Synthesis, Wiley-VCH: Weinheim, 2009.
The compounds disclosed herein can exist in solvated as well as unsolvated forms with pharmaceutically acceptable solvents such as water, éthanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. In one embodiment, the compound is amorphous. In one embodiment, the compound is a single polymorph. In another embodiment, the compound is a mixture of polymorphs. In another embodiment, the compound is in a crystalline form.
The invention also embraces isotopically labeled compounds of the invention which are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F, and 36Cl, respectively. For example, a compound of the invention may hâve one or more H atom replaced with deuterium.
Certain isotopically-labeled disclosed compounds (e.g., those labeled with 3H and 14C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon-14 (i.e., 14C) isotopes are particularly preferred for their ease of préparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labeled compounds of the invention can generally be prepared by following procedures analogous to those disclosed in the examples herein by substituting an isotopically labeled reagent for a nonisotopically labeled reagent.
The term therapeutically suitable sait, refers to salts or zwitterions of pharmaceutical compounds which are water or oil-soluble or dispersible, suitable for treatment of disorders and effective for their intended use. The salts may be prepared, for instance, during the final isolation and purification of the compounds or separately by reacting an amino group of the compounds with a suitable acid. For example, a compound may be dissolved in a suitable solvent, such as but not limited to methanol and water, and treated with at least one équivalent of an acid, for instance hydrochloric acid. The resulting sait may precipitate out and be isolated by filtration and dried under reduced pressure. Altematively, the solvent and excess acid may be removed under reduced pressure to provide the sait. Représentative salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycérophosphate, hemisulfate, heptanoate, hexanoate, form ate, isethionate, fumarate, lactate, maleate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, oxalate, maleate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate, glutamate, para-toluenesulfonate, undecanoate, hydrochloric, hydrobromic, sulfuric, phosphoric, and the like. The amino groups of a compound may also be quatemized with alkyl chlorides, bromides, and iodides such as methyl, ethyl, propyl, isopropyl, butyl, lauryl, myristyl, stearyl, and the like.
Basic addition salts may be prepared, for instance, during the final isolation and purification of pharmaceutical compounds by reaction of a carboxyl group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a métal cation such as lithium, sodium, potassium, calcium, magnésium, or aluminum, or an organic primary, secondary, or tertiary amine. Quatemary amine salts may derived, for example, from methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, Ν,Ν-dimethylaniline, N-methylpiperidine, Nmethylmorpholine, dicyclohexylamine, procaine, dibenzylamine, Ν,Ν-dibenzylphenethylamine, 1ephenamine, and Ν,Ν'-dibenzylethylenediamine, ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine, and the like.
The term “therapeutically suitable prodrug,” refers to those prodrugs or zwitterions which are suitable for use in contact with the tissues of subjects and are effective for their intended use. The term “prodrug” refers to compounds that are transformed in vivo to a pharmaceutical compound, for example, by hydrolysis in blood. The term “prodrug,” refers to compounds that contain, but are not limited to, substituents known as “therapeutically suitable esters.” The term “therapeutically suitable ester,” refers to alkoxycarbonyl groups appended to the parent molécule on an available carbon atom. More specifically, a “therapeutically suitable ester,” refers to alkoxycarbonyl groups appended to the parent molécule on one or more available aryl, cycloalkyl and/or heterocycle groups. Compounds containing therapeutically suitable esters are an example, but are not intended to limit the scope of compounds considered to be prodrugs. Examples of prodrug ester groups include pivaloyloxymethyl, acetoxymethyl, phthalidyl, indanyl and methoxymethyl, as well as other such groups known in the art. Other examples of prodrug ester groups are found in T. Higuchi and
V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Sériés, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incoiporated herein by reference.
The terms pharmaceutically effective amount and “effective amount”, as used herein, refer to an amount of a pharmaceutical formulation that will elicit the desired therapeutic effect or response when administered in accordance with the desired treatment regimen. US2011/0144086 describes the use of some diabenzothiazepine molécules (DBTs) as anti-malarial “inhibitors of the plasmodial surface anion channel.” However, no study of DBT molécules as anti-virais has yet been reported.
1. Disclosed compounds contemplated herein may in some embodiments be represented by Formula 1:
Formula 1 wherein:
T is selected from the group consisting of-C(O)-, -CH2-C(O)-, -N(C(O)-CH3)-, -NH-, -O-, and -S(O)Z-, where z is 0, 1 or 2;
Y is C(Rn)2 , S(O)y, NRy and O wherein y is 0, 1, or 2;
Ry is selected from the group consisting of H, methyl, ethyl, propyl, phenyl and benzyl;
Rl is selected from the group consisting of H, methyl, and -C(O)-Ci-3alkyl;
L is a bond or Cm straight chain alkylene optionally substituted by one or two substituents each independently selected from the group consisting of methyl (optionally substituted by halogen or hydroxyl), ethenyl, hydroxyl, NR’R”, phenyl, heterocycle, and halogen and wherein the Cm straight chain alkylene may be interrupted by an -O-;
R2 is selected from the group consisting of H, phenyl or naphthyl (wherein the phenyl or naphthyl may be optionally substituted with one, two , three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, C2-6alkenyl, C2-6alkynyl, Ci_6alkoxy, NR’R”, -C(O)- NR’R”, -C(O)-Ci. ealkyl, -C(O)-Ci_6alkoxy, phenyl (optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, cyano, Ci-ôalkyl, C2. ealkenyl, C2.6alkynyl, Cj-galkoxy, NR’R”, C(O)- NR’R”, -C(O)-Ci_6alkyl, -C(O)-Cwalkoxy, S(O)w-Ci_6alkyl (where w is 1, 2 or 3), S(O)W-NR’R” (where w is 1, 2 or 3),-NR’-S(O)w, and S(O)w-NR’R”(where w is 1, 2 or 3)), heteroaryl (optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci^alkyl, C2.6alkenyl, C2.6alkynyl, Ci_6alkoxy, NR’R”, C(O)- NR’R”, -C(O)-Ci_6alkyl, -C(O)-Ci.6alkoxy, S(O)w-C!.6alkyl (where w is 1, 2 or 3), NR’-S(O)W, and -S(O)w-NR’R”(where w is 1, 2 or 3)), C3. ôcycloalkyl, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -S(O)W-NR’R” (where w is 1, 2 or 3), and NR’-S(O)W, (where w is 1, 2 or 3)),
5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from O, N and S (wherein the 5-6 membered heteroaryl may be optionally substituted on a carbon with one, two , three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci_galkyl, C2_6alkenyl, C2-6alkynyl, Ci.galkoxy, phenyl (optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci^alkyl, C2-6alkenyl, C2-6alkynyl, Cj-ôalkoxy, NR’R”, C(O)- NR’R”, -C(O)-Ci_6alkyl, C(O)-OH, -C(O)-Ci_6alkoxy, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -NR’-S(O)W, and -S(O)WNR’R”(where w is 1, 2 or 3)), heteroaryl, heterocycle, NR’R”, -C(O)- NR’R”, -C(O)-Ci.6alkyl, C(O)-C!.6alkoxy, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -NR’-S(O)W, and -S(O)W-NR’R”(where w is 1, 2 or 3), and on a nitrogen by R’),
Ci-ôalkyl, Ci_6alkoxy, C2-6alkenyl, C3_iocycloalkyl (optionally substituted with one, two , three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, NR’R”, -C(O)- NR’R”, =CNR’, Ci_6alkyl, Ci_6alkoxy, -C(O)-Ci_6alkyl, and -C(O)-Ci_ ôalkoxy, and wherein the C3_iocycloalkyl may optionally be a bridged cycloalkyl)), and a 4-6 membered heterocycloalkyl having one or two heteroatoms each independently selected from O, N and S (wherein the 4-6 membered heterocycloalkyl may be optionally substituted with one, two , three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, NR’R”, -C(O)- NR’R”, Cj^alkyl, Ci_6alkoxy, -C(O)-Ci-6alkyl, and -C(O)-Ci_6alkoxy);
R’ is selected, independently for each occurrence, from H, methyl, ethyl, propyl, phenyl, and benzyl;
R” is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, carboxybenzyl, -C(O)-methyl and -C(O)-ethyl, or R’ and R” taken together may form a 4-6 membered heterocycle;
each of moieties R4, R5, R6, R7, R8, R9, R10, and R11 are independently selected for each occurrence from the group consisting of hydrogen, Ci^alkyl, C2-6alkenyl, C2-6alkynyl, halogen, hydroxyl, nitro, cyano, NR’R”, -C(O)- NR’R”, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -NR’S(O)W; and -S(O)W-NR’R”(where w is 0, 1 or 2), Ci-6alkoxy,-C(O)-OH, -C(O)-Ci-6alkyl, and C(O)-Ci_6alkoxy;
wherein for each occurrence, Ci^alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C2.6alkenyl, C2-6alkynyl, Ci„6alkoxy, phenyl, NR’R”, -C(O)- NR’R”, S(O)w-methyl (where w is 1, 2 or 3), -NR’-S(O)W; and S(O)W-NR’R”(where w is 0, 1 or 2); Ci-galkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, phenyl, NR’R”, -C(O)-NR’R”, S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -NR’-S(O)W; and S(O)W-NR’R” (where w is 0, 1 or 2); and C3_6cycloalkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, Ci_6alkoxy, -C(O)-Ci-6alkyl, -C(O)-Ci-6alkoxy, and NR’R”; and pharmaceutically acceptable salts thereof.
For example, in certain embodiments, L may be selected from the group consisting of a bond, -CH2, -CH2-CH2-, or CH2(CH2)-CH2-. For example, in certain embodiments, L is C2-3alkylene, or in other embodiments, L is selected from the group consisting of-CH2-CH2-, -CH2(CH2)-CH2-, -CH2CH2(OH)-, -CH2-CH2(CH3OH)-, and -CH2-CH2(OH)-CH2-. L may be a bond, or for example, L may be C2-3alkylene-O-. For example, L may be -O-CH2-CH2(OH)-, -CFL-CFLÎCFLOH)-, or — CH2-CH2(OH)-CH2-. In other embodiments, L is -O-.
Y, in certain embodiments, may be S(0)y (where y is 0, 1 or 2), or NRy. In certain embodiments y is 0 or 2, for example, Y may be S.
In certain other embodiments, R2 is phenyl, for example, R2 may be phenyl substituted by Ci^alkyl or Ci-ôalkoxy. In other embodiments, R2 is phenyl substituted by one or two substituents each selected from the group consisting of fluorine, chlorine, Ci^alkyl (optionally substituted by one, two or three fluorines), Ci_6alkoxy (optionally substituted by one, two or three fluorines), hydroxyl, NR’R”, -S(O)2-NR’R”, heteroaryl, and phenyl (optionally substituted by halogen or hydroxyl). For example, R2 may be phenyl substituted by an 5-6 membered heteroaryl selected from the group consisting of:
an exemplary embodiment R2 is phenyl substituted by
Tn other embodiments, R2 may be a 5-6 membered heteroaryl, for example, R2 may be selected from the group consisting of:
In another embodiment, R may be a 4-6 membered heterocycloalkyl, which may be optionally substituted as described above. For example, R2 may be selected from the group consisting of:
wherein R32 is selected from the group consisting of H, halogen, phenyl, and Cj-galkyl (optionally substituted by one, two or three halogens); R52 is selected from the group consisting of H, halogen, phenyl, and Ci^alkyl (optionally substituted by one, two or three halogens); and R42 is selected from the group consisting of H, halogen, phenyl, Ci_6alkyl (optionally substituted by one, two or three halogens), Ci_6alkoxy (optionally substituted by one, two or three halogens), NH2, -OCH3, NHCH3, andN(CH3)2.
R42, in some embodiments, may be independently selected for each occurrence from the group consisting of H, methyl, ethyl, propyl, -CF3, -CH2CH3, Cl, F, phenyl, -NH2, -OCH3, NHCH3, and
N(CH3)2.
In other embodiments, e.g. when R2 is a heteroaryl, R2 may be optionally substituted on a carbon by one or two substitutents each selected from the group consisting of fluorine, chlorine, phenyl, -NH2;
NH Ci-6alkyl, and N(Ci-6alkyI)2, Ci-ôalkyl, and Ci-ôalkoxy. In certain embodiments, R5 * * * * 10 11 * * * 15 is CH2 or CH2(CH3)Also contemplated herein is a compound of formula 1 or Γ wherein R2 is a 4-6 membered heterocycloalkyl or C4-6cycloalkyl, for example, R2 is selected from the group of: tetrahydropyranyl, tetrahydrofuran, cyclopentane, cyclohexane, and cyclobutane. In an embodiment, R2 is selected from the group consisting of:
A compound represented by:
is also contemplated herein, wherein
Y is S(O)y, wherein y is 0, 1,2;
L is a bond or ϋμ straight chain alkylene optionally substituted by one or two substituents each independently selected from the group consisting of methyl (optionally substituted by halogen or hydroxyl), hydroxyl and halogen;
R2 is selected from phenyl optionally substituted with one, two , three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci_6alkyl, C2. ealkenyl, C2.6alkynyl, Ci_6alkoxy, NR’R”, -C(O)- NR’R”, -C(O)-Ci_6alkyl, -C(O)-Cwalkoxy, phenyl (optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci-ôalkyl, C2-6alkenyl, C2-6alkynyl, Ci_6alkoxy, NR’R”, C(O)- NR’R”, -C(O)-Ci_6alkyl, -C(O)-Ci-6alkoxy, -S(O)w-Ci-6alkyl (where w is 1, 2 or 3), NR’S(O)W, and -S(O)W-NR’R”(where w is 1, 2 or 3)), 5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from O, N and S (optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci.6alkyl, C2.6alkenyl, C2.6alkynyl, Ci_6alkoxy, NR’R”, C(O)-NR’R”, -C(O)-Ci_6alkyl, -C(O)-Ci_ 6alkoxy, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -NR’-S(O)W, and -S(O)w-NR’R”(where w is 1, 2 or 3)), C3_6cycloalkyl, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), S(O)W-NR’R” (where w is 1, 2 or 3), and -NR’-S(O)W, (where w is 1, 2 or 3)), and a 5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from O, N and S (wherein the 5-6 membered heteroaryl may be optionally substituted on a carbon with one, two , three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci-galkyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkoxy, phenyl (optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Cj^alkyl, C2.âalkenyl, C2-6alkynyl, Cj. ealkoxy, NR’R”, C(O)- NR’R”, -C(O)-Ci.6alkyl, -C(O)-Ci_6alkoxy, -S(O)w-Ci.6alkyl (where w is 1, 2 or 3), S(O)W-NR’R” (where w is 1, 2 or 3),-NR’-S(O)w, and -S(O)w-NR’R”(where w is 1, 2 or 3)), heteroaryl, heterocycle, NR’R”, -C(O)-NR’R”, -C(O)-Ci.6alkyl, -C(O)-Cwalkoxy, -S(O)w-Ci. 6alkyl (where w is 1,2 or 3),-NR’-S(O)w, and -S(O)w-NR’R”(where w is 1, 2 or 3), and on a nitrogen by R’);
R’ is selected, independently for each occurrence, from H, methyl, ethyl, and propyl,
R” is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, C(O)-methyl and -C(O)-ethyl, or R’ and R’ ’ taken together may form a 4-6 membered heterocycle;
each of moieties R4, R5, R6, R7, R8, R9, R10, and R11 are independently selected for each occurrence from the group consisting of hydrogen, Ci^alkyl, C2-6alkenyl, C2-6alkynyl, halogen, hydroxyl, nitro, cyano, NR’R”, -C(O)- NR’R”, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), NR’-S(O)Wj and S(O)W-NR’R”(where w is 0, 1 or 2), Ci_6alkoxy,-C(O)-OH, -C(O)-Ci-6alkyl, and -C(O)-Ci_ ëalkoxy;
wherein for each occurrence, Ci^alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C2_6alkenyl, C2.6alkynyl, Ci.6alkoxy, phenyl, NR’R”, -C(O)- NR’R”, S(O)w-methyl (where w is 1, 2 or 3), -NR’-S(O)W> and S(O)W-NR’R”(where w is 0, 1 or 2); Ci_6alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci_6alkyl, phenyl, NR’R”, -C(O)- NR’R”, S(O)w-C!.6alkyl (where w is 1, 2 or 3), -NR’-S(O)W> and S(O)W-NR’R” (where w is 0, 1 or 2); and C3_6cycloalkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, Ci-6alkoxy, -C(O)-Ci-6alkyl, -C(O)-Ci_6alkoxy, and NR’R” and pharmaceutically acceptable salts thereof.
In some embodiments, compounds of Formula 1, Γ and/or 1” may hâve R7 selected from H and F; and/or R6 is selected from H and F; and/or R5 is selected from H and F. In some embodiments, compounds of Formula 1,1’ and/or 1” may hâve R10 selected from the group consisting of H, methyl and F and/or R4, R5, R6, R7, R8, R9, R10, and/or R11 may be H.
In another embodiment, a compound represented by Formula 2 is provided:
wherein
Rm and Rm are each independently selected from the group consisting of H, halogen, Cj. ôalkyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), NR’R’ ’, and hydroxyl;
R22 is selected for each occurrence from the group consisting of H, halogen, hydroxyl, nitro, cyano, carboxy, Cj-galkyl, C2-6alkenyl, C2-6alkynyl, Ci_6alkoxy, NR’R”, -C(O)-Ci_6alkyl, C(O)-Ci_6alkoxy, phenyl, heteroaryl, C3_6cycloalkyl, -S(O)w-Ci.6alkyl (where w is 1, 2 or 3), -S(O)WNR’R” (where w is 1, 2 or 3), and -NR’-S(O)W, (where w is 1, 2 or 3));
R’ is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;
R” is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, -C(O)-methyl and -C(O)-ethyl, or R’ and R” taken together with the nitrogen to which they are attached may form a 4-6 membered heterocycle;
each of moieties R4, R5, R6, R7, R8, R9, and R10 is independently selected for each occurrence from the group consisting of hydrogen, Ci^alkyl, C2-6alkynyl, C2-6alkenyl, halogen, hydroxyl, nitro, cyano, andNR’R”;
wherein for each occurrence, Ci^alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C2-6alkenyl, C2-6alkynyl, Ci_6alkoxy, NR’R”, -NR’-S(O)W, and S(O)W-NR’R”; Ci.6alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, NR’R”, -NR’-S(O)W) and S(O)W-NR’R”; C3. ôcycloalkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, Ci_6alkoxy, -C(O)-Ci-6alkyl, -C(O)-Ci_6alkoxy, and NR’R”; phenyl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci-ôalkyl, C2.6alkenyl, C2.6alkynyl, Ci.6alkoxy, NR’R”, C(O)-NR’R”, -C(O)-Ci_6alkyl, -C(O)-Ci.6alkoxy, 5 S(0)w-Ci_6alkyl (where w is 1, 2 or 3), NR’-S(O)W, and -S(O)w-NR’R”(where w is 1, 2 or 3), and heteroaryl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci^alkyl, C2_6alkenyl, C3_6cycloalkyl, C2. ealkynyl, Ci_6alkoxy, NR’R”, C(O)-NR’R”, -C(O)-Ci_6alkyl, -C(O)-Ci_6alkoxy, -S(O)w-Ci.6alkyl (where w is 1, 2 or 3), NR’-S(O)W, and -S(O)w-NR’R”(where w is 1, 2 or 3)), C3_6cycloalkyl; and pharmaceutically acceptable salts thereof.
For example, a compound of Formula 2 may hâve R is selected from H and F; and/or R is selected from H and F; and/or R5 is selected from H and F; and/or R10 is selected from the group consisting of H, methyl and F; and/or each of R4, R5, R6, R7, R8, R9, R10, and R11 may be H.
For example, provided herein is a compound represented by
, wherein the R moieties are described above. For example, in an embodiment, provided herein is a compound represented by:
O
wherein R22 for example,is selected from the group consisting of:
OI
and “MX, >
R'
Also provided are compounds of Formula 3:
Formula 3
3 wherein the moiety R is selected from the group consisting of phenyl and naphthyl. R is optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, carboxy, alkoxy, amino-cycloalkyl, phenyl, carbonyl-alkoxy, sulfonyl-alkyl, sulfonyl-amino, and sulfonyl-amino-alkyl.
In addition, compounds of Formula 4 are provided:
Formula 4
wherein moiety R4 is selected from the group consisting of pyridinyl, pyrimidinyl, thiazolyl, oxazolyl, piperidinyl, and piperazinyl. R4 may be optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, carboxy, alkoxy, 15 amino-cycloalkyl, phenyl, carbonyl-alkoxy, sulfonyl-alkyl, sulfonyl-amino, and sulfonylaminoalkyl.
In another embodiment, a compound represented by:
R62 (Formula 5) is provided wherein
Y is C(Rn)2, S(O)y, NRy and O wherein y is 0, 1, or 2;
Ry is selected from the group consisting of H, methyl, ethyl, propyl, phenyl and benzyl;
Rm and Rm are each independently selected from the group consisting of H, halogen, Ci. ôalkyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), C2-6alkenyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), NR’R”, and hydroxyl (e.g., Rm and Rm may each be H in certain embodiments);
R62 is selected for each occurrence from the group consisting of H, halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, C2_6alkenyl, C2.6alkynyl, Ci.6alkoxy, NR’R”, -C(O)-Ci.6alkyl, -C(O)-Ci_ galkoxy, phenyl, heteroaryl, C3_6cycloalkyl, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -S(O)W-NR’R” (where w is 1, 2 or 3), and -NR’-S(O)W, (where w is 1, 2 or 3));
R’ is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;
R” is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, C(O)-methyl and -C(O)-ethyl, or R’ and R’ ’ taken together with the nitrogen to which they are attached may form a 4-6 membered heterocycle;
each of moieties R4, R5, R6, R7, R8, R9, and R10 is independently selected for each occurrence from the group consisting ofhydrogen, Ci^alkyl, C2.6alkynyl, C2.6alkenyl, halogen, hydroxyl, nitro, cyano, andNR’R”;
wherein for each occurrence, Ci_6alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy,
C2_6alkenyl, C2-6alkynyl, Ci.galkoxy, NR’R”, -NR’-S(O)W> and S(O)W-NR’R”; Ci_6alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Cj^alkyl, NR’R”, -NR’-S(O)W, and S(O)W-NR’R”; C3ôcycloalkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, Ci_6alkoxy, -C(O)-Ci-6alkyl, -C(O)-Ci_6alkoxy, and NR’R”; phenyl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci^alkyl, C2.6alkenyl, C^alkynyl, Ci_6alkoxy, NR’R”, C(O)-NR’R”, -C(O)-Ci_6alkyl, -C(O)-Ci.6alkoxy, S(O)w-Ci-6alkyl (where w is 1, 2 or 3), NR’-S(O)W, and -S(O)w-NR’R”(where w is 1, 2 or 3), and heteroaryl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci^alkyl, C2-6alkenyl, C2.6alkyn.yl, Cj. 6alkoxy, NR’R”, C(O)- NR’R”, -C(O)-Ci-6alkyl, -C(O)-Ci.6alkoxy, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), NR’-S(O)W, and -S(O)W-NR’R”(where w is 1, 2 or 3)), and C3_6cycloalkyl; and pharmaceutically acceptable salts thereof.
In an embodiment, a compound of Formula 5 may hâve R selected from H and F and/or R is selected from H and F and/or R5 may be selected from H and F; and/or R10 may be selected from the group consisting of H, methyl and F; and/or R4, R5, R6, R7, R8, R9, R10, and R11 may be H.
In some embodiments,Y of Formula 5 may be S.
A compound represented by:
wherein
Y is C(Ru)2 , S(O)y, NRy and O wherein y is 0, 1, or 2;
RY is selected from the group consisting of H, methyl, ethyl, propyl, phenyl and benzyl;
Rm and Rm are each independently selected from the group consisting of H, halogen, Cj. ôalkyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), C2-6alkenyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), NR’R”, and hydroxyl (e.g., Rm and Rm may each be H in certain embodiments);
Rc is H or Cbgalkyl;
R72 is selected for each occurrence from the group consisting of H, halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, C2-6alkenyl, C2-6alkynyl, Ci_6alkoxy, NR’R”, -C(O)-Ci_6alkyl, -C(O)-Ci_ galkoxy, phenyl, heteroaryl, C3„6cycloalkyl, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -S(O)W-NR’R” (where w is 1, 2 or 3), and -NR’-S(O)W, (where w is 1, 2 or 3));
R’ is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;
R” is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, C(O)-methyl and -C(O)-ethyl, or R’ and R’ ’ taken together with the nitrogen to which they are attached may form a 4-6 membered heterocycle;
each of moieties R4, R5, R6, R7, R8, R9, and R10 is independently selected for each occurrence from the group consisting of hydrogen, Ci„6alkyl, C2-6alkynyl, C2-6alkenyl, halogen, hydroxyl, nitro, cyano, and NR’R’ ’ ;
wherein for each occurrence, Ci^alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C2-6alkenyl, C2-6alkynyl, Ci_6alkoxy, NR’R”, -NR’-S(O)W, and S(O)W-NR’R”; Ci_6alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, NR’R”, -NR’-S(O)W> and S(O)W-NR’R”; C3. ôcycloalkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, Ci.galkoxy, -C(O)-Ci_6alkyl, -C(O)-Ci_6alkoxy, and NR’R”; phenyl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci^alkyl, C2.6alkenyl, C2.6alkynyl, Ci_6alkoxy, NR’R”, C(O)-NR’R”, -C(O)-C1.6alkyl, -CiOj-C^ealkoxy, S(O)w-Ci.6alkyl (where w is 1, 2 or 3), NR’-S(O)W, and -S(O)w-NR’R”(where w is 1, 2 or 3), and heteroaryl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci^alkyl, C2-6alkenyl, C2.6alkynyl, Ci. galkoxy, NR’R”, C(O)- NR’R”, -C(O)-Ci_6alkyl, -C(O)-Ci.6alkoxy, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), NR’-S(O)W, -S(O)W-NR’R”(where w is 1, 2 or 3)), and C3.6cycloalkyl, and pharmaceutically acceptable salts thereof.
In some embodiments, Rc of a compound of formula 6 may be H or methyl, e.g., H; and/or R7 may be selected from H and F; and/or R6 may be selected from H and F; and/or R5 may be selected from H and F; and/or R10 may beselected from the group consisting of H, methyl and F; and/or R4, R5, R6, R7, R8, R9, R10, and R11 may be H.
In certain embodiments, the Y moiety of Formula 6 is S.
Provided herein, in certain embodiments, is a compound represented by:
wherein
Y is C(Rn)2 , S(O)y, NRy and O wherein y is 0, 1, or 2;
Ry is selected from the group consisting of H, methyl, ethyl, propyl, phenyl and benzyl;
Rm’ and Rm are each independently selected from the group consisting of H, halogen, Ci. 6alkyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), C2-6alkenyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), NR’R”, and hydroxyl(e.g., Rm and Rm may each be H in certain embodiments);
Rc is H or Ci-ôalkyl;
R78 is selected from the group consisting of H, halogen, hydroxyl, nitro, cyano, carboxy, Ci. 6alkyl, C2.6alkenyl, C2-6alkynyl, Ci.6alkoxy, NR’R”, -C(O)-Ci.6alkyl, -C(O)-Ci_6alkoxy, phenyl, heteroaryl, C3.6cycloaJ.kyl, -S(O)w-Ci.6alkyl (where w is 1, 2 or 3), -S(O)W-NR’R” (where w is 1,2 or 3), and -NR’-S(O)W, (where w is 1, 2 or 3));
R79 is selected from the group consisting of H, halogen, hydroxyl, nitro, cyano, carboxy, Ci. ealkyl, C2_6alkenyl, C2-6alkynyl, Ci.6alkoxy, NR’R”, -C(O)-Ci.6alkyl, -C(O)-Ci-6alkoxy, phenyl, heteroaryl, C3.6cycloalkyl, -S(O)w-Ci.6alkyl (where w is 1, 2 or 3), -S(O)W-NR’R” (where w is 1, 2 or 3), and -NR’-S(O)W, (where w is 1, 2 or 3));
R’ is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;
R” is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, C(O)-methyl and -C(O)-ethyl, or R’ and R’ ’ taken together with the nitrogen to which they are attached may form a 4-6 membered heterocycle;
each of moieties R4, R5, R6, R7, R8, R9, and R10 is independently selected for each occurrence from the group consisting ofhydrogen, Ci^alkyl, C2-6alkynyl, C2-6alkenyl, halogen, hydroxyl, nitro, cyano, andNR’R”;
wherein for each occurrence, Ci.galkyl may be optionally substituted with one, two, tihree or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C2-6alkenyl, C2-6alkynyl, Ci.6alkoxy, NR’R”, -NR’-S(O)Wj and S(O)W-NR’R”; Cj.6alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, NR’R”, -NR’-S(O)W> and S(O)W-NR’R”; C3. ôcycloalkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, Ci_6alkoxy, -C(O)-Ci.6alkyl, -C(O)-Ci.6alkoxy, and NR’R”; phenyl may be optionally substituted by one, two or tliree substituents each independently selected from the group consisting of halogen, hydroxyl, Ci.6alkyl, C2-6alkenyl, C2-6alkynyl, Ci.6alkoxy, NR’R”, C(O)-NR’R”, -C(O)-Ci-6alkyl, -C(O)-Ci_6alkoxy, S(O)w-Ci.6alkyl (where w is 1, 2 or 3), NR’-S(O)W, and -S(O)w-NR’R”(where w is 1, 2 or 3), and heteroaryl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci^alkyl, C2-6alkenyl, C2-6alkynyl, C3. ecycloalkyl, Ci.6alkoxy, NR’R”, C(O)- NR’R”, -C(O)-Ci.6alkyl, -C(O)-C^alkoxy, -S(O)w-Ci_ 6alkyl (where w is 1, 2 or 3), NR’-S(O)W, and -S(O)w-NR’R”(where w is 1, 2 or 3), and pharmaceutically acceptable salts thereof.
R° is H or methyl.
In certain embodiments, compound of formula 7 may hâve Rc as H; and/or R7 may be selected from H and F; and/or R6 may be selected from H and F; and/or R5 may be selected from H and F; and/or R10 may be selected from the group consisting of H, methyl and F; and/or each of R4, R5, R6, R7, R8, R9, R10, and R11 may be H.
For example, the présent disclosure also provides, in part, a compound selected from the group consisting a compound of Table 1, 2, 3, 4, 5, 6 and 7. Also contemplated herein are compounds: N((2-methylthiazol-5-yl)methyl)-l l-oxo-10,1 l-dihydrodibenzo[b,f][l,4]thiazepine-8-carboxamide 5oxide, N-((2-aminothiazol-5-yl)methyl)-l l-oxo-10,1 l-dihydrodibenzo[b,f|[l,4]thiazepine-8carboxamide 5-oxide, N-((2-methylthiazol-5-yl)methyl)-l l-oxo-10,11dihydrodibenzo[b,f][l,4]thiazepine-8-carboxamide 5,5-dioxide, N-((2-aminothiazol-5-yl)methyl)1 l-oxo-10,1 l-dihydrodibenzo[b,f][l,4]thiazepine-8-carboxamide 5,5-dioxide, 1 l-oxo-N-(2phenylbutyl)-10,l l-dihydrodibenzo[b,f][l,4]thiazepine-8-carboxamide 5,5-dioxide, N-(2-(4,4difhiorocyclohexyl)ethyl)-l l-oxo-10,1 l-dihydrodibenzo[b,f][l,4]thiazepine-8-carboxamide 5,5dioxide, 3'-(5,5-dioxido-l l-oxo-10,1 l-dihydrodibenzo[b,f][l,4]thiazepine-8-carboxamido)-[l,rbiphenyl]-2-carboxylic acid, 9-methyl-N-((2-methylthiazol-5-yl)methyl)-l l-oxo-10,11dihydrodibenzo[b,f] [1,4]thiazepine-8-carboxamide, N-(2-(4'-fluoro-[l, 1 -biphenyl]-4-yl)ethyl)-11oxo-10,1 l-dihydrodibenzo[b,f][l,4]thiazepine-8-carboxamide 5,5-dioxide, N-((2-aminothiazol-5yl)methyl)-9-methyl-l l-oxo-10,1 l-dihydrodibenzo[b,f][l,4]thiazepine-8-carboxamide, 11-oxo-N(pyrimidin-5-ylmethyl)-10,l l-dihydro-5H-dibenzo[b,e][l,4]diazepine-8-carboxamide, 1 l-oxo-N-(2(pyridin-2-yl)ethyl)-10,l l-dihydro-5H-dibenzo[b,e][l,4]diazepine-8-carboxamide, 1 l-oxo-N-(2(pyridin-3-yl)ethyl)-10,l l-dihydro-5H-dibenzo[b,e][l,4]diazepine-8-carboxamide, 11-oxo-N(pyridin-3 -ylmethyl)-10,11 -dihydro-5H-dibenzo[b,e] [ 1,4]diazepine-8-carboxamide, N-(2-([ 1, Γbiphenyl]-4-yl)ethyl)-l l-oxo-10,1 l-dihydro-5H-dibenzo[b,e][l,4]diazepine-8-carboxamide, 11-oxoN-(pyridin-4-yl)-10,11 -dihydro-5H-dibenzo[b,e] [ 1,4]diazepine-8-carboxamide, N-(4-(N,Ndimethylsulfamoyl)phenethyl)-11 -oxo-10,11 -dihydro-5H-dibenzo[b,e] [1,4]diazepine-8carboxamide, N-([l,l'-biphenyl]-3-yl)-ll-oxo-10,1 l-dihydro-5H-dibenzo[b,e][l,4]diazepine-8carboxamide, (Z)-N-((3-(methylimino)prop-l-en-2-yl)oxy)-l l-oxo-10,11dihydrodibenzo[b,f][l,4]thiazepine-8-carboxamide, 1 l-oxo-N-(pyrimidin-5-yloxy)-10,l 1dihydrodibenzo[b,f] [ 1,4]thiazepine-8-carboxamide, 1 l-oxo-N-(4-(pyrimidin-5-yl)benzyl)-10,1125 dihydrodibenzo[b,f] [ 1,4]thiazepine-8-carboxamide,N-(2-(4'-fluoro-[ 1,1 -biphenyl]-4-yl)ethyl)-11 oxo-10,ll-dihydrodibenzo[b,f][l,4]thiazepine-8-carboxamide,2-chloro-N-((2-methylthiazol-5yl)methyl)-l l-oxo-10,1 l-dihydrodibenzo[b,f][l,4]thiazepine-8-carboxamide,2-chloro-l 1-oxo-N(pyridin-3-ylmethyl)-10,ll-dihydrodibenzo[b,f][l,4]thiazepine-8-carboxamide, 2-chloro-l 1-oxo-N(pyrimidin-5-ylmethyl)-10,11 -dihydrodibenzo[b,f][l,4]thiazepine-8-carboxamide, 3-chloro-N-((2methylthiazol-5-yl)methyl)-11 -oxo-10,11 -dihydrodibenzo[b,f] [ 1,4]thiazepine-8-carboxamide,3chloro-ll-oxo-N-(pyridin-3-ylmethyl)-10,ll-dihydrodibenzo[b,f][l,4]thiazepine-8-carboxamide, 3chloro-11 -oxo-N-(pyrimidin-5-ylmethyl)-10,11 -dihydrodibenzo[b,fj [ 1,4]thiazepine-8-carboxamide, ll-methyl-N-((2-methylthiazol-5-yl)methyl)-6-oxo-6,ll-dihydro-5H-dibenzo[b,e]azepine-3carboxamide, 1 l-methyl-6-oxo-N-(pyridin-3-ylmethyl)-6,l l-dihydro-5H-dibenzo[b,e]azepine-3carboxamide, 1 l-methyl-6-oxo-N-(pyrimidin-5-ylmethyl)-6,l l-dihydro-5H-dibenzo[b,e]azepine-3carboxamide, 2-chloro-l l-oxo-N-(thiazol-5-ylmethyl)-10,ll-dihydrodibenzo[b,f][l,4]thiazepine-8carboxamide, 3-chloro-ll-oxo-N-(thiazol-5-ylmethyl)-10,ll-dihydrodibenzo[b,f][l,4]thiazepine-8carboxamide, 1 l-methyl-6-oxo-N-(thiazol-5-ylmethyl)-6,l l-dihydro-5H-dibenzo[b,e]azepine-3carboxamide, and ll-oxo-N-(2-(thiazol-5-yl)propan-2-yl)-10,lldihydrodibenzo[b,f|[l,4]thiazepine-8-carboxamide;
or a pharmaceutically acceptable sait thereof.
In a second aspect, a method for the synthesis of disclosed compounds is provided. The method foliows Synthetic Scheme 1, as illustrated in FIG. 1. A first mixture comprising reagents 1 and 2 is formed for synthetic step A to yield synthetic intermediate 3. Synthetic step A may be conducted in an organic solvent, for instance a polar aprotic solvent such as dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dioxane, hexamethylphosphorotriamide, and tetrahydrofuran. The reaction may be conducted in the presence of a base, for example a carbonate such as IÂ2CO3, Na2CO3, K2CO3, Rb2CO3, Cs2CO3, MgCO3, CaCO3, SrCO3, and BaCO3.
In reagent 1, moiety-YH is selected from the group consisting of-SH, -OH, and -N(R12)H, wherein R12 is selected from the group consisting of hydrogen and alkyl. In intermediates 3, 4, 5, and in product 6, moiety-Y- is selected from the group consisting of-S-, -O-, and -N(R12)-. Moieties P1 and P2 are independently selected carboxyl protecting groups, such as methoxyl or ethoxyl groups. In some cases, at least one of P3 and P4 is an amino protecting group, for example selected from the group consisting of carbobenzyloxy (Cbz), p-methoxybenzyl-carbonyl (Moz or 26
MeOZ), tert-butyloxycarbonyl (BOC), 9-fluorenylmethyloxycarbonyl (FMOC), acetyl (Ac), benzoyl (Bz), benzyl (Bn), carbamate group, p-Methoxybenzyl (PMB), 3,4-dimethoxybenzyl (DMPM), pmethoxyphenyl (PMP), tosyl (Ts), sulfonamides (Nosyl andNps). Alternatively, moiety-N(P3)(P4) may be a group that can be transformed in an amino group by appropriate chemical reactions. By way of example, moiety -N(P3)(P4) may be an -NO2 group that is transformed into an amino (NH2) moiety by reaction with a reductant.
In synthetic step B, protecting groups P1 and P2 are removed to yield carboxyl moieties. In instances where P1 and P2 are alkoxy groups, this may be achieved by hydrolysis, for example in the presence of a base or acid. Group -N(P3)(P4) is transformed into an amino moiety, as exemplified above, to yield intermediate 4. In synthetic step C, the amino group of intermediate 4 is reacted with the carboxy group on the other phenyl moiety, forming the l,4-thiazepan-5-one moiety of intermediate 5. The formation of this amide bond may be speeded up by the addition of activators. Example activators include carbodiimides, such as Ν,Ν'-dicyclohexylcarbodiimide (DCC), N,N'diisopropylcarbodiimide (DIC), and carbonyl diimidazole (CDI); and triazolols, such as 1-hydroxybenzotriazole (HOBt) and l-hydroxy-7-aza-benzotriazole (HOAt). Other activators include HBTU, HATU, HCTU, TBTU, and PyBOP.
In synthetic step D, intermediate 5 is reacted with a molécule of formula R2NH2 to create an amide bond and yield products of Formula 6. As with synthetic step C, the formation of the amide bond may be speeded up with an activator. An exemplary Synthetic Scheme is illustrated in FIG. 2.
In a further aspect, a method for treating a hepatitis B infection in a patient in need thereof is provided, comprising administering to a subject or patient an effective amount of a disclosed compound, and/or administering a first disclosed compound and optionally, and additional, different disclosed compound(s). In another embodiment, a method for treating a hepatitis B infection in a patient in need thereof is provided, comprising administering to a subject or patient a therapeutically effective amount of a pharmaceutical composition comprising a disclosed compound, or two or more disclosed compounds.
For use in accordance with this aspect, the appropriate dosage is expected to vary depending on, for example, the particular compound employed, the mode of administration, and the nature and severity of the infection to be treated as well as the spécifie infection to be treated and is within the purview of the treating physician. Usually, an indicated administration dose may be in the range between about 0.1 to about 1000 pg/kg body weight. In some cases, the administration dose of the compound may be less than 400 pg/kg body weight. In other cases, the administration dose may be less than 200 pg/kg body weight. In yet other cases, the administration dose may be in the range between about 0.1 to about 100 pg/kg body weight. The dose may be conveniently administered once daily, or in divided doses up to, for example, four times a day or in sustained release form.
A compound may be administered by any conventional route, in particular: enterally, topically, orally, nasally, e.g. in the form of tablets or capsules, via suppositories, or parenterally, e.g. in the form of injectable solutions or suspensions, for intravenous, intra-muscular, sub-cutaneous, or intraperitoneal injection. Suitable formulations and pharmaceutical compositions will include those formulated in a conventional manner using one or more physiologically acceptable carriers or excipients, and any of those known and commercially available and currently employed in the clinical setting. Thus, the compounds may be formulated for oral, buccal, topical, parentéral, rectal or transdermal administration or in a form suitable for administration by inhalation or insufflation (either orally or nasally).
For oral administration, pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnésium stéarate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate). Tablets may be coated by methods well known in the art. Liquid préparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid préparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose dérivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid). Préparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
Préparations for oral administration may also be suitably formulated to give controlled-release or sustained release of the active compound(s) over an extended period. For buccal administration the compositions may take the form of tablets or lozenges formulated in a conventional manner known to the skilled artisan.
A disclosed compound may also be formulated for parentéral administration by injection e.g. by bolus injection or continuons infusion. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or émulsions in oily or aqueous vehicles, and may contain additives such as suspending, stabilizing and/or dispersing agents. Alternatively, the compound may be in powder form for constitution with a suitable vehicle, e.g. stérile pyrogen-free water, before use. Compounds may also be formulated for rectal administration as suppositories or rétention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
In some cases, a disclosed compound may be administered as part of a combination therapy in conjunction with one or more antivirals. Example antivirals include nucleoside analogs, interferon a, and other assembly effectors, for instance heteroaryldihydropyrimidines (HAPs) such as methyl 4-(2-chloro-4-fluorophenyl)-6-methyl-2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate (HAP1). For example, provided herein is a method of treating patient suffering from hepatitis B comprising administering to a subject a first amount of a disclosed compound and a second amount of an antiviral, or other anti HBV agent, for example a second amount of a second compound selected from the group consisting of: another HBV caspid assembly promoter (such as certain compounds disclosed herein or for example, GLS4, BAY 41-4109, AT-130, DVR-23 (e.g., as depicted below),
DVR-23
NVR 3-778, NVR1221 (by code); and N890 (as depicted below):
OH other CpAMs such as those disclosed in the following patent applications hereby incorporated by reference: W02014037480, WO2014184328, W02013006394, WO2014089296, W02014106019, WO2013102655, WO2014184350, WO2014184365, WO2014161888, WO2014131847,
WO2014033176, WO2014033167, and W02014033170; Nucleoside analogs interfering with viral polymerase, such as entecavir (Baraclude), Lamivudine, (Epivir-HBV), Telbivudine (Tyzeka, Sebivo), Adefovir dipivoxil (Hepsera), Tenofovir (Viread), Tenofovir alafenamide fumarate (TAF), prodrugs of tenofavir (e.g. AGX-1009), L-FMAU (Clevudine), LB80380 (Besifovir) and:
viral entry inhibitors such as Myrcludex B and related lipopeptide dérivatives; HBsAg sécrétion inhibitors such as REP 9AC’ and related nucleic acid-based amphipathic polymers, HBF-0529 (PBHBV-001), PBHBV-2-15 as depicted below: :
disruptors of nucleocapsid formation or integrity such as NZ-4/W28F:
cccDNA formation inhibitors: such as BSBI-25, CCC-0346, CCC-0975 (as depicted below):
HBc directed transbodies such as those described in Wang Y, et al, Transbody against hepatitis B virus core protein inhibits hepatitis B virus réplication in vitro, Int. Immunopharmacol (2014), located at //dx.doi.org/10.1016/j.intimp .2015.01.028; antiviral core protein mutant (such as Cpl83V124W and related mutations as described in WO/2013/010069, W02014/074906 each incorporated by reference ); inhibitors of HBx-interactions such as RNAi, antisense and nucleic acid based polymère targeting HBV RNA;, e.g., RNAi (for example ALN-HBV, ARC-520, TKM-HBV, ddRNAi), antisense (ISIS-HBV), or nucleic acid based polymer: (REP 2139-Ca); immunostimulants such as Interferon alpha 2a (Roferon), Intron A (interferon alpha 2b), Pegasys (peginterferon alpha 2a), Pegylated IFN 2b, IFN lambda la and PEG IFN lambda la, Wellferon, Roferon, Infergen, lymphotoxin beta agonists such as CBE11 and BS1); Non-Interferon Immune enhancers such as Thymosin alpha-1 (Zadaxin) and Interleukin-7 (CYT107); TLR-7/9 agonists such as GS-9620, CYT003, Resiquimod; Cyclophilin Inhibitors such as NVP018; OCB-030; SCY-635; Alisporivir; NIM811 and related cyclosporine analogs; vaccines such as GS-4774, TGI050, Core antigen vaccine; SMAC mimetics such as birinapant and other LAP-antagonists; Epigenetic modulators such as KMT inhibitors (EZH1/2, G9a, SETD7, Suv39 inhibitors), PRMT inhibitors, HDAC inhibitors, SIRT agonists, HAT inhibitors, WD antagoniste (e.g. OICR-9429), PARP inhibitors, APE inhibitors, DNMT inhibitors, LSD1 inhibitors, JMJD HDM inhibitors, and Bromodomain antagonists; kinase inhibitors such as TKB1 antagoniste, PLK1 inhibitors, SRPK inhibitors, CDK2 inhibitors, ATM & ATR kinase inhibitors; STING Agonists; Ribavirin; N-acetyl cysteine ; NOV-205 (BAM205); Nitazoxanide (Alinia), Tizoxanide; SB 9200 Small Molécule
Nucleic Acid Hybrid (SMNH); DV-601; Arbidol; FXR agonists (such as GW 4064 and Fexaramin); antibodies, therapeutic proteins, gene therapy, and biologics directed against viral components or interacting host proteins.
In some embodiments, the first and second amounts together comprise a pharmaceutically effective amount. The first amount, the second amount, or both may be the same, more, or less than effective amounts of each compound administered as monotherapies. Therapeutically effective amounts of a disclosed compound and antiviral may be co-administered to the subject, i.e., administered to the subject simultaneously or separately, in any given order and by the same or different routes of administration. In some instances, it may be advantageous to initiate administration of a disclosed compound first, for example one or more days or weeks prior to initiation of administration of the antiviral. Moreover, additional drugs may be given in conjunction with the above combination therapy.
In another embodiment, a disclosed compound may be conjugated (e.g., covalently bound directly or through molecular linker to a free carbon, nitrogen (e.g. an amino group), or oxygen (e.g. an active ester) of a disclosed compound), with a détection moiety, e.g. a fluorophore moiety (such a moiety may for example re-emit a certain light frequency upon binding to a virus and/or upon photon excitation. Contemplated fluorophores include AlexaFluor® 488 (Invitrogen) and BODIPY FL (Invitrogen), as well as fluorescein, rhodamine, cyanine, indocarbocyanine, anthraquinones, fluorescent proteins, aminocoumarin, methoxycoumarin, hydrooxycoumarin, Cy2, Cy3, and the like. Such disclosed compounds conjugated to a détection moiety may be used in e.g. a method for detecting HBV or biological pathways of HBV infection, e.g., in vitro or in vivo', and/or methods of assessing new compounds for biological activity.
EXAMPLES
The compounds described herein can be prepared in a number of ways based on the teachings contained herein and synthetic procedures known in the art. In the description of the synthetic methods described below, it is to be understood that ail proposed reaction conditions, including choice of solvent, reaction atmosphère, reaction température, duration of the experiment and workup procedures, can be chosen to be the conditions standard for that reaction, unless otherwise indicated. It is understood by one skilled in the art of organic synthesis that the functionality présent on various portions of the molécule should be compatible with the reagents and reactions proposed. Substituents not compatible with the reaction conditions will be apparent to one skilled in the art, and altemate methods are therefore indicated. The starting materials for the examples are either commercially available or are readily prepared by standard methods from known materials.
Example 1: Synthesis of ll-oxo-10,11-dihydrodibenzo [A f\ [1,41 thiazepine-8-carboxylic acid (6) - a common intermediate
Synthesis of methyl 4-((2-(methoxycarbonyl) phenyl) thio)-3-nitrobenzoate (3):
To a stirred solution of methyl 4-fluoro-3-nitrobenzoate 2 (30 g, 150.67 mmol) in DMF (300 mL) under inert atmosphère were added césium carbonate (58.76 g, 180.8 mmol) and methyl 2mercaptobenzoate 1 (22.6 mL, 165.47 mmol) at RT; heated to 55-60 °C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (1500 mL) and the precipitated solid was filtered to obtain the crude. The crude was washed with water (500 mL), hexane (200 mL) and dried in vacuo to afford compound 3 (48.8 g, 93%) as yellow solid. TLC: 20% EtOAc/ hexanes (Rf. 0.4); 1H NMR (CDCI3, 400 MHz): δ 8.85 (s, 1H), 7.99-7.92 (m, 2H), 7.66-7.56 (m, 3H), 6.93 (d, J= 8.6 Hz, 1H), 3.94 (s, 3H), 3.79 (s, 3H).
Synthesis of methyl 3-amino-4-((2-(methoxycarbonyl) phenyl) thio) benzoate (4):
To a stirred solution of compound 3 (48 g, 138.32 mmol) in MeOH (1000 mL) under inert atmosphère was added 10% Pd/C (20 g, wet) at RT under hydrogen atmosphère in an autoclave (100 psi pressure) and stirred for 24 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite, washed with 50% MeOH/ CH2CI2 (500 mL). The filtrate was removed in vacuo to obtain the crude which as triturated with diethyl ether (200 mL), washed with hexane (200 mL) and dried in vacuo to afford compound 4 (40 g, 91%) as yellow solid. TLC: 10% EtOAc/ hexanes (R/ 0.3); XH NMR (DMSO-^, 400 MHz): δ 7.95 (dd, J= 7.8, 1.4 Hz, 1H), 7.48-7.35 (m, 3H), 7.23 (td, J= 7.5, 1.1 Hz, 1H), 7.15 (dd, J= 8.0, 1.8 Hz, 1H), 6.66 (dd, 8.2, 0.8 Hz, 1H), 5.67 (br s, 2H), 3.88 (s, 3H), 3.84 (s, 3H).
Synthesis of 3-amino-4-((2-carboxyphenyI) thio) benzoic acid (5):
To a stirred solution of compound 4 (40 g, 126.18 mmol) in THF: H2O (5: 1, 400 mL) was added lithium hydroxide monohydrate (26 g, 619.0 mmol) at 0 C; warmed to RT and stirred for 48 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The pH of the residue was acidifîed with 2 N HCl to ~2. The precipitated solid was filtered and dried in vacuo to afford compound 5 (34.6 g, 95%) as an off-white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.1); XH NMR (DMSO-rftf, 500 MHz): δ 13.00 (br s, 2H), 7.93 (dd, J= Ί.Ί, 1.0 Hz, 1H), 7.42 (s, 1H), 7.40-7.31 (m, 2H), 7.18 (t, J= 7.4 Hz, 1H), 7.13 (dd, J= 8.0, 1.6 Hz, 1H), 6.61 (d, J= 7.8 Hz, 1H), 5.55 (br s, 2H).
Synthesis of ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-carboxylic acid (6):
To a stirred solution of compound 5 (31 g, 107.26 mmol) in THF (600 mL) under inert atmosphère was added CDI (86.88 g, 536.29 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was acidifïed with 2 N 5 HCl to pH~4. The obtained solid was filtered and further dried by using toluene (2 x 200 mL) to afford compound 6 (26 g, 90%) as white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.3); *H NMR (DMSO-rf6, 400 MHz): δ 13.22 (br s, 1H), 10.81 (s, 1H), 7.78 (s, 1H), 7.72-7.64 (m, 3H), 7.57-7.44 (m, 3H).
Example 2: Synthesis of 2-chloro-ll-oxo-10,11-dihydrodibenzo [6, f\ fl, 41 thiazepine-810 carboxylic acid (14) - a common intermediate
Synthesis of 5-chloro-2-((4-methoxybenzyl) thio) benzonitrile (9):
To a stirred solution of 5-chloro-2-fluorobenzonitrile 7 (1 g, 6.41 mmol) in DMF (10 mL) under inert atmosphère was added césium carbonate (2.30 g, 7.05 mmol) at RT; heated to 40 °C and to this was added (4-methoxyphenyl) methanethiol 8 (1.08 g, 7.05 mmol); heated to 60 C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 3-5% EtOAc/ hexanes to afford compound 9 (1 g, 54%) as white solid. TLC: 10% EtOAc/ hexanes (Rf. 0.6); ^-NMR (CDC13, 500 MHz): δ 7.57 (s, 1H), 7.39 (d, J= 8.0 Hz, 1H), 7.28-7.27 (m, 1H), 7.20 (d, J= 9.0 Hz, 2H), 6.81 (d, J= 9.0 Hz, 2H), 4.15 (s, 2H), 3.78 (s, 3H).
Synthesis of 5-chloro-2-mercaptobenzonitrile (10):
A stirred solution of compound 9 (1 g, 3.47 mmol) in trifluoro acetic acid (10 mL) under inert atmosphère was stirred at 70 C for 5 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude compound 10 (590 mg) which was carried to the next step without further purification. TLC: 30% EtOAc/ hexanes (Rf. 0.2); ’H-NMR (CDC13, 500 MHz): δ 7.57 (s, 1H), 7.41 (d, J= 9.0 Hz, 1H), 7.34 (d, J= 9.0 Hz, 1H), 4.08 (s, 1H).
Synthesis of methyl 4-((4-chloro-2-cyanophenyl) thio)-3-nitrobenzoate (11):
To a stirred solution of compound 10 (620 mg, 3.11 mmol) in DMF (10 mL) under inert atmosphère was added césium carbonate (1.1 g, 3.42 mmol) at RT; heated to 40 °C and stirred for 10 min. To this was added methyl 4-fluoro-3-nitrobenzoate 2 (582 mg, 3.42 mmol) at 60 C and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over sodium sulfate, fïltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 25% EtOAc/ hexanes to afford compound 11 (600 mg, 55%) as pale yellow solid. TLC: 30% EtOAc/ hexanes (Rf. 0.4); ’lI-NMR (DMSO-ify, 400 MHz): δ 8.66 (s, 1H), 8.33 (s, 1H), 8.05-8.03 (m, 1H), 7.98-7.92 (m, 2H), 7.02 (d, 7= 8.4 Hz, 1H), 3.86(s, 3H).
Synthesis of methyl 3-amino-4-((4-chloro-2-cyanophenyl) thio) benzoate (12):
To a stirred solution of compound 11 (450 mg, 1.29 mmol) in acetic acid (15 mL) under inert atmosphère was added iron powder (724 mg, 12.9 mmol) at RT; heated to 90 C and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was basified with saturated NaHCC>3 solution (15 mL) and extracted with CH2CI2 (2 x 20 mL). The combined organic extracts were dried over sodium sulfate, fïltered and concentrated in vacuo to obtain the crude. The crude was triturated with 3% EtOAc/ hexanes (2x5 mL) to afford compound 12 (290 mg, 70%) as pale yellow solid. TLC: 20% MeOH/ CH2CI2 (Rf 0.7); Tl-NMR (DMSO-rf6, 400 MHz): δ 8.05 (s, 1H), 7.63-7.60 (m, 1H), 7.48 (s, 1H), 7.43 (d, J= 8.0 Hz, 1H), 7.14 (d, J= 8.8 Hz, 1H), 6.75 (d, J= 8.8 Hz, 1H), 5.88 (s, 2H), 3.84 (s, 3H).
Synthesis of 2-((2-amino-4-carboxyphenyI) thio)-5-chIorobenzoic acid (13):
co2h
To a stirred solution of compound 12 (450 mg, 1.41 mmol) in MeOH (10 mL) was added potassium hydroxide (792 mg, 14.1 mmol) in water (3 mL) at 0 °C; heated to 90 C and stirred for 9 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was acidified with 1 N HCl to pH~4.0. The obtained solid was filtered, washed with ether (2x5 mL) and dried in vacuo to afford compound 13 (350 mg, 76%) as an off-white solid. TLC: 20% MeOH/ CH2C12 (Rf. 0.3); *H-NMR (DMS(Wd, 400 MHz): δ 12.92 (br s, 2H), 7.89 (s, 1H), 7.44-7.38 (m, 3H), 7.14 (d, J= 8.8 Hz, 1H), 6.60 (d, J= 8.8 Hz, 1H), 5.64 (br s, 2H).
Synthesis of 2-chloro-ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-carboxyIic acid (14):
To a stirred solution of compound 13 (30 mg, 0.09 mmol) in THF (2 mL) under inert atmosphère was added CDI (45 mg, 0.27 mmol) at RT and stirred for 7 h. The reaction was monitored by TLC;
after completion of the reaction, the volatiles were removed in vacuo. The residue was acidified with 2 N HCl to pH~4.0. The obtained solid was filtered, washed with ether (2x3 mL) and dried in vacuo to afford compound 14 (15 mg, 53%) as an off-white solid. TLC: 15% MeOH/ CH2C12 (Rf.
0.5); *H-NMR (DMSO-i/tf, 400 MHz): δ 13.05 (br s, 1H), 10.98 (s, 1H), 7.80 (s, 1H), 7.72-7.70 (m, 3H), 7.64 (s, 2H).
Example 3: Synthesis of 3-chloro-ll-oxo-10,11-dihydrodibenzo [/>, /1 [1, 4] thiazepine-8carboxylic acid (21) - a common intermediate
Synthesis of 4-chloro-2-((4-methoxybenzyI) thio) benzonitrile (16):
To a stirred solution of 4-chloro-2-fluorobenzonitrile 15 (1 g, 6.41 nunol) in DMF (25 mL) under inert atmosphère was added césium carbonate (2.30 g, 7.05 mmol) at RT; heated to 40 C and to this was added (4-methoxyphenyl) methanethiol 8 (1.08 g, 7.05 mmol); heated to 60 C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 4% EtOAc/ hexanes to afford compound 16 (900 mg, 48%) as white solid. TLC: 10% EtOAc/ hexanes (Rf. 0.6); 1H-NMR (CDC13, 400 MHz): δ 7.51 (d, J= 8.4 Hz, 1H), 7.33 (s, 1H), 7.23-7.20 (m, 3H), 6.84 (d, J= 8.4 Hz, 2H), 4.19 (s, 2H), 3.79 (s, 3H).
Synthesis of 4-chloro-2-mercaptobenzonitrile (17):
A stirred solution of compound 16 (900 mg, 3.11 mmol) in trifluoro acetic acid (10 mL) under inert atmosphère at RT was heated to 70 °C and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude compound 17 (527 mg) as brown solid. The crude was carried to the next step without further purification. TLC: 5% MeOH/ CH2C12 (Rf. 0.1); ’H-NMR (CDC13, 400 MHz): δ 7.52 (d, J= 8.4 Hz, 1H), 7.41 (s, 1H), 7.22-7.19 (m, 1H), 4.13 (s, 1H).
Synthesis of methyl 4-((5-chloro-2-cyanophenyl) thio)-3-nitrobenzoate (18):
To a stirred solution of compound 17 (550 mg, 2.76 mmol) in DMF (15 mL) under inert atmosphère was added césium carbonate (988 mg, 3.04 mmol) at RT; heated to 40 °C and stirred for 10 min. To o
this was added methyl 4-fluoro-3-nitrobenzoate 2 (515 mg, 3.04 mmol) at 60 C and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL). The obtained solid was fîltered, washed with 15% EtOAc/ hexanes (2 x mL) and dried in vacuo to afford compound 18 (700 mg, 73%) as yellow solid. TLC: 20%
EtOAc/ hexanes (Rf. 0.3); ^-NMR (DMSO-<4, 500 MHz): δ 8.69 (s, 1H), 8.18-8.15 (m, 2H), 8.10 (d, J= 8.5 Hz, 1H), 7.92 (d, J= 8.5 Hz, 1H), 7.10 (d, J= 9.0 Hz, 1H), 3.90 (s, 3H).
Synthesis of methyl 3-amino-4-((5-chloro-2-cyanophenyI) thio) benzoate (19):
To a stirred solution of compound 18 (700 mg, 2.01 mmol) in acetic acid (15 mL) under inert atmosphère was added iron powder (1.12 g, 20.11 mmol) at RT; heated to 90 C and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was basified with 10% NaHCO3 solution (20 mL) and extracted with CH2C12 (2 x 30 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 19 (500 mg, 78%) as yellow solid. TLC: 30%
EtOAc/ hexanes (Rf 0.8); 'ïï-NMR (DMSO-<4, 500 MHz): δ 7.92 (d, J= 7.5 Hz, 1H), 7.51-7.43 (m, 3H), 7.17 (d, J= 8.0 Hz, 1H), 6.66 (s, 1H), 5.96 (s, 2H), 3.86 (s, 3H).
Synthesis of 2-((2-amino-4-carboxyphenyI) thio)-4-chlorobenzoic acid (20):
To a stirred solution of compound 19 (500 mg, 1.57 mmol) in MeOH (6 mL) was added potassium hydroxide (1.32 mg, 23.5 mmol) in water (6 mL) at 0 °C; heated to 90 C and stirred for 24 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (20 mL) and extracted with EtOAc (2 x 25 mL). The aqueous layer was acidified with 1 N HCl to pH~6.0. The obtained solid was filtered, washed with ether (2x7 mL) and dried in vacuo to afford compound 20 (375 mg, 74%) as an off-white solid. TLC: 20% MeOH/ CH2C12 (Rf. 0.2); ’H-NMR (CDCI3j 400 MHz): δ 8.05 (d, J= 8.4 Hz, 1H), 7.55-7.47 (m, 3H), 7.17-7.14 (m, 1H), 6.67 (s, 1H).
Synthesis of 3-chloro-ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-carboxylic acid (21):
To a stirred solution of compound 20 (375 mg, 1.16 mmol) in THF (10 mL) under inert atmosphère was added CDI (564 mg, 3.48 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (15 mL) and acidified with 6 N HCl to pH~1.0. The obtained solid was filtered, washed with ether (2x5 mL) and dried in vacuo to afford compound 21 (285 mg, 81%) as an off-white solid. TLC: 20% MeOH/ CH2C12 (Rf. 0.4); ’H-NMR (DMSO-î/6, 400 MHz): δ 14.56 (br s, 2H), 10.90 (s, 1H), 9.11 (s, 1H), 7.71-7.65 (m, 4H).
Example 4: Synthesis of l-fluoro-ll-oxo-10,11-dihydrodibenzo \b, f\ [1, 4] thiazepine-8carboxylic acid (28) - a common intermediate
Synthesis of methyl 2-fluoro-6-((4-methoxybenzyl) thio) benzoate (23):
To a stirred solution of methyl 2, 6-difluorobenzoate 22 (10 g, 58.13 mmol) in DMF (100 mL) under inert atmosphère were added (4-methoxyphenyl) methanethiol 8 (8.96 g, 58.13 mmol), césium carbonate (20.8 g, 63.95 mmol) at 0 °C; warmed to 10 C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water 10 (200 mL) and extracted with EtOAc (2 x 800 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacno to obtain the crude. The crude was purified through silica gel column chromatography using 10-15% EtOAc/ hexanes to afford compound 23 (7.5 g, 42%) as white solid. TLC: 10% EtOAc/ hexanes^/ 0.3); NMR (DMSO-î/6, 400 MHz) δ
7.53-7.44 (m, 1H), 7.35 (d, J= 8.0 Hz, 1H), 7.26 (d, J= 8.6 Hz, 2H), 7.15 (t, J= 9.0 Hz, 1H), 6.86 (d, J= 8.7 Hz, 2H), 4.22 (s, 2H), 3.72 (s, 3H), 3.33 (s, 3H).
Synthesis of methyl 2-fluoro-6-mercaptobenzoate (24):
A stirred solution of compound 23 (7.5 g, 24.5 mmol) in trifluoro acetic acid (100 mL) at RT under inert atmosphère was heated to 60-65 C and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed and dried in vacuo to obtain compound 24 (4.6 g) as brown syrup. The crude was carried forward for next step without further purification. TLC: 10% EtOAc/ hexanes (Rf. 0.7).
Synthesis of methyl 2-fluoro-6-((4-(methoxycarbonyl)-2-nitrophenyl) thio) benzoate (25):
To a stirred solution of methyl 4-fluoro-3-nitrobenzoate 2 (4.5 g, 22.61 mmol) in DMF (100 mL) under inert atmosphère were added compound 24 (4.6 g, crude), césium carbonate (11 g, 33.91 mmol) at RT; heated to 60-65 °C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (600 mL) and stirred for 1 h. The precipitated solid was filtered, titurated with 10% EtOAc/ hexanes(2 x 20 mL) and dried in vacuo to afford compound 25 (7 g, 85%) as yellow solid. TLC: 20% EtOAc/ hexanes (Rf. 0.3); 1H NMR (DMSO-îZ6, 400 MHz): δ 8.65 (s, 1H), 8.08 (dd, J= 8.6, 1.9 Hz, 1H), 7.79-7.72 (m, 1H), 7.67-7.61 (m, 2H), 7.01 (d, J= 8.6 Hz, 1H), 3.88 (s, 3H), 3.72 (s, 3H).
Synthesis of methyl 2-((2-amino-4-(methoxycarbonyl) phenyl) thio)-6-fluorobenzoate (26):
To a stirred solution of compound 25 (7.09 g, 19.17 mmol) in MeOH (200 mL) under inert atmosphère was added 10% Pd/ C (3.5 g) at RT and stirred under hydrogen at 80 psi for 16 h in an autoclave. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite and washed with 40% MeOH/ CH2CI2 (3 x 500 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude compound was triturated with 20% EtOAc/ hexanes (200 mL) and dried in vacuo to afford compound 26 (5 g, 78%) as an off-white solid. TLC: 20% EtOAc/ hexanes (Rf 0.4); *H NMR (DMSO-é?6, 400 MHz): δ 7.45-7.36 (m, 3H), 7.19-7.11 (m, 2H), 6.68 (d, J= 7.7 Hz, 1H), 5.71 (s, 2H), 3.90 (s, 3H), 3.83 (s, 3H).
Synthesis of 2-((2-amino-4-carboxyphenyl) thio)-6-fluorobenzoic acid (27):
To a stirred solution of compound 26 (5 g, 14.92 mmol) in THF: H2O (5: 1, 90 mL) was added lithium hydroxide monohydrate (3.13 g, 74.62 mmol) at RT and stirred for 16 h and heated to 80 C for 5 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (200 mL) and acidified with 2 N HCl to pH~4. The precipitated solid was filtered and dried in vacuo to afford compound 27 (4 g, 87%) as an off-white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.1); *H NMR (DMSO-J6,400 MHz): δ 12.89 (br s, 1H), 7.42-7.36 (m, 2H), 7.35-7.31 (m, 1H), 7.14 -7.08 (m, 2H), 6.63 (d, J= 8.0 Hz, 1H), 5.75 (br s,2H).
Synthesis of l-fluoro-ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-carboxylic acid (28):
To a stirred solution of compound 27 (4 g, 13.02 mmol) in THF (100 mL) under inert atmosphère was added CDI (10.56 g, 65.1 mmol) at RT and stirred for 26 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted 5 with ice cold water (80 mL) and acidified with 2 N HCl to pH~4. The precipitated solid was filtered and dried in vacuo to afford compound 28 (3.3 g, 88%) as an off-white solid. TLC: 15% MeOH/ CH2C12 (Rf. 0.2); JH NMR (DMSO-rZd, 400 MHz): δ 13.33 (br s, 2H), 11.00 (s, 1H), 7.77 (s, 1H), 7.69-7.67 (m, 2H), 7.53-7.47 (m, 1H), 7.42-7.39 (m, 1H), 7.35-7.29 (m, 1H).
Example 5: Synthesis of 2-fluoro-ll-oxo-10,11-dihydrodibenzo |7x f\ fl, 41 thiazepine-810 carboxylic acid (35) - a common intermediate
Synthesis of methyl-5-fluoro-2-((4-methoxybenzyl) thio) benzoate (30):
To a stirred solution of methyl 2, 5-difluorobenzoate 29 (1 g, 5.80 mmol) in DMF (20 mL) under argon atmosphère were added (4-methoxyphenyl) methanethiol 8 (985 mg, 6.39 mmol), césium carbonate (2.07 g, 6.39 mmol) at RT and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (30 mL) and extracted with CH2CI2 (2x30 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 5-7% EtOAc/ hexanes to afford compound 30 (700 mg, 40%) as white solid. TLC: 10% EtOAc/hexanes (Rf Q3)·, *H-NMR (CDC13, 400 MHz): δ 7.64-7.61 (m, 1H), 7.32-7.29 (m, 3H), 7.17-7.09 (m, 1H), 6.86-6.82 (m, 2H), 4.09 (s, 2H), 3.90 (s, 3H), 3.79 (s, 3H).
Synthesis of methyl 5-fluoro-2-mercaptobenzoate (31):
A stirred solution of compound 30 (700 mg, 2.28 mmol) in trifluoro acetic acid (7 mL) at RT under argon atmosphère was heated to 60-65 °C and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed and dried in vacuo to obtain compound 31 (380 mg, 89%) as brown syrup. TLC: 10% EtOAc/ hexanes (Rf. 0.7); ’H-NMR (DMSO-r/g, 400 MHz): δ 7.70-7.58 (m, 2H), 7.42-7.35 (m, 1H), 5.42 (s, 1H), 3.86 (s, 3H).
Synthesis of methyl 5-fluoro-2-((4-(methoxycarbonyl)-2-nitrophenyl) thio) benzoate (32):
To a stirred solution of methyl 4-fluoro-3-nitrobenzoate 2 (350 mg, 1.75 mmol) in DMF (10 mL) under argon atmosphère were added compound 31 (360 mg, 1.93 mmol), césium carbonate (1.14 g, 3.51 mmol) at RT; heated to 60-65 °C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (30 mL) and extracted with CH2CI2 (2 x 40 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 7-10% EtOAc/ hexanes to afford compound 32 (500 mg, 78%) as yellow solid. TLC: 10% EtOAc/hexanes (Rf. 0.3); ^-NMR (DMSO-4, 400 MHz): δ 8.64 (s, 1H), 8.048.02 (m, 1H), 7.83-7.79 (m, 2H), 7.64-7.59 (m, 1H), 7.01 (d, J = 8.4 Hz, 1H), 3.88 (s, 3H), 3.71 (s, 3H).
Synthesis of methyl 2-((2-amino-4-(methoxycarbonyl) phenyl) thio)-5-fluorobenzoate (33):
To a stirred solution of compound 32 (500 mg, 1.36 mmol) in MeOH (10 mL) under argon atmosphère was added 10% Pd/ C (300 mg) at RT and stirred under hydrogen atmosphère (balloon pressure) for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was fiitered through celite and washed with 20% MeOH/ CH2CI2 (2 x 30 mL). The combined organic extracts were dried over sodium sulfate, fiitered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 8-10% EtOAc/ hexanes to afford compound 33 (300 mg, 66%) as pale yellow solid. TLC: 30% EtOAc/ hexanes^/ 0.5); *H-NMR (DMSO-4,400 MHz): δ 7.78 (d, 9.6 Hz, 1H), 7.45-7.41 (m, 2H),
7.35-7.30 (m, 1H), 7.14 (d, 9.6 Hz, 1H), 6.68-6.65 (m, 1H), 5.70 (s, 2H), 3.89 (s, 3H), 3.83 (s,
3H).
Synthesis of 2-((2-amino-4-carboxyphenyI) thio)-5-fluorobenzoic acid (34):
To a stirred solution of compound 33 (300 mg, 0.89 mmol) in THF: H2O (5: 1, 6 mL) under argon atmosphère was added lithium hydroxide monohydrate (188 mg, 4.47 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (15 mL) and acidified with 6 N HCl to pH~4. The precipitated solid was fiitered and dried in vacuo to afford compound 34 (180 mg, 66%) as white solid. TLC: 50% EtOAc/ hexanes(R/ 0.2); *H-NMR (DMSO-J* 400 MHz): δ 12.99-12.96 (m, 2H), 7.69 (d, 7= 6.8 Hz, 1H), 7.40 (t, J= 7.2 Hz, 2H), 7.29 (t, J= 7.2 Hz, 1H), 7.13 (d, 7= 7.2
Hz, 1H), 6.64-6.61 (m, 1H), 5.64-5.61 (m, 2H).
Synthesis of 2-fluoro-ll-oxo-10,11-dihydrodibenzo [b,j\ [1, 4] thiazepine-8-carboxylic acid (35):
To a stirred solution of compound 34 (180 mg, 0.58 mmol) in THF (10 mL) under argon atmosphère was added CDI (284 mg, 1.75 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with ice cold water (10 mL) and acidifïed with 6 N HCl to pH~4. The precipitated solid was filtered and dried in vacuo to afford compound 35 (80 mg, 47%) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.2); *H-NMR (DMSO-Jtf, 400 MHz): δ 13.30 (br s, 1H), 10.93 (s, 1H), 7.70 (s, 1H), 7.67 (d, 7= 7.6 Hz, 2H), 7.59 (t, 7= 7.6 Hz, 1H), 7.48 (t, 7= 7.6 Hz, 1H), 7.40-7.35 (m, 1H).
Example 6: Synthesis of 3-fluoro-ll-oxo-10,11-dihydrodibenzo [6, f\ [1, 41 thiazepine-8carboxylic acid (42) - a common intermediate
Synthesis of methyl 4-fluoro-2-((4-methoxybenzyl) thio) benzoate (37):
CO2Me
To a stirred solution of methyl 2-bromo-4-fluorobenzoate 36 (2 g, 8.58 mmol) in 1,4-dioxane (50 mL) under inert atmosphère were added (4-methoxyphenyl) methanethiol 8 (1.58 g, 10.25 mmol), césium carbonate (4.18 g, 12.80 mmol) at RT and purged under argon atmosphère for 30 min. To this was added Pd(dppf)2Cl2 (306 mg, 0.42 mmol); heated to 120 °C and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 250 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 7% EtOAc/ hexanes to afford compound 37 (1.6 g, 61%) as an off-white solid. TLC: 10% EtOAc/ hexanes(R/ 0.4); JH NMR (CDC13, 400 MHz): δ 8.01 (dd, J= 8.7, 6.2 Hz, 1H), 7.34 (d, J= 7.9 Hz, 2H), 7.04 (dd, J= 10.3, 2.4 Hz, 1H), 6.88-6.80 (m, 3H), 4.09 (s, 2H), 3.88 (s, 3H), 3.80 (s, 3H).
Synthesis of methyl 4-fluoro-2-mercaptobenzoate (38):
'SH
A stirred solution of compound 37 (2.2 g, 7.18 mmol) in trifluoro acetic acid (30 mL) at RT under inert atmosphère was heated to 90 °C and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain compound 38 (1.33 g, crude) as brown syrup. The crude was carried forward for next step without further purification. TLC: 10% EtOAc/hexanes (R/. 0.8).
Synthesis of methyl 4-fluoro-2-((4-(methoxycarbonyl)-2-nitrophenyl) thio) benzoate (39):
To a stirred solution of methyl 4-fluoro-3-nitrobenzoate 2 (1.29 g, 6.93 mmol) in DMF (50 mL) under inert atmosphère were added césium carbonate (2.93 g, 9.01 mmol) and compound 38 (1.2 g,
O
6.03 mmol) at RT; heated to 55-60 C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL), the precipitated solid was filtered to obtain the crude. The crude was washed with pentane (2 x 20 mL) and dried in vacuo to afford compound 39 (1.5 g, 68%) as yellow solid. TLC: 10% EtOAc/ hexanes (Rf. 0.3);
*H-NMR (DMSO-iZtf, 400 MHz): δ 8.63 (s, 1H), 8.13-8.04 (m, 2H), 7.53-7.46 (m, 2H), 7.24 (d, J= 8.4 Hz, 1H), 3.89 (s, 3H), 3.72 (s, 3H).
Synthesis of 2-((4-carboxy-2-nitrophenyl) thio)-4-fluorobenzoic acid (40):
To a stirred solution of compound 39 (1.5 g, 4.10 mmol) in THF: H2O (4: 1, 20 mL) was added lithium hydroxide monohydrate (690 mg, 16.4 mmol) at RT, heated to 80 C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The pH of the residue was acidified with 2 N HCl to ~6. The precipitated solid was filtered and dried in vacuo to afford compound 40 (1.2 g, 86%) as an off-white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.2); ^-NMR (DMSO-<4, 400 MHz): δ 13.46 (br s, 2H), 8.58 (s, 1H), 8.08-8.01 (m, 2H), 7.45-7.40 (m, 1H), 7.38-7.35 (m, 1H), 7.29 (d, J= 8.4 Hz, 1H).
Synthesis of 2-((2-amino-4-carboxyphenyl) thio)-4-fluorobenzoic acid (41):
To a stirred solution of compound 40 (1.2 g, 3.56 mmol) in MeOH (50 mL) under inert atmosphère was added 10% Pd/ C (300 mg) at RT and stirred under hydrogen atmosphère (balloon pressure) for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite, washed with MeOH (20 mL). The fîltrate was removed in vacuo to obtain the crude which as triturated with 10% EtOAc/ n-pentane (50 mL) to afford compound 41 (1 g, 91%) as an off-white solid. TLC: 10% MeOH/ CH2C12 (R/. 0.3); ^-NMR (DMSO-î/6,400 MHz): δ 12.96 (br s, 2H), 8.06-8.02 (m, 1H), 7.46 (s, 1H), 7.40 (d, J= 8.0 Hz, 1H), 7.16 (d, J= 8.0 Hz, 1H), 7.077.02 (m, 1H), 6.24 (d, J= 8.0 Hz, 1H), 5.67 (br s, 2H).
Synthesis of 3-fluoro-ll-oxo-10,11-dihydrodibenzo [b,f\ [1,4] thiazepine-8-carboxylic acid (42):
To a stirred solution of compound 41 (1 g, 3.25 mmol) in THF (30 mL) under inert atmosphère was added CDI (1.61 g, 9.77 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was acidified with 2 N HCl to pH~4. The obtained solid was filtered, washed with water (20 mL), ether (2x5 mL) and dried in vacuo to afford compound 42 (760 mg, 80%) as white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.3); ^-NMR (DMSO-^, 400 MHz): δ 13.24 (br s, 1H), 10.83 (s, 1H), 7.78-7.74 (m, 2H), 7.69-7.66 (m, 2H), 7.47.7.44 (m, 1H), 7.35-7.30 (m, 1H).
Example 7: Synthesis of 4-fluoro-ll-oxo-10,11-dihydrodibenzo Γ/x fi [1, 4] thiazepine-815 carboxylic acid (50) - a common intermediate
Synthesis of methyl 2, 3-difluorobenzoate (44):
F
F .CO2Me
To a stirred solution of 2, 3-difluorobenzoic acid 43 (1 g, 6.28 mmol) in MeOH (10 mL) under inert o atmosphère was added Conc. H2SO4 (5 mL) at 0 C and heated to reflux for 36 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (25 mL) and pH adjusted to ~8 with saturated sodium bicarbonate solution (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 44 (800 mg, 74%) as an off-white solid. TLC: 40% EtOAc/ hexanes (Rf 0.8); XH NMR (DMSO-<4, 500 MHz) δ 7.80 - 7.65 (m, 2H), 7.41-7.23 (m, 1H), 3.88 (s, 3H).
Synthesis of methyl 3-fluoro-2-((4-methoxybenzyl) thio) benzoate (45):
•SPMB
To a stirred solution of compound 44 (800 mg, 4.65 mmol) in DMF (10 mL) under inert atmosphère were added (4-methoxyphenyl) methanethiol 8 (282 mg, 5.11 mmol), césium carbonate (1.66 g, 5.11 mmol) at RT and stirred for 6 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted water (25 mL) and extracted with ether (2 x 40 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 45 (750 mg, 53%) as an off-white solid. TLC: 20% EtOAc/ hexanes (Rf. 0.4); Ή NMR (DMSO-zZ* 500 MHz): δ 7.49-7.36 (m, 3H), 7.10 (d, J = 8.9 Hz, 2H), 6.79 (d, J= 8.9 Hz, 2H), 4.06 (s, 2H), 3.81 (s, 3H), 3.70 (s, 3H);
Synthesis of methyl 3-fiuoro-2-mercaptobenzoate (46):
A stirred solution of compound 45 (750 mg, 2.45 mmol) in trifluoro acetic acid (7 mL) at RT under inert atmosphère was heated to 70 C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain compound 46 (1.1 g, crude) as colorless liquid. The crude was carried forward for next step. TLC: 30% EtOAc/ hexanes (Rf. 0.8).
Synthesis of methyl 3-fluoro-2-((4-(methoxycarbonyl)-2-nitrophenyl) thio) benzoate (47):
To a stirred solution of compound 46 (5.96 g, 3.20 mmol) in DMF (100 mL) under inert atmosphère were added methyl 4-fluoro-3-nitrobenzoate 2 (5.8 g, 2.91 mmol), césium carbonate (10.41 g, 3.20 mmol) at RT; heated to 80 °C and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice cold water (25 mL). The obtained solid was fîltered, washed with hexane (2x10 mL) and dried in vacuo to afford compound 47 (7.8 g, 73%) as an pale yellow solid. TLC: 30% EtOAc/ hexanes(R/ 0.5); 1H NMR (DMSO-d«, 500 MHz): δ 8.67 (s, 1H), 8.05 (dd, J= 8.7, 1.7 Hz, 1H), 7.94-7.75 (m, 2H), 7.73-7.67 (m, 1H), 7.00 (d, J= 8.4 Hz, 1H), 3.88 (s, 3H), 3.77-3.64 (m, 3H).
Synthesis of methyl 2-((2-amino-4-(methoxycarbonyl) phenyl) thio)-3-fluorobenzoate (48):
To a stirred solution of compound 47 (670 mg, 1.83 mmol) in MeOH (10 mL) under inert atmosphère was added 10% Pd/C (150 mg) at RT and stirred under hydrogen atmosphère (balloon pressure) for 12 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was fîltered through celite and the filtrate was concentrated in vacuo to afford compound 48 (500 mg, 81%) as an off-white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.4); *H NMR (DMSO-rfô, 400 MHz): δ 7.58-7.50 (m, 2H), 7.48-7.41 (m, 1H), 7.33 (s, 1H), 7.04 (s, 2H), 5.59 (br s, 2H), 3.82 (s, 3H), 3.79 (s, 3H).
Synthesis of 2-((2-amino-4-carboxyphenyI) thio)-3-fluorobenzoic acid (49):
To a stirred solution of compound 48 (500 mg, 1.49 mmol) in THF: H2O (4: 1, 20 mL) was added lithium hydroxide monohydrate (376 mg, 8.95 mmol) at RT; heated to 80 C and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (25 mL) and washed with diethyl ether (2 x 25 mL). The aqueous layer was acidified with 2 N HCl to pH~4 and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude which was washed with diethyl ether (2x5 mL) and dried in vacuo to afford compound 49 (300 mg, 65%) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.2); *H NMR (DMSO-rfô, 500 MHz): δ 12.68 (br s, 2H), 7.54-7.45 (m, 2H), 7.39-7.32 (m, 1H), 7.28 (s, 1H), 7.097.06 (m, 1H), 7.02-6.96 (m, 1H), 5.56 (br s, 2H);
Synthesis of 4-fluoro-ll-oxo-10,11-dihydrodibenzo {b,f\ [1, 4] thiazepine-8-carboxylic acid (50):
To a stirred solution of compound 49 (300 mg, 0.97 mmol) in THF (15 mL) under inert atmosphère was added CDI (474 mg, 2.92 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The pH of the residue was acidified with 4 N HCl to ~2. The obtained solid was filtered, washed with diethyl ether (2x5 mL) and dried in vacuo to afford compound 50 (150 mg, 53%) as an off-white solid. TLC: 15%
MeOH/ CH2C12 (Rf. 0.5); *H NMR (DMSO-J6,400 MHz): δ 13.38 (br s, 1H), 10.92 (s, 1H), 7.79 (s,
1H), 7.75-7.66 (m, 2H), 7.55-7.46 (m, 3H).
Example 8: Synthesis of 7-fluoro-ll-oxo-10,11-dihydrodibenzo \b, f\ Fl, 41 thiazepine-8carboxylic acid (55) - a common intermediate
Synthesis of methyl 2-fluoro-4-((2-(methoxycarbonyl) phenyl) thio)-5-nitrobenzoate (52):
o
COOMe
S2
To a stirred solution of methyl 2, 4-difluoro-5-nitrobenzoate 51 (9.0 g, 41.45 mmol) in DMF (100 mT,) under inert atmosphère were added methyl 2-mercaptobenzoate 1 (6.97 g, 41.45 mmol), césium 10 carbonate (14.82 g, 45.60 mmol) at 0 °C; warmed to 10 °C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (800 mT,) and extracted with EtOAc (2 x 500 mL). The combined organic extracts were dried under sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 10% EtOAc/ hexanes to afford compound 52 (11 g, 15 73%) as an off-white solid. TLC: 10% EtOAc/ hexanes (Rf. 0.4); JH NMR (DMSO-î/^400 MHz):
δ 8.69 (d, J= 6.8 Hz, 1H), 8.04-7.92 (m, 1H), 7.81-7.69 (m, 3H), 6.60 (d, J= 11.5 Hz, 1H), 3.88 (s, 3H), 3.73 (s, 3H).
Synthesis of methyl 5-amino-2-fluoro-4-((2-(methoxycarbonyl) phenyl) thio) benzoate (53):
ο
COOMe
Το a stiired solution of compound 52 (11 g, 30.13 mmol) in MeOH (400 mL) under inert atmosphère was added 10% Pd/ C (5 g) at RT and stirred under hydrogen atmosphère (balloon pressure) for 24 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was fïltered through celite, washed with 30% MeOH/ CH2CI2 (3 x 60 mL). The filtrate was removed in vacuo to afford compound 53 (6.5 g, 64%) as an off-white solid. TLC: 20% EtOAc/ hexanes (Rf. 0.4); Ti NMR (DMSO-J6j400 MHz): δ 8.01-7.88 (m, 1H), 7.45-7.40 (m, 1H), 7.34-7.24 (m, 3H), 6.72 (dd, J= 8.2, 0.8 Hz, 1H), 5.51 (s, 2H), 3.88 (s, 3H), 3.85 (s, 3H).
Synthesis of 5-amino-4-((2-carboxyphenyI) thio)-2-fluorobenzoic acid (54):
COOH
To a stirred solution of compound 53 (6.5 g, 19.4 mmol) in THF: H2O (4: 1, 90 mL) was added lithium hydroxide monohydrate (4 g, 97.01 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The pH of the residue was acidified with 2 N HCl to ~4. The precipitated solid was fïltered and dried in vacuo to afford compound 54 (4.5 g, 75.6%) as an off-white solid. TLC: 30% EtOAc/ hexane (Rf. 0.2); JH NMR (DMSO-îZ6) 400 MHz): δ 13.19 (br s, 2H), 7.96 (dd, J= 7.7, 1.5 Hz, 1H), 7.39 (t, J= 7.3 Hz, 1H), 7.30 (d, J= 6.6 Hz, 1H), 7.27-7.20 (m, 2H), 6.68 (dd, J= 8.2, 0.7 Hz, 1H), 5.42 (br s, 2H).
Synthesis of 7-fluoro-ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-carboxylic acid (55):
To a stirred solution of compound 54 (4.5 g, 14.65 mmol) in THF (100 mL) under inert atmosphère was added CDI (11.88 g, 73.28 mmol) at 0 °C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with 2 N HCl to pH~4; the precipitated solid was fîltered, dried in vacuo to afford compound 55 (3.5 g, 83%) as an off-white solid. TLC: 15% MeOH/ CH2C12 (Rf. 0.2); *H NMR (DMSO-d6i400 MHz): δ 13.61 (br s, 1H), 10.75 (s, 1H), 7.74-7.65 (m, 2H), 7.59-7.45 (m, 4H).
Example 9: Synthesis of 7, 9-difluoro-ll-oxo-10,11-dihydrodibenzo [b, f\ fl, 4] thiazepine-8carboxylic acid (62) - a Common Intermediate
Synthesis of 2, 4, 6-trifluoro-3-nitrobenzoic acid (57):
To 2, 4, 6-trifluorobenzoic acid 56 (15 g, 85.22 mmol) at 0 °C, fuming nitric acid (20 mL) was added dropwise for 10 min; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice cold water (500 mL) and extracted with EtOAc (2 x 200 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to afford compound 57 (20 g) as pale yellow liquid. TLC: 5% MeOH/ CH2C12+ 0.05 mL CH3COOH (Rf. 0.2); *H NMR (DMSO-îZ6,400 MHz): δ 14.12 (br s, 1H), 7.83 (td, J= 10.5, 2.1 Hz, 1H).
Synthesis of methyl 2, 4, 6-trifluoro-3-nitrobenzoate (58):
To a stirred solution of compound 57 (20 g) in MeOH (200 mL) under argon atmosphère was added concentrated sulfuric acid (20 mL) dropwise for 20 min at 0 C and heated to reflux for 48 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (500 mL) and extracted with EtOAc (4 x 200 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 5-8% EtOAc/ hexanes to afford compound 58 (14 g, 70% for 2 steps) as pale yellow syrup. TLC: 20% EtOAc/ hexane (Rf. 0.8); *H NMR (DMSO-î/6, 400 MHz): δ 7.88 (td, 10.6, 2.2 Hz, 1H), 3.93 (s, 3H).
Synthesis of methyl 2, 6-difluoro-4-((2-(methoxycarbonyl) phenyl) thio)-3-nitrobenzoate (59):
F O
COOMe
To a stirred solution of compounds 58 (14 g, 59.57 mmol) in DMF (300 mL) under inert atmosphère were added methyl 2-mercaptobenzoate 1 (11.1 g, 66.07 mmol), césium carbonate (38.77 g, 119.14 mmol) at 0 °C; warmed to RT and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice cold water (200 mL) and extracted with EtOAc (3 x 300 mL). The combined organic extracts were washed with water (200 mT,), brine (200 mL), dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography to afford compound 59 (14.5 g, 64%) as yellow syrup. TLC: 10% EtOAc/ hexanes (Rf. 0.2); JH NMR (DMSO-î/ô, 500
MHz): δ 7.98 (dd, J= Ί.Ί, 1.3 Hz, 1H), 7.66-7.61 (m, 1H), 7.59-7.55 (m, 1H), 7.46 (d, J= 7.8 Hz,
1H), 7.19 (d, J= 9.3 Hz, 1H), 3.93 (s, 3H), 3.81 (s, 3H).
Synthesis of methyl 3-amino-2, 6-difluoro-4-((2-(methoxycarbonyl) phenyl) thio) benzoate (60):
F O
COOMe
To a stirred solution of compound 59 (18 g, 46.99) in MeOH (400 mL) under inert atmosphère was added Pd/C (9 g, 50% wet) at RT and stirred under hydrogen atmosphère in an autoclave (5 kg/cm2 pressure) for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite, washed with MeOH (500 mL). The filtrate was concentrated in vacuo to afford compound 60 (15.1 g, 91%) as colorless semi solid. TLC: 20% EtOAc/ hexanes (À/ 0.5); Tl NMR (DMSO-J6,500 MHz): δ 8.00-7.93 (m, 1H), 7.48-7.42 (m, 1H), 7.31-7.21 (m, 2H), 6.76-6.64 (m, 1H), 5.54-5.47 (m, 2H), 3.91 (s, 3H), 3.89 (s, 3H).
Synthesis of 3-amino-4-((2-carboxyphenyl) thio)-2, 6-difluorobenzoic acid (61):
F O
COOH
To a stirred solution of compound 60 (15.1 g, 39.42 mmol) in THF: H2O (4: 1, 250 mL) was added lithium hydroxide monohydrate (8.3 g, 197.61 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo, diluted with water (100 mL) and washed with EtOAc (2 x 100 mL). The pH of the aqueous layer was acidified with 4 N HCl to ~4. The precipitated solid was filtered, washed with water (100 mL), pentane (100 mL). The obtained solid was further dried using toluene (150 mL) to afford compound 61 (11 g, 79%) as an off-white solid. TLC: 20% EtOAc/ hexanes (Rf. 0.2); *H NMR (DMSO-îZô, 400 MHz): δ 13.24 (br s, 1H), 7.97 (dd, J= 7.7, 1.4 Hz, 1H), 7.46-7.39 (m, 1H), 7.28-7.19 (m, 2H), 6.66 (d, J= 8.2 Hz, 1H), 5.39 (br s, 2H).
Synthesis of 7, 9-difluoro-ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-carboxylic acid (62):
To a stirred solution of compound 61 (10 g, 30.76 mmol) in THF (200 mL) under argon atmosphère 5 was added CDI (14.9 g, 81.97 mmol) at RT and stirred for 24 h. The reaction was monitored by
TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (300 mL) and the pH was adjusted to ~3 with 2 N HCl. The obtained solid was filtered, washed with water (100 mL), pentane (50 mL) and diethyl ether (150 mL) and dried in vacuo to obtain compound 62 (2.83 g, 30%) as brick red solid. TLC: 15% MeOH/ CH2CI2 (Rf. 0.3); 3H
NMR (DMSO-rfe, 500 MHz): δ 14.19 (br s, 1H), 10.64 (s, 1H), 7.73-7.66 (m, 2H), 7.58- 7.48 (m, 3H).
Example 10: 2-methoxy-ll-oxo-10, 11-dihydrodibenzo [Z>, f\ il, 41 thiazepine-8-carboxylic acid (70) - a common intermediate
Synthesis of methyl 5-methoxy-2-(((trifluoromethyl) sulfonyl) oxy) benzoate (64):
To a stirred solution of methyl 2-hydroxy-5-methoxybenzoate 63 (2 g, 10.97 mmol) in pyridine (8 mL) under inert atmosphère was added triflic anhydride (3.56 g, 12.62 mmol) at 0 °C; warmed to RT 5 and stirred for 2 h; heated to 40 C and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (40 mL) and extracted with ether (3 x 40 mL). The combined organic extracts were washed with 1 N HCl (40 mL), water (40 mL), brine (40 mL), dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using
5-10% EtOAc/ hexanes to afford compound 64 (2.9 g, 85%) as colorless liquid. TLC: 10% EtOAc/ hexanes (Rf. 0.6); ^-NMR (CDC13, 500 MHz): δ 7.50 (s, 1H), 7.09 (d, J= 7.5 Hz, 1H), 7.03 (d, J = 7.5 Hz, 1H), 3.94 (s, 3H), 3.84 (s, 3H).
Synthesis of methyl-5-methoxy-2-((4-methoxybenzyl) thio) benzoate (65):
To a stirred solution of compound 64 (500 mg, 1.59 mmol) in 1, 4-dioxane (10 mL) under inert atmosphère were added (4-methoxyphenyl) methanethiol 8 (270 mg, 1.75 mmol), césium carbonate (1.035 g, 3.18 mmol) at RT and degassed for 20 min. To this was added Pd(dppf)2C12 (29.1 mg, 0.039 mmol); heated to 110 °C and stirred for 10 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with
EtOAc (2 x 30 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 10-15% EtOAc/ hexanes to afford compound 65 (280 mg, 55%) as pale yellow solid. TLC: 10% EtOAc/hexanes(Æ/ 0.4); 1H-NMR (CDCI3, 500 MHz): δ 7.42 (s, 1H), 7.28-7.25 (m, 3H), 6.98 (d, J= 8.5 Hz, 1H), 6.84 (d, J= 8.5 Hz, 2H), 4.08 (s, 2H), 3.93 (s, 3H), 3.83 (s,3H),3.81 (s,3H).
Synthesis of methyl 2-mercapto-5-methoxybenzoate (66):
CO2Me
SH
A stirred solution of compound 65 (280 mg, 0.88 mmol) in trifluoro acetic acid (10 mL) at RT under inert atmosphère was heated to 70 C and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain compound 66 (170 mg, crude) as brown syrup. TLC: 10% MeOH/ CH2C12 (Rf. 0.8); ’H-NMR (DMSO-Jtf, 400 MHz): δ 7.68 (d, 8.0 Hz, 1H), 7.48 (d, J= 7.2 Hz, 1H), 7.39 (s, 1H), 5.13 (s, 1H), 3.88 (s, 3H), 3.84 (s,
3H).
Synthesis of methyl 5-methoxy-2-((4-(methoxycarbonyl)-2-nitrophenyl) thio) benzoate (67):
To a stirred solution of compound 66 (150 mg, 0.75 mmol) in DMF (5 mL) under inert atmosphère were added methyl 4-fluoro-3-nitrobenzoate 2 (164 mg, 0.82 mmol), césium carbonate (490 mg, 1.50 mmol) at RT; heated to 55-60 °C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with CH2C12 (2 x 30 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 15-25% EtOAc/hexanes to afford compound 67 (200 mg, 70%) as yellow solid. TLC: 10% EtOAc/ hexanes^/ 0.3); ’H-NMR (DMSO-î/6, 400 MHz): δ 8.64 (s, 1H), 8.02 (d, J= 8.4 Hz, 1H), 7.69 (d, J= 8.8 Hz, 1H), 7.59-7.54 (m, 1H), 7.31 (d, J= 8.8 Hz, 1H), 6.94 (d, J = 8.8 Hz, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.68 (s, 3H).
Synthesis of methyl 2-((2-amino-4-(methoxycarbonyl) phenyl) thio)-5-methoxybenzoate (68):
To a stirred solution of compound 67 (200 mg, 0.53 mmol) in MeOH (10 mL) under inert atmosphère was added 10% Pd/ C (100 mg) at RT and stirred under hydrogen atmosphère (balloon pressure) for 26 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite and washed with 50% CH2CI2/ MeOH (2 x 25 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 15-20% EtOAc/ hexanes to afford compound 68 (120 mg, 65%) as yellow solid. TLC: 30% EtOAc/ hexanesÇK/ 0.6); ’H-NMR (DMSO-d6, 400 MHz): δ 7.42 (s, 2H), 7.36 (d, J= 8.0 Hz, 1H), 7.12 (d, 7= 8.0 Hz, 1H), 7.05 (d, 7= 8.4 Hz, 1H), 6.66 (d, 7= 8.8 Hz, 1H), 5.61 (s, 2H), 3.87 (s, 3H), 3.83 (s, 3H), 3.75 (s, 3H).
Synthesis of 2-((2-amino-4-carboxyphenyl) thio)-5-methoxybenzoic acid (69):
nh2
To a stirred solution of compound 68 (120 mg, 0.34 mmol) in THF: H2O (4: 1,5 mL) was added lithium hydroxide monohydrate (72.5 mg, 1.72 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (10 mL) and acidified with 6 N HCl to pH~4. The precipitated solid was filtered and dried in vacuo to afford compound 69 (80 mg, 73%) as an off-white solid. TLC: 40% EtOAc/ hexanes (Rf. 0.2); *H-NMR (DMSO-76, 400 MHz): δ 12.99 (br s, 2H), 7.41 (d, 7= 8.4 Hz, 2H), 7.35 (d, 7= 7.6 Hz, 1H), 7.12 (d, 7= 7.6 Hz, 1H), 7.01 (d, 7= 8.8 Hz, 1H), 6.61 (d, 7= 8.8 Hz, 1H), 5.54 (br s, 2H), 3.74 (s, 3H).
Synthesis of 2-methoxy-ll-oxo-10,11-dihydrodibenzo [b,f\ [1, 4] thiazepine-8-carboxylic acid (70):
To a stirred solution of compound 69 (80 mg, 0.25 mmol) in THF (5 mL) under inert atmosphère was added CDI (122 mg, 0.75 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (10 mL) and acidified with 6 N HCl to pH~4. The precipitated solid was filtered and dried in vacuo to afford compound 70 (40 mg, 53%) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.4); *H-NMR (DMSO-</6, 400 MHz): δ 13.15 (br s, 1H), 10.79 (s, 1H), 7.78 (s, 1H), 7.69-7.66 (m, 2H), 7.44-7.42 (m, 1H), 7.20-7.19 (m, 1H), 7.08-7.05 (m, 1H), 3.77 (s, 3H).
Example 11: 7-methoxy-ll-oxo-10,11-dihydrodibenzo |7x f] [1, 4] thiazepine-8-carboxylic acid (76) - a common intermediate
Synthesis of methyl 4-fluoro-2-methoxy-5-nitrobenzoate (72):
To a stirred solution of methyl 4-fhroro-2-methoxybenzoate 71 (500 mg, 2.50 mmol) in sulfuric acid 15 (1 mL) under inert atmosphère was added the mixture of nitric acid (0.125 mL), sulfuric acid (0.5 mL) at -5 C and stirred for 10 min. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (25 mL) and extracted with CH2C12 (2 x 30 mL). The combined organic extracts were washed with 10% NaHCO3 solution (20 mL), dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was triturated with diethyl ether (2x5 mL) to afford compound 72 (200 mg, 33%) as an off-white solid. TLC: 20%
EtOAc/ hexanes (Rf. 0.4); ’H-NMR (CDCI3j 400 MHz): δ 8.69 (d, J= 8.8 Hz, 1H), 6.83 (d, J= 12.8 Hz, 1H), 4.01 (s, 3H), 3.92 (s, 3H).
Synthesis of methyl 2-methoxy-4-((2-(methoxycarbonyl) phenyl) thio)-5-nitrobenzoate (73):
CO2Me
To a stirred solution of compound 72 (200 mg, 0.81 mmol) in DMF (4 mL) under inert atmosphère were added methyl 2-mercaptobenzoate 1 (151 mg, 0.89 mmol), césium carbonate (318 mg, 0.97 mmol) at RT; heated to 80 C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice water (20 mL) and extracted with EtOAc (2 x 35 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 15% EtOAc/ hexanes to afford compound 73 (200 mg, 61%) as yellow solid.
TLC: 20% EtOAc/ hexanes (Rf. 0.4); *H-NMR (CDC13, 400 MHz): δ 8.80 (s, 1H), 7.94-7.92 (m, 1H), 7.70 (t, 7= 8.0 Hz, 1H), 7.61-7.59 (m, 2H), 6.30 (s, 1H), 3.90 (s, 3H), 3.82 (s, 3H), 3.52 (s, 3H).
Synthesis of methyl 5-amino-2-methoxy-4-((2-(methoxycarbonyl) phenyl) thio) benzoate (74):
Y^S'^^OMe
CO2M©
To a stirred solution of compound 73 (200 mg, 0.53 mmol) in MeOH (15 mL) under inert atmosphère was added 10% Pd/C (100 mg) at RT and stirred under hydrogen atmosphère (balloon pressure) for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite and the filtrate was concentrated in vacuo to obtain the crude. The crade was purified through silica gel column chromatography using 15% EtOAc/ hexanes to afford compound 74 (110 mg, 60%) as yellow sticky solid. TLC: 20% EtOAc/ hexanes (Rf. 0.6); ’H-NMR (CDCI3,400 MHz): δ 7.99 (d, 7= 8.0 Hz, 1H), 7.54 (s, 1H), 7.34-7.31 (m, 1H),
7.20 (t, J= 8.0 Hz, 1H), 7.12 (s, 1H), 6.80 (d, J= 8.4 Hz, 1H), 3.96 (s, 3H), 3.88 (s, 3H), 3.80 (s, 3H).
Synthesis of 5-amino-4-((2-carboxyphenyl) thio)-2-methoxybenzoic acid (75):
To a stirred solution of compound 74 (110 mg, 0.31 mmol) in THF: H2O (5: 1,3 mL) was added lithium hydroxide monohydrate (66 mg, 1.58 mmol) at RT; heated to 70 C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (15 mL) and extracted with EtOAc (2 x 25 mL). The aqueous layer was acidifîed to pH~2 with 6 N HCl, the obtained solid was filtered, washed with n-hexane (2x5 mL) and dried in vacuo to afford compound 75 (70 mg, 70%) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.2); ’H-NMR (DMSO-rf6, 500 MHz): δ 12.78 (br s, 2H), 7.94 (d, J= 7.5 Hz, 1H), 7.36 (t, J= 7.5 Hz, 1H), 7.20 (t, J= 7.5 Hz, 1H), 7.13 (s, 1H), 7.05 (s, 1H), 6.67 (d, J= 8.5 Hz, 1H), 5.11 (br s, 2H), 3.68 (s, 3H).
Synthesis of 7-methoxy-ll-oxo-10,11-dihydrodibenzo [b,f\ [1, 4] thiazepine-8-carboxylic acid (76):
To a stirred solution of compound 75 (70 mg, 0.21 mmol) in THF (2 mL) under inert atmosphère was added CDI (106 mg, 0.65 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo, diluted with ice water (15 mL), acidifîed with 6 N HCl, the obtained solid was filtered, washed with 20% EtOAc/ hexanes and dried in vacuo to afford compound 76 (40 mg, 61%) as an off-white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.3); ’H-NMR (DMSO-d6,400 MHz): δ 12.88 (br s, 1H), 10.64 (s, 1H), 7.71-7.69 (m, 1H), 7.58-7.42 (m, 4H), 7.28 (s, 1H), 3.81 (s, 3H).
Example 12: Synthesis of 6-methyl-ll-oxo-10,11-dihydrodibenzo [6, M [1, 41 thiazepine-8carboxylic acid (82) - a common intermediate
Synthesis of methyl 4-bromo-3-methyl-5-nitrobenzoate (78):
To a stirred solution of methyl 4-bromo-3-methylbenzoate 77 (500 mg, 2.18 mmol) in sulfuric acid: trifluoro acetic acid (1: 0.1, 6.6 mL) under inert atmosphère was added potassium nitrate (231 mg, 2.29 mmol) at 0 °C; warmed to RT and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with ice water (20 mL) and extracted 10 with EtOAc (2 x 20 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to afford crude compound 78 (540 mg, 95%) as yellow oil. TLC: 10% EtOAc/hexanes (Rf. 0.4); *H-NMR (DMSO-r/d, 400 MHz): δ 8.25 (s, 1H), 8.17 (s, 1H), 3.89 (s, 3H), 2.53 (s, 3H).
Synthesis of methyl 4-((2-(methoxycarbonyl) phenyl) thio)-3-methyl-5-nitrobenzoate (79):
To a stirred solution of methyl 2-mercaptobenzoate 1 (575 mg, 2.18 mmol) in DMF (6 mL) under inert atmosphère were added césium carbonate (1.42 g, 4.37 mmol), compound 78 (385 mg, 2.29 mmol) at RT; heated to 65 °C and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were washed with water (15 mL), brine (15 mL), dried over sodium sulfate, filtered and concentrated in vacuo to afford the crude. The crude was recrystallized using CH2CI2: n-pentane (1: 4, 5 mL) to afford compound 79 (120 mg, 16%) as yellow solid. TLC: 20% EtOAc/ hexanes (Rf. 0.4); ’H-NMR (DMSO-rfd, 400 MHz): δ 8.32 (s, 1H), 8.24 (s, 1H), 7.63-7.59 (m, 1H), 7.49-7.45 (m, 1H), 7.23 (t, J= 8.0 Hz, 1H), 6.61 (d, J= 8.0 Hz, 1H), 3.92 (s, 3H), 3.89 (s, 3H), 2.35 (s, 3H).
Synthesis of methyl 3-amino-4-((2-(methoxycarbonyl) phenyl) thio)-5-methylbenzoate (80):
To a stirred solution of compound 79 (200 mg, 0.55 mmol) in MeOH (5 mL) under inert atmosphère was added Pd/C (70 mg) at RT and stirred under hydrogen atmosphère for 6 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude compound 80 (175 mg, 96%) as yellow solid. TLC: 30% EtOAc/ hexanes (Rf. 0.7); 1HNMR (DMSO-ίήί, 400 MHz): δ 7.96 (d, J= 7.6 Hz, 1H), 7.38-7.31 (m, 2H), 7.24-7.20 (m, 1H), 7.14 (s, 1H), 6.56 (d, J= 8.0 Hz, 1H), 5.67 (s, 2H), 3.89 (s, 3H), 3.83 (s, 3H), 2.25 (s, 3H).
Synthesis of 3-amino-4-((2-carboxyphenyl) thio)-5-methylbenzoic acid (81):
To a stirred solution of compound 80 (160 mg, 0.48 mmol) in THF: H2O (3: 1.5, 4.5 mL) was added lithium hydroxide (118 mg, 2.90 mmol) at RT and stirred for 24 h; heated to reflux and stirred for 12 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (15 mL), fiitered the precipitated solid and dried in vacuo to afford the crude compound 81 (140 mg, 96%) as an off-white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.2); *H-NMR (DMSO-r/6, 400 MHz): δ 13.00 (br s, 2H), 7.95 (d, J= 8.0 Hz, 1H), 7.35-7.29 (m, 2H), 7.19 (t, J= 7.6 Hz, 1H), 7.13 (s, 1H), 6.54 (d, J= 8.0 Hz, 1H), 5.30 (br s, 2H), 2.25 (s, 3H).
Synthesis of 6-methyl-ll-oxo-10,11-dihydrodibenzo [b,j\ [1, 4] thiazepine-8-carboxyIic acid (82)
To a stirred solution of compound 81 (140 mg, 0.46 mmol) in THF (5 mL) under inert atmosphère was added CDI (375 mg, 2.31 mmol) at RT and stirred for 24 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo and neutralized with 1 N 15 HCl, fiitered the precipitated solid and dried in vacuo to afford the crude compound 82 (120 mg,
91%) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.4); ’H-NMR (DMSO-rf6, 400 MHz): δ 13.05 (br s, 1H), 10.73 (s, 1H), 7.69-7.58 (m, 4H), 7.51-7.44 (m, 2H), 2.56 (s, 3H).
Example 13: Synthesis of 7-methyl-ll-oxo-10, 11-dihydrodibenzo \b, f\ [1, 4] thiazepine-8carboxylic acid (88) - a common intermediate
Synthesis of 4-fluoro-2-methyl-5-nitrobenzoic acid (84):
To a stirred solution of 4-fluoro-2-methylbenzoic acid 83 (500 mg, 3.24 mmol) in concentrated sulfuric acid (2.5 mL) under inert atmosphère was added potassium nitrate (655 mg, 6.49 mmol) at 0 °C; warmed to RT and stirred for 6 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with ice water (20 mL), filtered the precipitated solid and dried in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 5% MeOH/ CH2CI2 to afford compound 84 (300 mg, 60%) as brown syrup.
TLC: 10% MeOH/ CH2C12 (Rf. 0.3); ^I-NMR (DMSO-46,500 MHz): δ 13.56 (br s, 1H), 8.52 (d, J = 8.0 Hz, 1H), 7.61 (d, J= 12.5 Hz, 1H), 2.63 (s, 3H).
Synthesis of 4-((2-(methoxycarbonyl) phenyl) thio)-2-methyl-5-nitrobenzoic acid (85):
CC^Me NO2
To a stirred solution of methyl 2-mercaptobenzoate 1 (514 mg, 3.08 mmol) in DMF (10 mL) under inert atmosphère were added césium carbonate (1.81 g, 5.57 mmol), compound 84 (560 mg, 2.78 mmol) at RT; heated to 60 °C and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed under reduced pressure. The residue was diluted with water (20 mL) and pH was adjusted to ~2 with 1 N HCl, fîltered the precipitated solid and dried in vacuo to afford compound 85 (500 mg, 52%) as an off-white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.4); ’H-NMR (DMSO-î/6, 400 MHz): δ 13.47 (br s, 1H), 8.59 (s, 1H), 7.94 (d, J= 7.2 Hz, 1H), 7.68-7.60 (m, 3H), 6.83 (s, 1H), 3.72 (s, 3H), 2.40 (s, 3H).
Synthesis of methyl 3-amino-4-((2-(methoxycarbonyl) phenyl) thio)-5-methylbenzoate (86):
To a stirred solution of compound 85 (500 mg, 1.45 mmol) in THF: H2O (2:1, 15 mL) was added lithium hydroxide monohydrate (300 mg, 7.31 mmol) at RT and stirred for 8 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (15 mL), and pH was adjusted to ~2 with 1 N HCl, fîltered the precipitated solid and dried in vacuo to afford crude compound 86 (500 mg) as an off-white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.1); *H-NMR (DMSO-rfô, 400 MHz): δ 13.51 (br s, 2H), 8.57 (s, 1H), 7.92 (d, J= 7.2 Hz, 1H), 7.64-7.58 (m, 2H), 7.53 (t, J= 8.0 Hz, 1H), 6.89 (s, 1H), 2.41 (s, 3H).
Synthesis of 5-amino-4-((2-carboxyphenyl) thio)-2-methy!benzoic acid (87):
co2h nh2
To a stirred solution of compound 86 (500 mg) in MeOH (15 mL) under inert atmosphère was added Pd/ C (250 mg) at RT and stirred under hydrogen atmosphère for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to afford crude compound 87 (430 mg) as an off-white solid. TLC: MeOH/ CH2C12 (Rf. 0.1); LC-MS: 84.24%;
304.5 (M++l); (column; X-Select CSH C-18, (50 x 3.0 mm, 3.5 pm); RT 3.75 min. 0.05% TFA (Aq): ACN; 0.8 mL/min).
Synthesis of 7-methyl-ll-oxo-10,11-dihydrodibenzo [b,/] [1, 4] thiazepine-8-carboxylic acid (88):
To a stirred solution of compound 87 (430 mg) in THF (20 mL) under inert atmosphère was added
CDI (1.15 g, 7.09 mmol) at RT and stirred for 18 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo and neutralized with 1 N HCl, fïltered the precipitated solid and dried in vacuo to afford the crude compound 88 (290 mg) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.5); ^-NMR (DMSO-rf6, 500 MHz): δ 13.15 (br s, 1H), 10.68 (s, 1H), 7.69-7.68 (m, 2H), 7.67-7.44 (m, 4H), 2.44 (s, 3H).
Example 14: 9-methyl-ll-oxo-10,11-dihydrodibenzo \b„ f\ [1,41 thiazepine-8-carboxylic acid (96) - a common intermediate and Synthesis of 7-methyI-ll-oxo-10,11-dihydrodibenzo FA f] fl, 4] thiazepine-8-carboxyIic acid (88) a common intermediate - Alternate Approach
Synthesis of mixture of 4-fluoro-2-methyl-3-nitrobenzoic acid (89) and 4-fluoro-2-methyl-5nitrobenzoic acid (84):
To a stirred solution of 4-fluoro-2-methylbenzoic acid 83 (10 g, 64.51 mmol) in acetic acid (50 mL) under inert atmosphère was added fuming nitric acid (50 mL) at RT and heated to 80 °C for 6 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice cold water (100 mL). The precipitate was filtered and dried in vacuo to afford mixture of compounds 84 and 89 (5.3 g, 40%) as white solid. TLC: 70% EtOAc/ hexanes (Rf. 0.4); 1H NMR (DMSO-dô,400 MHz): δ 13.30 (br s, 2H), 8.52 (d, J= 8.0 Hz, 2H), 8.10 (dd, J= 8.9 5.9, Hz, 1H), 7.60 (d, J= 12.5 Hz, 2H), 7.56 (t, J= 9.3 Hz, 1H), 2.63 (s, 6H), 2.48 (s, 3H); (’H NMR showed mixture of compounds 84 and 89 in the ratio of 2: 1).
Synthesis of methyl 4-fluoro-2-methyl-3-nitrobenzoate (91) and methyl 4-fluoro-2-methyl-5nitrobenzoate (90):
To a stirred solution of compound 84 and 89 (10 g) in MeOH (100 mL) under argon atmosphère was conc. sulfuric acid (20 mL) at 0 °C and heated to reflux for 48 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to afford mixture of compounds 90 & 91 (6 g) as colorless thick syrup. TLC: 30% EtOAc/ hexane (Rf. 0.5); ’H NMR (DMSO-î/6, 500 MHz): δ 8.51 (d, .7=7.8 Hz, 1H), 8.09 (dd, J= 8.8, 5.6 Hz, 0.5H), 7.63 (d, J= 12.4 Hz, 1H), 7.58 (t, 9.1 Hz, 0.5H), 3.87 (s,
4.5H), 2.62 (s, 3H), 2.45 (s, 1.5H); ^H NMR showed mixture of compounds 90: 91 in the ratio of 2: 1).
Synthesis of methyl 4-((2-(methoxycarbonyl) phenyl) thio)-2-methyl-3-nitrobenzoate (93) and methyl 4-((2-(methoxycarbonyl) phenyl) thio)-2-methyl-5-nitrobenzoate (92):
To a stirred solution of compounds 90 and 91 (11 g) in DMF (100 mL) under inert atmosphère were added methyl 2-mercaptobenzoate 1 (10.4 g, 61.97 mmol), césium carbonate (18.5 g, 56.81 mmol) at 0 °C; heated to 80 °C and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice cold water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic extracts were washed with water (200 mL), brine (200 mL), dried over sodium sulfate, filtered and concentrated in vacuo to afford a mixture of compounds 93 and 92 (12 g) as a yellow solid. TLC: 20% EtOAc/ hexanes (Rf 0.2); LC-MS: 12.57% + 81.14%; 370.8 (M%1); (column; X-Select CSH C18, (50 x 3.0 mm, 3.5 pm); RT 2.77 min. 0.05% Aq. TFA: ACN; 0.8 mL/min); RT 4.05, 4.14 min.
Synthesis of methyl 3-amino-4-((2-(methoxycarbonyl) phenyl) thio)-2-methylbenzoate (95) and Synthesis of methyl 5-amino-4-((2-(methoxycarbonyl) phenyl) thio)-2-methylbenzoate (94):
95
To a stirred solution of compound 93 and 92 (14 g, crude) in MeOH (500 mL) under inert atmosphère was added Pd/C (1.4 g, 50% wet) at RT and stirred under hydrogen atmosphère in an autoclave (6 kg/ cm2 pressure) for 18 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite, washed with MeOH (100 mL). The filtrate was concentrated in vacuo to obtain the crude. The crude was recrystallized with EtOH (20 mL) and further purified through silica gel column chromatography column chromatography using 10% EtOAc/ hexanes to afford compound 95 (3 g, 30%) and 94 (8 g, 63%) as sticky off-white solids. TLC: 30% EtOAc/ hexanes (Rf. 0.4); *H NMR (DMSO-d6>400 MHz) (95): δ 7.94 (d, J= 7.1 Hz, 1H), 7.40 (t, J= 7.3 Hz, 1H), 7.33-7.26 (m, 2H), 7.22 (dt, J= 7.6, 1.1 Hz, 1H), 6.67 (dd, J= 8.2, 0.8 Hz, 1H), 5.41 (s, 2H), 3.89 (s, 3H), 3.83 (s, 3H), 2.33 (s, 3H). *H NMR (DMSO-46,400 MHz) (94): δ 7.94 (dd, .7 = 7.8, 1.4 Hz, 1H), 7.42-7.38 (m, 1H), 7.32 (s, 1H), 7.26 (s, 1H), 7.22 (td, J =7.5, 1.0 Hz, 1H), 6.67 (dd, J= 8.1, 0.8 Hz, 1H), 5.41 (s, 2H), 3.88 (s, 2H), 3.82 (s, 3H), 2.33 (s, 3H).
Synthesis of 3-amino-4-((2-carboxyphenyl) thio)-2-methylbenzoic acid (96):
To a stirred solution of compound 95 (2 g, 6.04 mmol) in THF: H2O (4: 1, 50 mL) was added lithium hydroxide monohydrate (2.5 g, 10.0 mmol) at 0 C; warmed to RT and stirred for 48 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (10 mL) and washed with diethyl ether (2 x 50 mL). The pH of the aqueous layer was acidified with 4 N HCl to ~1. The precipitated solid was filtered and dried in vacuo to afford compound 96 (1.2 g, 66%) as white solid. TLC: 20% MeOH/ CH2CI2 (Rf. 0.2); *H NMR (DMSO-J6,400 MHz): δ 13.01 (br s, 2H), 7.94 (d, J= 7.4 Hz, 1H), 7.36 (t, J= 7.8 Hz, 1H), 7.28 (d, J= 8.0 Hz, 1H), 7.20 (dt, J= 7.4, 6.3 Hz, 1H), 6.95 (d, J= 8.0 Hz, 1H), 6.61 (d, J = 7.4 Hz, 1H), 5.25 (br s, 2H), 2.27 (s, 3H).
Synthesis of 9-methyl-ll-oxo-10,11-dihydrodibenzo \b,j\ [1, 4] thiazepine-8-carboxylic acid (97):
To a stirred solution of compound 96 (2.6 g, 4.30 mmol) in THF (30 mL) under argon atmosphère was added CDI (3.5 g, 21.50 mmol) at RT; heated to 80 °C and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (20 mL) and pH was adjusted with 4 N HCl to ~2. The obtained solid was filtered, washed with diethyl ether and dried in vacuo to obtain compound 97(1.6 g, 67%) as an off white solid. TLC: 15% MeOH/ CH2C12 (Rf 0.2); XH NMR (DMSO-rf6)400 MHz): δ 13.20 (br s, 1H), 10.23 (s, 1H), 7.74-7.60 (m, 1H), 7.56-7.51 (m, 2H), 7.50-7.42 (m, 3H), 2.47 (s, 3H).
Example 15: Synthesis of 3-carbamoyl-ll-oxo-10,11-dihydrodibenzo (b, f\ [1, 41 thiazepine-8carboxylic acid (135) - a common intermediate
Synthesis of dimethyl 2-((4-methoxybenzyl) thio) terephthalate (126):
To a stirred solution of dimethyl 2-bromoterephthalate 125 (1 g, 3.66 mmol) in 1, 4-dioxane (50 mL) under inert atmosphère were added (4-methoxyphenyl) methanethiol 8 (620 mg, 4.02 mmol), césium carbonate (2.38 g, 7.32 mmol), Pd(dppf)2C12 (67 mg, 0.09 mmol) at RT and stirred under argon for 30 min; heated to 110 °C and stirred for 20 h in a sealed tube. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 75 mL). The combined organic extracts were dried over sodium sulfate, 10 filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 10% EtOAc/ hexanes to afford compound 126 (680 mg, 54%) as an off-white solid. TLC: 10% EtOAc/hexanes (Rf. 0.3); *H-NMR (CDC13, 500 MHz): δ 8.06 (s, 1H),
7.99 (d, J= 8.5 Hz, 1H), 7.77 (d, J= 8.0 Hz, 1H), 7.34 (d, J= 8.5 Hz, 2H), 6.85 (d, J= 8.5 Hz, 2H),
4.18 (s, 2H), 3.93 (s, 3H), 3.91 (s, 3H), 3.79 (s, 3H).
Synthesis of dimethyl 2-mercapto terephthalate (127):
CO2Me
MeO2C SH
127
A stirred solution of compound 126 (1.47 g, 4.24 mmol) in trifluoro acetic acid (25 mL) under inert
O atmosphère at RT was heated to 80 C and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude compound 127 (950 mg) as pale green semi-solid which was carried to the next step without any purification. TLC: 15% EtOAc/ hexanes (Rf. 0.7).
Synthesis of dimethyl 2-((4~(teri-butoxycarbonyl)-2-nitrophenyl) thio) terephthalate (129):
To a stirred solution of tert-butyl 4-fluoro-3-nitrobenzoate 128 (400 mg, 1.65 mmol) in DMF (20 mL) under inert atmosphère were added compound 127 (525 mg, crude), césium carbonate (1.07 g, 3.31 mmol) at RT ; heated to 60 C and stirred for 1 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted water (25 mL) and extracted with EtOAc (2 x 40 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 5-7% EtOAc/ hexanes to afford compound 129 (400 mg, 54%) as yellow solid. TLC: 10% EtOAc/ hexanes (Rf. 0.4); XH-NMR (CDC13, 400 MHz): δ 8.76 (s, 1H), 8.25 (s, 1H), 8.20-8.17 (m, 1H), 7.98 (d, J= 8.4 Hz, 1H), 7.92 (d, J= 8.4 Hz, 1H), 6.91 (d, J= 8.4 Hz, 1H), 3.93 (s, 3H), 3.82 (s, 3H), 1.58 (s, 9H).
Synthesis of dimethyl 2-((2-amino-4-(tert-butoxycarbonyl) phenyl) thio) terephthalate (130):
To a stirred solution of compound 129 (1 g, 2.23 mmol) in MeOH (50 mL) under inert atmosphère was added 10% Pd/C (500 mg) at RT and stirred under hydrogen atmosphère (balloon pressure) for 24 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite and the filtrate was concentrated in vacuo to obtain the crude. The crude was triturated with 2% EtOAc/ w-pentane (2x5 mL) and dried in vacuo to afford compound 130 (800 mg, 86%) as an off-white solid. TLC: 15% EtOAc/ hexanes (Rf. 0.4); ’H-NMR (DMSO-Jô, 400 MHz): δ 8.05 (d, J= 8.0 Hz, 1H), 7.76-7.73 (m, 1H), 7.43-7.40 (m, 2H), 7.27 (s, 1H), 7.13-7.10 (m, 1H), 5.68 (br s, 2H), 3.91 (s, 3H), 3.75 (s, 3H), 1.55 (s, 9H).
Synthesis of 2-((2-amino-4-(to't-butoxycarbonyi) phenyl) thio) terephthalic acid (131):
To a stirred solution of compound 130 (250 mg, 0.59 mmol) in THF: H2O (4: 1, 10 mL) under inert atmosphère was added lithium hydroxide monohydrate (123 mg, 2.99 mmol) at RT and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (25 mL) and extracted with diethyl ether (2 x 25 mL). The aqueous layer was acidified with 2 N HCl to pH~6. The obtained solid was filtered and dried in vacuo to afford compound 131 (180 mg, 77%) as yellow solid. TLC: 10% MeOH/ CH2CI2 (Rf 0.2); ^-NMR (DMSO-<4, 400 MHz): δ 13.16 (br s, 2H), 8.02 (d, J= 8.0 Hz, 1H), 7.70 (d, J= 8.4 Hz, 1H), 7.44-7.40 (m, 2H), 7.16 (s, 1H), 7.13-7.09 (m, 1H), 5.64 (br s, 2H), 1.55 (s, 9H).
Synthesis of 8-(to'i-butoxycarbonyl)-ll-oxo-10,11-dihydrodibenzo [b,f\ [1, 4] thiazepine-3carboxylic acid (132):
132
To a stirred solution of compound 131 (180 mg, 0.46 mmol) in THF (9 mL) under inert atmosphère was added CDI (225 mg, 1.39 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (15 mL) and acidified with HCl. The obtained solid was fîltered and dried in vacuo to afford compound 132 (150 mg, 87%) as an off-white solid. TLC: 7% MeOH/ CH2CI2 (Rf. 0.2); 1HNMR (DMSO-r/6, 400 MHz): δ 13.32 (br s, 1H), 10.93 (s, 1H), 8.02 (d, J= 8.4 Hz, 1H), 7.97-7.94 (m, 1H), 7.81-7.77 (m, 2H), 7.71-7.62 (m, 1H), 7.43-7.42 (m, 1H), 1.55-1.51 (m, 9H).
Synthesis of to7-butvl 3-carbamoyl-ll-oxo-10,11-dihydrodibenzo \b,J\ [1, 4] thiazepine-8carboxylate (134):
134
To a stirred solution of compound 132 (150 mg, 0.40 mmol) in DMF (9 mL) under inert atmosphère were added HATU (307 mg, 0.80 mmol), ammonium chloride 133 (43 mg, 0.80 mmol), diisopropyl ethyl amine (0.3 mL, 1.60 mmol) at 0 °C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL). The obtained solid was fîltered, triturated with 10% EtOAc/ hexanes (2x5 mL) and dried in vacuo to afford compound 134 (95 mg, 63%) as white solid. TLC: 7% MeOH/ CH2CI2 (Rf. 0.6); 1HNMR (DMSO-Jfi, 400 MHz): δ 10.89 (s, 1H), 8.15 (s, 1H), 8.00 (s, 1H), 7.89 (d, J= 8.0 Hz, 1H), 7.77-7.76 (m, 2H), 7.74-7.69 (m, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.58 (br s, 1H), 1.52 (s, 9H).
Synthesis of 3-carbamoyl-ll-oxo-10,11-dihydrodibenzo \h,f\ [1,4] thiazepine-8-carboxylic acid (135):
135
To a stirred solution of compound 134 (95 mg, 0.25 mmol) in EDC (10 mL) under inert atmosphère was added trifluoroacetic acid (293 mg, 2.56 mmol) at RT; heated to 80 C and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered.
The obtained solid was triturated with 5% CH2CI2 (2x5 mL) and dried in vacuo to afford compound 135 (70 mg, 87%) as white solid. TLC: 10% MeOH/ CH2C12 (Rf 0.2); *H-NMR (DMSO-^, 500 MHz): δ 10.93 (s, 1H), 8.16 (s, 1H), 8.01 (s, 1H), 7.90 (d, J= 8.5 Hz, 1H), 7.817.76 (m, 2H), 7.72-7.68 (m, 2H), 7.59 (s, 1H).
Example 16: ll-oxo-10,11-dihydrodibenzo f\ [1,4] thiazepine-7-carboxylic acid (140) - a common intermediate
Synthesis of methyl 3-((2-(methoxycarbonyl) phenyl) thio)-4-nitrobenzoate (137):
To a stirred solution of methyl 3-fluoro-4-nitrobenzoate 136 (100 mg, 0.50 mmol) in DMF (3 mL) under argon atmosphère was added césium carbonate (180 mg, 0.55 mmol) at RT and heated to 40
C. To this was added methyl 2-mercaptobenzoate 1 (93 mg, 0.55 mmol) in DMF (1 mL) drop wise for 3 min and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was diluted with water (30 mL) and extracted with CH2CI2 (2 x 30 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to afford compound 137 (120 mg, 69%) as yellow crystalline solid. TLC: 20% EtOAc/ hexanes (Rf. 0.3); ^-NMR (DMSO-46, 400 MHz): δ 8.30 (d, J= 8.4 Hz, 1H), 7.99-7.93 (m, 2H), 7.65-7.60 (m, 3H), 7.49 (d, J= 7.6 Hz, 1H), 3.80 (s, 3H), 3.74 (s, 3H).
Synthesis of 3-((2-carboxyphenyl) thio)-4-nitrobenzoic acid (138):
To a stirred solution of compound 137 (100 mg, 0.26 mmol) in THF (7 mL) under argon atmosphère was added lithium hydroxide monohydrate (28 mg, 0.66 mmol) in water (3 mL) at RT; heated to reflux and stirred for 2 h. The reaction was monitored by TLC; after completion ofthe reaction, the volatiles were removed in vacuo, diluted with water (20 mL) and pH was adjusted to ~2 with 1 N HCl. The obtained solid was filtered and dried in vacuo to afford compound 138 (72 mg, 85%) as yellow solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.2); Tl-NMR (DMSO-d6, 400 MHz): δ 13.49 (br s, 2H), 8.25 (d, J= 8.4 Hz, 1H), 7.96-7.91 (m, 2H), 7.66 (s, 1H), 7.60-7.54 (m, 2H), 7.40 (d, J= 7.6 Hz, 1H).
Synthesis of 4-amino-3-((2-carboxyphenyl) thio) benzoic acid (139):
To a stirred solution of compound 138 (70 mg, 0.20 mmol) in MeOH (5 mL) under argon atmosphère was added 10% Pd/C (10 mg) and stirred under hydrogen atmosphère (balloon pressure) for 24 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite, washed with MeOH (2x5 mL) and the filtrate was concentrated in vacuo to afford compound 139 (53 mg, 90%) as an off-white solid. TLC: 20% MeOH/ CH2CI2 (Rf.
0.3); ’H-NMR (DMSO-76, 400 MHz): δ 12.91 (br s, 2H), 7.94 (d, J= 6A Hz, 1H), 7.86 (s, 1H),
7.76 (d, 7= 8.4 Hz, 1H), 7.37 (t, 7= 8.0 Hz, 1H), 7.19 (t, J= 7.6 Hz, 1H), 6.83 (d, 7= 8.8 Hz, 1H), 5 6.63 (d, 7= 8.0 Hz, 1H), 6.14 (br s, 2H).
Synthesis of ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-7-carboxylic acid (140):
To a stirred solution of compound 139 (50 mg, 0.17 mmol) in dry THF (3 mL) under argon atmosphère was added CDI (84 mg, 0.51 mmol) at 0 °C; warmed to RT and stirred for 12 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with 1 N HCl (3 mL), water (10 mL). The obtained solid was filtered, washed with ether (2x5 mL) and dried in vacuo to afford compound 140 (28 mg, 61%) as white solid. TLC: 20% MeOH/ CH2CI2 (Rf. 0.5); *H-NMR (DMSO-7fi, 400 MHz): δ 13.10 (br s, 1H), 10.97 (s, 1H), 8.05 (s, 1H), 7.89 (d, 7= 8.4 Hz, 1H), 7.69 (d, 7= 7.6 Hz, 1H), 7.57 (d, 7= 7.6 Hz, 1H), 7.53-7.44 (m, 2H), 7.31 (d, 7= 8.4 Hz, 1H).
Example 17: Synthesis of 8-aminodibenzo f] [1, 41 thiazepin-11 (lOZQ-one (145) - a common intermediate
Synthesis of methyl 2-((4-amino-2-nitrophenyl) thio) benzoate (142):
To a stirred solution of 4-fluoro-3-nitroaniline 141 (500 mg, 3.20 mmol) in DMF (6 mL) under inert atmosphère was added césium carbonate (1.14 g, 3.50 mmol) at RT and heated to 40 C. To this was added methyl 2-mercaptobenzoate 1 (592 mg, 3.50 mmol) in DMF (1 mL) drop wise for 3 min and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (35 mL) and extracted with CH2CI2 (2x35 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 15% EtOAc/ hexanes to afford compound 142 (600 mg, 62%) as brown syrup. TLC: 30% EtOAc/ hexanes (Rf 0.5); ’H-NMR (DMSO-rf6, 400 MHz): δ 7.91 (d, J= 8.0 Hz, 1H), 7.44 (t, J= 8.0 Hz, 1H), 7.3015 7.20 (m, 2H), 7.10 (s, 1H), 6.87-6.84 (m, 1H), 6.79 (d, J= 8.0 Hz, 1H), 6.24 (s, 2H), 3.84 (s, 3H).
Synthesis of 2-((4-amino-2-nitrophenyl) thio) benzoic acid (143):
To a stirred solution of compound 142 (600 mg, 1.98 mmol) in THF: H2O (10: 3, 13 mL) under inert atmosphère was added lithium hydroxide monohydrate (406 mg, 9.90 mmol) at RT; heated to 60 °C and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The aqueous layer was acidifïed with HCl to pH~2. The obtained solid was fïltered and dried in vacuo to afford compound 143 (350 mg, 61%) as orange solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.3); ’H-NMR (DMSO-îA, 500 MHz): δ 13.18 (s, 1H), 7.89 (d, J= 7.5 Hz, 1H), 7.38 (t, J= 7.0 Hz, 1H), 7.28 (d, J= 9.0 Hz, 1H), 7.19 (t, J= 8.0 Hz, 1H), 7.07 (s, 1H), 6.84 (d, J= 8.5 Hz, 1H), 6.71 (d, J= 8.5 Hz, 1H), 6.23 (s, 2H).
Synthesis of 2-((2, 4-diaminophenyI) thio) benzoic acid (144):
To a stirred solution of compound 143 (350 mg, 1.20 mmol) in MeOH (10 mL) under inert atmosphère was added 10% Pd/C (100 mg) at RT and stirred under hydrogen atmosphère (balloon pressure) for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was fïltered and the filtrate was concentrated in vacuo to obtain the crude. The crude was washed with n-pentane (2x10 mL) and dried in vacuo to afford compound 144 (250 mg, 80%) as white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.3); ’H-NMR (DMSO-rfé, 400 MHz): δ 12.60 (br s, 1H), 7.87 (d, J= 7.6 Hz, 1H), 7.32 (t, J= 8.4 Hz, 1H), 7.12 (t, 6.8 Hz, 1H), 6.90 (d, 8.0
Hz, 1H), 6.72 (d, J= 8.0 Hz, 1H), 6.02 (s, 1H), 5.93 (d, J= 8.4 Hz, 1H), 5.02-4.98 (m, 4H).
Synthesis of 8-aminodibenzo \b,f\ [1, 4] thiazepin-11 (ÎO//)-0116 (145):
To a stirred solution of compound 144 (150 mg, 0.57 mmol) in DMF (4 mL) under inert atmosphère were added HOBt (233 mg, 1.73 mmol), EDCI.HC1 (330 mg, 5.19 mmol), diisopropyl ethyl amine (0.5 mL, 2.87 mmol) at 0 °C; warmed to RT and stirred for 6 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice cold water (30 mL). The obtained solid was fiitered, washed with hexanes (2x10 mL) and dried in vacuo to afford compound 145 (80 mg, 57%) as an off-white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.5); 'H-NMR (DMSO-rftf, 400 MHz): δ 10.40 (s, 1H), 7.63 (d, J= 6.8 Hz, 1H), 7.45-7.37 (m, 3H), 7.12 (d, J= 8.4 Hz, 1H), 6.39 (s, 1H), 6.31 (d, J= 8.4 Hz, 1H), 5.46 (s, 2H).
Example 18: Synthesis of ll-oxo-10,11-dihydrodibenzo ΓΖ>, f\ [1, 4] thiazepine-8-carboxylic acid 5-oxide (156) - a common intermediate
Synthesis of ll-oxo-10,11-dihydrodibenzo [b,f\ [1, 4] thiazepine-8-carboxylic acid 5-oxide (156):
To a stirred solution of 6 (2.5 g, 9.21 mmol) in CH2C12 (50 mL) under inert atmosphère was added m-chloro perbenzoic acid (1.59 g, 9.21 mmol) at RT and stirred for 48 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was the volatiles were removed in vacuo to obtain the crude. The crude was triturated with 10% MeOH/ CH2C12 (2x5 mL), isopropanol (10 mL) to afford compound 156 (2.3 g, 87%) as white solid. TLC: 10% MeOH/ CH2C12+ 0.05 mL CH3COOH (Rf. 0.4); *H NMR (DMSO-îZ6,500 MHz): δ 13.36 (br s, 1H), 11.08 (s, 1H), 7.96 (d, J= 7.8 Hz, 1H), 7.92-7.87 (m, 1H), 7.85-7.66 (m, 3H), 7.63 (t, J= 7.8 Hz, 1H), 7.53 (t, J = 7.8 Hz, 1H);
Example 19: Synthesis of ll-oxo-10,11-dihydrodibenzo [/>, fi [1, 4] thiazepine-8-carboxylic acid 5, 5-dioxide (159) - a common intermediate
Synthesis of methyl ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-carboxylate (157):
To a stirred solution of 6 (500 mg, 1.84 mmol) in MeOH: CH2CI2 (1: 1, 20 mL) under argon atmosphère was added CH2N2 (prepared in situ using 7V-nitrosomethyl urea (0.95 g, 9.2 mmol) +
KOH (0.51 g, 9.22 mmol) at 0 °C; warmed to RT and stirred for 1 h. The reaction was monitored by
TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 157 (450 mg, 86%) as white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.5); 'H-NMR (DMSO-y/6, 500 MHz): δ 10.82 (s, 1H), 7.82 (s, 1H), 7.75-7.69 (m, 3H), 7.58-7.63 (m, 3H), 3.82 (s, 3H).
Synthesis of methyl ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-carboxylate 5, 515 dioxide (158):
o o
158
To a stirred solution of 157 (5 g, 17.54 mmol) in acetic acid (25 mL) was added 30% aqueous hydrogen peroxide (100 mL) at 0 °C; warmed to 50 °C and stirred for 72 h. The reaction was monitored by TLC; after completion of the reaction, the obtained solid was filtered, washed with water (100 mL), 10% EtOAc/ hexanes (100 mL) and dried in vacuo to afford compound 158 (3.5 g,
64%) as white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.3); Ή NMR (DMSO-rf6, 500 MHz): δ 11.58 (s, 1H), 8.09 (d, J= 8.4 Hz, 1H), 8.01-7.95 (m, 3H), 7.93-7.83 (m, 3H), 3.88 (s, 3H).
Synthesis of ll-oxo-10,11-dihydrodibenzo [6,/] [1, 4] thiazepine-8-carboxylic acid 5, 5-dioxide (159):
OH
159
To a stirred solution of compound 158 (3.5 g, 11.04 mmol) in a mixture of THF: MeOH: H2O (2: 2: 1, 25 mL) was added lithium hydroxide monohydrate (1.3 g, 33.12 mmol) portion wise for 10 min at 0 °C; warmed to RT and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (20 mL) and acidified with 1 N HCl to pH~2. The obtained solid was filtered, washed with isopropyl alcohol (15 mL) and dried in vacuo to obtain compound 159 (2.8 g, 84%) as white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.1); *H NMR (DMSO-rf6, 400 MHz): δ 13.65 (br s, 1H), 11.55 (s, 1H), 8.07 (d, J= 8.3 Hz, 1H), 8.03-7.82 (m, 6H).
Example 20: Synthesis of 5-methyl-ll-oxo-10, ll-dihvdro-5W-dibenzo [/?. e] [1, 4] diazepine-8carboxylic acid (164) - a common intermediate
Synthesis of methyl 4-((2-(methoxycarbonyl) phenyl) amino)-3-nitrobenzoate (161):
161
To a stirred solution of methyl 2-aminobenzoate 160 (5 g, 33.07 mmol) in NMP (13 mL) under inert 5 atmosphère were added diisopropylethylamine (18 mL, 103.46 mmol), methyl 4-fluoro-3nitrobenzoate 2 (9.87 g, 49.61 mmol) at RT; heated to 120 °C in a sealed tube and stirred for 24 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with diethyl ether (50 mL) and stirred for 1 h. The obtained solid was filtered, washed with diethyl ether (10 mL) and dried in vacuo to afford compound 161 (3.2 g, 29%) as yellow solid.
TLC: 20% EtOAc/ hexanes (Rf. 0.4); XH NMR (DMSO-J6,400 MHz): δ 11.13 (s, 1H), 8.67 (s, 1H), 8.11-7.94 (m, 2H), 7.70-7.62 (m, 2H), 7.58 (d, J= 9.0 Hz, 1H), 7.32-7.27 (m, 1H), 3.87 (s, 6H).
Synthesis of methyl 4-((2-(methoxycarbonyI) phenyl) (methyl) amino)-3-nitrobenzoate (162):
To a stirred solution of compound 161 (3 g, 9.09 mmol) in DMF (30 mL) under inert atmosphère were added césium carbonate (5.9 g, 18.15 mmol), methyl iodide (0.84 mL, 13.59 mmol) at RT and stirred for 6 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice-cold water (60 mL) and extracted with EtOAc (2 x 100 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 162 (2.73 g, 88%) as yellow solid. TLC: 30% EtOAc/ hexanes (Rf. 0.4); JH NMR (DMSO-d6,400 MHz): δ 8.07 (s, 1H), 8.06 (d, J= 7.8 Hz, 1H), 7.71 (dd, J= 7.8, 1.5 Hz, 1H), 7.62 (t, J= 7.3 Hz, 1H), 7.40-7.26 (m, 3H), 3.84 (s, 3H), 3.53 (s, 3H), 3.38 (s, 3H).
Synthesis of methyl 5-methyl-ll-oxo-10, ll-dihydro-5/7-dibenzo [b, e] [1, 4] diazepine-8carboxylate (163):
To a stirred solution of compound 162 (2.73 g, 7.93 mmol) in acetic acid (36 mL) under inert atmosphère was added iron powder (7 g, 127.2 mmol) at RT; heated to 80 C and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with CH2CI2 (50 mL), stirred for 2 h and filtered through celite and the filtrate was concentrated in vacuo to obtain the crude. The crude was dissolved in CH2CI2 (200 mL), washed with saturated aqueous NaHCO3 solution (100 mL), brine (100 mL). The organic extract was dried over sodium sulfate, filtered and concentrated in vacuo to afford compound 163 (2 g, 91%) as an off-white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.4); *H NMR (DMSO-d6,500 MHz): δ 10.33 (s, 1H), 7.68 (dd, J = 8.5, 1.9 Hz, 1H), 7.65-7.61 (m, 2H), 7.50 (t, J= 7.8 Hz, 1H), 7.28 (d, 8.4 Hz, 1H), 7.21 (d, J=
8.1 Hz, 1H), 7.10 (t, J= 7.4 Hz, 1H), 3.80 (s, 3H), 3.33 (s, 3H).
Synthesis of 5-methyl-ll-oxo-10, ll-dihydro-577-dibenzo [b, e] [1, 4] diazepine-8-carboxylic acid (164):
To a stirred solution of compound 163 (2 g, 7.09 mmol) in THF: H2O (1: 1, 80 mL) was added lithium hydroxide monohydrate (900 mg, 21.42 mmol) at RT and stirred for 12 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The pH of the residue was adjusted to ~2 with 2 N HCl. The precipitated solid was fîltered and dried in vacuo to afford compound 164 (1.7 g, 89%) as an off-white solid. TLC: 40% EtOAc/ hexanes (Rf. 0.2); *H NMR (DMSO-d6,400 MHz): δ 12.82 (br s, 1H), 10.33 (s, 1H), 7.70-7.60 (m, 3H), 7.51 (t, J= 7.8
Hz, 1H), 7.27 (d, J= 8.5 Hz, 1H), 7.21 (d, J= 7.8 Hz, 1H), 7.11 (t, J= 7.2 Hz, 1H), 3.32 (s, 3H).
Example 21: Synthesis of 5-ethyi-ll-oxo-10, ll-dihydro-5jH-dibenzo [Z>. e] fl, 4] diazepine-8carboxylic acid (167) - a common intermediate
Synthesis of methyl 4-(ethyl (2-(methoxycarbonyl) phenyl) amino)-3-nitrobenzoate (165):
COoMe C02Me
Et NO2 165
To a stirred solution of compound 161 (2.9 g, 8.78 mmol) in DMF (40 mL) under inert atmosphère were added césium carbonate (6 g, 18.46 mmol), ethyl iodide (1.06 mL, 12.82 mmol) at RT and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice-cold water (60 mL), extracted with EtOAc (2 x 100 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude which was titurated with «-pentane (20 mL) to afford compound 165 (2.8 g, 89%) as pale yellow solid. TLC: 30% EtOAc/ hexanes (Rf. 0.5); *H NMR (DMSO-<Z6,500 MHz): δ 8.05 (dd, J= 9.0, 2.0 Hz, 1H), 8.02 (s, 1H), 7.62-7.57 (m, 2H), 7.45 (d, J= 9.0 Hz, 1H), 7.33 (d, J= 8.1
Hz, 3H).
Synthesis of methyl 5-ethyl-ll-oxo-10, ll-dihydro-5H-dibenzo [b, e] [1, 4] diazepine-8carboxylate (166):
To a stirred solution of compound 165 (2.8 g, 7.82 mmol) in acetic acid (40 mL) under inert atmosphère was added iron powder (6.8 g, 125.1 mmol) at RT; heated to 80 C and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with CH2CI2 (50 mL), stirred for 2 h and filtered through celite. The filtrate was concentrated in vacuo to obtain the crude. The crude was diluted with CH2CI2 (200 mL), washed with saturated aqueous sodium bicarbonate solution (100 mL) and brine (100 mL). The organic extract was dried over sodium sulfate, filtered and concentrated in vacuo to afford compound 166 (2.2 g, 96%) as an off-white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.3); *H NMR (DMSO-<Z6,500 MHz): δ 10.35 (br s, 1H), 7.70 (dd, J = 8.5, 1.9 Hz, 1H), 7.67 (s, 1H), 7.62 (d, J= 7.5 Hz, 1H), 7.51 (t, J= 8.1 Hz, 1H), 7.29 (d, J= 8.4 Hz, 1H), 7.22 (d, J= 8.1 Hz, 1H), 7.12 (t, J= ΊΑ Hz, 1H), 3.31 (s, 5H), 1.11 (t, J= 6.9 Hz, 3H).
Synthesis of 5-ethyl-ll-oxo-10, ll-dihydro-577-clibenzo [b, e] [1, 4] diazepine-8-carboxylic acid (167):
167
To a stirred solution of compound 166 (2.1 g, 7.09 mmol) in THF: H2O (1: 1, 60 mL) was added lithium hydroxide monohydrate (890 mg, 21.26 mmol) at RT and stirred for 12 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The pH of the residue was acidified to ~2 with 2 N HCl. The precipitated solid was filtered, washed with water (50 mL) and dried in vacuo to afford compound 167 (1.6 g, 80%) as an off-white solid. TLC: 30% 92
EtOAc/ hexanes (Rf. 0.2); lH NMR (DMSO-76,400 MHz): δ 12.82 (br s, 1H), 10.33 (s, 1H), 7.697.59 (m, 3H), 7.53-7.48 (m, 1H), 7.24 (dd, 7= 19.7, 8.2 Hz, 2H), 7.12 (t, 7= 7.5 Hz, 1H), 3.79 (br s, 2H), 1.12 (t, 7= 7.0 Hz, 3H).
Example 22: Synthesis of 5-benzyl-ll-oxo-lO, ll-dihvdro-5/Z-dibe.nzo \b, é\ [1, 4] diazepine-85 carboxylic acid (170) - a common intermediate
Synthesis of methyl 4-(benzyI (2-(methoxycarbonyI) phenyl) amino)-3-nitrobenzoate (168):
168
To a stirred solution of compound 161 (2.5 g, 7.57 mmol) in DMF (40 mL) under inert atmosphère were added césium carbonate (4.92 g, 15.15 mmol), benzyl bromide (1.34 mL, 11.36 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice-cold water (60 mL) and extracted with EtOAc (2 x 100 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 10%
EtOAc/ hexanes to afford compound 168 (3 g, 91%) as colorless thick syrup. TLC: 20% EtOAc/ hexanes (Rf. 0.4); XH NMR (DMSO-76,500 MHz): δ 8.04 (s, 1H), 7.97 (dd, 7= 8.8, 1.9 Hz, 1H), 7.61-7.57 (m, 1H), 7.56- 7.50 (m, 3H), 7.40 (t, 7= 8.2 Hz, 2H), 7.34 (t, 7= 7.7 Hz, 2H), 7.28-7.23 (m, 2H), 5.20 (s, 2H), 3.81 (s, 3H), 3.39 (s, 3H).
Synthesis of methyl 5-benzyl-ll-oxo-10, ll-dihydro-5H-dîbenzo [b, e] [1, 4] diazepine-8carboxylate (169):
To a stirred solution of compound 168 (950 mg, 2.26 mmol) in acetic acid (10 mL) under inert
O atmosphère was added ironpowder (2 g, 36.36 mmol) at RT; heated to 80 C and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with CH2CI2 (50 mL), filtered through celite and the filtrate was concentrated in vacuo to obtain the crude. The crude was dissolved in CH2CI2 (200 mL), washed with saturated aqueous sodium bicarbonate solution (100 mL) and brine (100 mL). The organic extract was dried over sodium sulfate, filtered and concentrated in vacuo to afford compound 169 (800 mg, 98%) as an off-white solid. TLC: 20% EtOAc/ hexanes (Rf. 0.4); *H NMR (DMSO-J6,500 MHz): δ 10.42 (s, 1H), 7.66 (s, 1H), 7.62 (d, J= 8.1 Hz, 2H), 7.48- 7.34 (m, 4H), 7.33-7.21 (m, 3H), 7.15 (t, J= 7.2 Hz, 1H), 7.09 (t, J= 7.4 Hz, 1H), 5.04 (br s, 2H), 3.79 (s, 3H).
Synthesis of 5-benzyl-ll-oxo-10, ll-dihydro-5//-dibenzo [b, e] [1, 4] diazepine-8-carboxylic acid (170):
Bn
170
To a stirred solution of compound 169 (2 g, 5.58 mmol) in THF: H2O (1: 1, 80 mL) was added lithium hydroxide monohydrate (703 mg, 16.73 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The pH of the residue was acidified with 6 N HCl to pH ~2 and stirred for 1 h. The precipitated solid was filtered and dried in vacuo to afford compound 170 (1.5 g, 78%) as an off-white solid. TLC: 50% EtOAc/hexanes (Rf. 0.2); 3H NMR (DMSO-^, 500 MHz): δ 12.87 (br s, 1H), 10.39 (s, 1H), 7.657.55 (m, 3H), 7.47- 7.21 (m, 7H), 7.16-7.04 (m, 2H), 5.02 (br s, 2H).
Example 23: Synthesis of 3-methoxy-ll-oxo-lO, 11-dihydrodibenzo \b, f\ [1, 41 fhiazepine-8carboxylic acid (P-42)
Synthesis of methyl 4-methoxy-2-(((trifluoromethyl) sulfonyl) oxy) benzoate (P-36): To a stirred solution of methyl 2-hydroxy-4-methoxybenzoate P-35 (1 g, 5.49 mmol) in pyridine (5 mL) under argon atmosphère was added triflic anhydride (1 mL, 6.31 mmol) drop wise at 0 C; warmed to RT and stirred for 2 h; heated to 40 C and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (25 mT,) and extracted with diethyl ether (2x30 mL). The combined organic extracts were washed with 1 N HCl (15 mL), water (15 mL), dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 10% EtOAc/ hexanes to afford compound P-36 (1.58 g, 92%) as colorless syrup. TLC: 10% EtOAc/ hexanes (Rf 0.6); *H-NMR (CDC13, 500 MHz): δ 8.06 (d, J= 9.0 Hz, 1H), 6.95 (d, J= 8.5 Hz, 1H), 6.78 (s, 1H), 3.93 (s, 3H), 3.88 (s, 3H).
Synthesis of methyl-4-methoxy-2-((4-methoxybenzyl) thio) benzoate (P-37): To a stirred solution of compound P-36 (1 g, 3.18 mmol) in 1, 4-dioxane (15 mL) under argon atmosphère were added (4-methoxyphenyl) methanethiol (539 mg, 3.50 mmol), césium carbonate (2 g, 6.36 mmol) at RT and degassed under argon for 20 min. To this was added Pd(dppf)2C12 (233 mg, 0.31 mmol); heated to 80 °C and stirred for 8 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2x35 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 5-7% EtOAc/ hexanes to afford compound P-37 (340 mg, 30%) as an off-white solid. TLC: 10% EtOAc/ hexanes (Rf. 0.4); ’H-NMR (CDC13, 500 MHz): δ 7.96 (d, J= 8.5 Hz, 1H), 7.38-7.37 (m, 1H), 7.35 (d, J= 9.0 Hz, 1H), 6.85 (d, 8.0 Hz, 2H), 6.82 (s, 1H), 6.64 (d, J= 8.5 Hz, 1H), 4.10 (s, 2H),
3.86 (s, 3H),3.79(s, 6H).
Synthesis of methyl 2-mercapto-4-methoxybenzoate (P-38): A stirred solution of compound P-37 (330 mg, 1.03 mmol) in trifluoroacetic acid (5 mL) under argon atmosphère was heated to reflux and stirred for 6 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude compound P-38 (340 mg) as brown syrup which was carried to the next step without any further purification. TLC: 10% EtOAc/ hexanes (Rf. 0.7).
Synthesis of methyl 4-methoxy-2-((4-(methoxycarbonyl)-2-nitrophenyl) thio) benzoate (P-39):
To a stirred solution of compound P-38 (200 mg, 1.01 mmol) in DMF (5 mL) under argon atmosphère were added methyl 4-fluoro-3-nitrobenzoate (201 mg, 1.01 mmol), césium carbonate (656 mg, 2.02 mmol) at RT; heated to 40 C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (20 mL) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were washed with water (20 mL), dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 15% EtOAc/ hexanes to afford compound P-39 (280 mg, 74%) as yellow solid. TLC: 20% EtOAc/ hexanes (Rf. 0.4); *H-NMR (CDC13, 400 MHz): δ 8.84 (d, J= 7.2 Hz, 1H), 8.03 (d, J= 8.8 Hz, 1H), 7.96-7.92 (m, 1H), 7.78 (s, 1H), 7.17-7.12 (m, 1H), 7.08-6.93 (m, 1H), 3.96-3.93 (m, 3H), 3.85 (s, 3H), 3.803.74 (m, 3H).
Synthesis of methyl 2-((2-amino-4-(methoxycarbonyl) phenyl) thio)-4-methoxybenzoate (P-40): To a stirred solution of compound P-39 (270 mg, 0.71 mmol) in MeOH (10 mL) under argon atmosphère was added 10% Pd/C (80 mg) at RT and stirred under hydrogen atmosphère (balloon pressure) for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was fîltered through celite, washed with CH2CI2 (2 x 25 mL) and the filtrate was concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 15% EtOAc/ hexanes to afford compound P-40 (180 mg, 79%) as colorless syrup. TLC: 20% EtOAc/ hexanes (Rf. 0.5); ’H-NMR (CDC13, 400 MHz): δ 8.03 (d, 7= 8.8 Hz, 1H), 7.54-7.40 (m, 1H), 7.08 (d, 7= 8.8 Hz, 1H), 6.79-6.72 (m, 1H), 6.66-6.63 (m, 1H), 6.21-6.14 (m, 1H), 3.95-3.88 (m, 5H), 3.85 (s, 3H), 3.65 (s, 3H).
Synthesis of 2-((2-amino-4-carboxyphenyl) thio)-4-methoxybenzoic acid (P-41): To a stirred solution of compound P-40 (160 mg, 0.46 mmol) in THF: H2O (2: 1, 6 mL) under argon atmosphère was added lithium hydroxide monohydrate (96 mg, 2.30 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo, diluted with water (20 mL), acidifïed with 1 N HCl to pH~6. The obtained precipitate was filtered and dried in vacuo to afford compound P-41 (85 mg, crude) as an off-white solid. TLC: 50% EtOAc/ hexanes (Rf. 0.2); Ή-NMR (DMSO-76,400 MHz): δ 12.84 (br s, 2H), 7.95 (d, J= 8.8 Hz, 1H), 7.44 (s, 1H), 7.40 (d, 7= 8.0 Hz, 1H), 6.13 (s, 1H), 5.58 (br s, 2H), 3.80-3.69 (m, 2H), 3.60 (s, 3H).
Synthesis of 3-methoxy-ll-oxo-10,11-dihydrodibenzo \b,j\ [1, 4] thiazepine-8-carboxylic acid (P-42): To a stirred solution of compound 41 (80 mg, 0.25 mmol) in THF (8 mL) under argon atmosphère was added CDI (203 mg, 1.25 mmol) at 0 °C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo, diluted with water (20 mL), acidified with dilute HCl. The obtained precipitate was filtered and dried in vacuo to afford compound P-42 (50 mg, crude) as an off-white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.3); ’H-NMR (DMSO-^, 400 MHz): δ 13.18 (br s, 1H), 10.64 (s, 1H), 7.77 (s, 1H), 7.66 (s, 2H), 7.16-7.07 (m, 1H), 7.01 (d, 7= 8.8 Hz, 1H), 6.82-6.79 (m, 1H), 3.80 (s, 3H).
Example 24: Synthesis of 2-methyl-ll-oxo-10,11-dihydrodibenzo [A f] [1, 41 thiazepine-8carboxylic acid (P-51)
Synthesis of methyl 2-hydroxy-5-methylbenzoate (P-44): To a stirred solution of 2-hydroxy-5methylbenzoic acid P-43 (2 g, 13.15 mmol) in MeOH (65 mL) under argon atmosphère was added sulphuric acid (0.65 mL) at RT; heated to reflux and stirred for 20 h. The reaction was monitored by 5 TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with ice water (50 mL) and extracted with ether (3 x 40 mL). The combined organic extracts were washed with 10% aqueous NaHCCL solution (until the pH becomes neutral), dried over sodium sulfate, filtered and concentrated in vacuo to obtain compound P-44 (2 g, 92%) as colorless liquid. TLC: 10% EtOAc/ hexanes (Rf. 0.7); ^-NMR (CDC13, 500 MHz): δ 10.57 (s, 1H), 7.65 (s, 1H), 10 7.29 (d, J= 7.5 Hz, 1H), 6.90 (d, J= 8.0 Hz, 1H), 3.96 (s, 3H), 2.30 (s, 3H).
Synthesis of methyl 5-methyl-2-(((trifluoromethyl) sulfonyl) oxy) benzoate (P-45): To a stirred solution of compound P-44 (2 g, 12.04 mmol) in pyridine (8 mL) under argon atmosphère was added trifluoro methane sulfonic anhydride (2.3 mL, 13.85 mmol) at 0 C; warmed to RT and stirred for 2 h; heated to 40 °C and stirred for 8 h. The reaction was monitored by TLC; after completion of 15 the reaction, the volatiles were removed in vacuo. The residue was diluted with water (50 mL) and extracted with ether (3 x 50 mL). The combined organic extracts were washed with water (50 mL), brine (50 mT,), 1 N HCl (40 mL), dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 3-5% EtOAc/hexanes to afford compound P-45 (2.6 g, 72%) as colorless liquid. TLC: 7% EtOAc/ hexanes (Rf. 0.6); ’H-NMR (CDC13, 500 MHz): δ 7.88 (s, 1H), 7.40 (d, J= 8.5 Hz, 1H), 7.17 (d, J = 8.0 Hz, 1H), 3.96 (s, 3H), 2.42 (s, 3H).
Synthesis of methyl 2-((4-methoxybenzyl) thio)-5-methylbenzoate (P-46): To a stirred solution of compound P-45 (1 g, 3.35 mmol) in 1, 4-dioxane (15 mL) under argon atmosphère were added (4-methoxyphenyl) methanethiol (568 mg, 3.69 mmol), césium carbonate (2.18 g, 6.71 mmol) atRT and degassed for 20 min. To this was added Pd(dppf)2C12 (61.4 mg, 0.083 mmol); heated to 110 C and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 40 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 3-5% EtOAc/ hexanes to afford compound P-46 (290 mg, 29%) as yellow solid. TLC: 10% EtOAc/ hexanes (Rf. 0.5); ’H-NMR (CDC13, 400 MHz): δ 7.75 (s, 1H), 7.30 (d, J= 8.8 Hz, 2H), 7.22-7.21 (m, 2H), 6.83 (d, J= 8.8 Hz, 2H), 4.09 (s, 2H), 3.89 (s, 3H), 3.79 (s, 3H), 2.32 (s, 3H).
Synthesis of methyl 2-mercapto-5-methylbenzoate (P-47): A stirred solution of compound P-46 (200 mg, 0.66 mmol) in trifluoro acetic acid (10 mL) at RT under argon atmosphère was heated to 70-75 °C and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to afford compound P-47 (100 mg, crude) as yellow syrup. TLC: 10% EtOAc/ hexanes (Rf. 0.7); ’H-NMR (DMSO-46, 500 MHz): δ 7.74 (s, 1H), 7.44 (d, J= 8.0 Hz, 1H), 7.26 (d, J= 7.5 Hz, 1H), 5.20 (s, 1H), 3.82 (s, 3H), 2.28 (s, 3H).
Synthesis of methyl 2-((4-(methoxycarbonyl)-2-nitrophenyl) thio)-5-methylbenzoate (P-48): To a stirred solution of compound P-47 (100 mg, 0.50 mmol) in DMF (5 mL) under argon atmosphère were added methyl 4-fluoro-3-nitrobenzoate (100 mg, 0.55 mmol), césium carbonate (326 mg, 1.00 mmol) at RT; heated to 60 °C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (30 mL) and extracted with CH2C12 (2x30 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 10% EtOAc/ hexanes to afford compound P-48 (100 mg, 55%) as yellow solid. TLC: 10% EtOAc/ hexanes (Rf. 0.3); ’H-NMR (DMSO-i/g, 400 MHz): δ 8.63 (s, 1H), 8.03 (d, J= 8.8 Hz, 1H), 7.78 (s, 1H), 7.61 (d, 7.6 Hz, 1H), 7.55-7.53 (m,
1H), 6.99 (d, J= 8.4 Hz, 1H), 3.87 (s, 3H), 3.68 (s, 3H), 2.43 (s, 3H).
Synthesis of methyl 2-((2-amino-4-(methoxycarbonyl) phenyl) thio)-5-methylbenzoate (P-49):
To a stirred solution of compound P-48 (400 mg, 1.10 mmol) in MeOH (20 mL) under argon atmosphère was added 10% Pd/ C (200 mg) at RT and stirred under hydrogen atmosphère (balloon pressure) for 24 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite and washed with 50% MeOH/ CH2CI2 (2 x 25 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 7-10% EtOAc/ hexanes to afford compound P-49 (220 mg, 60%) as pale yellow solid. TLC: 20% EtOAc/ hexanes (Rf. 0.5); ‘lI-NMR (DMSO-d* 500 MHz): δ 7.77 (s, 1H), 7.44 (s, 1H), 7.40 (d, J= 7.5 Hz, 1H), 7.21 (d, J= 8.0 Hz, 1H), 7.16-7.14 (m, 1H), 6.57 (d, J= 8.5 Hz, 1H), 5.63 (br s, 2H), 3.87 (s, 3H), 3.84 (s, 3H), 2.27 (s, 3H).
Synthesis of 2-((2-amino-4-carboxyphenyl) thio)-5-methylbenzoic acid (P-50): To a stirred solution of compound P-49 (220 mg, 0.66 mmol) in THF: H2O (5: 1,6 mL) under argon atmosphère was added lithium hydroxide monohydrate (139 mg, 3.32 mmol) at RT and stirred for 20 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (15 mL) and acidified with 6 N HCl to pH~4. The precipitated solid was filtered and dried in vacuo to afford compound P-50 (110 mg, 55%) as an offwhite solid. TLC: 20% EtOAc/ hexanes (Rf. 0.2); JH-NMR (DMSO-r/6, 500 MHz): δ 12.96 (br s, 2H), 7.76 (s, 1H), 7.42 (s, 1H), 7.37 (d, J= 8.0 Hz, 1H), 7.18 (d, J= 8.0 Hz, 1H), 7.15-7.13 (m, 1H), 6.54 (d, J= 8.0 Hz, 1H), 5.54 (br s, 2H), 2.26 (s, 3H).
Synthesis of 2-methyl-ll-oxo-10,11-dihydrodibenzo [b, f\ [1, 4] thiazepine-8-carboxylic acid (P-51): To a stirred solution of compound P-50 (110 mg, 0.36 mmol) in THF (10 mL) under argon atmosphère was added CDI (176 mg, 1.08 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with ice cold water (20 mL) and acidified with 6 N HCl to pH~4. The precipitated solid was filtered and dried in vacuo to afford compound P-51 (60 mg, 58%) as white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.6); ’H-NMR (DMSO-î/6, 400 MHz): δ 13.21 (br s, 1H), 10.76 (s, 1H), 7.76 (s, 1H), 7.65 (s, 2H), 7.50 (s, 1H), 7.41 (d, J= 8.0 Hz, 1H), 7.30 (d, J= 8.0 Hz, 1H), 2.29 (s, 3H).
100
Example 25: Synthesis of 3-methyI-ll-oxo-lO, 11-dihydrodibenzo [Z>, f\ [1, 41 thiazepine-8carboxylic acid (P-8)
Synthesis of methyl 4-methyl-2-(((trifluoromethyI) sulfonyl) oxy) benzoate (P-2): To a stirred solution of methyl 2-hydroxy-4-methylbenzoate P-l (950 mg, 5.70 mmol) in pyridine (9.5 mL) under argon atmosphère was added triflic anhydride (1.05 mL, 6.20 mmol) drop wise at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was acidified with 6 N HCl and extracted with diethyl ether (2 x 50 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 2% EtOAc/ hexanes to afford compound P-2 (1.2 g, 71%) as colorless liquid. TLC: 10% EtOAc/ hexanes (Rf. 0.7); ’lI-NMR (CDC13, 400 MHz): δ 7.98 (d, J= 8.0 Hz, 1H), 7.28 (d, 8.0 Hz, 1H),
7.09 (s, 1H), 3.94 (s, 3H), 2.45 (s, 3H).
101
Synthesis of methyl 2-((4-methoxybenzyl) thio)-4-methylbenzoate (P-3): To a stirred solution of compound 2 (600 mg, 2.01 mmol) in 1, 4-dioxane (12 mL) under argon atmosphère were added (4methoxyphenyl) methanethiol (341 mg, 2.21 mmol), césium carbonate (1.3 g, 4.02 mmol) at RT and degassed under argon for 20 min. To this was added Pd(dppf)2C12 (36.8 mg, 0.05 mmol); heated to
O
100 C and stirred for 48 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (25 mL) and extracted with EtOAc (2x35 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 3% EtOAc/ hexanes to afford compound 3 (200 mg, 33%) as sticky solid. TLC: 10% EtOAc/ hexanes (Rf. 0.4); *H-NMR (CDC13, 500 MHz): δ 7.85 (d, J= 8.5 Hz, 1H), 7.32 (d, J= 8.0 Hz, 2H), 7.14 (s, 1H), 6.94 (d, J= 8.5 Hz, 1H), 6.84 (d, 8.0 Hz, 2H), 4.10 (s, 2H), 3.86 (s, 3H), 3.78 (s, 3H), 2.34 (s, 3H).
Synthesis of methyl 2-mercapto-4-methylbenzoate (P-4): A stirred solution of compound P-3 (200 mg, 0.65 mmol) in trifluoro acetic acid (4 mL) under argon atmosphère at RT was heated to 80 C and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude compound P-4 (115 mg) which was carried to the next step without any further purification. TLC: 10% EtOAc/ hexanes (Rf. 0.8).
Synthesis of methyl 2-((4-(methoxycarbonyI)-2-nitrophenyl) thio)-4-methylbenzoate (P-5): To a stirred solution of methyl 4-fluoro-3-nitrobenzoate (120 mg, 0.60 mmol) in DMF (4 mL) under argon atmosphère were added compound P-4 (115 mg, crude), césium carbonate (392 mg, 1.20 mmol) at RT; heated to 60 °C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2x35 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 10% EtOAc/ hexanes to afford compound P-5 (120 mg, 55%) as yellow solid. TLC: 15% EtOAc/ hexanes (Rf. 0.7); Ή-NMR (CDC13, 400 MHz): δ 8.85 (s, 1H), 7.95-7.89 (m, 2H), 7.46 (s, 1H), 7.38 (d, J= 8.8 Hz, 1H), 6.93 (d, J= 8.4 Hz, 1H), 3.93 (s, 3H), 3.76 (s, 3H), 2.42 (s, 3H).
Synthesis of methyl 2-((2-amino-4-(methoxycarbonyl) phenyl) thio)-4-methylbenzoate (P-6): To a stirred solution of compound P-5 (120 mg, 0.33 mmol) in MeOH (10 mL) under argon
102 atmosphère was added 10% Pd/C (60 mg) at RT and stirred under hydrogen atmosphère (balloon pressure) for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite, washed with w-pentane (2x5 mL) and dried in vacuo to afford compound P-6 (90 mg, 82%) as yellow sticky solid. TLC: 15% EtOAc/ hexanes (Rf. 0.5); ’H-NMR (DMSO-76, 400 MHz): δ 7.86 (d, J= 8.0 Hz, 1H), 7.45 (s, 1H), 7.40 (d, 7= 8.0 Hz, 1H), 7.15 (d, 7= 8.0 Hz, 1H), 7.05 (d, J= 8.0 Hz, 1H), 6.44 (s, 1H), 5.65 (br s, 2H), 3.85-3.84 (m, 6H), 2.13 (s, 3H).
Synthesis of 2-((2-amino-4-carboxyphenyl) thio)-4-methylbenzoic acid (P-7): To a stirred solution of compound P-6 (90 mg, 0.27 mmol) in THF: H2O (2: 1,3 mL) under argon atmosphère was added lithium hydroxide monohydrate (56 mg, 1.35 mmol) at RT and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (15 mL) and extracted with EtOAc (2 x 20 mL). The aqueous layer was acidified with 2 N HCl, the obtained solid was filtered, washed with n-hexane (2x5 mL) and dried in vacuo to afford compound P-7 (60 mg, 73%) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.2); XHNMR (DMSO-i/é, 500 MHz): δ 12.95 (br s, 2H), 7.85 (d, J= 8.0 Hz, 1H), 7.44 (s, 1H), 7.38 (d, 7= 8.0 Hz, 1H), 7.15 (d, J= 7.5 Hz, 1H), 7.02 (d, 7= 8.0 Hz, 1H), 6.42 (s, 1H), 5.57 (br s, 2H), 2.13 (s, 3H).
Synthesis of 3-methyl-ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-carboxylic acid (P-8): To a stirred solution of compound P-7 (60 mg, 0.19 mmol) in THF (4 mL) under argon atmosphère was added CDI (96 mg, 0.59 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the réaction, the volatiles were removed in vacuo, diluted with water (20 mL), acidified with dil. HCl to pH~ 3. The obtained precipitate was filtered and dried in vacuo to afford compound P-8 (45 mg, 80%) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.3); *H-NMR (DMSO-76, 400 MHz): δ 13.12 (br s, 1H), 10.72 (s, 1H), 7.76 (d, 7= 8.0 Hz, 2H), 7.59 (d, 7= 8.0 Hz, 2H), 7.37 (s, 1H), 7.26 (s, 1H), 2.30 (s, 3H).
Example 26: Préparation of Compounds
Acids similar to compound 6 (compounds 14, 21, 28, 35, 42, 50, 55, 62, 70, 76, 82, 88, 97,135,140, 145,150,155,156,159,164,167,170, P-8, P-42, P-51) were synthesized as mentioned above and
103 converted to final products either using commercially available amines or by using prepared amines employing Procedures A, B, C, D, E, F, G, H and the results are captured in Table 1.
Procedure A:
To a stirred solution of 6 (50 mg, 0.18 mmol) in DMF (3 mL) under argon atmosphère were added EDCI.HC1 (50 mg, 0.22 mmol), HOBt (35 mg, 0.22 mmol), 2-(5-methyl-l, 3, 4-thiadiazol-2-yl) ethan-l-amine hydrochloride 187 (50 mg, 0.22 mmol) and diisopropyl ethyl amine (0.1 mL, 0.55 mmol) at 0 °C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and stirred for 1 h. The crude was extracted with EtOAc or the precipitated material was either directly dried in vacuo or triturated or purified through silica gel column chromatography to afford the desired compound.
Procedure B:
To a stirred solution of 6 (40 mg, 0.14 mmol) in DMF (4 mL) under argon atmosphère were added pyridin-3-amine 182 (15 mg, 0.16 mmol), HATU (84 mg, 0.22 mmol), diisopropyl ethyl amine (0.05 mL, 0.29 mmol) at 0 °C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice cold water (15 mL), the obtained precipitate was fîltered, or extracted with EtOAc (2x30 mL). The combined organic extracts were dried over sodium sulfate, fîltered, concentrated in vacuo to obtain the crude. The crude was extracted with EtOAc or the precipitated material was directly dried in vacuo, triturated or purified through silica gel column chromatography to afford the desired compound.
Procedure C:
To a stirred solution of compound 35 (50 mg, 0.17 mmol) in CH2CI2 (5 mL) were added oxalyl chloride (0.03 mL, 0.34 mmol) or (0.06 mL, 0.69 mmol), DMF (0.01 mL) under argon atmosphère at 0 °C; warmed to 10 °C and stirred for 2-3 h. After completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was carried to the next step without further purification.
104
To a stirred solution of crude acid chloride (70 mg, crude) in CH2CI2 (5.mL) under argon atmosphère were added 2-chloro-4-fluoroaniIine 184 (25 mg, 0.17 mmol) and pyridine (0.07 mL, 0.86 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with CH2CI2 (2x30 mL). The combined organic extracts were washed with 1 N HCl (20 mL), 10% NaHCCL solution (30 mL), brine (15 mL) dried over sodium sulfate, filtered and concentrated in vacuo to obtain crude. The precipitated material was either directly dried in vacuo or triturated or purified through silica gel column chromatography /préparative HPLC or by acid-base treatment to afford the desired compound.
Procedure D:
To a stirred solution of 6 (40 mg, 0.14 mmol) in DMF (3 mL) under argon atmosphère was added CDI (71.7 mg, 0.17 mmol) at 0 °C; warmed to RT and stirred for 2 h. To this were added (4(trifluoromethoxy) phenyl) methanamine 172 (33.8 mg, 0.17 mmol), and diisopropyl ethyl amine (0.05 mL, 0.29 mmol) and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mass was diluted with water (15 mL) and stirred for 1 h. The precipitate was filtered or extracted with EtOAc or CH2CI2 and the obtained solid was dried in vacuo or purified by column chromatography or triturated to afford the desired product.
Procedure E:
A stirred solution of 6 (40 mg, 0.14 mmol) in thionyl chloride (1 mL) under argon atmosphère was heated to 90 °C and stirred for 1 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain acid chloride (50 mg, crude) which was carried to the next step without further purification. To a stirred solution of 2-amino pyridine 181 (15 mg, 0.16 mmol) in CH2CI2 (5 mL) under argon atmosphère were added pyridine (0.035 mL), acid chloride (50 mg, crude) at 0 °C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude which was purified through silica gel column chromatography using 2% MeOH/ CH2CI2 to afford the desired product.
Procedure F:
105
To a stirred solution of compound 35 (50 mg, 0.17 mmol) in CH2CI2 (5 mL) under argon atmosphère were added ethyl 2-amino-2-(pyridin-2-yl) acetate hydrochloride 249 (26 mg, 0.17 mmol), propylphosphonic anhydride (-50% solution in EtOAc, 0.22 mL, 0.34 mmol), NMM (0.037 mL, 0.34 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo and diluted with water (20 mL) or the pH of the reaction mixture was adjusted to -8 and extracted with CH2CI2 (2 x 30 mL). The combined organic extracts were dried over sodium sulfate, fïltered and concentrated in vacuo to obtain the crude. The crude was purified either through silica gel column chromatography or triturated to afford the desired product.
Procedure G:
To a stirred solution of compound 159 (100 mg, 0.33 mmol) in CH3CN (2 mL) under argon atmosphère was added thiazol-2-amine 231 (36 mg, 0.36 mmol), propylphosphonic anhydride (-50% solution in EtOAc, 0.8 mL, 1. 32 mmol) and NMM (0.14 mL, 1.32 mmol) at RT in a microwave vial and heated at 100 °C and stirred for 1 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo and diluted with water (20 mL) and the precipitated solid was fïltered. The obtained solid was either directly dried in vacuo or titurated or purified by column chromatography to afford the desired product.
Procedure H:
To a stirred solution of compound 159 (100 mg, 0.33 mmol) in CH2C12 (12 mL) under argon atmosphère were added EDCI.HC1 (188.8 mg, 0.98 mmol), 6-fluorobenzo [<7] thiazol-2-amine 241 (61 mg, 0.36 mmol) and DMAP (120.7 mg, 0.98 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the precipitated solid was fïltered washed with water and titurated to afford the desired product.
106
Représentative Commercially Available Amines Used for Synthesis
171
172
173
174
175
188
185
187
CIH
HNh2n~^n'N
194
191
192
196 197 198 199
H2N | N--. Me—L | ^nh2 | r-N JL ^~ci 1 S |
S | nh2 |
201
202
203
Me
205 h2n
206
208
209
133
207
107
108
Préparation of amines for compound synthesis
Synthesis of 2-cyclohexylethanamine hydrochloride (261):
To a stirred solution of 2-(cyclohex-l-en-l-yl) ethanamine 260 (500 mg, 4.00 mmol) in MeOH (10 mL) under argon atmosphère was added 10% Pd/C (50 mg) at RT and stirred under hydrogen atmosphère (balloon pressure) for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was fiitered through celite, washed with MeOH (2x5 mL) and the filtrate was concentrated in vacuo. The residue was triturated with CH2CI2: EtOAc (1: 1,2 mL), diethyl ether in 1 N HCl (4 mL) to afford compound 261 (250 mg, 38%) as white solid. TLC: 20% EtOAc/ hexanes (Rf. 0.3); *H-NMR (DMSO-J6, 500 MHz): δ 7.79 (br s, 2H), 2.77 (t, J= 7.5 Hz, 2H), 1.66-1.59 (m, 5H), 1.45-1.41 (m, 2H), 1.32-1.28 (m, 1H), 1.23-1.11 (m, 3H), 0.91-0.84 (m, 2H).
Synthesis of 2-(4-fluorophenoxy) ethan-l-amine hydrochloride (265)
109
Synthesis of 2-(4-fluorophenoxy) acetonitrile (264): To a stirred solution of 4-fluorophenol 262 (1.74 mL, 18.96 mmol) in acetone (50 mL) under argon atmosphère were added potassium carbonate (6.5 g, 47.40 mmol), chloro acetonitrile 263 (1 mL, 15.80 mmol) at RT; heated to reflux and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was fîltered and the fîltrate was concentrated in vacuo. The residue was extracted with diethyl ether (3 x 40 mL). The combined organic extracts were washed withNaOH solution (30 mL), water (30 mL), dried over sodium sulfate, fîltered and concentrated in vacuo to afford compound 264 (2.4 g, 90%) as brown syrup. TLC: 10% EtOAc/ hexanes (Rf. 0.3); ’H-NMR (CDC13, 400 MHz): δ 7.06-7.01 (m, 2H), 6.98-6.89 (m, 2H), 4.73 (s, 2H).
Synthesis of 2-(4-fluorophenoxy) ethan-l-amine hydrochloride (265): To a stirred solution of compound 264 (200 mg, 1.32 mmol) in MeOH (10 mL) under argon atmosphère were added HCl (0.3 mL), Pd/C (90 mg) and stirred under hydrogen atmosphère (balloon pressure) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with saturated sodium potassium tartrate solution (20 mL) and extracted with diethyl ether (2 x 20 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to afford compound 265 (130 mg, 65%) as an off-white solid. TLC: 10% EtOAc/hexanes (Rf. 0.2); ’H-NMR (DMSO-rf6, 400 MHz): δ 8.31-8.28 (m, 2H), 7.17-7.12 (m, 2H), 7.02-6.98 (m, 2H), 4.16 (t, J= 5.2 Hz, 2H), 3.17 (t, 5.2 Hz, 2H).
Synthesis of 2-(4-fluorocyclohexyl) ethan-l-amine hydrochloride (269)
110
Synthesis of 2-(4-hydroxycyciohexyl) acetonitrile (267): To a stirred solution of 2-(4oxocyclohexyl) acetonitrile 266 (200 mg, 1.45 mmol) in EtOH (10 mL) under argon atmosphère was added sodium borohydride (82.7 mg, 2.18 mmol) at 0 °C; warmed to 10-15 °C and stirred for 1 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with ice cold water (2 mL) and the volatiles were removed in vacuo. The residue was diluted with water (20 mL) and extracted with CH2CI2 (2 x 25 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to afford compound 267 (180 mg, 89%) as colorless syrup. TLC: 50% EtOAc/ hexanes (Rf. 0.4); ’H-NMR (CDC13, 400 MHz): δ 3.62-3.55 (m, 1H), 2.30-2.24 (m, 2H), 2.06-2.01 (m, 2H), 1.92-1.88 (m, 2H), 1.80-1.78 (m, 1H), 1.70-1.63 (m, 2H), 1.59-1.56 (m, 1H), 1.40-1.16 (m, 2H).
Synthesis of 2-(4-fluorocyclohexyl) acetonitrile (268): To a stirred solution of compound 267 (180 mg, 1.29 mmol) in CH2CI2 (5 mL) under argon atmosphère was added DAST (313 mg, 1.94 mmol) at -20 °C; warmed to RT and stirred for 6 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with ice cold water (20 mL) and extracted with CH2CI2 (2x30 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 5-7% EtOAc/hexanes to afford compound 268 (35 mg, 19%) as colorless syrup. TLC: 20% EtOAc/ hexanes (Rf. 0.4); ’lI-NMR (CDC13, 500 MHz): δ 4.88-4.79 (m, 1H), 2.27 (d, J= 7.0 Hz, 2H), 2.10-2.08 (m, 2H), 1.77-1.70 (m, 3H), 1.57-1.33 (m, 4H).
Synthesis of 2-(4-fluorocycIohexyl) ethan-l-amine hydrochloride (269): To a stirred solution of compound 268 (35 mg, 0.24 mmol) in ether (5 mL) under argon atmosphère was added lithium aluminium hydride (18.8 mg, 0.49 mmol) at 0 °C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with saturated sodium potassium tartrate solution (10 mL) at 0-5 °C and extracted with ether (2 x 20 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was dissolved in ether (3 mL), slowly added 2 N HCl in ether (10 mL) and stirred for 1 h. The precipitated solid was filtered and dried in vacuo to afford compound 269 (12 mg, 33%) as pale yellow solid. TLC: 30% EtOAc/ hexanes (Rf. 0.2); 1H-NMR (DMSO-dô, 400 MHz): δ 7.81 (br s, 2H), 4.87 (br s, 1H), 4.75 (br s, 1H), 2.82-2.77 (m, 2H), 1.89-1.84 (m, 2H), 1.59-1.40 (m, 6H), 1.20 (t, J= 10.0 Hz, 2H).
111
Synthesis of 3-methoxy-3-methylbutan-l-amine (273)
y 7 - MeO^^ | TsCI OTs -------*- Y J “ ... MeO^~^ pyridine | NaN3 DMF | yJ“3 MeO^^ |
270 | 271 | 272 |
H2, Pd/C \f NH2
EtOH
273
Synthesis of 3-methoxy-3-methylbutyI 4-methylbenzenesulfonate (271): To a stirred solution of 3-methoxy-3-methylbutan-l-ol 270 (1 g, 8.46 mmol) inpyridine (15 mL) under argon atmosphère was added tosyl chloride (1.6 g, 8.46 mmol) at 0 °C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was quenched with saturated NaHCO3 solution (20 mL) and extracted with EtOAc (2x10 mL). The combined organic extracts were dried over sodium sulphate, filtered and concentrated in vacuo to afford compound 271 (1.8 g, 78%) as colorless syrup. TLC: 30% EtOAc/ hexanes (Rf. 0.7); XH-NMR (CDC13, 400 MHz): δ 7.79 (d, J= 8.4 Hz, 2H), 7.34 (d, 7= 7.6 Hz, 2H), 4.13 (t, 7= 7.2 Hz, 2H), 3.10 (s, 3H), 2.45 (s, 3H), 1.87 (t, 7= 7.6 Hz, 2H), 1.12 (s, 6H).
Synthesis of l-azido-3-methoxy-3-methyIbutane (272): To a stirred solution of compound 271 (1 g, 3.67 mmol) in DMF (10 mL) under argon atmosphère was added sodium azide (478 mg, 7.34 mmol) at 0 °C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over sodium sulphate, filtered and concentrated in vacuo to afford compound 272 (525 mg, 76%) as white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.7); ’H-NMR (CDC13, 400 MHz): δ 3.34 (t, 7= 7.6 Hz, 2H), 3.18 (s, 3H), 1.78 (t, J =8.0Hz,2H), 1.18 (s, 6H).
Synthesis of 3-methoxy-3-methylbutan-l-amine (273): To a stirred solution of compound 272 (400 mg, 2.79 mmol) in EtOH (5 mL) under argon atmosphère was added 10% Pd/C (250 mg) at RT and stirred under hydrogen atmosphère (balloon pressure) for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite and the filtrate was
112 concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 80% EtOAc/ hexanes to afford compound 273 (320 mg, 33%) as colorless syrup. TLC: 70% EtOAc/hexanes (Rf. 0.3); ’H-NMR (CDC13, 400 MHz): δ 3.18 (s, 3H), 2.80 (t, J = 8.0 Hz, 0.5 H), 2.70 (t, J= 7.6 Hz, 1H), 2.49 (t, J= 8.0 Hz, 0.5H), 1.71 (t, J= 7.6 Hz, 2H), 1.56 (s, 6H).
Synthesis of 3-phenyl-3-(pyrrolidin-l-yI) propan-l-amine (277)
Synthesis of 3-phenyl-3-(pyrrolidin-l-yl) propanenitrile (276): To a stirred solution of cinnamonitrile 274 (500 mg, 3.87 mmol) in H2O (15 mL) were added pyrrolidine 275 (412 mg, 5.80 mmol), ceric ammonium nitrate (2.1 g, 3.87 mmol) at RT, heated to 60 C and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2x30 mL). The combined organic extracts were dried over sodium sulphate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 25% EtOAc/ hexanes to afford compound 276 (300 mg, 39%) as colorless syrup. TLC: 30% EtOAc/ hexanes (Rf. 0.5); ’H-NMR (CDCI3, 400 MHz): δ 7.39-7.31 (m, 5H), 3.50-3.35 (m, 1H), 2.80-2.70 (m, 2H), 2.60-2.45 (m, 4H), 1.89-1.72 (m, 4H).
Synthesis of 3-phenyl-3-(pyrrolidin-l-yl) propan-l-amine (277): To a stirred solution of compound 276 (150 mg, 0.75 mmol) in THF (10 mL) under argon atmosphère were added lithium aluminium hydride (57 mg, 1.50 mmol), H2SO4 (0.04 mL, 0.75 mmol) at 0 °C; warmed to RT and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with saturated sodium sulphate and the reaction mixture was filtered through celite, washed with EtOAc (2x5 mL).The volatiles were removed in vacuo to afford compound 277(100 mg, 65%) as an off-white solid. TLC: 10% MeOH/ EtOAc (Rf. 0.3); 1H-NMR (CDCI3,
113
400 MHz): δ 7.31-7.30 (m, 5H), 3.26-3.22 (m, 1H), 2.59-2.40 (m, 4H), 2.39-2.37 (m, 2H), 2.142.10 (m, 1H), 2.10 -2.04 (m, 1H), 1.98-1.72 (m, 6H).
Synthesis of 2-(5-methyl-l, 3,4-oxadiazoI-2-yl) ethan-l-amine hydrochloride (283) h2n ^/CO2H (Boc)2O
IMNaOH, THF
BocHN'''x-''C°2H h2n'V
280 O --------------> EDCI.HCI, HOBt, Et3N, CH2CI2
278
279
BocHN^x/^'N'NJ|/ H O
281 l2, TPP,
Et3N, CH2CI2
282
CH2CI2
4N HCl in 1, 4-Dioxane
283
Synthesis of 3-((tert-butoxycarbonyl) amino) propanoic acid (279): To a stirred solution of 3aminopropanoic acid 278 (5 g, 51.02 mmol) in THF (50 mL) were added 1 M aqueous sodium hydroxide solution (25 mL) and Boc-anhydride (11.3 mL, 51.02 mmol) at 0 C; warmed to RT and stirred for 12 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The aqueous layer was washed with diethyl ether (2 x 50 mL) and the pH was adjusted to ~6 with 4 M HCl and extracted with diethyl ether (4 x 50 mL). The combined organic extracts were washed with brine (100 mL), dried over sodium sulphate, filtered and concentrated in vacuo to obtain compound 279 (8 g, 79%) as an off-white solid. TLC: 50% EtOAc/ hexanes (Rf. 0.3); ’H-NMR (DMSO-^, 500 MHz): δ 12.18 (br s, 1H), 6.81 (t, J= 4.8 Hz, 1H), 3.11 (q, J= 6.9 Hz, 2H), 2.34 (t, J= 7.1 Hz, 2H), 1.36 (s, 9H).
Synthesis of to'Abutyl (3-(2-acetylhydrazinyl)-3-oxopropyl) carbamate (281) To a stirred solution of compound 279 (1 g, 5.29 mmol) in CH2C12 (15 ML) under argon atmosphère were added EDCI.HCI (1.3 g, 6.87 mmol), HOBt (714 mg, 5.29 mmol), triethyl amine (0.99 ML, 6.87 mmol), acetic acid hydrazide 280 (430 mg, 5.82 mmol) at 0 °C; warmed to RT and stirred for 1.5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice cold water (5 mL) and extracted with CH2C12 (4 x 20 mL). The combined organic extracts were dried over sodium sulphate, filtered and concentrated in vacuo to obtain crude. The crude was purified through silica gel column cbromatography using 10% EtOAc/ hexanes to afford compound
114
281 (610 mg, 50%) as an off white solid. TLC: 10% EtOAc/ hexanes (Rf. 0.3); ‘H-NMR (DMSOd6, 400 MHz): δ 9.70 (s, 2H), 6.73 (t, J= 4.Ί Hz, 1H), 3.13 (q, J= 6.6 Hz, 2H), 2.27 (t, J= ΊΑ Hz, 2H), 1.83 (s, 3H), 1.37 (s, 9H).
Synthesis of teri-butyl (2-(5-methyl-l, 3,4-oxadiazol-2-yl) ethyl) carbamate (282): To a stirred solution of triphenyl phosphine (428 mg, 1.63 mmol) in CH2CI2 (5 mL) under argon atmosphère were added iodine (414 mg, 1.63 mmol) and stirred for 15 min. To this were added triethyl amine (0.47 mL, 3.26 mmol), compound 281 (200 mg, 0.81 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 4% EtOAc/ hexanes to afford crude compound 282 (360 mg) as an off-white solid. TLC: 10% EtOAc/ hexanes (Rf. 0.7); 1H NMR shows mixture of compound and TPPO as major impurity. ’H-NMR (DMSO-î/6, 400 MHz): δ 7.68-7.49 (m, 48H-TPPO as impurity), 6.97 (t, J= 5.0 Hz, 1H), 3.27 (q, J = 6.5 Hz, 2H), 2.89 (t, J= 6.7 Hz, 2H), 2.43 (s, 3H), 1.35 (s, 9H).
Synthesis of 2-(5-methyl-l, 3, 4-oxadiazol-2-yl) ethan-l-amine hydrochloride (283): To a stirred solution of compound 282 (350 mg) in CH2CI2 (5 mL) under argon atmosphère was added 4 N HCl in 1, 4-dioxane (4 mL) at 0 °C; warmed to RT and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was titurated with CH2CI2 (2 mL), diethyl ether (5 mL) and 77-pentane (5 mL) and dried in vacuo to afford crude compound 283 (60 mg) as brown solid. TLC: 10% EtOAc/ hexanes (Rf. 0.1).
Synthesis of (2-ethylthiazol-5-yl) methanamine hydrochloride (292)
115
Synthesis of ethyl 2-chloro-3-oxopropanoate (286): To a stiired solution of ethyl 2-chloroacetate 284 (5 g, 40.98 mmol) and 285 (3.03 g, 40.98 mmol) in diisopropyl ether (100 mL) under argon atmosphère was added potassium tert-butoxide (5.49 g, 45.08 mmol) portion wise for 10 min at 0 C; warmed to RT and stirred for 24 h. The reaction was monitored by TLC; after completion of the reaction, the pH of the reaction mixture was adjusted to ~ 6 using 5 N HCl. The obtained solid was fîltered, washed with diethyl ether (200 mL) and dried in vacuo to afford compound 286 (6 g) as pale brown syrup. TLC: 30% EtOAc/ hexanes (Rf. 0.2); LC-MS: 21.49% + 75.58%; 149.0 (MF-l); (column; X-Select C-18, (50 x 3.0 mm, 3.5 pm); RT 0.56 min, 0.77 min. 5 Mm Aq.hffiLOAc: ACN 0.8 mL/min).
Synthesis of ethyl 2-ethylthiazole-5-carboxyIate (288): To a stirred solution of compound 286 (1
g) in éthanol (25 mL) under argon atmosphère were added propanethioamide 287 (594 mg, 6.67 mmol), dry magnésium sulfate (4 g) at RT and heated to reflux for 24 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo, diluted with EtOAc (2 x 100 mL). The combined organic extracts were washed with saturated sodium bicarbonate solution (2 x 100 mL), brine (50 mL), dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through flash column chromatography using 6% EtOAc/ hexanes to afford compound 288 (330 mg, 27%) as brown syrup. TLC: 10% EtOAc/ hexanes (Rf. 0.4); ^-NMR (DMSO-îZ6, 400 MHz): δ 8.29 (s, 1H), 4.30 (q, J= 7.1 Hz, 2H), 3.04 (q, J= 7.5 Hz, 2H), 1.31 (t, J= 7.3 Hz, 3H), 1.29 (t, J= 7.3 Hz, 3H).
116
Synthesis of (2-ethylthiazol-5-yl) methanol (289) (SAP-MA1426-31): To a stirred suspension of lithium aluminium hydride (205 mg, 5.40 mmol) in dry THF (15 mL) under inert atmosphère was added compound 288 (500 mg, 2.70 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was cooled to 0 C, quenched with 20% aqueous sodium hydroxide solution (3 mL), filtered through celite and washed with EtOAc (3 x 100 mL). The filtrate was dried over sodium sulfate, filtered and concentrated in vacuo to afford compound 289 (310 mg, 80%) as pale yellow solid. TLC: 50% EtOAc/ hexanes (Rf. 0.4). Tl-NMR (CDC13, 400 MHz): δ 7.51 (s, 1H), 4.82 (s, 2H), 3.01 (q, J= 7.5 Hz, 2H), 1.38 (t, J= 7.6 Hz, 3H).
Synthesis of 5-(chloromethyl)-2-ethylthiazole (290) (SAP-MA1426-34): To a stirred solution of compound 289 (300 mg, 2.09 mmol) in CH2CI2 (15 ML) under inert atmosphère were added triethyl amine (0.6 mL, 4.20 mmol), DMAP (25.6 mg, 0.21 mmol) and mesyl chloride (0.19 mL, 2.51 mmol) at 0 C; warmed to RT and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (50 mL) and extracted with CH2CI2 (3 x 100 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to afford compound 290 (500 mg, crude) as pale yellow syrup. TLC: 30% EtOAc/hexanes (Rf. 0.8); LC-MS: 30.71%; 162.0 (ML+l); (column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 2.14 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min).
Synthesis of 5-(azidomethyl)-2-ethylthiazole (291) (SAP-MA1426-35): To a stirred solution of compound 290 (500 mg, 2.26 mmol) in DMF (20 mL) under inert atmosphère was added sodium azide (294 mg, 4.52 mmol) at RT and heated to 80 °C for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice cold water (50 mL) and extracted with EtOAc (3 x 100 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through flash column chromatography using 15% EtOAc/ hexanes to afford compound 291 (250 mg, 71%) as pale yellow syrup. TLC: 20% EtOAc/ hexanes (Rf. 0.4); 1H-NMR (CDC13, 400 MHz): δ 7.56 (s, 1H), 4.49 (s, 2H), 3.03 (q, J= 7.6 Hz, 2H), 1.40 (t, J= 7.6 Hz, 3H);
Synthesis of (2-ethylthiazol-5-yl) methanamine hydrochloride (292): To a stirred solution of compound 291 (250 mg, 1.48 mmol) in THF: H2O (5:1, 12 mL) was added triphenyl phosphine (780
117 mg, 2.97 mmol) at RT and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The obtained solid was further dried using toluene (2x5 mL) to obtain the crude amine.
The above compound was dissolved in CH2CI2 (5 mL) added 4 N HCl in 1, 4-dioxane (4 mL) under 5 inert atmosphère at 0 °C and stirred for 30 min. The volatiles were removed in vacuo to obtain the crude, which was titurated with EtOAc (2 mL), diethyl ether (2 mL) and pentane (5 mL) to afford compound 292 (180 mg, 68%) as an off-white solid. TLC: 5% MeOH/ CH2C12 (Rf 0.2); *H NMR (DMSO-î/ô,500 MHz): δ 8.48 (br s, 3H), 7.74 (s, 1H), 4.25 (q, 7= 5.5 Hz, 2H), 2.98 (q, 7= 7.5 Hz, 2H), 1.28 (t, 7= 7.5 Hz, 3H);
Synthesis of (2-isopropylthiazol-5-yl) methanamine hydrochloride (298)
Synthesis of ethyl 2-isopropylthiazole-5-carboxylate (294): To a stirred solution of compound
286 (3.05 g) in éthanol (60 mL) under argon atmosphère were added 2-methylpropanethioamide 293 (1.5 g, 14.56 mmol), dry magnésium sulfate (5 g) at RT and heated to reflux for 24 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with saturated sodium bicarbonate solution (100 mL), extracted with EtOAc (3 x 100 mT,). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through flash column chromatography using 2% EtOAc/ hexanes to afford compound 294 (550 mg, 17%) as brown syrup. TLC: 10% EtOAc/
118 hexanes (Rf 0.5); *H NMR (500 MHz, DMSO-î/6) δ 8.31 (s, 1H), 4.30 (q, J= 7.0 Hz, 2H), 3.363.29 (m, 1H), 1.34 (d, J= 6.9 Hz, 6H), 1.29 (t, J= 7.1 Hz, 3H).
Synthesis of (2-isopropylthiazol-5-yl) methanol (295): To a stirred solution of compound 294 (550 mg, 2.76 mmol) in dry THF (10 mL) under inert atmosphère was added lithium aluminium hydride (210 mg, 5.52 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was o monitored by TLC; after completion of the reaction, the reaction mixture was cooled to 0 C, quenched with 15% aqueous sodium hydroxide solution (3 mL), fiitered through celite and washed with EtOAc (100 mL). The filtrate was dried over sodium sulfate, fiitered and concentrated in vacuo to afford compound 295 (360 mg, 83%) as pale yellow syrup. TLC: 50% EtOAc/ hexanes (Rf. 0.3). ’H NMR (400MHz, DMSO-^) δ 7.47 (s, 1H), 5.43 (t, J= 5.7 Hz, 1H), 4.61 (dd, 5.6, 0.6 Hz, 2H), 3.26-3.19 (m, 1H), 1.30 (d, J= 6.9 Hz, 6H).
Synthesis of 5-(chloromethyI)-2-isopropylthiazole (296): To a stirred solution of compound 295 (350 mg, 2.23 mmol) in CH2CI2 (20 mL) under inert atmosphère were added triethyl amine (0.64 mL, 4.45 mmol), DMAP (27.2 mg, 0.22 mmol) and mesyl chloride (0.2 mL, 2.67 mmol) at 0 C; warmed to RT and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (50 mL) and extracted with CH2CI2 (2 x 100 mL). The combined organic extracts were dried over sodium sulfate, fiitered and concentrated in vacuo to afford compound 296 (500 mg, crude) as pale yellow syrup. TLC: 40% EtOAc/ hexanes (Rf. 0.8); LC-MS: 70.54%; 175.8 (M^+l); (column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 2.34 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min).
Synthesis of 5-(azidomethyl)-2-isopropylthiazole (297): To a stirred solution of compound 296 (500 mg, 2.26 mmol) in DMF (20 mL) under inert atmosphère was added sodium azide (445 mg, 6.85 mmol) at RT and heated to 80 °C for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice cold water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic extracts were dried over sodium sulfate, fiitered and concentrated in vacuo to obtain the crude. The crude was purified through column chromatography using 8% EtOAc/hexanes to afford compound 297 (255 mg, 63%) as colorless liquid. TLC: 10% EtOAc/ hexanes (Rf. 0.4); *H NMR (500 MHz, DMSO-îZ6): δ = 7.67 (s, 1H), 4.69 (s, 2H), 3.29-3.24 (m, 1H), 1.32 (d, J= 6.9 Hz, 8H).
119
Synthesis of (2-isopropylthiazol-5-yl) methanamine hydrochloride (298): To a stirred solution of compound 297 (250 mg, 1.37 mmol) in THF: H2O (5:1, 12 mL) was added triphenyl phosphine (720 mg, 2.74 mmol) at RT and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The obtained solid was further dried using toluene (2x5 mL) to obtain the crude amine.
The above crude compound was dissolved in CH2CI2 (5 mL) added 4 N HCl in 1, 4-dioxane (10 mL) under inert atmosphère at 0 C and stirred for 30 min. The volatiles were removed in vacuo to obtain the crude, which was titurated with EtOAc (2 mL), diethyl ether (2 mL) and pentane (5 mL) to afford compound 298 (170 mg, 65%) as low melting hygroscopic solid. TLC: 5% MeOH/
CH2CI2 (Rf. 0.2); XH NMR (500 MHz, DMSO-rf6): δ 8.29 (br s, 2H), 7.72 (s, 1H), 4.25 (d, J= 5.8
Hz, 2H), 3.29-3.24 (m, 1H), 1.30 (d, J= 6.9 Hz, 6H)
Synthesis of (2-methoxythiazol-5-yl) methanamine (300)
299
Na, MeOH
300
Synthesis of (2-methoxythiazol-5-yl) methanamine (300): Sodium métal (46.6 mg, 2.02 mmol) was added slowly to MeOH (5 mL) under argon atmosphère and stirred for 15 min in a sealed tube. To this was added (2-chlorothiazol-5-yl) methanamine 299 (100 mg, 0.67 mmol) and the reaction mixture was heated to 80 °C for 3 h. The reaction was monitored by TLC; after completion the reaction, the reaction mixture was extracted with 20% MeOH/ CH2CI2 (3 x 50 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude compound 300 (32 mg, 33%). The crude was carried forward for next step without purification. TLC: 5% MeOH/ CH2C12 (Rf. 0.2); LC-MS: 90.34%; 145.0 (MM); (column; XSelect CSH C18, (50 x 3.0 mm, 3.5 pm); RT 0.88 min. 2.5 mM Aq.NH4OOCH + 5% ACN: ACN + 5% 2.5 mM Aq. NH4OOCH; 1.2 mL/min).
Synthesis of 5-(aminomethyl) thiazol-2-amine dihydrochloride (303)
120
301 (Boc)2O
NiCI2,NaBH4, MeOH
NHBoc
N HCl in 1, 4-Dioxane
302
CH2CI2
HCl
303
Synthesis of tert-butyl ((2-((tert-butoxycarbonyl) amino) thiazol-5-yl) methyl) carbamate (302): To a stirred solution of 2-aminotbiazole-5-carbonitrile 301 (300 mg, 2.40 mmol) in MeOH (50 mL) were added Boc-anhydride (1.5 mL, 7.20 mmol), nickel(II) chloride (571 mg, 2.40 mmol) at 0 C. To this was added sodium borohydride (638 mg, 16.80 mmol) portion wise forlO min at 0 °C; warmed to RT and stirred for 18 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with EtOAc (100 mL) and water (75 mL), filtered through celite. The organic layer was dried over sodium sulphate, filtered and concentrated in vacuo to obtain compound 302 (300 mg) as colorless syrup. TLC: 10% MeOH/ CH2C12 (Rf. 0.5); ’H NMR (DMSO-d6,500 MHz): δ 11.24 (br s, 1H), 7.38 (br s, 1H), 7.11 (s, 1H), 4.17 (d, J= 5.5 Hz, 2H), 1.39 (s, 9H), 1.37 (s, 9H).
Synthesis of 5-(aminomethyl) thiazoI-2-amine dihydrochloride (303): To a stirred solution of compound 302 (300 mg) in CH2C12 (10 mL) was added 4 N HCl in 1, 4-dioxane (5 mL) under argon atmosphère at 0-5 °C; warmed to RT and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed under reduced pressure. The obtained solid was washed with CH2C12 (5 mL), EtOAc (5 mL) and dried in vacuo to afford compound 303 (120 mg, HCl sait) as yellow solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.2); *H NMR (DMSO-d6,500 MHz): δ 9.31 (br s, 1H), 8.53 (br s, 2H), 8.14 (br s, 1H), 7.37 (br s, 1H), 7.27 (br s, 1H), 7.17 (br s, 1H), 4.07 (d, J= 5.5 Hz, 2H).
Synthesis of 4-(aminomethyI)-A-niethylthiazoI-2-ainine hydrochloride (308)
121
Synthesis of teri-butyl ((2-chlorothiazol-4-yl) methyl) carbamate (305): To a stirred solution of (2-chlorothiazol-4-yl) methanamine 304 (200 mg, 1.35 mmol) in CH2CI2 (10 mL) were added triethylamine (0.6 mL, 4.14 mmol) and Boc-anhydride (0.6 mL, 2.7 mmol) at 0 °C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The aqueous layer was washed with CH2CI2 (50 mL), washed with water (50 mL). The organic extract was dried over sodium sulphate, filtered and concentrated in vacuo to obtain compound 305 (200 mg, 60%) as pale yellow sticky solid. TLC: 5% MeOH/ CH2CI2 (Rf. 0.4); XH NMR (DMSO-^,400 MHz): δ 7.56 (br s, 1H), 7.49 (s, 1H), 4.24 (d, J= 5.9 Hz, 3H), 1.39 (s, 9H).
Synthesis of to Abutvl ((2-(methylamino) thiazol-4-yl) methyl) carbamate (307): A mixture of compound 305 (100 mg, 0.41 mmol) and methyl amine 306 (5 mL, 33% solution in EtOH) in a sealed tube under argon atmosphère was added diisopropyl ethylamine (0.2 mL, 1.21 mmol) under argon atmosphère at RT and heated to 120 °C for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The crude was purified through silica gel column chromatography using 70% EtOAc/ hexanes to afford compound 307 (90 mg, 92%) as colorless sticky solid. TLC: 50% EtOAc/hexanes (Rf. 0.2); 3H NMR (DMSO-r/^400 MHz): δ 7.26 (d, J= 5.6 Hz, 2H), 6.77 (s, 1H), 4.05 (d, J= 5.7 Hz, 2H), 2.76 (d, J= 4.8 Hz, 3H), 1.38 (s, 9H).
Synthesis of 4-(aminomethyI)-7V-methylthiazol-2-amine hydrochloride (308) To a stirred solution of compound 307 (90 mg, 0.37 mmol) in CH2C12 (3 mL) under argon atmosphère was added 4 N HCl in 1, 4-dioxane (3 mL) at 0 °C; warmed to RT and stirred for 4 h. The reaction was
122 monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The crude was titurated with diethyl ether (5 mL) and dried in vacuo to afford compound 308 (70 mg, HCl sait) as brown solid. TLC: 30% EtOAc/ hexanes (Rf. 0.1); *11 NMR (DMSO-îZ6,400 MHz): δ 9.73-9.27 (m, 1H), 8.39 (br s, 3H), 7.35 (s, 1H), 4.08 (q, J= 5.3 Hz, 2H), 2.95 (s, 3H).
Synthesis of 4-(aminomethyl)-2V, A-dimethylthiazol-2-amine hydrochloride (310)
Synthesis of teri-butyl ((2-(dimethylamino) thiazol-4-yI) methyl) carbamate (310): To a stirred solution of compound 305 (100 mg, 0.41 mmol) in CH3CN (3 mL) under argon atmosphère were added dimethyl amine hydrochloride 310 (648 mg, 8.06 mmol) and diisopropyl ethylamine (0.2 mL, 1.21 mmol) in a sealed tube at RT and heated to 120 °C for 54 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with EtOAc (2 x 50 mL) washed with water (20 mL). The organic extract was dried over sodium sulphate, fïltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 310 (80 mg, 77%) as an off-white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.2); 2H NMR (DMSO-J6,400 MHz): δ 7.29 (t, J= 4.8 Hz, 1H), 6.89 (s, 1H), 4.08 (d, J= 5.9 Hz, 2H), 2.97 (s, 6H), 1.38 (s, 9H).
Synthesis of 4-(aminoinethyl)-7V, 7V-dimethylthiazol-2-amine hydrochloride (311): To a stirred solution of compound 310 (100 mg, 0.38 mmol) in CH2CI2 (3 mL) under argon atmosphère was added 4 N HCl in 1, 4-dioxane (3 mL) at 0 °C; warmed to RT and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The crude was titurated with diethyl ether (5 mL) and dried in vacuo to afford compound 311 (75 mg, HCl sait)
123 as an off-white solid. TLC: 50% EtOAc/ hexanes (Rf 0.1); *H NMR (DMSO-îZ6, 400 MHz): δ 8.44 (br s, 3H), 7.38 (s, 1H), 4.10 (q, J= 5.6 Hz, 2H), 3.14 (s, 6H).
Synthesis of (4-ethylthiazol-5-yl) methanamine hydrochloride (319)
Synthesis of ethyl 2-chloro-3-oxopentanoate (313): To a stirred solution of ethyl 3-oxopentanoate 312 (1 g, 6.94 mmol) in CH2CI2 (20 mL) under argon atmosphère was added sulfuryl chloride (0.56 ML, 6.94 mmol) at 0 °C; warmed to RT and stirred for 6 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to afford compound crude 313 (1 g) as colorless liquid. TLC: 10% EtOAc/ hexanes (Rf 0.5); 2H NMR (DMSO-J6,400 MHz): δ
5.66-5.55 (m, 1H), 5.66-5.55 (m, 1H), 4.22 (q, J= 7.1 Hz, 3H), 2.73-2.67 (m, 2H), 1.22 (t, J= 7.1
Hz, 3H), 0.99 (t, J= 7.2 Hz, 3H).
Synthesis of ethyl 4-ethylthiazole-5-carboxylate (315): To a stirred solution of compound 313 (1 g, crude) in EtOH (10 mL) under inert atmosphère was added thioformamide 314 (3.3 g, 55.55 mmol) at RT; heated at 80 °C and stirred for 24 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was purified through column chromatography using 40% EtOAc/ hexanes to afford compound 315 (300 mg, 30%) as yellow solid. TLC: 20% EtOAc/ hexanes (Rf. 0.4); LC-MS: 51.18%; 185.9 (MÉ+1); (column; Ascentis Express Cl8, (50 x 3.0 mm, 2.7 μιη); RT 2.24 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min).
124
Synthesis of (4-ethylthiazol~5-yl) methanol (316): To a stirred solution of compound 315 (300 mg, 1.62 mmol) in THF (10 mL) under inert atmosphère was added lithium aluminium hydride (123 mg, 3.24 mmol) at 0 C; warmed to RT and stirred for 1 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with saturated 10% NaOH solution (1 mL), filtered through celite. The filtrate was concentrated in vacuo to obtain the crude. The crude was purified through column chromatography using 30% EtOAc/ hexanes to afford compound 316 (200 mg, 86%) as yellow solid. TLC: 30% EtOAc/ hexanes (Rf. 0.4); 7H NMR (DMSO-^,400 MHz): δ 8.86 (s, 1H), 5.45 (t, J= 5.5 Hz, 1H), 4.62 (d, 7= 5.5 Hz, 2H), 2.67 (q, 7= 7.5 Hz, 2H), 1.17 (t, 7= 7.5 Hz, 3H).
Synthesis of 5-(chloromethyl)-4-ethylthiazoIe (317): To a stirred solution of compound 316 (200 mg, 1.39 mmol) in CH2CI2 (10 mL) under inert atmosphère were added triethyl amine (0.4 mL, 4.17 mmol), mesyl chloride (0.3 mL, 2.79 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution (5 mL). The organic extract was dried over sodium sulphate, filtered and concentrated in vacuo to obtain compound 317 (200 mg, crude) as yellow solid. TLC: 30% EtOAc/ hexanes (Rf. 0.7); *H NMR (DMSO-7,5,400 MHz): δ 9.01 (s, 1H), 5.08 (s, 2H), 2.76 (q, 7= 7.5 Hz, 2H), 1.20 (t, 7= 7.5 Hz, 3H).
Synthesis of 5-(azidomethyl)-4-ethyithiazoIe (318): To a stirred solution of compound 317 (400 mg, 2.48 mmol) in DMF (10 mL) under argon atmosphère was added sodium azide (322 mg, 4.96 mmol) at RT; warmed to 80 °C and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with ice-cold water (100 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over sodium sulphate, filtered and concentrated in vacuo to afford crude compound 318 (350 mg) as yellow liquid. The crude was carried forward for next step without further purification. TLC: 20% EtOAc/ hexanes (Rf. 0.5).
Synthesis of (4-ethylthiazoI-5-yl) methanamine hydrochloride (319): To a stirred solution of compound 318 (350 mg) in THF: H2O (4: 1, 20 mL) was added triphenyl phosphine (1.3 g, 5.20 mmol) at RT and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude.
125
The crude was diluted with CH2C12 (2 mL) cooled to 0 °C; added 4 N HCl 1, 4-dioxane (5 mL) under argon atmosphère and stirred for 1 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude which was titurated with diethyl ether (2x5 mL) dried in vacuo to afford compound 319 (136 mg) as an off-white solid.
TLC: 40% EtOAc/ hexanes (Rf. 0.2); LC-MS: 89.95%; 142.9 (h/T+l); (column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 1.29 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min).
Synthesis of (4-isopropylthiazoI-5-yl) methanamine hydrochloride (327)
Synthesis of ethyl 2-chloro-4-methyl-3-oxopentanoate (321): To a stirred solution of ethyl 4methyl-3-oxopentanoate 320 (5 g, 31.64 mmol) in Toluene (50 mL) under argon atmosphère was added sulfuryl chloride (4.26 g, 31.64 mmol) at 0 °C; warmed to RT and stirred for 24 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to afford compound crude 321 (6 g) as brown syrup. TLC: 10% EtOAc/ hexanes (Rf. 0.8).
Synthesis of ethyl 4-isopropyIthiazole-5-carboxylate (323): To a stirred solution of compound 321 (2.1 g) in éthanol (30 mL) under argon atmosphère was added thioformamide 322 (0.667 g, 10.93 mmol) at RT and heated to reflux for 30 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with EtOAc (200 mL), washed with saturated sodium bicarbonate solution (100 mL). The organic extract 126 was dried over sodium sulfate, fîltered and concentrated in vacuo to afford crude compound 323 (230 mg, 11%) as brown syrup. TLC: 10% EtOAc/hexanes (Rf. 0.5); LC-MS: 93.64%; 199.9 (JMT+1); (column; Ascentis Express Cl8, (50 x 3.0 mm, 2.7 pm); RT 2.49 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min).
Synthesis of (4-isopropyIthiazol-5-yl) methanol (324): To a stirred solution of compound 323 (230 mg, 1.15 mmol) in THF (10 mL) under inert atmosphère was added lithium aluminium hydride (87 mg, 2.28 mmol) at 0 °C; warmed to RT and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was cooled to 0 C, quenched with ice-cold water (10 mL), 15% aqueous sodium hydroxide solution (5 mL), fîltered through celite and washed with EtOAc (100 mL). The fîltrate was dried over sodium sulfate, fîltered and concentrated in vacuo to afford crude compound 324 (112 mg) as an off-white solid. TLC: 20% EtOAc/ hexanes (Rf. 0.2). *H NMR (DMSO-4,400 MHz): δ 8.85 (s, 1H), 5.45 (t, J= 5.5 Hz, 1H), 4.64 (d, 5.5 Hz, 2H),
3.14-3.07 (m, 1H), 1.19 (d, J= 6.8 Hz, 6H).
Synthesis of 5-(chloromethyl)-4-isopropylthiazole (325): To a stirred solution of compound 324 (112 mg) in CH2CI2 (10 mL) under inert atmosphère were added triethyl amine (0.21 mL, 2.13 mmol), mesyl chloride (0.08 mL, 0.97 mmol) at 0 C; warmed to RT and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with CH2CI2 (50 mL) washed with NaHCO3 solution (50 mL), brine (50 mL). The organic extract was dried over sodium sulfate, fîltered and concentrated in vacuo to afford compound 325 (126 mg) as brown thick syrup. TLC: 30% EtOAc/ hexanes (Rf. 0.8); LC-MS: 87.83%; 175.8 (MNl); (column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 2.30 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min).
Synthesis of 5-(azidomethyl)-4-isopropylthiazole (326): To a stirred solution of compound 325 (126 mg, 0.53 mmol) in DMF (10 mL) under inert atmosphère was added sodium azide (70 mg, 1.07 mmol) at RT and heated to 80 °C for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with EtOAc (75 mL) washed with water (50 mL). The organic extract were dried over sodium sulfate, fîltered and concentrated in vacuo to afford crude compound 326 (82 mg, 63%) as thick syrup. TLC: 30% EtOAc/ hexanes (Rf. 0.7); *H NMR (DMSO-<Z6,500 MHz): δ 9.01 (s, 1H), 4.74 (s, 2H), 3.30-3.21 (m, 1H), 1.21 (d, J= 6.8 Hz, 6H);
127
Synthesis of (4-isopropylthiazol-5-yl) naethanamine hydrochloride (327): To a stirred solution of compound 326 (80 mg, 0.43 mmol) in THF: H2O (4: 1, 10 mL) was added triphenyl phosphine (230 mg, 0.87 mmol) at RT and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The obtained solid was further 5 dried using toluene (2x5 mL) to obtain the crude.
. The crude compound was dissolved in CH2CI2 (3 mL) added 4 N HCl in 1, 4-dioxane (2 mL) under inert atmosphère at 0 C and stirred for 1 h. The volatiles were removed in vacuo to obtain the crude, which was washed with diethyl ether (2 mL) to afford compound 327 (42 mg, 50%) as an off-white solid. TLC: 10% MeOH/ CH2C12 (R/. 0.2); ‘HNMR (DMSO-A.400 MHz): δ 9.02 (s, 1H), 8.26 (br s, 2H), 4.24 (q, 5.6 Hz, 2H), 3.24-3.17 (m, 1H), 1.19 (d, J= 6.8 Hz, 6H).
Synthesis of (4-chIorothiazoI-5-yI) methanamine hydrochloride (337)
Synthesis of thiazolidine-2, 4-dione (329): To a stirred solution of 2-chloroacetic acid 328 (5 g, 52.9 mmol) in H2O (10 mL) was added thiourea 314 (3.80 g, 52.9 mmol) at 0 °C stirred for 30 min added concentrated HCl (6 mL) dropwise for 15 min; heated at 110 C and stirred for 24 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was cooled to
128 °C and stirred for 30 min. The precipitated solid was fîltered and dried in vacuo to afford compound 329 (3.2 g, 47%) as white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.2); Ή NMR (400 MHz, DMSO-rf6): δ 12.01 (br s. 1H), 4.15 (s, 2H).
Synthesis of 2,4-dichlorothiazole-5-carbaldehyde (330): A mixture of compound 329 (2.7 g, 23.07 mmol) in DMF (1.23 mL, 15.98 mmol) at 0 C under argon atmosphère was added phosphorous oxychloride (8.15 mL, 87.17 mmol) dropwise for 15 min at 0 °C; warmed to RT and stirred for 1 h; heated to 120 C and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was poured into ice cold water slowly and extracted with CH2CI2 (3 x 100 mL). The combined organic extracts were washed with saturated NaHCO3 solution (100 mL), water (100 mL), dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through column chromatography using 5% EtOAc/ hexanes to afford compound 330 (1.4 g, 33%) as brown color oil. TLC: 30% EtOAc/ hexanes (Rf. 0.8); ‘H NMR (500 MHz, DMSO-<Ztf). δ 9.87 (s, 1H).
. Synthesis of 2,4-dichloro-5-(l, 3-dioxoIan-2-yl) thiazole (331): To a stirred solution of compound 330 (1.4 g, 7.73 mmol) in Toluene (20 mL) under argon atmosphère was added ethane-1, 2-diol (1.43 g, 23.20 mmol),/7-toluenesulfonic acid (133 mg, 0.77mmol) at 0 C; heated at 110 °C and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with 10% aqueous NaHCO3 solution (50 mL) and extracted with EtOAc (2 x 100 mT,). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through column chromatography using 10% EtOAc/ hexanes to afford compound 331 (1.7 g, 98%) as yellow oil. TLC: 10% EtOAc/ hexanes (Rf. 0.2); *H NMR (400 MHz, CDC13): δ 6.04 (s, 1H), 4.14-4.07 (m, 2H), 4.06-4.00 (m, 2H).
Synthesis of 4-chloro-5-(l, 3-dioxolan-2-yl) thiazole (332): To a stirred solution of compound 331 (1.7 g, 7.55 mmol) in THF (20 ML) under argon atmosphère was added n-butyl lithium (3.9 mL, 9.82 mmol, 2.5 M solution in THF) dropwise for 10 min at -78 °C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with ice cold water (50 mT,) and extracted with EtOAc (2 x 100 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through column chromatography using 5% EtOAc/ hexanes to afford compound 332 (1.1 g,
129
76%) as yellow oil. TLC: 10% EtOAc/ hexanes (Rf. 0.2); 'il NMR (CDC13,500 MHz): δ 8.74 (s, 1H), 6.16 (s, 1H), 4.19-4.15 (m, 2H), 4.08-4.04 (m, 2H).
Synthesis of 4-chlorothiazole-5-carbaldehyde (333): To a stirred solution of compound 332 (1.1 g, 5.75 mmol) in THF (10 mL) was added 5 N aqueous HCl in 1, 4-dioxane (6 mL) at 0 °C; warmed to RT and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was poured into brine (20 mL) extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with saturated sodium bicarbonate (100 mL) dried over sodium sulfate, filtered and concentrated in vacuo to afford compound 333 (800 mg, 95%) as yellow oil. TLC: 10% EtOAc/ hexanes (Rf. 0.3); *H NMR (CDCI3j500 MHz): δ 10.11 (s, 1H), 9.00 (s, 1H).
Synthesis of (4-chIorothiazoI-5-yl) methanol (334): To a stirred solution of compound 333 (750 mg, 5.10 mmol) in dry THF (20 mL) under inert atmosphère was added lithium aluminium hydride (193 mg, 5.10 mmol) at 0 C; warmed to RT and stirred for 3 h. The reaction was monitored by o
TLC; after completion of the reaction, the reaction mixture was cooled to 0 C, quenched with 30% aqueous sodium hydroxide solution (3 mL) extracted with EtOAc (2 x 100 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to afford compound 334 (520 mg, 68%) as yellow oil. TLC: 10% EtOAc/ hexanes (Rf. 0.3); 'H NMR (CDCl3)500 MHz): δ 8.69 (m, 1H), 4.88 (s, 2H).
Synthesis of (4-chlorothiazol-5-yl) methyl methanesulfonate (335): To a stirred solution of compound 334 (520 mg, 3.48 mmol) in CH2CI2 (15 mL) under inert atmosphère were added triethyl amine (1.23 mL, 8.71 mmol) and mesyl chloride (0.34 mL, 4.18 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (50 mL) and extracted with CH2CI2 (2 x 50 mL). The combined organic extracts were washed with saturated NaHCO3 (50 mL) dried over sodium sulfate, filtered and concentrated in vacuo to afford compound 335 (600 mg, crude) as brown liquid. TLC: 10% EtOAc/ hexanes (Rf. 0.8'H NMR (CDCl3,500 MHz): δ 8.74 (s, 1H), 4.79 (s, 2H), 1.44 (s, 3H).
Synthesis of 5-(azidomethyl)-4-chlorothiazoIe (336): To a stirred solution of compound 335 (600 mg, 2.64 mmol) in DMF (10 mL) under inert atmosphère was added sodium azide (343 mg, 5.28 mmol) at RT and heated to 100 °C for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice cold water (100 mL) and extracted with
130 diethyl ether (2 x 50 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to afford compound 336 (250 mg, 54%) as yellow oil. TLC: 8% EtOAc/ hexanes (Rf 0.5); ’HNMR (CDCl3,400 MHz) δ 8.74 (s, 1H), 4.58 (s, 2H).
Synthesis of (4-chlorothiazoI-5-yl) methanamine hydrochloride (337): To a stirred solution of compound 336 (250 mg, 1.43 mmol) in THF: H2O (3:1, 13 ML) was added triphenyl phosphine (752 mg, 2.87 mmol) at RT and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo and the residue was acidified with 4 N HCl in 1, 4-dioxane (2 mL) at 0 C. The volatiles were removed in vacuo and the obtained solid was washed with EtOAc (2 mL), diethyl ether (2 mL) to afford compound 337 (110 mg) as yellow solid. TLC: 5% MeOH/ CH2C12 (Rf 0.2); ’lINMR (DMSO-^, 400 MHz): δ 9.19 (s, 1H), 8.52 (br s, 3H), 4.24 (q, J= 5.6 Hz, 2H);
Synthesis of oxetan-3-ylmethanamine (341)
f°- | CH3N02 | O2N ΓΤΟΗ o—1 | MsCI, Et3N | o2n | Pd(OH)2 | H2N |
Et3N | CH2CI2 | MeOH | ||||
338 | 339 | 340 | 341 |
Synthesis of 3-(nitromethyl) oxetan-3-ol (339): To a stirred solution of oxetan-3-one 338 (500 mg, 0.69 mmol) in nitromethane (1.25 mL) under argon atmosphère was added triethyl amine (0.25 mL) at RT and stirred for 12 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain crude. The crude was purified through silica gel column chromatography using 25% EtOAc/ hexanes to afford compound 339 (750 mg, 81%) as an off white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.3); JH NMR (DMSO-<Z6,400 MHz): δ 6.47 (s, 1H), 4.93 (s, 2H), 4.64 (d, J= 7.5 Hz, 2H), 4.49 (d, J= 7.3 Hz, 2H).
Synthesis of 3-(nitromethylene) oxetane (340): To a stirred solution of compound 339 (750 mg, 5.63 mmol) in CH2C12 (10 mL) under inert atmosphère were added triethyl amine (3.17 mL, 22.55 mmol), mesyl chloride (1.20 mL, 15.50 mmol), at 0 °C; cooled -78 C and stirred for 1 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain crude. The crude was purified through silica gel column chromatography using 25% EtOAc/ hexanes to afford compound 340 (380 mg, 58%) as an off white solid. TLC: 10% EtOAc/
131 hexanes (Rf. 0.5¾ NMR (CDCI3,400 MHz): δ 6.94-6.92 (m, 1H), 5.68-5.64 (m, 2H), 5.41-5.36 (m, 2H).
Synthesis of oxetan-3-ylmethanamine (341): To a stirred solution of compound 340 (500 mg, 4.34 mmol) in MeOH (10 mL) under inert atmosphère was added Pd(OH)2 (100 mg) at RT; heated at 45 °C stirred under hydrogen atmosphère (balloon pressure) for 5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite and washed with MeOH (20 mL). The filtrate was evaporated in vacuo to obtain the crude which was triturated with diethyl ether (2 x 10 mL) to afford crude compound 341 (100 mg) as pale brown solid. TLC: 10% MeOH / CH2C12 (Rf. 0.2); Mass (m/z) (Agilent 6310 Ion Trap): 88.5 (M++l).
Synthesis of 2, 2,2-trifluoro-l-((2-(oxazol-5-yl) ethyl)-k4-azanyl) ethan-l-one (347)
Synthesis of oxazol-5-ylmethanol (343): To a stirred solution of ethyl oxazole-5-carboxylate 342 (2 g, 14.18 mmol) in EtOH (20 mL) under argon atmosphère was added sodium borohydride (1.07 g, 28.36 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with saturated ammonium chloride solution (25 mL) and extracted with 5% MeOH/ CH2CI2 (2 x 20 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 5% MeOH/ CH2CI2 to afford compound 343 (810 mg, 58%) as colorless syrup. TLC: 5% MeOH/ CH2CI2 (Rf. 0.3); 1HNMR (DMSO-î/6, 500 MHz): δ 8.28 (s, 1H), 7.04 (s, 1H), 5.36 (t, 7= 6.0 Hz, 1H), 4.47 (d, 7= 6.0 Hz, 2H).
Synthesis of 5-(chIoromethyl) oxazole (344): To a stirred solution of compound 343 (800 mg, 8.08 mmol) in CH2C12: w-hexane (1: 1, 10 mL) under argon atmosphère was added thionyl chloride (1.2
132 mL, 16.16 mmol) at 0 C; heated to reflux and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was neutralized with saturated NaHCO3 solution (20 mL) and extracted with ether (2 x 20 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude compound 344 (700 mg) as colorless syrup. TLC: 40% EtOAc/ hexanes (Rf. 0.5); JH-NMR (CDC13, 400 MHz): δ 7.89 (s, 1H), 7.10 (s, 1H), 4.62 (s, 2H).
Synthesis of 2-(oxazol-5-yl) acetonitrile (345): To a stirred solution of compound 344 (700 mg, 5.95 mmol) in DMF (8 mL) under argon atmosphère was added sodium cyanide (1.02 g, 20.85 o
mmol) at RT; heated to 70 C and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with ether (2 x 20 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude compound 345 (650 mg) as colorless syrup. TLC: 40% EtOAc/hexanes (Rf. 0.3); 1H-NMR (CDC13, 400 MHz): δ 7.89 (s, 1H), 7.10 (s, 1H), 3.84 (s, 2H).
Synthesis of tert-butyl (2-(oxazol-5-yl) ethyl) carbamate (346): To a stirred solution of compound 345 (50 mg, 0.46 mmol) in MeOH (3 mL) under argon atmosphère were added Boc-anhydride (0.21 mL, 0.92 mmol), nickel chloride hexahydrate (11 mg, 0.04 mmol), sodium borohydride (122 mg, 3.24 mmol) portion wise for 5 min at 0 C; warmed to RT and stirred for 6 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with MeOH (10 mL), filtered through celite and the fïltrate was concentrated in vacuo to obtain the crude. The crude was purifïed through silica gel column chromatography using 30% EtOAc/ hexanes to afford compound 346 (68 mg, 71%) as colorless syrup. TLC: 50% EtOAc/ hexanes (Rf. 0.5); ’H-NMR (CDCI3, 400 MHz): δ 7.82 (s, 1H), 6.85 (s, 1H), 4.64 (br s, 1H), 3.42-3.40 (m, 2H), 2.89 (t, J= 6.4 Hz, 2H), 1.43 (s, 9H).
Synthesis of 2, 2,2-trifluoro-l-((2-(oxazol-5-yl) ethyl)-/?-azanyl) ethan-l-one (347): To a stirred solution of compound 346 (65 mg, 0.30 mmol) in CH2CI2 (3 mL) under argon atmosphère was added trifluoro acetic acid (0.14 mL, 1.83 mmol) at 0 °C; warmed to RT and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude compound 347 (50 mg) as colorless syrup. TLC: 60% EtOAc/ hexanes (Rf. 0.2); *H-NMR (DMSO-^, 500 MHz): δ 8.30 (s, 1H), 7.85-7.79 (m, 2H), 7.02 (s, 1H), 3.103.05 (m, 2H), 2.98 (t, J= 7.5 Hz, 2H).
133
Synthesis of 2, 2, 2-trifluoro-l-((2-(thiazol-5-yl) ethyl)-k4-azanyl) ethan-l-one (352)
Synthesis of 5-(chloromethyl) thiazole (349): To a stirred solution of thiazol-5-ylmethanol 348 (1 g, 8.69 mmol) in CH2CI2 (50 mL) under argon atmosphère were added mesyl chloride (1.09 g, 9.56 mmol) drop wise for 15 min, diisopropyl ethyl amine (1.23 g, 9.56 mmol) at 0-5 C; warmed to RT and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was washed with saturated NaHCCL solution (20 mL) and purified through silica gel column chromatography using 50% EtOAc/ hexanes to afford compound 349 (650 mg, 57%) as yellow liquid. TLC: 5% MeOH/ CH2CI2 (Rf. 0.7); ’H-NMR (CDCI3, 500 MHz): δ 8.84 (s, 1H), 7.86 (s, 1H), 4.84 (s, 2H).
Synthesis of 2-(thiazol-5-yl) acetonitrile (350): To a stirred solution of compound 349 (650 mg, 4.92 mmol) in EtOH: H2O (4: 1, 10 mL) under argon atmosphère was added sodium cyanide (361 mg, 7.38 mmol) at RT; heated to 80 °C and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (20 mL) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 70% EtOAc/ hexanes to afford compound 350 (250 mg, 41%) as colorless semi-solid. TLC: 70% EtOAc/ hexanes (Rf 0.4); !H-NMR (CDCI3, 500 MHz): δ 8.81 (s, 1H), 7.85 (s, 1H), 3.84 (s, 2H).
Synthesis of tert-buty! (2-(thiazol-5-yI) ethyl) carbamate (351): To a stirred solution of compound 350 (50 mg, 0.40 mmol) in MeOH (3 mL) under argon atmosphère were added Boc-anhydride (175 mg, 0.80 mmol), nickel chloride hexahydrate (9.75 mg, 0.04 mmol), sodium borohydride (107 mg, 2.82 mmol) portion wise for 5 min at 0-5 °C; warmed to RT and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered, washed with 134
EtOAc (2x10 mL) and the filtrate was concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 50% EtOAc/ hexanes to afford compound 351 (20 mg, 22%) as brown solid. TLC: 70% EtOAc/ hexanes (Rf. 0.6); *H-NMR (DMSO-d6, 400 MHz): δ 8.92 (s, 1H), 7.65 (s, 1H), 6.98-6.96 (m, 1H), 3.15 (q, 2H), 2.95 (t, J= 6.8 Hz, 2H), 1.39 (s, 9H).
Synthesis of 2-(thiazol-5-yl) ethan-l-amine (352): To a stirred solution of compound 351 (20 mg, 0.08 mmol) in CH2CI2 (3 mL) under argon atmosphère was added trifluoro acetic acid (60 mg, 0.53 mmol) at 0-5 °C; warmed to RT and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude compound 352 (10 mg) as colorless liquid. The crude was carried to the next step without any further purification. TLC: 70% EtOAc/ hexanes (Rf. 0.2); *H-NMR (DMSO-4fi, 400 MHz): δ 9.01 (s, 1H), 7.95-7.89 (m, 2H), 7.76 (s, 1H), 3.16-3.10 (m, 4H).
Synthesis of 2-(4-(pyrimidin-5-yl) phenyl) ethan-l-amine (359)
Synthesis of 5-(4-bromophenyl) pyrimidine (355): To a stirred solution of 5-bromopyrimidine 353 (1 g, 6.32 mmol) in DMF: H2O (4: 1, 25 mL) were added sodium carbonate (1 g, 9.43 mmol) and (4bromophenyl) boronic acid 354 (1.26 g, 6.32 mmol), purged under argon atmosphère for 30 min. To this was added Pd(PPh3)4 (731 mg, 0.63 mmol) at RT; heated to 80 °C and stirred for 2.5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mass was filtered through celite; the filtrate was diluted with water (100 mL) and extracted with EtOAc (3x15 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to
135 obtain the crude. The crude was purified through silica gel column chromatography using 15% EtOAc/ hexanes to afford compound 355 (1 g, 67%) as white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.3); *H-NMR (DMSO-rfà, 500 MHz): δ 9.20 (s, 1H), 9.15 (s, 2H), 7.93 (d, J= 8.5 Hz, 2H), 7.74 (d, J =9.0 Hz, 2H).
Synthesis of (£)-3-(4-(pyrimidin-5-yl) phenyl) acrylamide (357): To a stirred solution of 5-(4bromophenyl) pyrimidine 355 (1 g, 4.27 mmol) in DMF (10 mL) under inert atmosphère was added acrylamide 356 (364 mg, 5.12 mmol) at RT and purged under argon for 10 min. To this were added o-tolyl phosphine (142 mg, 0.47 mmol), Pd(OAc)2 (4.78 mg, 0.021 mmol), and diisopropyl ethyl amine (0.9 mL, 7.32 mmol) at RT; heated to 130 C and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite washed with 50% MeOH/ CH2C12 (2x10 mL), the fîltrate was concentrated under reduced pressure to afford the crude. The crude was washed with 50% MeOH/ CH2C12 (2x15 mL), dried in vacuo to afford compound 357 (600 mg, 62%) as white solid. TLC: 40% EtOAc/ hexanes (Rf. 0.2); ]H NMR (400MHz, DMSO-dg) δ 9.23-9.16 (m, 3H), 7.88 (d, J= 8.3 Hz, 2H), 7.72 (d, J= 8.3 Hz, 2H), 7.56 (br s, 1H), 7.48 (d, J= 15.9 Hz, 1H), 7.14 (br s, 1H), 6.70 (d, J= 15.9 Hz, 1H).
Synthesis of 3-(4-(pyrimidin-5-yI) phenyl) propanamide (358): To a stirred solution of compound 357(150 mg, 0.64 mmol) in EtOH (4 mL) under inert atmosphère were added 10% Pd/ C (50 mg) and triethylamine (0.092 mL, 0.64 mmol) at RT and stirred under H2 (balloon pressure) for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite. The fîltrate was concentrated in vacuo to obtain the crude which was purified by silicagel column. chromatography using 3% MeOH/ CH2Cl2to afford compound 358 (65 mg, 43%) as white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.2); ^-NMR (DMSO-rf6, 400 MHz): δ 9.16 (s, 1H), 9.12 (s, 2H), 7.72 (d, J= 8.0 Hz, 2H), 7.37 (d, J= 8.0 Hz, 2H), 7.29 ( br s, 1H), 6.76 (br s, 1H), 2.87 (t, J= 8.0 Hz, 2H), 2.39 (t, J= 8.0 Hz, 2H).
Synthesis of 2-(4-(pyrimidin-5-yI) phenyl) ethan-l-amine (359): To a stirred solution of compound 358 (65 mg, 0.28 mmol) in THF: H2O (1:1,3 mL) were added NaOH (128 mg, 0.91 mmol), phenyl-X3-iodanediyl diacetate (92 mg, 0.28 mmol) at 0 C and stirred for 1 h. The reaction was monitored by TLC; after completion of the reaction, the pH of the reaction mixture was adjusted to ~ 2 using 3 N HCl and extracted with CH2C12 (2 x 50 mL). The pH of the aqueous layer was basified to ~ 8 with 3 N NaOH, extracted with THF (2 x 100 mL). The combined organic
136 extracts were dried over sodium sulphate, fîltered and concentrated in vacuo to afford crude compound 359 (40 mg) as white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.3); XH-NMR (DMSO-t/6, 400 MHz): δ 9.16 (s, 1H), 9.11 (s, 2H), 7.72 (d, J= 8.4 Hz, 2H), 7.37 (d, J= 8.0 Hz, 2H), 2.81-2.66 (m, 2H), 1.78-1.69 (m, 2H).
Synthesis of 2-(2-phenylpyrimidin-5-yI) ethan-l-amine hydrochloride (366)
Synthesis of 5-bromo-2-iodopyrimidine (361): To a stirred solution of 5-bromo-2-chloropyrimidine 360 (1 g, 5.16 mmol) in CH2C12 (10 mL) was added hydrogen iodide (5 mL, 57% aqueous solution) at -10 °C; warmed to 0 °C and stirred for 5 h. The reaction was monitored by TLC; after completion 10 of the reaction, the reaction mixture was quenched with solid K2CO3 (2 g), diluted with water (100 mL) and extracted with CH2C12 (2 x 100 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to obtain crude compound 361 (1.4 g, 94%) as yellow solid. TLC: 10% EtOAc/ hexanes (Rf. 0.7); ’H-NMR (DMSO-îZ6, 400 MHz): δ 8.55 (s, 2H).
Synthesis of 5-bromo-2-phenylpyrimidine (363): To a stirred solution of compound 361 (1.4 g) in 15 DMF: H2O (4:1, 20 mL) were added sodium carbonate (783 mg, 7.39 mmol) and phenylboronic acid 362 (451 mg, 3.69 mmol), purged under argon for 30 min. To this was added Pd(PPh3)4 (570 mg, 0.49 mmol) at RT; heated to 80 °C and stirred for 2 h. The reaction was monitored by TLC;
after completion of the reaction, the reaction mass was fîltered through celite; the filtrate was diluted
137 with water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic extracts were dried over sodium sulfate, filtered, concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 2% EtOAc/ hexanes to afford compound 363 (400 mg, 35%) as white solid. TLC: 10% EtOAc/ hexanes (Rf. 0.9); ’H-NMR (DMSO-Jtf, 400 MHz): δ 8.83 (s, 2H), 8.41-8.39 (m, 2H), 7.50-7.48 (m, 3H).
Synthesis of (£j-3-(2-phenylpyrimidin-5-yl) acrylamide (364): To a stirred solution of compound
363 (300 mg, 1.28 mmol) in DMF (20 mL) under inert atmosphère was added acrylamide 356 (109 mg, 1.53 mmol) at RT and purged under argon for 10 min. To this were added o-tolyl phosphine (42 mg, 0.07 mmol), palladium acetate (15.7 mg, 0.07 mmol), and diisopropyl ethyl amine (0.28 mL,
1.53 mmol) at RT; heated to 140 C and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted water (100 mL) and extracted with 10% MeOH/ CH2CI2 (2 x 50 mL). The combined organic extracts were dried over sodium sulphate, filtered and concentrated in vacuo to obtain the crude. The crude compound was triturated with 50% EtOAc/ hexanes (10 mL) and dried in vacuo to afford compound 364 (50 mg, 17%) as an off-white solid. TLC: 70% EtOAc/hexanes (Rf. 0.2); XH-NMR (DMSO-J6, 400 MHz): δ 9.10 (s, 2H), 8.438.41 (m, 2H), 7.64 (br s, 1H), 7.55-7.54 (m, 3H), 7.47 (d, 7= 16.0 Hz, 1H), 7.22 (br s, 1H), 6.85 (d, 7= 16.0 Hz,1H).
Synthesis of 3-(2-phenylpyrimidin-5-yl) propanamide (365): To a stirred solution of compound
364 (50 mg, 0.22 mmol) in EtOH (2 mL) under inert atmosphère were added triethyl amine (0.032 mL, 0.22 mmol), 10% Pd/ C (17 mg, dry) at RT and stirred under hydrogen atmosphère (balloon pressure) for 4 h. The reaction was monitored by LC-MS; after completion of the reaction, the reaction mixture was filtered through celite and the filtrate was concentrated in vacuo to obtain the crude which was triturated with 10% EtOAc/ n-pentane (2x5 mL) and dried in vacuo to afford compound 365 (30 mg, 60%) as an off-white solid. TLC: 5% MeOH/ CH2CI2 (Rf. 0.5); ’H-NMR (DMSO-76, 400 MHz): δ 8.76 (s, 2H), 8.37-8.35 (m, 2H), 7.52-7.50 (m, 3H), 7.31 (br s, 1H), 6.80 (br s, 1H), 2.85 (t, 7= 7.2 Hz, 2H), 2.46 (t, 7= 7.2 Hz, 2H).
Synthesis of tert-butyl (2-(2-phenylpyrimidin-5-yl) ethyl) carbamate (366): To a stirred solution of compound 365 (15 mg, 0.06 mmol) in THF (2 mL) were added sodium hydroxide (8 mg, 0.2 mmol) in water (0.5 mL), phenyl-X3-iodanediyl diacetate (21 mg, 0.06 mmol) at 0 C and stirred for 30 min. The reaction was monitored by TLC; after completion of the reaction, the volatiles were
138 removed in vacuo. The residue was diluted with water (25 mL) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over sodium sulfate, fïltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 366 (10 mg, 51%) as sticky solid. TLC: 50% EtOAc/ hexanes (Rf. 0.9); *H-NMR (CDC13, 400 MHz): δ 8.65 (s, 2H), 8.42-8.40 (m, 2H), 7.49-7.47 (m, 3H), 4.62 (br s, 1H), 3.43-3.38 (m, 2H), 2.84 (t, J= 7.2 Hz, 2H), 1.43 (s, 9H).
Synthesis of 2-(2-phenylpyrimidin-5-yl) ethan-l-amine hydrochloride (367): To a stirred solution of compound 366 (80 mg, 0.35 mmol) in CH2CI2 (3 ML) was added 4N HCl in 1, 4Dioxane (0.7 mL) under argon atmosphère at 0 C; warmed to RT and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude and was washed with 20% CH2CI2/ n-pentane (2x5 mL) and dried in vacuo to afford compound 367 (50 mg, HCl sait) as white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.1); XHNMR (DMSO-^, 400 MHz): δ 8.84 (s, 2H), 8.40-8.37 (m, 2H), 8.07 (br s, 2H), 7.54-7.52 (m, 3H), 3.19-3.14 (m, 2H), 2.97 (t, J= 7.2 Hz, 2H).
Synthesis of (4-(pyrimidin-5-yl) phenyl) methanamine (372)
Synthesis of (4-(pyrimidin-5-yl) phenyl) methanol (369): To a stirred solution of 4-(pyrimidin-5yl) benzaldehyde 368 (500 mg, 2.71 mmol) in MeOH (20 mL) under argon atmosphère and sodium borohydride (155 mg, 39.99 mmol) at 0 °C; warmed to RT and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, volatiles were removed in vacuo. The residue
139 was diluted with brine solution (100 mL), extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over sodium sulphate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 5% MeOH/ CH2CI2 to afford compound 369 (260 mg, 51%) as white solid. TLC: 20% EtOAc/ hexanes (Rf. 0.4); 'H-NMR (CDCI3, 500 MHz): δ 9.20 (s, 1H), 8.93 (s, 2H), 7.58 (d, J= 8.5 Hz, 2H), 7.53 (d, 7= 8.0 Hz, 2H), 4.79 (s, 2H).
Synthesis of 4-(pyrimidin-5-yl) benzyl methanesulfonate (370): To a stirred solution of compound 369 (260 mg, 1.39 mmol) in CH2CI2 (10 mL) under argon atmosphère were added
O triethyl amine (0.3 mL, 2.09 mmol), methane sulfonyl chloride (0.16 mL, 2.09 mmol) at 0 C; warmed to RT and stirred for 14 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL), washed with 10% NaHCC>3 solution (30 mL), dried over sodium sulfate, filtered and concentrated in vacuo to obtain crude compound
370 (300 mg) as thick syrup. The crude was carried to the next step without further purification. TLC: 5% MeOH/ CH2C12 (Rf. 0.4).
Synthesis of 5-(4-(azidomethyl) phenyl) pyrimidine (371): To a stirred solution of compound 370 (300 mg, crude) in DMF (6 mL) under argon atmosphère was added sodium azide (74 mg, 1.13 mmol) at RT; heated to 60 °C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice water (20 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain crude. The crude was purified through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 371 (45 mg) as colorless thick syrup. TLC: 30% EtOAc/ hexanes (Rf. 0.6); \H-NMR (CDCI3, 400 MHz): δ 9.22 (s, 1H), 8.96 (s, 2H), 7.61 (d, 7= 8.4 Hz, 2H), 7.48 (d, 7= 8.0 Hz, 2H), 4.43 (s, 2H).
Synthesis of (4-(pyrimidin-5-yl) phenyl) methanamine (372): To a stirred solution of compound
371 (40 mg, 0.18 mmol) in THF: H2O (9:1, 2 mL) was added triphenyl phosphine (74 mg, 0.28 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 10% MeOH/ CH2CI2 to afford compound 372 (23 mg, 66%) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.2); *H-NMR (DMSO-7Ô, 400 MHz): δ
140
9.21 (s, 1H), 9.17 (s, 2H), 8.27 (br s, 2H), 7.87 (d, J= 8.0 Hz, 2H), 7.64 (d, J= 8.4 Hz, 2H), 4.07 (s, 2H).
Synthesis of (2-phenylpyrimidin-5-yl) methanamine (377)
Synthesis of (2-phenylpyrimidin-5-yl) methanol (374): To a stirred solution of 2phenylpyrimidine-5-carbaldehyde 373 (200 mg, 1.08 mmol) in MeOH (20 mL) under argon atmosphère was added sodium borohydride (74 mg, 2.17 mmol) at 0 C; warmed to RT and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice cold water (50 mL), extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over sodium sulphate, fiitered and concentrated in vacuo to obtain the crude. The crude was purifïed through silica gel column chromatography using 5% MeOH/ CH2CI2 to afford compound 374 (135 mg, 65%) as colorless solid. TLC: 40% EtOAc/ MeOH (Rf. 0.3); ‘ïï-NMR (DMSO-îZ6, 500 MHz): δ 8.83 (s, 2H), 8.40-8.38 (m, 2H), 7.53-7.51 (m, 3H), 5.45 (t, J= 5.5 Hz, 1H), 4.58 (d, J= 5.5 Hz, 2H).
Synthesis of (2-phenylpyrimidin-5-yl) methyl methanesulfonate (375): To a stirred solution of compound 374 (130 mg, 0.69 mmol) in CH2C12 (5 mL) under argon atmosphère were added triethyl amine (0.4 mL, 2.09 mmol) and methane sulfonyl chloride (0.07 mL, 0.84 mmol) at 0 C; warmed to RT and stirred for 30 min. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted CH2CI2 (50 mL), washed with water (2 x 20 mL). The organic extract was dried over sodium sulfate, fiitered and concentrated in vacuo to obtain crude compound 375 (150 mg) as yellow oil. The crude was carried to the next step without further purification. TLC: 50% EtOAc/ hexanes (Rf. 0.5); 'Η-NMR (DMSO-^, 500 MHz): 9.00 (t, J= 10.0 Hz, 2H), 8.42-8.41 (m, 2H), 7.56-7.55 (m, 3H), 5.40 (s, 2H), 3.32 (s, 3H).
141
Synthesis of 5-(azidomethyl)-2-phenylpyrimidine (376): To a stirred solution of compound 375 (150 mg) in DMF (6 mL) under argon atmosphère was added sodium azide (56 mg, 0.76 mmol) at RT; heated to 60 C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice water (20 mL) and extracted with diethyl ether (2 x 50 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain crude. The crude was purified through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 376 (60 mg, 49%) as colorless syrup. TLC: 40% EtOAc/ hexanes (Rf. 0.9); ’HNMR (DMSO-4, 400 MHz): δ 8.94 (s, 2H), 8.41 (dd, J= 6.8, 3.0 Hz, 2H), 7.56-7.53 (m, 3H), 4.63 (s, 2H).
Synthesis of (2-phenylpyrimidin-5-yl) methanamine (377): To a stirred solution of compound 376 (90 mg, 0.42 mmol) in THF: H2O (9:1, 4 mL) was added triphenyl phosphine (167 mg, 0.63 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 10% MeOH/ CH2CI2 to afford compound 377 (30 mg, 38%) as yellow solid. TLC: 10% MeOH/ CH2C12 (Rf 0.2); JH NMR (DMSO-7d, 500 MHz): δ 8.96 (s, 2H), 8.40 (d, J= 3.9 Hz, 2H), 7.59-7.45 (m, 3H), 6.84 (br s, 2H), 4.01 (s, 2H).
Synthesis of thiazol-5-amine hydrochloride (380)
378 f-BuOH
379
N·
380
Synthesis of ieri-butyl thiazol-5-yIcarbamate (379): To a stirred solution of thiazole-5-carboxylic acid 378 (400 mg, 3.1 mmol) in t-butanol (6 mL) were added diphenylphosphonic azide (1.34 mL, 6.18 mmol) and triethyl amine (0.89 mL, 6.18 mmol) at RT and heated to 100 C for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 30% EtOAc/ hexanes to afford compound 379 (300 mg, 48%) as white solid. TLC: 50% EtOAc/ hexanes (Rf. 0.8); ’H-NMR (DMSO-76, 400 MHz): δ 10.60 (br s, 1H), 8.51 (s, 1H), 8.40 (s, 1H), 1.49 (s, 9H).
142
Synthesis of thiazol-5-amine hydrochloride (380): To a stirred solution of compound 379 (300 mg, 1.5 mmol) in MeOH (5 mL) was added 4 N HCl in 1, 4-Dioxane (5 mL) under argon o
atmosphère at 0 C; warmed to RT and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was washed with n-pentane (2x5 mL) and dried in vacuo to afford compound 380 (150 mg, HCl sait) as pale yellow solid. TLC: 50% EtOAc/ hexanes (Rf. 0.1); *H-NMR (DMSO-rf6, 500 MHz): δ 9.10 (s, 1H), 7.22 (s, 1H).
Synthesis of 3-(pyrimidin-5-yI) aniline (383)
Synthesis of 5-(3-nitrophenyl) pyrimidine (382): To a stirred solution of 5-bromopyrimidine 353 (2 g, 12.58 mmol) and (3-nitrophenyl) boronic acid 381 (2.3 g, 13.84 mmol) in 1, 2-dimethoxy ethane: H2O (4:1, 20 mL) under inert atmosphère were added sodium carbonate (2.66 g, 25.17 mmol) at RT and purged under argon atmosphère for 20 min. To this was added Pd(PPh3)4 (726 mg, 0.62 mmol) and heated to 110 °C for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The obtained solid was filtered, dried in vacuo to obtain the crude which was purified through silicagel column chromatography in 50% EtOAc/ hexanes to afford compound 382 (2.5 g, 68%) as an off-white solid. TLC: 60% EtOAc/ hexanes (Rf. 0.3); XH NMR (DMSO-i/g, 400 MHz): δ 9.27 (s, 3H), 8.66-8.63 (m, 1H), 8.37-8.25 (m, 2H), 7.84 (t, J= 8.0 Hz, 1H).
Synthesis of 3-(pyrimidin-5-yl) aniline (383): To a stirred solution of compound 382 (1.7 g, 8.45 mmol) in EtOH (30 mL) under inert atmosphère was added 10% Pd/C (500 mg) under argon
143 atmosphère and stirred under H2 atmosphère (balloon pressure) for 5 h. After completion of the reaction, the reaction mixture was filtered through celite, washed with 5% MeOH/ CH2C12 (50 mL). The filtrate was concentrated in vacuo to obtain the crude which was triturated with mixture of ether: pentane (1:1, 10 ML) and dried in vacuo to afford compound 383 (1.2 g, 86%) as an off-white solid. TLC: 70% % EtOAc/hexanes (Rf. 0.2); *H NMR (DMSO-<4, 400 MHz): δ 9.15 (s, 1H), 9.00 (s, 2H), 7.17 (t, J= 7.8 Hz, 1H), 6.91 - 6.86 (m, 2H), 6.69-6.64 (m, 1H), 5.27 (s, 3H).
Synthesis of 3-(pyrimidin-4-yl) aniline (386)
Synthesis of 2, 4-dichIoro-6-(3-nitrophenyl) pyrimidine (385): To a stirred solution of 2, 4, 6trichloropyrimidine 384 (500 mg, 2.76 mmol) and (3-nitrophenyl) boronic acid 382 (594 mg, 2.76 mmol) in 1, 2-dimethoxy ethane (10 mL) under inert atmosphère were added sodium carbonate (878 mg, 8.28 mmol) at RT and purged under argon atmosphère for 20 min. To this was added Pd(PPh3)4 (159 mg, 0.13 mmol) and heated to 80 C for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite and the filtrate was concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 10% EtOAc/ hexanes to afford crude compound 385 (200 mg) as yellow solid which was carried forward for next step. TLC: 10% EtOAc/ hexanes (Rf. 0.7).
Synthesis of 3-(pyrimidin-4-yl) aniline (386): To a stirred solution of compound 385 (200 mg, crude) in EtOAc (50 mL) under inert atmosphère were added sodium acetate (304 mg, 3.71 mmol), 10% Pd/C (100 mg, wet) under argon atmosphère and stirred under H2 atmosphère (balloon pressure) for 6 h. After completion of the reaction, the reaction mixture was filtered through celite, washed with 50% MeOH/ CH2C12 (50 mL). The filtrate was concentrated in vacuo to obtain the
144 crude which was purified through silicagel column chromatography in 90% EtOAc/ hexanes to afford compound 386 (100 mg, 78%) as an off-white solid. TLC: 70% % EtOAc/ hexanes (A/ 0.4);
JH NMR (400 MHz, DMSO-ife): δ 9.19 (s, 1H), 8.80 (d, J= 5.4 Hz, 1H), 7.91 (dd, J= 5.4, 1.4 Hz, 1H), 7.45-7.43 (m, 1H), 7.30 (d, J= 7.7 Hz, 1H), 7.18 (t, J= 7.8 Hz, 1H), 6.74 (d, J= 7.5 Hz, 1H), 5.31 (s, 2H).
Synthesis of 3-(thiazol-5-yl) aniline (389)
To a stirred solution of 5-bromothiazole 387 (350 mg, 2.13 mmol) in 2-methyl THF (5 mL) under inert atmosphère were added 3-aminophenylboronic acid pinacol ester 388 (600 mg, 2.35 mmol), sodium carbonate (565 mg, 5.33 mmol), at RT and stirred under argon atmosphère for 20 min. To this was added Pd(dppf)2C12 (78 mg, 0.106 mmol) and heated to 110 C and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was fîltered through celite and the filtrate was concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 80% EtOAc/ hexanes to afford compound 389 (200 mg, 52%) as yellow syrup. TLC: 70% EtOAc/ hexanes (Rf. 0.4); LC-MS: 84.49%; 176.8 (MT+1); (column; Ascentis Express Cl8, (50 x 3.0 mm, 2.7 pm); RT 1.40 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min).
Synthesis of 3’-amino-[l, l’-biphenyl]-4-ol (392)
To a stirred solution of 3-bromoaniline 390 (400 mg, 2.32 mmol) and (4-hydroxyphenyl) boronic acid 391 (353 mg, 2.55 mmol) in MeOH (4 mL) under inert atmosphère were added sodium carbonate (493 mg, 4.65 mmol) at RT and purged under argon atmosphère for 20 min. To this was
145 added Pd(OAc)2 (156 mg, 0.23 mmol) and heated to 80 C for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was fîltered through celite, washed with MeOH (20 mL). The filtrate was concentrated in vacuo to obtain the crude. The crude was purifïed through silica gel column chromatography in 20% EtOAc/ hexanes to afford compound 392 (160 mg) as brick red solid. TLC: 30% EtOAc/ hexanes (Rf. 0.4); LC-MS: 67.89%; 185.9 (M++l); (column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 2.10 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min).
Synthesis of 5-phenyloxazoI-2-amine (396)
Synthesis of 2-bromo-2-phenylacetaldehyde (394): To a stirred solution of 2-phenylacetaldehyde 393 (500 mg, 4.16 mmol) in 1, 4-Dioxane (2 mL) under inert atmosphère was added bromine (0.27 mL, 4.99 mmol) at 0 C and stirred for 20 min; warmed to RT and stirred for 1 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to afford crude compound 394 (800 mg) as green syrup. The crude was carried forward for next step without further purification. TLC: 10% EtOAc/ hexanes (Rf. 0.7);
Synthesis of 5-phenyloxazol-2-amine (396): To a stirred solution of compound 394 (800 mg, crude) in EtOH (10 mL) under inert atmosphère was added urea 395 (482 mg, 8.04 mmol) at RT; heated at 80 °C and stirred for 6 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo and the residue was diluted with water (60 mL). The pH was neutralized with 10% aqueous NaHCO3 solution (10 mL) and extracted with EtOAc (2 x 100 mT,). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through flash column chromatography using 23% MeOH/ CH2CI2 to afford compound 396 (200 mg, 32%) as an off-white solid. TLC: 5% MeOH/ CH2CI2 (Rf. 0.5); 1H NMR (400 MHz, DMSO-Jd): δ 7.45 (d, J= 7.2 Hz, 2H), 7.36 (t, J= 7.8 Hz, 2H), 7.21-7.16 (m, 2H), 6.81 (s, 2H);
146
Synthesis of 5-phenylthiazol-2-amine (397)
Synthesis of 5-phenylthiazoi-2-amine (397): To a stirred solution of 2-bromo-2phenylacetaldehyde 394 (860 mg, crude) in EtOH (20 mL) under inert atmosphère was added thiourea (658 mg, 8.64 mmol) at RT; heated at 80 °C and stirred for 8 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The pH of the residue was neutralized with 10% aqueous NaHCO3 solution (10 mL) and extracted with EtOAc (2 x 200 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purifîed through flash column chromatography using 2-3% MeOH/ CH2CI2 to afford compound 397 (500 mg, 66%) as an offwhite solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.6); JH NMR (400 MHz, DMSO-d6): δ 7.43-7.38 (m, 3H), 7.32 (t, J= 7.8 Hz, 2H), 7.17 (tt, J= 7.5, 0.9 Hz, 1H), 7.12 (s, 2H).
Synthesis of l-methoxy-3-(pyrimidin-5-yl) propan-2-amine hydrochloride (401)
Synthesis of teri-butyl (l-hydroxy-3-(pyrimidin-5-yl) propan-2-yl) carbamate (399): To a stirred solution of methyl 2-((tert-butoxycarbonyl) amino)-3-(pyrimidin-5-yl) propanoate 398 (200 mg, 0.71 mmol) in MeOH (5 mL) under inert atmosphère was added sodium borohydride (105 mg, 2.84 mmol) at 0 °C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (25 mL) and extracted with 10% MeOH/ CH2C12 (5 x 25 mL). The combined organic extracts were dried over sodium sulfate,
147 filtered and concentrated in vacuo to obtain the crude. The crude was purifîed through silica gel column chromatography using 8% MeOH/ CH2C12 to afford compound 399 (110 mg, 61%) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.4); *H NMR (DMSO-76,400 MHz): δ 8.99 (s, 1H), 8.61 (s, 2H), 6.70 (d, 7 = 9.0 Hz, 1H), 4.82 (t, 7= 5.4 Hz, 1H), 3.61 (br s, 2H), 3.45-3.34 (m, 2H), 2.93-2.82 (m, 1H), 1.26 (s, 9H)
Synthesis of tert-butyl (l-methoxy-3-(pyrimidin-5-yI) propan-2-yl) carbamate (400): To a stirred solution of compound 399 (100 mg, 0.39 mmol) in THF (10 mL) were added triethyl benzyl ammonium chloride (9 mg, 0.03 mmol), 50% aqueous sodium hydroxide solution (3.5 mL) and methyl iodide (0.02 mL, 0.39 mmol) at 0 °C; warmed to RT and stirred for 24 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (25 mL) and extracted with EtOAc (3 x 25 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purifîed through silica gel column chromatography using 3% MeOH/ CH2CI2 to afford compound 400 (70 mg, 67%) as colorless syrup. TLC: 5% MeOH/ CH2C12 (Rf 0.5); ]H NMR (DMSO-76,400 MHz): δ 9.00 (s, 1H), 8.62 (s, 2H), 6.84 (d, 7= 8.8 Hz, 1H), 3.78 (brs, 2H), 3.29-3.23 (m, 5H), 2.85 (dd, 7= 13.8, 4.1 Hz, 1H), 1.28-1.21 (m, 9H).
Synthesis of l-methoxy-3-(pyrimidin-5-yl) propan-2-amine hydrochloride (401): To a stirred solution of compound 400 (60 mg, 0.22 mmol) in CH2C12 (3 mL) was added 4 N HCl in 1, 4Dioxane (1 mL) under argon atmosphère at 0 °C; warmed to RT and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was washed with n-pentane (2x5 mL) and dried in vacuo to afford compound 401 (40 mg, HCl sait) as brown solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.1); JH NMR (DMSO-/4, 400 MHz); δ 9.11 (s, 1H), 8.75 (s, 2H), 8.24 (br s, 2H), 3.68-3.59 (m, 1H), 3.53-3.48 (m, 1H), 3.39 (dd, 7= 10.5, 5.7 Hz, 1H), 3.30 (s, 3H), 2.95 (t, 7= 7.3 Hz, 2H).
Synthesis of 4-(2-aininoethyl)-/V, /V-dimethylbenzenesulfonamide hydrochloride (406)
148
Synthesis of 4-(2-bromoethyl) benzenesulfonyl chloride (403): To a stirred solution of (2bromoethyl) benzene 402 (5 g, 27.02 mmol) in CH2CI2 (15 mL) under argon atmosphère was added chlorosulfonic acid (5.4 mL, 81.08 mmol) at 0 C; warmed to RT and stirred for 3 h. The reaction was monitored by TLC; after completion the reaction, the reaction mixture was poured into ice-cold water (100 mL) extracted with CH2CI2 (2 x 150 mL). The combined organic extracts were washed with brine (100 mL), separated dried over sodium sulfate, fîltered and concentrated in vacuo to afford crude compound 403 (5 g) as colorless thick syrup. TLC: 10% EtOAc/ hexanes (Rf. 0.6); ΉNMR (DMSO-ritf, 400 MHz): δ 8.00 (d, 8.4 Hz, 2H), 7.47 (d, J= 8.8 Hz, 2H), 3.62 (t, J= 7.2
Hz, 2H), 3.30 (t, 7.2 Hz, 2H).
Synthesis of 4-(2-bromoethyl)-A', A-dimethylbenzenesulfonamide (404): To a stirred solution of compound 403 (5 g, crude) in THF (100 mL) under argon atmosphère were added pyridine (14.37 mL, 176.05 mmol), dimethylamine hydrochlori.de 309 (7.1 g, 88.02 mmol) at 0 C; warmed to RT and stirred for 1 h. The reaction was monitored by TLC; after completion the reaction, the volatiles were removed in vacuo. The residue was diluted with CH2CI2 (500 mL) and washed with 1 N HCl (15 mL). The organic layer was dried over sodium sulfate, fîltered and concentrated in vacuo to obtain crude. The crude was titurated with pentane (30 mL) and dried in vacuo to afford compound 404 (3.5 g, 68%) as an off-white solid. TLC: 20% EtOAc/ hexane (Rf. 0.5); 1H NMR (CDCI3, 400 MHz): δ 7.74 (d, J= 8.4 Hz, 2H), 7.39 (d, J= 8.5 Hz, 2H), 3.60 (t, J= 7.2 Hz, 2H), 3.25 (t, J= 7.3 Hz, 2H), 2.72 (s, 6H).
149
Synthesis of 4-(2-azidoethyl)-7V, 7V-dimethylbenzenesulfonamide (405): To a stirred solution of compound 404 (500 mg, 1.71 mmol) in DMF (10 mL) under inert atmosphère was added sodium azide (335 mg, 5.15 mmol) at RT and heated to 80 °C for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice-cold water (20 mL) and extracted with CH2CI2 (2 x 200 mL). The combined organic extracts were dried under sodium sulfate, fîltered and concentrated in vacuo to afford compound 405 (350 mg, 80%) as thick syrup. TLC: 20% EtOAc/ hexane (Rf. 0.6); ’H-NMR (DMSO-^, 400 MHz): δ 7.73 (d, J= 8.4 Hz, 2H), 7.40 (d, J= 6.8 Hz, 2H), 3.56 (t, J= 6.8 Hz, 2H), 2.97 (t, J= 6.8 Hz, 2H), 2.71 (s, 6H).
Synthesis of 4-(2-aminoethyl)-7V, 7V-dimethylbenzenesulfonamide hydrochloride (406): To a stirred solution of compound 405 (350 mg, 1.37 mmol) in a mixture of THF: H2O (4:1, 10 mL) was added triphenyl phosphine (1.08 g, 4.13 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 3-5% MeOH/ CH2Cl2to afford ffee amine (200 mg) as thick syrup.
To a stirred solution of the ffee amine (200 mg) in CH2CI2 (2 mL) under argon atmosphère was added 4 N HCl in 1, 4-dioxane (0.5 mL) at 0 °C and stirred for 10 min. The volatiles were removed in vacuo to obtain the crude which was washed with diethyl ether (2x5 mL) and dried in vacuo to afford compound 406 (125 mg, 35%) as white solid. TLC: 10% MeOH/ CH2CI2 (Rf. 0.2); 1H-NMR (DMSO-îZô, 400 MHz): δ 8.04 (br s, 2H), 7.70 (d, J= 8.4 Hz, 2H), 7.54 (d, J= 8.4 Hz, 2H), 3.153.05 (m, 2H), 3.01-2.98 (m, 2H), 2.60 (s, 6H).
Synthesis of 4-(3-aminopropyl)-7V, /V-dimethylbenzencsulfonamide hydrochloride (410)
150
Synthesis of 4-(3-bromopropyl) benzenesulfonyl chloride (407): To a stirred solution of (2bromoethyl) benzene 402 (5 g, 27.02 mmol) in CHCI3 (15 mL) under argon atmosphère was added chlorosulfonic acid (5.4 mL, 81.08 mmol) at 0 °C; warmed to RT and stirred for 3 h. The reaction was monitored by TLC; after completion the reaction, the reaction mixture was poured into ice-cold water (100 mL) extracted with CH2CI2 (2 x 100 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to afford crude compound 407 (5 g) as colorless thick syrup. TLC: 10% EtOAc/ hexanes (Rf. 0.4); XH NMR (CDCI3, 400 MHz): δ 7.97 (d, J= 8.8 Hz, 2H), 7.45 (d, J= 8.8 Hz, 2H), 3.40 (t, J= 6.4 Hz, 2H), 2.93 (t, J= 7.2 Hz, 2H), 2.24-2.17 (m, 2H).
Synthesis of 4-(3-cliloropropyl)-A?, .'V-dimethyibenzenesulfonamide (408): To a stirred solution of compound 407 (5 g, crude) in THF (100 mL) under argon atmosphère were added pyridine (14.42 mL, 176.6 mmol), dimethylamine hydrochloride 309 (7.2 g, 88.33 mmol) at 0 C; warmed to RT and stirred for 1 h. The reaction was monitored by TLC; after completion the reaction, the volatiles were removed the in vacuo. The residue was diluted with water (100 mL) and extracted with CH2CI2 (2 x 100 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 408 (3 g) as white sticky solid. TLC: 20% EtOAc/ hexanes (Rf. 0.5); JH NMR (CDC13, 400 MHz): δ 7.71 (d, J= 8.4 Hz, 2H), 7.37 (d, J= 8.0 Hz, 2H), 3.53 (t, J= 6.4 Hz, 1H), 3.40 (t, J= 6.4 Hz, 1H), 2.87 (t, J= 7.2 Hz, 2H), 2.71 (s, 6H), 2.23-2.08 (m, 2H).
Synthesis of 4-(3-azidopropyl)-7V, 7V-dimethyIbenzenesulfonamide (409): To a stirred solution of compound 408 (3 g, 9.83 mmol) in DMF (50 mL) under inert atmosphère was added sodium azide (1.91 g, 29.50 mmol) at RT and heated to 70-80 °C for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice-cold water (20 mL) and extracted with EtOAc (2 x 150 mL). The combined organic extracts were dried under sodium sulfate, filtered and concentrated in vacuo to afford compound 409 (2 g, 76%) as colorless thick syrup. TLC: 20% EtOAc/ hexane (Rf. 0.6); *H NMR (CDC13, 500 MHz): δ 7.71 (d, J= 8.1 Hz, 2H), 7.36 (d, J= 8.1 Hz, 2H), 3.32 (t, J= 6.7 Hz, 2H), 2.82-2.77 (m, 2H), 2.71 (s, 6H), 1.98-1.91 (m, 2H).
151
Synthesis of 4-(3-aminopropyI)-7V, Λ-dimethyibeiizenesulfonainide hydrochloride (410): To a stirred solution of compound 409 (2.35 g, 8.76 mmol) in a mixture of THF: H2O (4: 1, 100 mL) was added triphenyl phosphine (6.89 g, 26.30 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 15% MeOH/ CH2Cl2to afford free amine (2 g) as thick syrup.
To a stirred solution of the above compound (2 g) in CH2CI2 (20 mL) under argon atmosphère was added 4 N HCl in 1, 4-dioxane (10 mL) at 0 C and stirred for 10 min. The solvent was decanted and the obtained solid was dried in vacuo to afford compound 410 (1.5 g, 70%) as white solid. TLC: 10% MeOH/ CH2CI2 (Rf. 0.2); XH-NMR (DMSO-d6, 400 MHz): δ 8.08 (br s, 3H), 7.68 (d, J= 8.4 Hz, 2H), 7.50 (d, J= 8.4 Hz, 2H), 2.81-2.75 (m, 4H), 2.59 (s, 6H), 1.94-1.86 (m, 2H).
Synthesis of 3'-methoxy-[l, l'-biphenyl]-3-amine (412)
To a stirred solution of 3-bromoaniline 390 (1 g, 5.81 mmol) and (3-methoxyphenyl) boronic acid 411 (883 mg, 5.81 mmol) in Toluene: MeOH (1:1, 20 mL) under inert atmosphère were added sodium carbonate (2.15 g, 20.34 mmol in 10 mL of H2O) at RT and purged under argon atmosphère for 20 min. To this was added Pd(PPh3)4 (335 mg, 0.28 mmol) and heated to 100 C for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite, washed with 50% MeOH/ CH2CI2 (150 mL). The filtrate was evaporated in vacuo to obtain the crude which was purified through silica gel column chromatography in 70% EtOAc/ hexanes to afford compound 412 (500 mg, 54%) as yellow thick syrup. TLC: 70% EtOAc/ hexanes (Rf. 0.5); *H NMR (400 MHz, CDC13): δ 7.35-7.30 (m, 1H), 7.25-7.19 (m, 1H), 7.17-7.13 (m, 1H), 7.10-7.08 (m, 1H), 7.00-6.96 (m, 1H), 6.92-6.85 (m, 2H), 6.68-6.65 (m, 1H), 3.85 (s, 3H), 3.72 (br s, 2H);
Synthesis of 3'-amino-[l, l'-biphenyl]-3-ol (413)
152
A mixture of compound 412 (400 mg, 2.01 mmol) in hydrogen iodide (5 mL, 57% aqueous solution) was refluxed for 5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with ice-cold water and the pH was neutralized with 10% sodium bicarbonate solution (5 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The obtained solid was filtered, dried in vacuo to obtain the crude which was purified through silicagel column chromatography in 80% EtOAc/ hexanes to afford compound 413 (200 mg, 54%) as an off-white solid. TLC: 50% EtOAc/ hexanes (Rf. 0.4); *H NMR (400 MHz, DMSO-îZ6): δ 9.41 (s, 1H), 7.20 (t, J= 7.8 Hz, 1H), 7.06 (t, J= 7.8 Hz, 1H), 6.99-6.88 (m, 2H), 6.78-6.76 (m, 1H), 6.73-6.68 (m, 2H), 6.55-6.52 (m, 1H), 5.12 (s, 2H).
Synthesis of 2-(tetrahydrofuran-2-yl) ethan-l-amine hydrochloride (415)
i) LAH, ether,RT, 16 h CIH H2N^ | |
r \ n | |
ii) 4 N HCl in 1,4-Dioxane | |
414 | 415 |
To a stirred solution of 2-(tetrahydrofuran-2-yl) acetonitrile 414 (2 g, 17.99 mmol) in ether (20 mL)
O under argon atmosphère was added lithium aluminium hydride (1.36 g, 35.83 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with saturated sodium potassium tartrate solution (30 mL) at 0-5 °C and extracted with ether (2 x 50 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude.
The crude was dissolved in CH2CI2 (5 mL) cooled to 0 C and added 4 N HCl in 1, 4-dioxane (10 mL) under argon atmosphère and stirred at the same température for 30 min. The volatiles were removed in vacuo. The obtained solid was titurated with CH2C12 (2x5 mL) and in vacuo to afford compound 415 (500 mg, HCl sait) as sticky solid. TLC: 10% MeOH/ CH2CI2 (Rf. 0.2).
153
Synthesis of 4-(27/-1, 2, 3-triazol-2-yl) benzaldehyde & 4-(121-1,2, 3-triazol-l-yl) benzaldehyde (418 & 419): To a stirred solution of 4-fluorobenzaldehyde 417 (2 g, 16 mmol) in DMF (50 mL) under argon atmosphère were added 177-1, 2, 3-triazole 417 (1.32 g, 19.2 mmol), potassium carbonate (3.3 g, 24 mmol) at RT; heated to 100 C and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice cold water (35 mL) and extracted with EtOAc (2 x 40 mL). The combined organic extracts were dried over sodium sulfate, fïltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 418 (800 mg, 29%) and using 40% EtOAc/ hexanes to afford compound 419 (1 g, 36%) as yellow solids.
Compound 418 analytical data: TLC: 20% EtOAc/hexanes (Rf. 0.8); 'h-NMR (DMSO-îZô, 400 MHz): δ 10.05 (s, 1H), 8.27 (s, 2H), 8.25 (d, J= 8.8 Hz, 2H), 8.11 (d, J= 8.8 Hz, 2H).
Compound 419 analytical data: TLC: 20% EtOAc/hexanes (Rf. 0.3); 1H-NMR (DMSO-Js, 400 MHz): δ 10.07 (s, 1H), 8.98 (s, 1H), 8.19 (d, J= 8.8 Hz, 2H), 8.13 (d, J= 8.8 Hz, 2H), 8.04 (s, 1H).
Synthesis of (jE)-2-(4-(2-nitrovinyI) phenyl)-227-l, 2, 3-triazole (420): To a stirred solution of compound 418 (400 mg, 2.31 mmol) in AcOH (10 mL) under argon atmosphère were added nitromethane (1.41 mL, 23.12 mmol), ammonium acetate (267 mg, 3.46 mmol) at RT; heated to 100 °C and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo and diluted with water (20 mL). The obtained solid was fïltered, washed with n-hexane and dried in vacuo to afford compound 420 (400 mg, 80%) as yellow solid. TLC: 20% EtOAc/ hexanes (Rf. 0.3); ’H-NMR (DMSO-</6, 400 MHz): δ 8.29-8.18 (m, 4H), 8.138.05 (m, 4H).
154
Synthesis of 2-(4-(223-1, 2, 3-triazol-2-yl) phenyl) ethan-l-amine hydrochloride (421): To a stirred solution of compound 420 (200 mg, 0.92 mmol) in MeOH (10 mL) under argon atmosphère were added 10% Pd/C (100 mg), HCl (0.2 mL) at RT and stirred under hydrogen atmosphère (balloon pressure) for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite and the filtrate was concentrated in vacuo to obtain the crude. The crude was triturated with 2 M HCl in Et2O (2x5 mL) and dried in vacuo to afford compound 421 (100 mg, 48%) as an off-white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.2); 'H-NMR (DMSO-î/6, 400 MHz): δ 8.16 (s, 2H), 8.12 (br s, 2H), 7.98 (d, 7= 8.4 Hz, 2H), 7.46 (d, 7= 8.4 Hz, 2H), 3.10-3.05 (m, 2H), 2.96 (t, 7= 8.4 Hz, 2H).
Synthesis of benzyl (4-(4-(2-aminoethyl) phenoxy) butyl) carbamate hydrochloride (427)
Synthesis of terf-butyi (4-hydroxyphenethyl) carbamate (423): To a stirred solution of 4-(2aminoethyl) phénol 422 (1 g, 7.29 mmol) in 1, 4-dioxane: H2O (1: 1, 30 mL) were added 2 M o
aqueous sodium hydroxide solution (2 mL) and Boc-anhydride (1.9 mL, 8.25 mmol) at 0 C;
warmed to RT and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the pH of the reaction mixture cooled to 0 C, acidified with 1 M HCl to ~3 and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over sodium sulphate, filtered and concentrated in vacuo to afford compound 423 (1.5 g, 87%) as an off-white solid. TLC: 50% EtOAc/hexanes (Rf. 0.8); Ή NMR (DMSO-J6,500 MHz): δ 9.15 (s, 1H), 6.95 (d,7= 8.4 Hz, 2H),
155
6.83 (t, J= 5.4 Hz, 1H), 6.64 (d, J= 8.1 Hz, 2H), 3.09-3.00 (m, 2H), 2.56-2.51 (m, 2H), 1.35 (s, 9H).
Synthesis of benzyl (4-hydroxybutyl) carbamate (425): To a stirred solution of 4-aminobutan-l-ol 424 (1.0 g, 11.23 mmol) in CH2CI2 (15 mL) under argon atmosphère were added triethyl amine (1.78 mL, 12.35 mmol) and benzyl chloroformate (1.76 mL, 12.35 mmol, 50% solution in toluene) at 0 C; warmed to RT and stirred for 6 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with saturated ammonium chloride (50 mL) at 0 C. The organic layer was washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated in vacuo to afford compound 425 (2.1 g, 84%) as colorless liquid. TLC: 50% EtOAc/ hexanes (Rf. 0.5); *H NMR (DMSO-d6_ 500 MHz): δ 7.40-7.22 (m, 6H), 4.98 (s, 2H), 4.37 (t, J= 5.1 Hz, 1H), 3.36 (q, J= 5.8 Hz, 2H), 2.97 (q, 6.3 Hz, 2H), 1.51-1.28 (m, 4H).
Synthesis of teri-butyl (4-(4-(((benzyloxy) carbonyl) amino) butoxy) phenethyl) carbamate (426): To a stirred solution of compound 423 (1.5 g, 6.32 mmol) and compound 425 (1.4 g, 6.32 mmol) in THF (50 mL) under argon atmosphère at 0 C were added triphenyl phosphine (1.65 g, 6.32 mmol), diisopropyl azodicarboxylate (1.4 mL, 6.96 mmol) at 0 C; warmed to RT and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was dissolved in 10% EtOAc/ hexanes (5 mL) and the precipitated solid was filtered, washed with hexane (20 mL), dried in vacuo to afford compound 426 (1.9 g, 68%) as an off-white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.7); ’H NMR (DMSO-î/6, 500 MHz): δ 8.89 (s, 1H), 7.68-7.51 (m, 5H), 7.40-7.24 (m, 2H), 7.07 (d, J= 8.4 Hz, 1H), 6.88-6.78 (m, 2H), 5.00 (s, 2H), 4.80-4.73 (m, 2H), 3.91 (t, J= 6.4 Hz, 2H), 3.11-3.02 (m, 2H), 2.60 (t, J= 7.5 Hz, 2H), 1.72-1.64 (m, 2H), 1.56-1.52 (m, 2H), 1.18 (d, J= 6.1 Hz, 9H).
Synthesis of benzyl (4-(4-(2-aminoethyl) phenoxy) butyl) carbamate hydrochloride (427): To a stirred solution of compound 426 (500 mg, 1.13 mmol) in CH2CI2 (5 mL) was added 4 N HCl in 1, 4-dioxane (3 mL) under argon atmosphère at 0-5 °C; warmed to RT and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed under reduced pressure. The obtained solid was washed with diethyl ether (10 mL), 72-pentane (10 mL) and dried in vacuo to afford compound 427 (200 mg, 47%) as white solid. TLC: 5% MeOH/ CH2CI2 (Rf. 0.4);
XH NMR (DMSO-rf6,500 MHz): δ 7.88 (br s, 3H), 7.39-7.28 (m, 5H), 7.15 (d, J= 8.7 Hz, 2H), 6.88
156 (d, J= 8.7 Hz, 2H), 5.00 (s, 2H), 3.93 (t, J= 6.4 Hz, 2H), 3.04 (q, J= 6.1 Hz, 2H), 2.97 (d, J= 6A
Hz, 2H), 2.81-2.76 (m, 2H), 1.73-1.65 (m, 2H), 1.57-1.51 (m, 2H).
Synthesis of 4-phenyloxazol-2-amine (429)
Synthesis of 4-phenyloxazol-2-amine (429): To a stirred solution of 2-bromo-l-phenylethan-l-one 428 (100 mg, 0.50 mmol) in CH3CN (5 ml) under inert atmosphère was added urea 395 (301 mg, 5.02 mmol) at RT; heated at 80 C and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was purified through flash column chromatography using 30% EtOAc/ hexanes to afford compound 429 (50 mg, 63%) as an off-white solid. TLC: 50% EtOAc/ hexanes (Rf. 0.6); 1H NMR (400 MHz,
DMSO-îZ6): δ 7.86 (s, 1H), 7.63 (d, 7= 7.0 Hz, 2H), 7.35 (t, 7= 7.6 Hz, 2H), 7.26-7.22 (m, 1H), 6.70 (s, 2H).
Table 1: Synthesis of compounds from compounds 6,14,21,28, 35, 42, 50, 55, 62, 70, 76, 82,
88, 97,103, 112,118, 124,135,140, 145,150,155,156,159,164,167,170, P-42 and various amines
t 1 t No.” » t _ 1 i * l ; f ' | - y Structure ’ ’ ‘1 ·' ..·ϊ· < ..· 1 | Procedure, ilntermediate , Amine | Rx Yield (%) e U | Mass Spec. Found | î 1 ,-Mass Spec.:* Calculated ”< | 'il-NMR . ' i t > 1 T 1 iV | |
1101 | H | D, 6 | 52 | 476.0701 | 476.0715 for C22H19N3O 4S2Na (M+Na)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 8.62 (t, J = 5.6 Hz, 1H), 7.76-7.59 (m, 5H), 7.57-7.35 (m, 6H), 7.26 (s, 2H), 3.47 (t, J = 6.6 Hz, 2H), 2.88 (t, J = 7.1 Hz, 2H). |
157
1102 | ....A CC/v Π0 | D, 6 | 51 | 504.1048 | 504.1028 for C24H23N3O 4S2Na (M+Na)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 8.60 (t, J = 5.6 Hz, 1H), 7.71-7.57 (m, 5H), 7.55-7.40 (m, 6H), 3.50 (q, J = 6.8 Hz, 2H), 2.91 (t, J = 7.1 Hz, 2H), 2.52 (s, 6H). | ||
1103 | 1 VHi 0 H | D, 6 | 83 | 453.0936 | 453.0943 for C23H21N2O 4S2 (M+H)+ | ‘H NMR (400 MHz, DMSOdfi) δ 10.78 (s, 1H), 8.60 (t,J= 5.5 Hz, 1H), 7.71-7.59 (m, 3H), 7.53 (d, J = 8.3 Hz, 1H), 7.51-7.42 (m, 2H), 7.27 (t,J= 7.3 Hz, 2H), 7.18(dd,J= 15.9, 7.3 Hz, 3H), 3.44 (q, J = 6.9 Hz, 2H), 2.80 (t, J= 7.4 Hz, 2H). | ||
1104 | D, 6 | 63 | 373.0999 | 373.1016 for C22H17N2O 2S (M-H)’ | ‘H NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 8.60 (t, J= 5.5 Hz, 1H), 7.71 - 7.59 (m, 3H), 7.53 (d, J = 8.3 Hz, 1H), 7.51-7.42 (m, 2H), 7.27 (t,J= 7.3 Hz, 2H), 7.18(dd,J= 15.9, 7.3 Hz, 3H), 3.44 (q, J = 6.9 Hz, 2H), 2.80 (t, J= 7.4 Hz, 2H). | |||
1105 | ” h ; | D, 6 | 80 | 381.1633 | 381.1637 for C22H25N2O 2S (M+H)+ | *H NMR (400 MHz, DMSOd6) δ 10.76 (s, 1H), 8.43 (t,J= 5.6 Hz, 1H), 7.71 - 7.59 (m, 3H), 7.58-7.40 |
158
(m, 4H), 3.28 - 3.17 (m, 2H), 1.73-1.53 (m, 6H), 1.37 (q, J = 7.0 Hz, 2H), 1.32-1.03 (m, 3H), 0.87 (tt, J = 11.5, 6.1Hz, 2H). | ||||||||
1107 | 0 y- NH o | D, 6 | 79 | 361.1001 | 361.1011 for C2lH[7N2O 2S (M+H)+ | *H NMR (400 MHz, DMSOd6) δ 10.77 (s, 1H), 9.08 (t,J= 6.0 Hz, 1H), 7.74-7.58 (m, 4H), 7.57-7.40 (m, 3H), 7.35 - 7.19 (m, 5H), 4.43 (d, J =6.0 Hz, 2H). | ||
1108 | 0 y-NH 0 ο ΓΜ O U | D, 6 | 71 | 389.1307 | 389.1324 for C23H2iN2O 2S (M+H)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.76 (s, 1H), 8.52 (t, J= 5.6 Hz, 1H), 7.71-7.60 (m, 3H), 7.60-7.42 (m, 4H), 7.30 - 7.13 (m, 5H), 3.23 (q, .7=6.6 Hz, 2H), 2.59 (t,J= 7.7 Hz, 2H), 1.83-1.74 (m, 2H). | ||
1109 | 0x r-NH 0 | D, 6 | 81 | 403.1496 | 403.1480 for C24H23N2O 2S (M+H)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.75 (s, 1H), 8.48 (t,J= 5.6 Hz, 1H), 7.71 - 7.59 (m, 3H), 7.58 - 7.40 (m, 4H), 7.29 7.09 (m, 5H), 3.23 (q,.7=6.5 Hz, 2H), 2.57 (t, J= 7.4 Hz, 2H), 1.63-1.44 (m,4H). |
159
1110 | 0x K»! P J } CWVXi | D, 6 | 65 | 447.1162 | 447.1143 for C26H20N2O 2SNa (M+Na)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.77 (s, 1H), 8.65 (t,J= 5.6 Hz, 1H), 7.83 (t, 7= 8.5 Hz, 3H), 7.78- 7.59 (m, 4H), 7.57-7.35 (m, 7H), 3.55 (q, J = 6.8 Hz, 2H), 2.97 (t, 7=7.3 Hz, 2H). | |
1111 | 0 ! >NH 0 A\ ί n ïM AA / A-vrAA | D, 6 | 36 | 473.1319 | 473.1300 for C2sH22N2O 2SNa (M+Na)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 8.63 (t, J = 5.7 Hz, 1H), 7.71-7.39 (m, 13H), 7.32 (dd, J =13.3,7.5 Hz, 3H), 3.48 (q, J =6.7 Hz, 2H), 2.85 (t, J = 7.2 Hz, 2H). | |
1112 | 0 Ÿ-Mll 0 | D, 6 | 82 | 459.1154 | 459.1143 for C27H2oN20 2SNa (M+Na)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 9.12 (t, J = 6.0 Hz, 1H), 7.76-7.29 (m, 16H), 4.48 (d, J = 5.9 Hz, 2H). | |
1113 | 0 >NH 0 A ΓΜ AA a .LJ 1 ν-λ J r MS H | D, 6 | 83 | 415.0894 | 415.0892 for C22H17N2O 2SFNa (M+Na)+ | Ή NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 8.57 (t, J = 5.7 Hz, 1H), 7.65 (ddd, J = 17.4, 6.5,2.8 Hz,3H), 7.57 — 7.40 (m, 4H), 7.23 (dd, J = 8.4, 5.6 Hz, 2H), 7.08 (t, J = 8.8 Hz, 2H), 3.43 (q, J =6.8 Hz, 2H), 2.79 (t, J = 7.2 Hz, 2H). |
160
1114 | 0 Μη p Us-VÎ-MJ χ | D, 6 | 78 | 427.109 | 427.1092 for C23H20N2O 3SNa (M+Na)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 8.57 (t, J = 5.6 Hz, 1H), 7.72-7.60 (m, 3H), 7.57 - 7.40 (m, 4H), 7.15 7.08 (m, 2H), 6.87-6.79 (m, 2H), 3.70 (s, 3H), 3.45-3.35 (m, 2H), 2.73 (t, J = 7.4 Hz, 2H). | ||
1115 | 0 Μη ρ /^νθΗ ÎAVrAr | D, 6 | 63 | 391.1121 | 391.1116 for C22H49N2O 3S (M+H)+ | Ή NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 9.14 (s, 1H), 8.55 (t, J = 5.6 Hz, 1H), 7.71 - 7.60 (m, 3H), 7.58 - 7.40 (m, 4H), 6.99 (d, J =8.2 Hz, 2H), 6.65 (d, J = 8.2 Hz, 2H), 3.37 (q, J = 6.8 Hz, 2H), 2.74- 2.63 (m, 2H). | ||
1117 | 0 Λ ζ~ΝΗ 0 0 Η γ\Α /*%Α ίλ-V ^·ν 0CHj | D, 6 | 81 | 455.1049 | 455.1041 for C24H20N2O 4SNa (M+Na)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 8.60 (t, J = 5.7 Hz, 1H), 7.86 (d, J =8.1 Hz, 2H), 7.71 - 7.60 (m, 3H), 7.57 - 7.40 (m, 4H), 7.36 (d, J = 8.0 Hz, 2H), 3.81 (s,3H), 3.48 (q, J = 6.7 Hz, 2H), 2.88 (t, J = 7.1 Hz, 2H). | ||
1118 | 0 0 CàsO'b'^-Q ΟΗ | D, 6 | 76 | 413.0937 | 413.0936 for C22H18N2O 3SNa (M+Na)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 9.23 (s, 1H), 8.59 (t, J = 5.6 Hz, 1H), 7.71 - 7.59 (m, 3H), 7.58-7.40 |
161
(m, 4H), 7.05 (t, J = 7.7 Hz, 1H), 6.59 (td, J = 9.0, 6.9 Hz, 3H), 3.40 (q, J =6.8 Hz, 2H), 2.70 (t, J = 7.5 Hz, 2H). | ||||||||
1120 | 0 Ζτ”ΝΗ νΛ C'N | D, 6 | 13 | 422.1 | 422.1 (M+Na)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 8.59 (t, J = 5.6 Hz, 1H), 7.83 - 7.33 (m, 11H), 3.47 (dd, J = 7.8, 5.1Hz, 2H), 2.90 (t, J = 7.0 Hz, 2H). | ||
1121 | ο, — /•ΝΗ 0 f\ 'LZ'S^V*' H W | D, 6 | 32 | 458.2 | 458.2 (M+H)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 8.57 (t, J = 5.6 Hz, 1H), 7.71-7.60 (m, 3H), 7.58-7.40 (m, 4H), 7.06- 6.96 (m, 2H), 6.87 - 6.78 (m, 2H), 3.42-3.32 (m, 2H), 3.04 (t, J =5.4 Hz, 4H), 2.68 (t, J = 7.5 Hz, 2H), 1.63 - 1.43 (m, 6H). | ||
1122 | 0 /-Nil 0 | D, 6 | 49 | 486.9872 | 486.9883 for C22H17N2O 2SClBr (M+Cl)· | ‘H NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 8.58 (t, J = 5.6 Hz, 1H), 7.65 (ddd, J = 17.0,5.8,2.1 Hz, 3H), 7.57- 7.40 (m, 6H), 7.17 (d, J = 8.3 Hz, 2H), 3.43 (q, J =6.7 Hz, 2H), 2.77 (t, J = 7.1 Hz, 2H). | ||
1123 | 0. /-NH 0 (l-Cr | D, 6 | 37 | 361.078 | 361.0778 for C18H18N2O 2SC1 | 'H NMR (400 MHz, DMSOd6) δ 10.75 (s, 1H), 8.45 (d, J |
162
(M+C1)· | = 5.7 Hz, 1H), 7.71-7.59 (m, 3H), 7.59 - 7.40 (m, 4H), 3.21 (q, J =6.7 Hz, 2H), 1.45 (p, J = 7.5 Hz, 2H), 1.27 (dt, J = 20.8,10.6 Hz, 2H), 0.86 (td, J = 7.2,2.4 Hz, 3H). | |||||
1124 | 0κ ^>-ΝΗ Ο S Η θ' | D, 6 | 48 | 439.2 | 439.2 (M+C1)· | Ή NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 8.59 (t, J = 5.6 Hz, 1H), 7.72-7.61 (m, 3H), 7.58-7.40 (m,4H), 7.18 (t, J =8.0 Hz, 1H), 6.81 — 6.71 (m, 3H), 3.70 (s, 3H), 3.44 (q, J = 7.1 Hz, 2H), 2.78 (t, J = 7.4 Hz, 2H). |
1125 | ο >-ΝΗ 0 / 0 | D, 6 | 59 | 433.1206 | 433.1222 for C24H2,N2O 4S | ‘H NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 8.56 (t, J = 5.6 Hz, 1H), 7.71-7.60 (m, 3H), 7.58-7.40 (m,4H), 6.89- 6.76 (m, 2H), 6.70 (dd,J = 8.2, 2.0 Hz, 1H), 3.68 (d, J = 2.0 Hz, 6H), 3.16 (d, J = 5.2 Hz, 2H), 2.73 (t, J = 7.3 Hz, 2H). |
1127 | ο, %-ΝΗ 0 \\ Χ„Λ J Ν-χχ / | D, 6 | 49 | 405.1269 | 405.1273 for C23H2iN2O 3S (M+H)+ | ‘H NMR (400 MHz, DMSOds) δ 10.78 (s, 1H), 8.55 (d, J = 6.3 Hz, 1H), 7.71-7.59 (m, 3H), 7.57-7.40 (m, 4H), 7.22 - 7.07 (m, 2H), |
163
6.94 (d, J =8.3 Hz, 1H), 6.84 (t, J = 7.6 Hz, 1H), 3.76 (d, J = 2.1Hz,3H), 3.40 (q, J =7.0 Hz, 2H), 2.82 - 2.74 (m, 2H). | ||||||
1130 | D, 6 | 41 | 391.091 | 391.0917 for C22H16N2O 2fs | ‘H NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 8.60 (t, J = 5.6 Hz, 1H), 7.75-7.57 (m, 3H), 7.57 - 7.39 (m, 4H), 7.30 (td, J = 8.0, 6.2 Hz, 1H), 7.09- 6.95 (m, 3H), 3.46 (q,J = 6.7 Hz, 2H), 2.83 (t, J = 7.2 Hz, 2H). | |
Ο >-ΝΗ 0 η'μ^λ F | ||||||
1149 | D, 6 | 28 | 404.1438 | 404.1433 for C23H22N3O 2s | ‘H NMR (400 MHz, DMSOd6) δ 10.75 (s, 1H), 8.49 (t, J = 5.7 Hz, 1H), 8.42 (d, J =5.1 Hz, 2H), 7.71 7.40 (m, 7H), 7.20 (d, J = 5.4 Hz, 2H), 3.24 (q, J =6.5 Hz, 2H), 2.49 (q, J = 2.8,1.7 Hz, 2H), 1.54 (dp, J = 41.6, 7.1Hz, 4H). | |
Cl | ||||||
1150 | D, 6 | 75 | 409.1961 | 409.1950 for c24h29n2o 2s | ‘H NMR (400 MHz, DMSOd6) δ 10.76 (s, 1H), 8.46 (t, J = 5.7 Hz, 1H), 7.71-7.40 (m, 7H),3.19(q,J = 6.6 Hz, 2H), 1.68-1.54 (m, 5H), 1.44 (p, J = 7.2 Hz, 2H), 1.33-1.03 (m, 8H), 0.83 (t, J = | |
<λ 'LÿZ·' S | ||||||
164
11.1 Hz, 2H). | ||||||
1151 | D, 6 | 74 | 355.1477 | 355.1480 for C20H23N2O 2s | ‘H NMR. (400 MHz, DMSOd6) δ 10.75 (s, 1H), 8.46 (t, J = 5.7 Hz, 1H), 7.71 - 7.40 (m, 7H), 3.20 (q, J = 6.6 Hz, 2H), 1.46 (p, J =6.9 Hz, 2H), 1.32- 1.20 (m,6H), 0.88 - 0.80 (m, 3H). | |
α %-νη Ρ | ||||||
1152 | D, 6 | 59 | 383.1802 | 383.1793 for C22H27N2O 2s | *H NMR (400 MHz, DMSOd6) δ 10.75 (s, 1H), 8.46 (t, J = 5.7 Hz, 1H), 7.71-7.40 (m, 7H),3.19(q,J = 6.6 Hz, 2H), 1.50-1.42 (m, 2H), 1.23 (q, J = 4.6,4.0 Hz, 10H), 0.83 (ζ J = 6.6 Hz, 3H). | |
η | ||||||
1154 | D, 6 | 38 | 462.186 | 462.1851 for C26H28N3O 3s | lH NMR (400 MHz, DMSOd6) δ 10.78 (s, 1H), 8.57 (t, J = 5.6 Hz, 1H), 7.71-7.60 (m, 3H), 7.57 - 7.40 (m, 4H), 7.10 (d, J =8.3 Hz, 2H), 6.83 (d, J = 8.2 Hz, 2H), 3.98 (t, J = 5.8 Hz, 2H), 3.44- 3.34 (m, 2H), 2.72 (t, J = 7.4 Hz, 2H), 2.58 (t, J = 5.8 Hz, 2H), 2.19 (s, 6H). | |
0 ^ΝΗ 0 Η W Ν | ||||||
1155 | D, 6 | 40 | 476.2007 | 476.2008 for ΰ27Η3ο39Ν3 O3S | ‘H NMR (400 MHz, DMSOd6) δ 10.79 (s, 1H), 10.43 (s, 1H), 8.60 (t, J = 5.6 Hz, 1H), | |
0 7-Νη 0 | CI- Cx^Xl ΝΛ-Ο^θ^^ν^Ι4 X/ S Η | ||||||
165
7.71-7.40 (m, 7H), 7.13 (d, J = 8.2 Hz, 2H), 6.84 (d, J =8.2 Hz, 2H), 3.99 (t, J =6.1 Hz, 2H), 3.40 (q, J = 6.8 Hz, 2H), 3.16 (dt, J= 13.2, 5.4 Hz, 2H), 2.75 (d, J = 5.0 Hz, 8H), 2.10 (dq, J = 12.2, 6.1 Hz, 2H). | ||||||
1156 | A K. LÂ.J/V? v hH**i. | D, 6 | 59 | 419.2 (M+l)+ | (DMSO-fZ6,400 MHz): δ 10.76 (brs, 1H), 8.54 (brs, 1H), 7.697.62 (m, 3H), 7.55-7.45 (m, 4H), 7.17-7.10 (m, 2H), 6.93 (d, .7=8.4 Hz, 1H), 6.82 (t,J= 7.2 Hz, 1H), 4.03-3.99 (m, 2H), 3.43 (d, J = 6.8 Hz, 2H), 2.78 (t, J = 6.8 Hz, 2H), 1.32 (t,J= 6.8 Hz, 3H); | |
1157 | 0 λ. ,A-hH Us, J~y< et· =J | D, 6 | 49 | 419.2 (M+l)+; | ‘H-NMR (DMSO-4d, 400 MHz): δ 10.79 (brs, 1H), 8.598.58 (m, 1H), 7.69-7.63 (m, 3H), 7.55-7.44 (m, 4H), 7.16 (t, J= 8.0 Hz, 1H), 6.75 (t,J= 8.0 Hz, 3H), 3.95 (q, 2H), 3.463.43 (m, 2H), 2.76 (t, J =7.6 Hz, 2H), 1.26 (t,J= 6.8 Hz, 3H) |
166
1158 | D, 6 | 52 | 389.2 (M+l)+; | (DMSO-ri,,, 500 MHz): δ 10.76 (s, 1H), 8.64 (t, J= 5.5 Hz, 1H), 7.67-7.62 (m, 3H), 7.55-7.42 (m, 4H), 7.127.06 (m, 4H), 3.40-3.36 (m, 2H), 2.77 (t, J= 8.0 Hz, 2H), 2.28 (s, 3H); | ||
1159 | α --¾. +O | D,6 | 35 | 391.3 (M+l)+; | (DMSO-ritf, 400 MHz): δ 10.76 (s, 1H), 8.888.87 (m, 1H), 7.72-7.63 (m, 4H), 7.55-7.43 (m, 3H), 7.22 (t, J= 7.2 Hz, 1H), 7.13 (d, .7=7.6 Hz, 1H), 6.98 (d, 7= 7.2 Hz, 1H), 6.87 (t,J= 7.2 Hz, 1H), 4.40 (d, .7=4.8 Hz, 2H), 3.80 (s, 3H); | |
1161 | 0 | D, 6 | 43 | 391.2 (M+l)+; | (DMSO-ri6,400 MHz): δ 10.76 (s, 1H), 8.99 (t, 7= 4.4 Hz, 1H), 7.69-7.59 (m, 4H), 7.54-7.43 (m, 3H), 7.20 (d, J= 8.4 Hz, 2H), 6.86 (d, J = 8.4 Hz, 2H), 4.36 (d,J= 5.6 Hz, 2H), 3.71 (s, 3H); | |
1163 | cCHa VaSZ T> | A, 6 | 36 | 375.0 (M+l)+; | (DMSO-di, 400 MHz): δ 10.76 (s, 1H), 9.04 (t, 7= 6.0 Hz, 1H), 7.71-7.61 (m, 4H), 7.55-7.43 (m, 3H), 7.18 (t, 7= 7.2 Hz, 1H), 7.08-7.03 (m, 3H), 4.40 (d,7 = 6.0 Hz, 2H), |
167
2.26 (s, 3H) | ||||||
1164 | ό CCzy-c ~· Sj-W' h! —K | D, 6 | 64 | 375.3 (M+l)+; | (DMSO-rfd, 400 MHz): δ 10.77 (s, 1H), 9.039.02 (m, 1H), 7.70-7.60 (m, 4H), 7.55-7.45 (m, 3H), 7.16 (d, 7= 8.0 Hz, 2H),7.10(d,7 = 8.0 Hz, 2H), 4.38 (d, 7=6.0 Hz, 2H), 2.25 (s, 3H) | |
1165 | yy_/ | A, 6 | 65 | 417.4 (M+l)+; | (DMSO-7tf, 400 MHz): δ 10.76 (brs, 1H), 9.02 (t, 7= 6.0 Hz, 1H), 7.71-7.60 (m, 4H), 7.557.43 (m, 3H), 7.32 (d, 7=8.4 Hz, 2H), 7.20 (d, 7= 8.4 Hz, 2H), 4.39 (d, 7 = 6.0 Hz, 2H), 1.24 (s, 9H); | |
1166 | 0 | D, 6 | 48 | 429.4 (M+l)+; | (DMSO-7d, 400 MHz): δ 10.77 (s, 1H), 9.17 (t, 7= 4.8 Hz, 1H), 7.72-7.67 (m, 3H), 7.64-7.59 (m, 6H), 7.577.43 (m, 2H), 4.52 (d,7=4.8 Hz, 2H); | |
1168 | Q CQm V*/ >4—-χ v f·1 | A, 6 | 62 | 379.1 (M+l)+; | (DMSO-7tf, 400 MHz): δ 10.77 (s, 1H), 9.11 (t, 7= 6.0 Hz, 1H), 7.72-7.62 (m, 4H), 7.55-7.44 (m, 3H), 7.36 (t, 7= 8.0 Hz, 1H), 7.13-7.04 (m, 3H), 4.45 (d, 7 = 6.0 Hz, 2H); |
168
1169 | ο | D, 6 | 56 | 367.3 (M+l)+; | (DMS0-<4 400 MHz): δ 10.75 (s, 1H), 8.46 (t, J= 6.0 Hz, 1H), 7.69-7.62 (m, 3H), 7.57-7.51 (m, 2H), 7.497.43 (m, 2H), 3.07-3.04 (m, 2H), 1.67-1.60 (m, 4H), 1.501.48 (m,2H), 1.17-1.12 (m, 3H), 0.93-0.87 (m, 2H); | |
1171 | q ..--7:-. JM» [ C J-v, ' S ^Z Π'Χ-ΟΙ,Η. | A, 6 | 40 | 329.1 (M+l)+; | (DMSO-dtf, 400 MHz): δ 10.76 (s, 1H), 8.58 (t, J= 6.8 Hz, 1H), 7.72-7.69 (m, 3H), 7.56-7.52 (m, 2H), 7.487.44 (m, 2H), 3.44-3.38 (m, 4H), 3.24 (s, 3H); | |
1172 | ο ^AnH [j’’X-ΟΗ | D, 6 | 82 | 315 (M+l)+; | (DMSO-i/ÿ, 400 MHz): δ 10.73 (s, 1H), 8.43 (t, J= 4.8 Hz, 1H), 7.66-7.56 (m, 3H), 7.54-7.40 (m, 4H), 4.65 (t, J=4.8Hz, 1H), 3.46-3.41 (m, 2H), 3.25-3.23 (m, 2H); | |
1173 | LXsi^y-C ai | D, 6 | 52 | 325.2 (M+l)+; | (DMSO-di, 400 MHz): δ 10.75 (s, 1H), 8.58 (t, J=4.8Hz, 1H), 7.69-7.59 (m, 4H), 7.57-7.55 (m, 3H), 7.537.43 (m, 2H), 3.10 (t,J= 6.4 Hz,2H), 1.010.97 (m, 1H), 0.43-0.38 (m, 2H), 0.21-0.19 (m, 2H); |
169
1176
1177
A, 6
D, 6
D, 6
339.1 (M+l)+;
403.1 (M+l)+
405.0 (M+l)+ (DMSO-cZà, 400 MHz): δ 10.75 (s, 1H), 8.488.46 (m, 1H), 7.69-7.63 (m, 3H), 7.57-7.43 (m, 4H), 3.263.23 (m, 2H), 2.50-2.49 (m, 1H), 1.97-1.91 (m, 2H), 1.821.76 (m,2H), 1.71-1.65 (m, 2H);
‘H NMR (400 MHz, DMSOd6) δ 10.75 (s, 1H), 8.47 (t, J = 5.8 Hz, 1H),
7.64 (ddd, J = 24.5, 5.6,1.9
Hz, 3H), 7.56 — 7.39 (m, 4H), 7.27 (t, J =7.6 Hz, 2H), 7.18 (d, J = 7.3 Hz, 3H), 3.40 (ddt, J = 24.8,13.3, 6.4 Hz, 2H), 2.76 (dt, J= 11.9, 5.8 Hz, 1H), 1.72 (ddd, J = 13.0,
7.1.4.9 Hz, 1H), 1.52 (ddd, J =16.5,14.1,
7.7 Hz, 1H), 0.69 (t, J = 7.3 Hz, 3H).
‘H NMR (400 MHz, DMSOd6) δ 10.75 (s, 1H), 9.19 (s, 1H), 8.32 (d, J = 8.2 Hz, 1H),
7.65 (dd, J = 18.8, 7.5 Hz,
3H), 7.49 (dt, J = 23.9, 8.6 Hz, 4H), 7.02 (t, J =
7.9 Hz, 1H), 6.60 (d, J = 7.6 Hz, 2H), 4.174.07 (m, 1H),
170
2.76 (dd, J = 13.1,7.3 Hz, 1H), 2.56 (dd, J = 12.9, 6.7 Hz, 1H), 1.08 (d, J = 6.5 Hz,3H). | ||||||
1182 | 0 | A, 6 | 46 | 459.2 (M++l); | (DMSO-d5,500 MHz): δ 10.76 (s, 1H), 8.598.58 (m, 1H), 7.66 (d, 7=7.0 Hz, 1H), 7.62 (d, 7= 7.5 Hz, 2H), 7.51-7.42 (m, 4H), 7.32 (d, 7= 8.0 Hz, 2H), 7.24 (d,7 = 8.0 Hz, 2H), 3.43 (t, 7= 6.5 Hz, 2H), 2.82 (t, 7= 7.0 Hz, 2H); | |
1183 | A, 6 | 43 | 389.2 (M+l)+; | (DMSO-A, 400 MHz): δ 10.76 (s, 1H), 9.04 (t, 7= 6.0 Hz, 1H), 7.71-7.61 (m, 4H), 7.55-7.43 (m, 3H), 7.18 (t, 7= 7.2 Hz, 1H), 7.08-7.03 (m, 3H), 4.40 (d,7 = 6.0 Hz, 2H), 2.72 (t, J = 6.0 Hz, 2H), 2.26 (s, 3H); | ||
1184 | 0 (Tm | A, 6 | 43 | 389.2 (M+l)+; | (DMSO-7i; 400 MHz): δ 10.77 (s, 1H), 8.588.57 (m, 1H), 7.69-7.63 (m, 3H), 7.55-7.45 (m, 4H), 7.097.07 (m, 4H), 3.44-3.39 (m, 2H), 2.75 (t, 7= 7.6 Hz, 2H), 2.24 (s, 3H); |
171
1185 | A, 6 | 42 | 403.2 (M+l)+; | (DMSO-<4 400 MHz): δ 10.76 (s, 1H), 8.588.57 (m, 1H), 7.67-7.61 (m, 3H), 7.53-7.41 (m, 4H), 7.107.08 (m, 4H), 3.42-3.37 (m, 2H), 2.74 (t,J= 7.2 Hz, 2H), 2.55-2.51 (m, 2H), 1.12 (t,J= 7.6 Hz, 3H); | ||
1186 | 0 OC | A, 6 | 28 | 443.2 (Nf+1); | (DMS0-<7d, 400 MHz): δ 10.78 (s, 1H), 8.59 (t, J= 5.6 Hz, 1H), 7.69-7.62 (m, 5H), 7.55-7.43 (m, 6H), 3.49 (q, 2H), 2.91 (t, J= 7.2 Hz, 2H); | |
1187 | 0 ^j_A-nh γΧ | D, 6 | 36 | 375.2 (M+l)+; | NMR(DMS0ds,400 MHz): δ 10.75 (br s, 1H), 8.92 (br s, 1H), 7.72-7.65 (m, 4H), 7.537.45 (m, 3H), 7.19-7.14 (m, 4H), 4.42 (br s, 2H), 2.29 (s, 3H); | |
1188 | 0 ° Q | A, 6 | 56 | 389.1 (M+l)+; | (DMSO-<4,400 MHz): δ 10.76 (s, 1H), 9.02 (t, J= 6.0 Hz, 1H), 7.71-7.60 (m, 4H), 7.55-7.43 (m, 3H), 7.19 (d, J =8.0 Hz, 2H), 7.13 (d, J = 8.0 Hz, 2H), 4.39 (d, .7=6.0 Hz, 2H), 2.582.54 (m, 2H), 1.14 (t,J= 7.6 Hz, 3H); |
172
1190 | 0 | D, 6 | 52 | 381.1 (M+l)+; | (CDC13,400 MHz): δ 10.79 (s, 1H), 8.678.66 (m, 1H), 7.69-7.64 (m, 3H), 7.57-7.45 (m,4H), 7.31 (d, J =4.8 Hz, 1H), 6.94-6.89 (m, 2H), 3.483.46 (m, 2H), 3.04-3.01 (m, 2H); | |
1191 | aJx Ή} | A, 6 | 46 | 383.2 (MXl); | (DMSO-rfd, 400 MHz): δ 10.77 (s, 1H), 8.488.47 (m, 1H), 7.69-7.63 (m, 3H), 7.57-7.43 (m, 4H), 3.823.78 (m, 2H), 3.26-3.20 (m, 4H), 1.57 (d, J = 9.6 Hz, 2H), 1.45-1.40 (m, 3H), 1.18-1.09 (m,2H); | |
1193 | 0 | A, 6 | 52 | 353.1 (MM); | (CDCI3,400 MHz): δ 10.75 (s, 1H), 8.508.49 (m, 1H), 7.69-7.63 (m, 3H), 7.57-7.43 (m, 4H), 3.14 (t, 7= 6.8 Hz, 2H), 2.13-2.06 (m, 1H), 1.66-1.60 (m, 2H), 1.561.45 (m,4H), 1.25-1.17 (m, 2H); | |
1194 | 0 ÆS\ \—Ç/t'5'· | A, 6 | 22 | 431.3 (M++l); | (DMSO-rftf, 400 MHz): δ 10.78 (s, 1H), 8.618.60 (m, 1H), 7.69-7.63 (m, 3H), 7.56-7.53 (m, 2H), 7.517.45 (m, 2H), 7.29 (d, 7=8.0 Hz, 2H), 7.13 (d, 7= 8.4 Hz, 2H), 3.45-3.41 |
173
(m, 2H), 2.782.74 (m, 2H), 1.24 (s, 9H); | ||||||
1195 | A, 6 | 58 | 443.7 (M+l)+ | (DMSO-A, 500 MHz): δ 10.77 (s, 1H), 8.59 (t, J= 6.0 Hz, 1H), 7.67 (d, .7=7.5 Hz, 1H), 7.62 (d, .7= 8.0 Hz, 2H), 7.56-7.42 (m, 8H), 3.503.46 (m, 2H), 2.92-2.87 (m, 2H); | ||
1196 | q CQm ^ΊΧ | A, 6 | 43 | 377.0 (M+l)+; | (DMSO-A, 500 MHz): δ 10.78 (s, 1H), 9.26 (br s, 1H), 8.96 (t, J = 6.0 Hz, 1H), 7.72-7.64 (m, 4H), 7.56-7.44 (m, 3H), 7.08 (d, J =8.5 Hz, 2H), 6.66 (d, J = 8.5 Hz, 2H), 4.31-4.29 (m, 2H); | |
1197 | A, 6 | 36 | 379.2 (M+l)+; | (DMSO-A, 400 MHz): δ 10.76 (s, 1H), 9.08 (t, J= 5.6 Hz, 1H), 7.71-7.61 (m, 4H), 7.55-7.43 (m, 3H), 7.32 (t, J= 6.0 Hz, 2H), 7.15-7.10 (m, 2H), 4.41 (d, J = 6.0 Hz, 2H); | ||
1199 | €λΛ,.Ό | A, 6 | 54 | 380.9 (M%1) | (DMSO-A, 500 MHz): δ 10.85 (s, 1H), 8.43 (t, J= 5.5 Hz, 1H), 8.02 (s, 1H), 7.78 (d, .7=8.5 Hz, 1H), 7.67 (d, J=7.5 Hz, 1H), 7.55-7.43 (m, 3H), 7.25 (d, J= 8.0 Hz, 1H), 3.25-3.21 (m, 2H), 1.69- |
174
1.57 (m,5H), 1.40-1.36 (m, 2H), 1.18-1.09 (m, 4H), 0.900.83 (m, 2H); | ||||||
1201 | Q CÊiS J \o=/ hn**\ | A, 6 | 60 | 459.2 (K/f+l); | (DMSO-7tf, 400 MHz): δ 10.76 (s, 1H), 8.598.58 (m, 1H), 7.69-7.64 (m, 3H), 7.53-7.38 (m, 5H), 7.267.16 (m,3H), 3.48-3.47 (m, 2H), 2.89-2.87 (m, 2H); | |
1202 | q, h a ^xx^JL ^^-δΆίχ H ''J OH | A, 6 | 36 | 377.1 (M++l); | (DMSO-îZî, 500 MHz): δ 10.79 (s, 1H), 9.29 (s, 1H), 9.03 (t, 7= 5.5 Hz, 1H), 7.72-7.62 (m, 4H), 7.55-7.45 (m, 3H), 7.08 (t, 7= 8.0 Hz, 1H), 6.68 (d, J= 12.0 Hz, 2H), 6.60 (d, 7=8.5 Hz, 1H), 4.35 (d, 7= 6.0 Hz, 2H); | |
1203 | CCFj | A, 6 | 45 | 445.1 (M+l)+; | (DMSO-76, 400 MHz): δ 10.77 (s, 1H), 9.15 (t, 7= 4.8 Hz, 1H), 7.71-7.61 (m, 4H), 7.55-7.43 (m,4H), 7.31 (d, 7= 8.0 Hz, 1H), 7.23 (d, 7 = 8.4 Hz, 2H), 4.48 (d,7=6.0 Hz, 2H); | |
1204 | c χΛ'>η | A,6 | 34 | 397.2 (M++l); | (DMSO-7;, 400 MHz): δ 10.74 (s, 1H), 8.46 (t, 7= 6.0 Hz, 1H), 7.74-7.64 (m, 3H), 7.54-7.42 (m, 4H), 4.40 (d, 7= 5.2 Hz, 1H), 3.26-3.20 |
175
(m,2H), 1.77 (d,J= 11.2 Hz, 2H), 1.68 (d, J = 11.2 Hz, 2H), 1.39-1.34 (m, 3H), 1.18-1.12 (m, 2H), 0.93- 0.84 (m, 2H); | ||||||
1205 | A, 156 | 50 | 459.2 (MM); | (DMSO-di, 400 MHz): δ 11.0511.04(m, 1H), 8.54-8.53 (m, 1H), 7.81-7.73 (m, 3H), 7.687.60 (m, 4H), 3.26-3.25 (m, 3H), 1.70-1.62 (m, 6H), 1.391.37 (m, 2H), 1.23-1.14 (m, 2H), 0.88-0.85 (m,2H); | ||
1209 | A, 6 | 56 | 369.1 (M*+l); | (DMSO-^, 400 MHz): δ 10.75 (s, 1H), 8.49 (t, J= 5.6 Hz, 1H), 7.69-7.63 (m, 3H), 7.56-7.45 (m, 4H), 3.773.70 (m, 2H), 3.59-3.54 (m, 1H), 3.26-3.24 (m, 2H), 1.981.90 (m, 1H), 1.83-1.76 (m, 2H), 1.69-1.63 (m, 2H), 1.431.34 (m, 1H); | ||
1210 | 0 y-NH p | A, 6 | 56 | 362.4 (M++l); | (DMSO-Jÿ, 500 MHz): δ 10.78 (s, 1H), 9.14 (t, J= 6.0 Hz, 1H), 8.49 (s, 1H), 7.74-7.65 (m, 5H), 7.55-7.44 (m, 3H), 7.287.23 (m, 2H), 4.53 (d, .7=5.5 Hz, 2H); |
176
1211 | 0 Am ο | A, 6 | 66 | 362.1 (MM); | (DMSO-dtf, 500 MHz): δ 10.76 (s, 1H), 9.12 (t, J= 6.0 Hz, 1H), 8.52 (s, 1H), 8.45-8.44 (m, 1H), 7.70 (d, J = 10.0 Hz, 1H), 7.67-7.60 (m, 4H), 7.55-7.44 (m, 3H), 7.33 (t, J= 6.5 Hz, 1H), 4.46 (d, 7=5.5 Hz, 2H); | |||
1212 | D, 6 | 44 | 389.1 (M+l)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.76 (s, 1H), 8.54 (t, J = 5.8 Hz, 1H), 7.71-7.58 (m, 3H), 7.48 (tt, J = 15.3,7.6 Hz, 4H), 7.23 (ddd, J = 25.3,16.4, 7.3 Hz, 5H), 3.45-3.26 (m, 2H), 3.01 (q, J = 7.1 Hz, 1H), 1.19 (d, J =6.9 Hz, 3H). | ||||
1213 | D, 6 | 54 | 403.1 (M+l)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.74 (s, 1H), 8.28 (t, J = 6.4 Hz, 1H), 7.71-7.58 (m, 3H), 7.57-7.35 (m, 6H), 7.29 (t, J = 7.6 Hz, 2H), 7.17 (t, J = 7.3 Hz, 1H), 3.41 (d, J =6.3 Hz, 2H), 1.26 (s, 6H). | ||||
1214 | 0 il Ί X—% 0 w ”V0„OE, | D, 6 | 60 | 419.5 (Mri-1); | NMR(DMSOd6,400 MHz): δ 10.77 (s, 1H), 8.56 (t, 7=4.8 Hz, 1H), 7.697.63 (m, 3H), 7.55-7.43 (m, 4H), 7.10 (d, J = 8.8 Hz, 2H), |
177
6.81 (d, 7 = 8.4 Hz, 2H), 3.96 (q, 2H), 3.423.37 (m, 2H), 2.72 (t,J= 7.2 Hz, 2H), 1.301.23 (m, 3H); | ||||||
1216 | 0 Μ·4ΙΙ P F cCow | A, 6 | 30 | 417.3 (M++l); | (DMSO-iZdj 400 MHz): δ 10.76 (s, 1H), 8.47 (t, J= 5.6 Hz, 1H), 7.69-7.63 (m, 3H), 7.57-7.45 (m, 4H), 3.303.25 (m, 2H), 2.00-1.93 (m, 2H), 1.78-1.76 (m, 4H), 1.451.43 (m, 3H), 1.18-1.10 (m, 2H); | |
1218 | q -¾ A-mi il ï Vrf, 0 J V4 HH-\ ' VSU; | A, 6 | 75 | 371.2 (M++l); | (DMSO-7tf, 400 MHz): δ 10.77 (s, 1H), 8.50 (t, J= 5.6 Hz, 1H), 7.69-7.63 (m, 3H), 7.58-7.43 (m, 4H), 3.403.37 (m, 2H), 3.28 (s, 2H), 1.10 (s, 9H); | |
1220 | q OH | A, 6 | 74 | 391.4 (KT+1); | (DMSO-76,400 MHz): δ 10.77 (s, 1H), 8.53 (t, J= 6.8 Hz, 1H), 7.69-7.63 (m, 3H), 7.57-7.43 (m, 4H), 7.357.29 (m, 4H), 7.23 (t,J= 6.8 Hz, 1H), 5.46 (d, .7=4.8 Hz, 1H), 4.76-4.71 (m, 1H), 3.473.41 (m, 1H); | |
1221 | ctbw OH | A, 6 | 62 | 329.1 (MM); | (DMSO-<4,400 MHz): δ 10.74 (s, 1H), 8.40 (t, J= 5.6 Hz, 1H), 7.69-7.43 (m, 7H), 4.68 (d, J = 4.8 Hz, 1H), |
178
3.77-3.71 (m, 1H), 3.16 (t, J= 6.0 Hz, 2H), 1.03 (d,J=6.4 Hz, 3H); | ||||||
1222 | 0 <5h | A, 6 | 41 | 329.2 (MM); | (DMSO-dtf, 400 MHz): δ 10.74 (s, 1H), 8.40 (t, J= 5.6 Hz, 1H), 7.69-7.58 (m, 4H), 7.55-7.45 (m, 3H), 4.68 (d, .7= 4.8 Hz, 1H), 3.77-3.71 (m, 1H), 3.16 (t, J= 6.0 Hz, 2H), 1.03 (d, .7=6.4 Hz, 3H); | |
1226 | H i DH | A, 6 | 75 | 391.6 (M++l); | (DMSO-φ, 400 MHz): δ 10.78 (s, 1H), 8.54 (t, J= 6.4 Hz, 1H), 7.69-7.63 (m, 3H), 7.57-7.43 (m, 4H), 7.357.29 (m, 4H), 7.23 (t, J= 7.2 Hz, 1H), 5.46 (d, .7= 4.8 Hz, 1H), 4.75-4.71 (m, 1H), 3.473.41 (m, 1H); | |
1227 | 0 CC^iÙ | A, 6 | 83 | 404.4 (M++l); | (DMSO-φ, 400 MHz): δ 10.77 (s, 1H), 8.97 (t, J= 6.0 Hz, 1H), 7.73 (s, 1H), 7.70-7.63 (m, 3H), 7.56-7.43 (m, 3H), 7.217.16 (m, 2H), 7.11 (d,J=7.6 Hz, 1H), 6.97 (t, .7= 7.2 Hz, 1H), 4.53 (d, J = 5.6 Hz, 2H), 2.64 (s, 6H); | |
1228 | 0 K ‘\ | A, 6 | 27 | 376.4 QVT+1); | (DMSO-φ, 400 MHz): δ 10.80 (s, 1H), 9.49 (s, 1H), 7.75 (s, 1H), 7.73-7.70 |
179
(m, 3H), 7.557.46 (m, 3H), 7.16 (t, .7= 7.6 Hz, 1H), 7.08 (d, J= 7.2 Hz, 1H), 6.95 (t, J = 7.6 Hz, 1H), 3.81 (s, 3H); | ||||||
1232 | C | D, 6 | 50 | 445.1 (M+l)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.79 (s, 1H), 9.08 (t, J = 5.9 Hz, 1H), 7.74-7.59 (m, 4H), 7.58-7.25 (m, 7H), 4.50 (d, J =5.7 Hz, 2H). | |
1233 | •n - JL+ '•srèrM '? - | D, 6 | 83 | 363.1 (M+l)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.77 (s, 1H), 9.15 (t, J = 5.9 Hz, 1H), 9.07 (s, 1H), 8.73 (s, 2H), 7.72 - 7.40 (m, 7H), 4.46 (d, J = 5.7 Hz, 2H). | |
1234 | O ^XjQm W'X) | A, 6 | 57 | 399.5 (MM); | (DMSO-dtf, 400 MHz): δ 10.79 (brs, 1H), 8.45 (t, J= 5.6 Hz, 1H), 7.67-7.73 (m, 1H), 7.667.63 (m, 2H), 7.58-7.56 (m, 1H), 7.46-7.43 (m, 1H), 7.357.30 (m, 1H), 3.27- 3.22 (m, 2H), 1.70-1.58 (m, 5H), 1.411.35 (m,2H), 1.27- 1.09 (m, 4H), 0.95-0.83 (m,2H); | |
1237 | o >-Vi 0 | A, 6 | 71 | 382.3 (MN-1); | (DMSO-<4, 400 MHz): δ 11.04 (brs, 1H), 8.72 (s, 1H), 8.65 (d, J =4.8 Hz, 1H), 8.46 (t,J= 5.6 |
180
Hz, 1H), 7.697.67 (m, 2H), 7.63-7.58 (m, 2H), 3.27-3.22 (m, 2H), 1.701.58 (m,4H), 1.41-1.35 (m, 2H), 1.27-1.14 (m, 4H), 0.930.83 (m, 3H); LC-MS: 93.50%; 382.3 (MM); | ||||||||
1240 | 0 ο \=s/ HM-\ M | A, 6 | 25 | 430.4 (MM); | (DMSO-A, 400 MHz): δ 10.77 (s, 1H), 8.92 (t, J= 5.2 Hz, 1H), 7.73 (s, 1H), 7.70-7.62 (m, 3H), 7.56-7.43 (m, 3H),7.12(t, 7= 7.6 Hz, 2H), 6.96 (d,7=8.0 Hz, 1H), 6.84 (t, 7= 6.8 Hz, 1H), 4.46 (d, 7 = 5.6 Hz, 2H), 3.10 (t, 7= 6.0 Hz, 4H), 1.87 (t,7= 6.0 Hz, 4H); | |||
1241 | 0 | A, 6 | 33 | 405.4 (MM); | (DMSO-A, 500 MHz): δ 10.75 (s, 1H), 8.58 (t, 7= 6.0 Hz, 1H), 7.67-7.45 (m, 7H), 7.26 (t, 7= 7.5 Hz, 2H), 6.91-6.89 (m, 3H), 3.99 (t, 7= 6.0 Hz, 2H), 3.41-3.30 (m, 2H), 1.94 (t, 7= 6.5 Hz, 2H); | |||
1245 | P ÿ-NH 0 S·»^ | D, 6 | 54 | 368.1 (M+l)+ | ‘H NMR (400 MHz, DMSOd6) δ 10.77 (s, 1H), 9.23 (t, J = 5.9 Hz, 1H), 8.95 (s, 1H), 7.79 (s, 1H), 7.71-7.40 (m, 7H), 4.64 (d, J |
181
= 5.8 Hz, 2H). | ||||||
1246 | A, 6 | 75 | 366.2 (JVT+1); | (DMS0-<4 400 MHz): δ 10.78 (s, 1H), 8.65 (t, J= 6.0 Hz, 1H), 8.21 (s, 1H), 7.69-7.64 (m, 3H), 7.54-7.43 (m,4H), 6.91 (s, 1H), 3.48 (q, 2H), 2.90 (t,J= 6.8 Hz, 2H); | ||
1247 | ο S-_ | A, 6 | 40 | 382.2 (i^+i); | (DMSO-45,400 MHz): δ 10.79 (s, 1H), 8.90 (s, 1H), 8.69-8.68 (m, 1H), 7.687.65 (m, 4H), 7.56-7.45 (m, 4H), 3.47 (q, 2H), 3.09 (t,J= 6.8 Hz, 2H); | |
1248 | 0 η | A, 6 | 28 | 441.4 (MU-1); | (DMSO-cZî, 400 MHz): δ 10.77 (s, 1H), 8.60 (t, J= 6.4 Hz, 1H), 8.19 (s, 1H), 7.69-7.65 (m, 4H), 7.55-7.43 (m, 6H), 7.34 (d, J =7.6 Hz, 2H), 7.08 (s, 1H), 3.51-3.46 (m, 2H), 2.86 (t, J= 7.6 Hz, 2H); | |
1249 | 0 U1U _ | A, 6 | 50 | 442.4 (ivr+l); | (DMSO-iZtf, 400 MHz): δ 10.78 (s, 1H), 9.22 (s, 1H), 8.62-8.61 (m, 1H), 8.20 (s, 1H), 7.75 (d, J= 8.4 Hz, 2H), 7.69-7.63 (m, 3H), 7.55-7.38 (m, 6H), 3.523.47 (m, 2H), 2.87 (t, <7= 6.0 Hz, 2H); |
182
1251 | 0 | A, 6 | 33 | 444.4 (ΆΤ+1); | (CDC13 + CD3OD, 400 MHz): δ 7.71 (d, .7= 8.0 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.51-7.40 (m, 4H), 7.34-7.28 (m, 6H), 4.01 (dd, J= 13.2, 4.8 Hz, 1H), 3.70-3.66 (m, 1H), 3.60-3.55 (m, 1H), 2.852.78 (m, 2H), 2.63-2.50 (m, 2H), 1.83 (t,J= 6.4 Hz, 4H); | |
1253 | οΟύλ tA· | A, 6 | 34 | 418.3 (IVrt+l); | (DMSO-i7d, 400 MHz): δ 10.76 (s, 1H), 9.69 (s,lH), 9.09 (t, J= 6.0 Hz, 1H), 7.72 (s, 1H), 7.68-7.66 (m, 2H),7.62 (d, J= 8.0 Hz, 1H), 7.55-7.51 (m, 2H), 7.50-7.43 (m, 2H), 7.257.20 (m, 2H), 7.10 (t, J= 7.2 Hz, 1H), 4.41 (d, .7= 5.6 Hz, 2H), 2.08 (s, 3H); | |
1256 | A, 6 | 46 | 442.3 (KT+l); | (DMSO-iZtf, 400 MHz): δ 10.78 (brs, 1H), 8.62 (brs, 1H), 8.08 (brs, 2H), 7.92 (d, J= 7.2 Hz, 2H), 7.69-7.65 (m, 3H), 7.547.40 (m, 6H), 3.50-3.49 (m, 2H), 2.88-2.87 (m,2H); | ||
1257 | dt-CrVo | A, 6 | 22 | 381.9 (NT+1); | (DMSO-îZî, 400 MHz): δ 10.96 (s, 1H), 8.77 (s, 1H), 8.61 (d, J = 5.2 Hz, 1H), |
183
8.47 (t, 7= 5.2 Hz, 1H), 7.70 (s, 1H), 7.66 (d, 7= 8.0 Hz, 1H), 7.60-7.56 (m, 2H), 3.27-3.24 (m, 2H), 1.711.58 (m, 5H), 1.41-1.36 (m, 2H), 1.29-1.09 (m, 4H), 0.910.83 (m, 2H); | ||||||
1258 | A, 6 | 42 | 404.9 (M++l); | (DMSO-A, 400 MHz): δ 10.75 (s, 1H), 8.45 (t, 7= 5.6 Hz, 1H), 7.68 (d, 7=7.2 Hz, 1H), 7.61 (d, 7= 8.0 Hz, 2H), 7.54-7.42 (m, 4H), 7.287.15 (m, 5H), 4.67 (t, 7= 5.2 Hz, 1H), 3.613.57 (m, 2H), 3.55-3.48 (m, 2H), 3.10-2.98 (m, 1H); | ||
1259 | h ; Όη | A, 6 | 34 | 404.9 (M++1); | (DMSO-rifl, 400 MHz): δ 10.74 (s, 1H), 8.43 (t, 7= 5.6 Hz, 1H), 7.67 (d, 7=6.0 Hz, 1H), 7.61 (d, 7= 8.0 Hz, 2H), 7.54-7.42 (m, 4H), 7.287.15 (m, 5H), 4.65 (t, 7= 5.2 Hz, 1H), 3.623.57 (m, 2H), 3.55-3.45 (m, 2H), 3.06-2.99 (m, 1H); | |
1260 | 0 | A, 6 | 59 | 403.5 (MV1); | (CD3OD + CDClj, 400 MHz): δ 7.73 (d, 7= 7.6 Hz, 1H), 7.62 (d, 7 = 8.0 Hz, 2H), 7.59-7.41 (m, 4H), 7.17 (t, 7= 7.2 Hz, 1H), |
184
7.03 (t,J= 7.6 Hz, 2H), 3.55 (t,J= 7.6 Hz, 2H), 2.86 (t, J= 7.6 Hz, 2H), 2.58 (q, 2H), 1.16 (t,J= 7.6 Hz, 3H); | ||||||||
1264 | O / NH /9 CXs-X^/hv% <W | D, 6 | 73 | 352.1 (M+l)+ | Ή NMR (400 MHz, DMSOd6) δ 10.74 (s, 1H), 9.04 (t, J = 5.6 Hz, 1H), 8.24 (s, 1H), 7.68-7.59 (m, 3H), 7.56 (dd, J = 8.2,1.9 Hz, 1H), 7.53-7.38 (m, 3H), 7.00 (s, lH),4.47(d, J =5.5 Hz, 2H). | |||
1266 | 0 LA -A4 «n | A, 6 | 41 | 442.5 (M++l); | (DMSO-4à, 400 MHz): δ 10.78 (s, 1H), 8.76 (s, 1H), 8.62 (t,J= 5.6 Hz, 1H), 7.94 (s, 1H), 7.80 (d,J=8.0 Hz, 2H), 7.697.63 (m, 3H), 7.55-7.42 (m, 6H), 3.51 (q, 2H), 2.90 (t,J= 6.8 Hz, 2H); | |||
1267 | û CQm | A, 6 | 43 | 442.5 (M++1); | (DMSO-di, 400 MHz): δ 10.80 (s, 1H), 9.10 (s, 2H), 8.63-8.61 (m, 1H), 7.747.57 (m, 6H), 7.56-7.36 (m, 5H), 3.52-3.46 (m, 2H), 2.912.89 (m, 2H); | |||
1270 | 0 ZW ''H CQv '-’S | A, 6 | 41 | 365.3 (MM); | (DMSO-</d, 400 MHz): δ 12.5012.36 (m, 1H), 10.77 (s, 1H), 8.60 (br s, 1H), 7.69-7.63 (m, 3H), 7.57-7.34 (m, 5H), 6.06 |
185
(brs, 1H), 3.49- 3.44 (m, 2H), 2.82-2.78 (m, 2H); | ||||||
1271 | 0 vCQm | A, P-42 | 28 | 411.8 (MX); | (DMSO-A 400 MHz): δ 10.59 (s, 1H), 8.43 (t, .7= 5.6 Hz, 1H), 7.65-7.59 (m, 3H), 7.55 (d, J = 8.4 Hz, 1H), 7.06 (s, 1H), 7.01 (d, .7=8.8 Hz, 1H), 3.80 (s, 3H), 3.263.23 (m, 2H), 1.71-1.58 (m, 5H), 1.41-1.36 (m, 2H), 1.291.23 (m, 1H), 1.19-1.09 (m, 3H), 0.91-0.83 (m, 2H); | |
1273 | A, P-8 | 29 | 395.9 (MX); | (DMSO-A 400 MHz): δ 10.66 (brs, 1H), 8.43 (t, J= 5.6 Hz, 1H), 7.64-7.53 (m, 4H), 7.36 (s, 1H), 7.26 (d, J= 7.6 Hz, 1H), 3.26-3.21 (m, 2H), 2.30 (s, 3H), 1.70-1.58 (m, 5H), 1.411.35 (m, 2H), 1.28-1.14 (m, 4H), 0.91-0.83 (m,2H); | ||
1274 | A, P-51 | 55 | 395.5 (M++l); | (DMSO-A 400 MHz): δ 10.70 (brs, 1H), 8.42 (t, J= 5.2 Hz, 1H), 7.62 (t,J= 5.6 Hz, 2H), 7.54 (d,J=7.2 Hz, 1H), 7.49 (s, lH),7.40(d, J= 7.6 Hz, 1H), 7.29 (d,J=7.6 Hz, 1H), 3.263.21 (m, 2H), 2.29 (s, 3H), |
186
1.70-1.62 (m, 5Η), 1.40-1.35 (m, 2Η), 1.26- 1.09 (m,4H), 0.95-0.83 (m, 2H); | ||||||
1279 | 0 îl'^Vs/ | Α, 135 | 50 | 418.8 (M*+l) | (DMSO-dft 500 MHz): δ 10.89 (s, 1H), 8.628.61 (m, 1H), 8.14 (s, 1H), 8.00 (s, 1H), 7.89 (d, 7=8.0 Hz, 1H), 7.75 (d, 7= 8.0 Hz, 1H), 7.66(d, 7 = 7.0 Hz, 2H), 7.55 (d,7=7.5 Hz, 2H), 7.297.26 (m, 2H), 7.22-7.17 (m, 3H), 3.47-3.43 (m, 2H), 2.80 (t, 7= 7.5 Hz, 2H); | |
1283 | Ο,ΌιιΊΟ Et | Α, 6 | 35 | 389.5 (W+1); | (DMSO-A, 400 MHz): δ 10.77 (s, 1H), 9.04 (t, 7= 5.6 Hz, 1H), 7.71-7.61 (m, 4H), 7.55-7.43 (m, 3H), 7.21 (t, 7= 7.6 Hz, 1H), 7.12-7.08 (m, 3H), 4.41 (d,7 = 5.6 Hz, 2H), 2.59-2.55 (m, 2H), 1.15 (t, 7= 7.6 Hz, 3H); | |
1285 | 0 FY?xtnh | Α, 35 | 55 | 399.7 (MM); | (DMSO-4,400 MHz): δ 10.88 (s, 1H), 8.46 (t, 7= 6.8 Hz, 1H), 7.66-7.62 (m, 2H), 7.58-7.55 (m, 2H), 7.46 (d, 7= 7.2 Hz, 1H), 7.38 (t, 7= 7.2 Hz, 1H), 3.28- 3.24 (m, 2H), 1.74-1.56 (m, 5H), 1.421.38 (m,2H), 1.28- 1.26 (m, |
187
1H), 1.22-1.08 (m, 3H), 0.940.85 (m, 2H); | ||||||
1290 | 0 wih 9 .. fAfA-A | A, 6 | 29 | 377.5 (lvT+1); | (DMSO-4, 500 MHz): δ 10.77 (s, 1H), 9.01 (s, 1H), 8.66 (s, 2H), 7.69-7.62 (m, 4H), 7.557.44 (m, 4H), 3.54-3.51 (m, 2H), 2.85 (t, 7= 5.6 Hz, 2H); | |
1291 | 0. wlH P HN«N OMuA XAsAJ h AJ | A, 6 | 60 | 442.6 (MA1); | (DMSO-7d, 400 MHz): δ 15.01 (brs, 1H), 10.77 (s, 1H), 8.61 (t, 7=5.6 Hz, 1H), 8.25 (brs, 1H), 7.76 (d, 7= 8.0 Hz, 2H), 7.69-7.63 (m, 3H), 7.557.43 (m, 4H), 7.30 (d,7=8.4 Hz, 2H), 3.503.45 (m, 2H), 2.84 (t, 7= 7.2 Hz, 2H); | |
1160 | 0 / NH iï U^'S'V' H T^OMe | A, 6, 171 (a = solvent DMF: CH2C12 1:1) | 52 | 391.3 (M*+l); | 390.10 for C22H18N2O 3S | ‘H-NMR DMS 400 MHz): δ 10.77 (s, 1H), 9.05 (t, 7= 5.6 Hz, 1H), 7.71-7.61 (m, 4H), 7.55-7.45 (m, 3H), 7.21 (t, 7= 8.0 Hz, 1H), 6.85-6.79 (m, 3H), 4.41 (d,7 = 5.6 Hz, 2H), 3.71 (s, 3H); |
1162 | 0 /-f NH J ΑΑ^Ά' ^ocf3 | D, 6,172 | 55 | 445.4 (W+l) | 444.08 for c22hI5f3n 2θ3 | ‘H-NMR DMSO-7d, 400 MHz): δ 10.78 (s, 1H), 9.13 (t, 7= 6.0 Hz, 1H), 7.72-7.61 (m, 4H), 7.55-7.39 (m, 5H), 7.30 (d, 7= 8.0 Hz, 2H), 4.46 (d, 7 |
188
= 6.0 Hz, 2H); | ||||||
1167 | ο ί'Ύ . ο | A, 6,173 | 54 | 379.3 (MM); | 378.08 for C21H15FN2 02S | ‘H-NMR DMSO-A, 400 MHz): δ 10.76 (s, 1H), 9.079.04 (m, 1H), 7.71-7.61 (m, 4H), 7.55-7.43 (m, 3H), 7.347.27 (m, 2H), 7.19-7.12 (m, 2H), 4.47 (d, J = 4.8 Hz, 2H); |
1170 | Η | A, 6,174 | 63 | 433.3 (MM); | 432.19 for C26H28N2O 2S | ‘H-NMR DMSO-ifo 400 MHz): δ 10.77 (brs, 1H), 8.40 (t, .7= 4.8 Hz, 1H), 7.69-7.62 (m, 3H), 7.557.43 (m, 4H), 3.25-3.20 (m, 2H), 1.91-1.90 (m, 3H), 1.671.58 (m, 6H), 1.49-1.47 (m, 6H), 1.30-1.26 (m, 2H); |
1189 | 0 ζ^Λ-νη ί 1 Ρ | A, 6,175 | 40 | 419.2 (MM); | 418.17 for Ο25Η26Ν2Ο 2s | ‘H-NMR DMSO-<Zà, 400 MHz): δ 10.74 (s, 1H), 8.29 (t, J= 6.0 Hz, 1H), 7.69-7.63 (m, 3H), 7.59-7.43 (m, 4H), 2.94 (d, J =6.4 Hz, 2H), 1.93-1.91 (m, 3H), 1.661.56 (m,6H), 1.46 (s, 6H); |
1192 | 0 ζ^Ζ^ΝΗ ('λ /? ~~ n^M-OPh | A, 6,176 | 35 | 391.2 (MM); | 390.10 for C22H18N2O 3S | ‘H-NMR DMSO-rftf, 400 MHz): δ 10.77 (s, 1H), 8.74 (t, J= 6.0 Hz, 1H), 7.69-7.64 (m, 3H), 7.60-7.58 (m, 1H), 7.547.43 (m, 3H), 7.28 (t, J =8.4 Hz, 2H), 6.92 |
189
(t, .7= 8.4 Hz, 3H), 4.07 (t,J= 6.0 Hz, 2H), 3.59 (q,2H); | ||||||
1175 | 0 Q Rj H | D, 6,177 | 59 | 384.3 (MM); | 383.13 for C20H21N3O 3s | ‘H-NMR DMSO<4, 400 MHz): δ 10.77 (s, 1H), 8.43 (t, J= 4.8 Hz, 1H), 7.69-7.64 (m, 3H), 7.56-7.43 (m, 4H), 3.553.53 (m, 4H), 3.35-3.33 (m, 2H), 2.50 (s, 2H), 2.44-2.38 (m, 4H); |
1208 | 0 χ^ΛΝΗ |[ ji 9 s \=/hn-\ °q | A, 6, 265 | 33 | 409.1 (M++l); | 408.09 for C22H17FN2 O3S | ‘H-NMR DMSO-<7d, 400 MHz): δ 10.77 (s, 1H), 8.72 (t, .7= 5.2 Hz, 1H), 7.69-7.58 (m, 3H), 7.55 (s, 1H), 7.53-7.45 (m, 3H), 7.09 (t, J= 8.8 Hz, 2H), 6.96-6.93 (m, 2H), 4.06 (t,J= 5.2 Hz, 2H), 3.58 (d, .7=5.6 Hz, 2H); |
1217 | 0 | A, 6, 269 | 28 | 399.3 (MM); | 398.15 for C22H23FN2 o2s | ‘H-NMR (DMSO-rftf, 400 MHz): δ 10.76 (s, 1H), 8.45 (t, J= 5.6 Hz, 1H), 7.65-7.63 (m, 3H), 7.56-7.45 (m, 4H), 4.844.72 (m, 1H), 3.30-3.29 (m, 2H), 1.87-1.78 (m, 3H), 1.541.51 (m, 2H), 1.42-1.41 (m, 4H), 1.21-1.18 (m, 2H); |
190
1238 | 0 Ci JSv OMe | A, 6,273 | 37 | 371.2 (M++l); | 370.14 for C20H22N2O 3s | ‘H-NMR (DMSO-7tf, 400 MHz): δ 10.74 (s, 1H), 8.41 (t, J= 5.6 Hz, 1H), 7.69-7.63 (m, 3H), 7.55-7.41 (m, 4H), 3.283.22 (m, 2H), 3.10 (s, 3H), 1.66 (t, 7=8.4 Hz, 2H), 1.11 (s, 6H); |
1252 | 0 o | A, 6,277 | 22 | 458.4 (MX1); | 457.18 for C27H27N3O 2s | ‘H-NMR (CDCI3 + CD3OD, 400 MHz): δ 7.73 (d, 7= 7.6 Hz, 1H), 7.61 (d, 8.0 Hz, 1H), 7.52 (d, 7= 8.4 Hz, 2H), 7.487.46 (m, 3H), 7.45-7.31 (m, 4H), 7.26 (d, 7 = 6.8 Hz, 1H), 3.31-3.30 (m, 1H), 3.25-3.17 (m, 1H), 3.063.00 (m, 1H), 2.68-2.67 (m, 2H), 2.44-2.42 (m, 2H), 2.362.28 (m, 1H), 2.13-2.04 (m, 1H), 1.78 (t, 7= 6.4 Hz, 4H); |
1219 | 0 x^Xnh Uk J^W ?H | A, 6,178 | 59 | 376.9 (Nf+1) | C2iH16N2O 3S 376.09 | ‘H-NMR (DMSO-7tf, 400 MHz): δ 10.75 (s, 1H), 9.50 (s, 1H), 8.91(1:, 7= 6.0Hz, 1H), 7.72-7.65 (m, 4H), 7.55-7.43 (m, 3H), 7.087.03 (m, 2H), 6.79 (d, 7=7.6 Hz, 1H), 6.72 (t, 7= 7.2 Hz, 1H), 4.3 8 (d, 7 = 5.6 Hz, 2H); |
191
1223 | ο | Α, 6,179 | 59 | 347.2 (Μ*+1); | C20H14N2O 2S 346.08 | ‘H-NMR (DMSO-4,400 MHz): δ 10.80 (s, 1H),10.25 (s, 1H), 7.75-7.71 (m, 6H), 7.55 (brs, 1H), 7.49 (t, 7= 8.8 Hz, 2H), 7.32 (t, 7= 6.8Hz, 2H), 7.10 (t, 7=7.2 Hz, 1H); |
1229 | ο ΗΟ | D, 6,180 | 34 | 363.5 (ΝΤΜ) | C2oHI4N20 3S 362.07 | ‘H-NMR (DMS0-7d, 400 MHz): δ 10.81 (s, 1H), 9.71 (br s, 1H), 9.51 (br s, 1H), 7.76 (s, 1H), 7.71 (s, 3H), 7.64 (d, 7 = 8.4 Hz, 1H), 7.57-7.45 (m, 3H), 7.02 (t, 7= 6.8 Hz, 1H), 6.90 (d, 7=7.2 Hz, 1H), 6.81 (t, 7= 8.0 Hz, 1H); |
1230 | 0 Η Ν | Ε, 6,181 | 35 | 348.4 (ΚΤ+1) | Ci9H13N3O 2S 347.07 | ‘H-NMR (DMS0-7tf, 500 MHz): δ 10.8510.82 (m, 2H), 8.38 (brs, 1H), 8.14 (d, 7= 8.0 Hz, 1H), 7.837.67 (m, 5H), 7.57-7.47 (m, 3H), 7.16 (t, 7= 7.5 Hz, 1H); |
1231 | 0 Η | Β, 6,182 | 61 | 348.2 (MM); | C19Hi3N3O 2S 347.07 | ‘H-NMR (DMSO-7d, 400 MHz): δ 10.85 (s, 1H), 10.48 (s, 1H), 8.88 (s, 1H), 8.31 (s, 1H), 8.15 (d, 7 = 8.4 Hz, 1H), 7.78-7.70 (m, 4H), 7.57-7.45 (m, 3H), 7.407.37 (m, 1H); |
192
1242 | 0 if^i NH AcHN | A, 6,183 | 28 | 404.2 (MV1); | c22h17n3o 3S 403.10 | ‘h-nmr (DMSO-iZtf, 400 MHz): δ 10.85 (s, 1H), 9.85 (s, 1H), 9.61 (s, 1H), 7.76 -7.68 (m,4H), 7.57 (t, J= 6.8 Hz, 2H), 7.53-7.47 (m, 3H), 7.19 (t, J = 4.4 Hz, 2H), 2.05 (s, 3H); |
1243 | 0 /W' NH H NHAc | A, 6,184 | 51 | 404.3 (M++l); | C22H[7N3O 3S 403.10 | ‘H-NMR (DMSO-4,400 MHz): δ 10.82 (brs, 1H), 10.29 (br s, 1H), 9.95 (brs, 1H), 8.06 (s, 1H), 7.75-7.70 (m, 4H), 7.577.47 (m, 3H), 7.37 (d,J= 7.6 Hz, 1H), 7.32 (d, J= 7.2 Hz, 1H), 7.23 (t,J= 7.6 Hz, 1H), 2.03 (s, 3H); |
1444 | O /“NH P r===\ | A, 6,185 | 32 | 347.9 (M++l); | Ci9HI3N3O 2S 347.07 | ‘H-NMR (DMSO-dd, 400 MHz): δ 10.85 (s, 1H), 10.62 (s, 1H), 8.48 (d, J= 6.1 Hz, 2H), 7.79-7.69 (m, 6H), 7.60-7.45 (m, 3H); |
1445 | O -Jz-NH /? «SX N^-A | A, 6,186 | 25 | 423.1 (KU+1); | C2eHi8N2O 2s 422.11 | ‘H-NMR (DMSO-dd, 400 MHz): δ 10.85 (s, 1H), 10.36 (s, 1H), 8.078.04 (m, 1H), 7.80-7.70 (m, 5H), 7.65-7.61 (m, 2H), 7.57 (dd, .7=7.7,1.6 Hz, 1H), 7.547.35 (m, 7H); |
193
1567 | ο. / / NH /? SZ\ ovv | A, 6, 187 | 44 | 396.9 (M>1); | C19H16N4O 2S2 396.07 | ‘H-NMR (DMSO-^, 400 MHz): δ 10.79 (s, 1H), 8.72 (t, J= 5.3 Hz, 1H), 7.71-7.63 (m, 3H), 7.59-7.41 (m, 4H), 3.59 (q, 7= 6.3 Hz, 2H), 3.29-3.25 (m, 2H), 2.66 (s, 3H); |
1568 | o nh2 /~NH 9 SA | A, 6, 188 | 55 | 398.0 (Nf+l) | c1sh15n5o 2S2 397.07 | ‘H-NMR (DMS 0-7,5,400 MHz): δ 10.78 (s, 1H), 8.69 (t, 7= 5.4 Hz, 1H), 7.74-7.63 (m, 3H), 7.60-7.43 (m, 4H), 6.97 (s, 2H), 3.51 (q, 7= 6.6 Hz, 2H), 3.03 (t, 7= 6.7 Hz, 2H); |
1582 | 0, / NH /9 o-/ fï ΠΑ-Α'Ν | B, 6,189 | 63 | 456.1 (MM); | C20H17N5O 4S2 455.07 | ‘H-NMR (DMSO-7,5,400 MHz): δ 10.78 (s, 1H), 8.71 (t, 7= 5.4 Hz, 1H), 7.74-7.62 (m, 4H), 7.56-7.41 (m, 4H), 7.32 (brs, 1H), 3.99 (s, 2H), 3.58 (q, 7= 6.5 Hz, 2H), 3.06 (t, 7=6.6 Hz, 2H); |
1569 | 0 / NH 1? \kJ / n-^^n-n H N | A, 6,190 | 75 | 377.1 (Nf+1) | C20H46N4O 2S 376.10 | ‘H-NMR (DMSO-75,400 MHz): δ 10.76 (s, 1H), 9.07 (dd, 7=4.4,2.0 Hz, 1H), 8.64 (t, 7= 5.5 Hz, 1H), 7.71-7.41 (m, 9H), 3.683.62 (m, 2H), 3.14 (t, 7= 7.0 Hz, 2H); |
194
1551 | 0 /? hn-λ | A, 6,191 | 22 | 366.0 (M++l); | Ci8H15N5O 2S 365.09 | ‘H-NMR (DMS0-dd, 400 MHz): δ 13.67 (brs, 1H), 10.77 (s, 1H), 8.64 (brs, 1H), 8.42 (br s, 0.4H), 7.82 (br s, 0.6H), 7.717.62 (m, 3H), 7.58-7.42 (m, 4H), 3.55 (q, J = 6.7 Hz, 2H), 3.00-2.82 (m, 2H); |
1583 | q. / /-NH P HN_-Z ζΧ-Ο'Λ''^' | Ba, 6,192 (a=RT8h) | 51 | 380.1 (M++l); | Ci9Hi7N5O 2S 379.11 | ‘H-NMR (DMSO-di, 500 MHz): δ 13.24 (d, .7= 9.8 Hz, 1H), 10.77 (br s, 1H), 8.698.57 (m, 1H), 7.71-7.63 (m, 3H), 7.58-7.43 (m, 4H), 3.563.47 (m, 2H), 2.87 (t, .7=7.1 Hz, 1H), 2.76 (t, J=7.5 Hz, 1H), 2.31-2.16 (s, 3H); |
1570 | v -P COOt^'” | A, 6,193 | 46 | 432.0 (M++l); | θ22Ηι7Ν5θ 3s 431.11 | 'H-NMR (DMSO-dà, 400 MHz): δ 13.80 (brs, 1H), 10.77 (s, 1H), 8.69 (brs, 1H), 7.74 (brs, 1H), 7.70-7.65 (m, 2H), 7.64 (s, 1H), 7.58-7.43 (m, 4H), 6.84 (brs, 1H), 6.59 (brs, 1H), 3.623.55 (m, 2H), 3.00-2.91 (m, 2H); |
1552 | _JXNH ο OsÎ^rÇS >rN | A, 6,194 | 31 | 442.1 CVr+1); | C24H49N5O 2s 441.13 | ‘H-NMR (DMSO-de, 400 MHz): δ 13.62 (brs, 1H), 10.75 (s, 1H), 9.01 (brs, 1H), |
195
8.38 (br s, 0.5H), 7.77 (br s, 0.5H), 7.717.62 (m, 3H), 7.60-7.42 (m, 4H), 7.37-7.32 (m,2H), 7.27 (t, J= 7.5 Hz, 2H), 7.22-7.17 (m, 1H), 5.47 (q, J = 7.7 Hz, 1H), 3.39-3.33 (m, 1H), 3.27-3.17 (m, 1H); | ||||||
1571 | 0 NH /? Ck /Fp νύν'Μ H T^N | A, 6,195 | 86 | 369.0 (Mri-1); | c17h12n4o 2S2 368.04 | ‘H-NMR (DMSO-<76,400 MHz): δ 10.79 (s, 1H), 9.539.48 (m, 2H), 7.73-7.67 (m, 3H), 7.62 (dd, J = 8.0,1.8 Hz, 1H), 7.57-7.43 (m, 3H), 4.86 (d, J =5.9 Hz, 2H); |
1584 | O _ nh P Ovum S H N=/ | A, 6,196 | 54 | 367.9 (MM); | cI8h13n3o 2s2 367.04 | ‘H-NMR (DMSO-ίήί, 400 MHz): δ 10.77 (s, 1H), 9.10 (t, J= 5.7 Hz, 1H), 9.04 (s, 1H), 7.74-7.62 (m, 4H), 7.57-7.42 (m, 4H), 4.58 (d, J=5.6Hz, 2H); |
1599 | 0 z-J' NH /? fX Xt'n'Vn H hT^n | A, 6,197 | 23 | 352.1 (M++l); | Ci7H13N5O 2s 351.08 | ‘H-NMR (DMSO-cZ,;, 400 MHz): δ 13.77 (brs, 1H), 10.79 (br s, 1H), 9.06 (brs, 1H), 8.33 (brs, 1H), 7.74-7.60 (m, 4H), 7.577.42 (m, 3H), 4.51 (d,J=4.8 Hz, 2H); |
196
1572 | 0 | A, 6,198 | 50 | 361.9 (MV1); | C20H15N3O 2S 361.09 | ‘H-NMR (DMSO-rfi, 400 MHz): δ 10.78 (s, 1H), 9.16 (t, J= 5.9 Hz, 1H), 8.48 (d, J =5.9 Hz, 2H), 7.767.63 (m, 4H), 7.57-7.42 (m, 3H), 7.27 (d,7 = 5.5 Hz, 2H), 4.46 (d, 7=5.7 Hz, 2H); |
1585 | 0 / NH /? UkAV n Ύ *1 X/ s H l^N | A, 6,199 | 64 | 362.9 (M^+l); | CI9H14N4O 2S 362.08 | ‘H-NMR (DMSO-Jà, 400 MHz): δ 10.79 (s, 1H), 9.22 (t, 7= 5.3 Hz, 1H), 9.09 (s, 1H), 8.71 (d, 7=5.2 Hz, 1H), 7.74 (s, 1H), 7.727.65 (m, 3H), 7.57-7.44 (m, 3H), 7.39 (d, J = 4.9 Hz, 1H), 4.52 (d, 7=5.9 Hz, 2H); |
1586 | O /ANH /? | A, 6, 200 | 60 | 362.9 (MV-1); | C19H14N4O 2S 362.08 | ‘H-NMR (DMS0-<4 400 MHz): δ 10.78 (s, 1H), 9.22 (t, 7= 5.7 Hz, 1H), 8.61 (s, 1H), 8.58- 8.56 (m, 1H), 8.54-8.51 (m, 1H), 7.73 (s, 1H), 7.717.63 (m, 3H), 7.57-7.43 (m, 3H), 4.59 (d, 7 = 5.7 Hz, 2H); |
1587 | 0 _pNH /9 fX IYWs H 11 J | A, 6, 201 | 67 | 362.9 CVT+1); | Ci9Hi4N4O 2s 362.08 | ‘H-NMR (DMSO-7,, 400 MHz): δ 10.80 (s, 1H), 9.10 (t, 7= 5.8 Hz, 1H), 8.74 (d,7=4.9 Hz, 2H), 7.73 (s, 1H), 7.717.65 (m, 3H), 7.57-7.43 (m, 3H), 7.38 (t, 7= |
197
4.9 Hz, 1H), 4.63 (d, .7=5.9 Hz, 2H); | ||||||
1588 | ο 'f-νη 9 CX ΧΧΝΎ% Η Τ^Ν Me | A, 6, 202 | 71 | 381.9 (M++l); | c19h15n3o 2S2 381.06 | *H-NMR (DMSO-cZ5, 400 MHz): δ 10.77 (s, 1H), 9.17 (t, J= 5.7 Hz, 1H), 7.71-7.64 (m, 3H), 7.59-7.42 (m, 5H), 4.55 (d, 7=5.6 Hz, 2H), 2.57 (s, 3H); |
1589 | 0 _JE-NH /? Γκ /Γ/ Η Τγ CI | A, 6, 203 | 72 | 401.9 (MM); | C18H12C1N 3O2S2 401.01 | ‘H-NMR (DMSO-d6>400 MHz): δ 10.77 (s, 1H), 9.28 (t, J= 5.7 Hz, 1H), 7.72-7.64 (m, 3H), 7.61-7.42 (m, 5H), 4.55 (d, .7= 5.4 Hz, 2H); |
1590 | 0 _Χ ΝΗ 0 xAs-U' H Ο | A, 6, 204 | 65 | 443.9 (NT+1); | C24H17N3O 2S2 443.08 | ‘H-NMR (DMSO-î4,400 MHz): δ 10.78 (s, 1H), 9.28 (t, .7= 5.7 Hz, 1H), 7.90-7.86 (m, 2H), 7.79 (s, 1H), 7.73-7.66 (m, 3H), 7.61 (dd, 7=8.2,1.8 Hz, 1H), 7.567.42 (m, 6H), 4.66 (d,7=5.6 Hz, 2H); |
1600 | ο Ζ'Χ-Νγ'νΧ Me | A, 6,205 | 28 | 382.0 (KT+i); | C19HI5N3O 2S2 381.06 | ‘H-NMR (DMSO-76 400 MHz): δ 10.76 (s, 1H), 9.15 (t, 7= 5.7 Hz, 1H), 8.83 (s, 1H), 7.70-7.64 (m, 3H), 7.59-7.43 (m, 4H), 4.55 (d, 7= 5.7 Hz, 2H), 2.39 (s, 3H); |
198
1605 | p xY hX | A0, 6,206 ô=24hRT | 32 | 443.9 (ΜΦ1); | C24HI7N3O 2s2 443.08 | ‘H NMR (DMSO-<Z6,400 MHz): δ 10.78 (s, 1H), 9.34 (t, J= 5.5 Hz, 1H), 9.02 (s, 1H), 7.74-7.66 (m, 5H), 7.60 (dd, J = 8.1,1.8 Hz, 1H), 7.56-7.39 (m, 6H), 4.74 (d, <7=5.5 Hz, 2H); |
1525 | Ox NH 0 O-s'C' NHz | B, 6,133 | 73 | 270.8 (JVT+1); | C14H10N2O 2S 270.05 | ‘H-NMR (DMSO-dfi, 400 MHz): δ 10.77 (s, 1H), 7.99 (br s, 1H), 7.727.58 (m, 4H), 7.56-7.43 (m, 4H); |
1592 | 0 Υχ- Ny\--A | A, 6,207 | 23 | 354.9 (Μ*+1) | C19H18N2O 3s 354.10 | ‘H-NMR (DMSO-φ, 400 MHz): δ 10.75 (brs, 1H), 8.55 (t, J= 5.4 Hz, 1H), 7.71-7.62 (m, 3H), 7.607.43 (m, 4H), 3.98-3.89 (m, 1H), 3.79-3.72 (m, 1H), 3.653.57 (m, 1H), 3.29-3.25 (m, 2H), 1.93-1.73 (m, 3H), 1.611.49 (m, 1H); |
1606 | 0 NH P 0¼ *-ο | A, 6,208 | 23 | 354.9 (JVT+1); | C19H1SN2O 3S 354.10 | ‘H-NMR (DMSO-φ, 400 MHz): δ 10.75 (brs, 1H), 8.60 (t, J= 5.5 Hz, 1H), 7.71-7.63 (m, 3H), 7.59 7.43 (m, 4H), 3.76-3.56 (m, 3H), 3.43 (dd, J = 8.5, 5.4 Hz, 1H), 3.26-3.14 (m, 2H), 2.472.38 (m, 1H), 1.96-1.86 (m, 1H), 1.63-1.51 |
199
(m, 1H); | ||||||
1607 | 0 | A, 6,209 | 22 | 354.9 (MM); | C20H20N2O 3S 368.12 | ‘H-NMR (DMSO-A, 400 MHz): δ 10.75 (s, 1H), 8.51 (t, J= 5.6 Hz, 1H), 7.71-7.62 (m, 3H), 7.60-7.43 (m, 4H), 3.82 (dd, 7=11.2, 2.5 Hz, 2H), 3.27-3.20 (m, 2H), 3.12 (t, 7= 6.3 Hz, 2H), 1.81-1.69 (m, 1H), 1.61-1.51 (m, 2H), 1.241.10 (m,2H); |
1578 | 0 ~~~ s HX-t? | A, 6,210 | 30 | 367.0 (MM); | C18H14N4O 3s 366.08 | ‘H-NMR (DMSO-A, 400 MHz): δ 10.79 (s, 1H), 9.26 (t, 7= 5.7 Hz, 1H), 7.72-7.67 (m, 3H), 7.62 (dd, 7 = 7.9,1.8 Hz, 1H), 7.57-7.43 (m, 3H), 4.63 (d, 7= 5.6 Hz, 2H), 2.45 (s, 3H); |
1603 | °k\ / / NH /9 OM 0LsJQX-^v | A, 6,283 | 70 | 381.0 (M%1); | Q9H16N4O 3S 380.09 | ‘H-NMR (DMSO-A, 400 MHz): δ 10.78 (s, 1H), 8.69 (t, 7= 5.7 Hz, 1H), 7.70-7.62 (m, 3H), 7.56-7.42 (m, 4H), 3.58 (q, 7= 6.6 Hz, 2H), 3.03 (t, 7= 6.8 Hz, 2H), 2.43 (s, 3H); |
1604 | 0 >-nh /9 H Τγ Et | B, 6, 292 | 89 | 395.9 (MM); | c20h17n3o 2S2 395.08 | ‘H-NMR (CDClj, 400 MHz): δ 10.77 (s, 1H), 9.18 (t, 7= 5.7 Hz, 1H), 7.71-7.64 (m, 3H), 7.60-7.43 (m, 5H), 4.56 (d, 7= 5.6 Hz, |
200
2H), 2.90 (q, J = 7.5 Hz, 2H), 1.24 (t, .7=7.5 Hz, 3H); | ||||||
1611 | 0 ΝΠ 0 H | B, 6,298 | 73 | 410.0 (M*+i); | C21H49N3O 2S2 409.09 | ‘H NMR (DMSO-^,400 MHz): δ 10.77 (s, 1H), 9.18 (t, J= 5.7 Hz, 1H), 7.72-7.64 (m, 3H), 7.61-7.42 (m, 5H), 4.57 (d, J=5.6Hz, 2H), 3.22-3.15 (m, 1H), 1.27 (d, .7= 6.9 Hz, 6H); |
1612 | 0 _y- nh o fx JP/ nXV\i OCH3 | B, 6,300 | 59 | 397.9 (NT+1); | C19H45N3O 3S2 397.06 | ‘H NMR (DMSO-îZ6,400 MHz): δ 10.76 (s, 1H), 9.15 (t, J= 5.6 Hz, 1H), 7.71-7.63 (m, 3H), 7.60-7.42 (m, 4H), 7.06 (s, lH),4.44(d, .7= 5.6 Hz, 2H), 3.95 (s, 3H); |
1613 | 0 _ JXnh /? H T^N nh2 | A, 6, 303 | 23 | 382.9 (KT+1); | C18H14N4O 2S2 382.06 | ‘H NMR (DMSO-4400 MHz): δ 10.76 (s, 1H), 9.00 (t, J= 5.5 Hz, 1H), 7.72-7.42 (m, 7H), 6.88 (brs, 2H), 6.81 (s, 1H), 4.35 (d, J = 5.5 Hz, 2H); |
1638 | O __Χνη_ο s HPç» ZNH | A, 6, 308 | 53 | 396.9 (Nf+l); | C19Hi6N4O 2S2 396.07 | ‘H NMR (DMSO-<4.500 MHz): δ 10.77 (s, 1H), 9.03 (t, .7= 5.6 Hz, 1H), 7.69-7.62 (m, 3H), 7.59-7.42 (m, 4H), 7.347.30 (m, 1H), 6.87 (s, 1H), 4.36 (d,J= 5.8 Hz, 2H), 2.72 (d, .7= 4.9 Hz, 3H); |
201
1639 | 0 >-NH /? νΧν W-sXX H T^N N— / | A, 6,311 | 61 | 411.0 (MX); | C20H18N4O 2s2 410.09 | ‘H NMR (DMSO-A 400 MHz): δ 10.75 (s, 1H), 9.05 (t, J= 5.7 Hz, 1H), 7.72-7.62 (m, 3H), 7.59-7.42 (m, 4H), 6.99 (s, 1H), 4.41 (d, J=5.5Hz,2H), 2.95 (s, 6H); |
1631 | 0 —N H 0 Et \ Jl νΧα. XsAW H T^N | A, 6,319 | 15 | 395.9 (MX); | C2oH17N30 2S2 395.08 | ‘H-NMR (DMSO-A 400 MHz): δ 10.78 (s, 1H), 8.69 (t, J= 5.7 Hz, 1H), 7.70-7.62 (m, 3H), 7.56-7.42 (m, 4H), 3.58 (q, J= 6.6 Hz, 2H), 3.03 (t,J= 6.8 Hz, 2H), 2.43 (s, 3H); |
1614 | 0 _ XnH 0 X- H | A, 6,327 (Reaction time 24h) | 27 | 409.9 (MX); | C2IH19N3O 2S2 409.09 | ‘H NMR (DMSO-4400 MHz): δ 10.77 (s, 1H), 9.15 (t, J= 5.8 Hz, 1H), 8.84 (s, 1H), 7.70-7.64 (m, 3H), 7.59-7.42 (m, 4H), 4.58 (d, .7=5.9 Hz, 2H), 3.32-3.29 (m, 1H), 1.21 (d, .7= 6.8 Hz, 6H); |
1632 | 0 _XnH /? Cl \ X. Λ nXm XsAW H T JM | A, 6, 337 | 33 | 401.9 (MX); | C18HI2C1N 3O2S2 401.01 | ‘H NMR (DMSO-A400 MHz): δ 10.77 (s, 1H), 9.31 (t, J= 5.5 Hz, 1H), 9.01 (s, 1H), 7.73-7.65 (m, 3H), 7.59 (dd, J = 7.9,1.8 Hz, 1H), 7.56-7.42 (m, 3H), 4.57 (d, .7= 5.7 Hz, 2H); |
202
1640 | 0 / NH /? W^S'M H Uo | A, 6, 341 (Reaction time 12 h) | 16 | 341.0 (Mf+1); | Ci8Hi6N2O 3s 340.09 | ‘H NMR (DMSO-Jd,400 MHz): δ 10.75 (s, 1H), 8.62 (t, J= 5.5 Hz, 1H), 7.70-7.63 (m, 3H), 7.59-7.43 (m, 4H), 4.60 (dd, .7=7.8, 6.0 Hz, 2H), 4.31 (t, J= 6.0 Hz, 2H), 3.50 (dd, J = 7.8, 6.0 Hz, 2H), 3.17-3.09 (m, 1H). |
1235 | 0 Clx^xJ^NH θ sUvhn-v_q | A, 14, 261 | 45 | 415.4 (M-+1); | C22H23C1N 2O2S 414.12 | ‘h-nmr (CDC13,400 MHz): δ 8.16 (brs, 1H), 7.81 (s, 1H), 7.61 (d, J= 8.0 Hz, 1H), 7.57 (s, 1H), 7.45-7.42 (m, 2H), 7.39-7.36 (m, 1H), 5.995.98 (m, 1H), 3.48-3.43 (m, 2H), 1.75-1.67 (m, 5H), 1.571.46 (m,2H), 1.34-1.31 (m, 1H), 1.27-1.16 (m, 3H), 0.980.92 (m, 2H); |
1250 | 0 ^/'nk 8^=/ί»-χ) | A, 21, 261 (285 mg) | 45 | 415.5 (κΓ+ΐ) | C22H23C1N 2O2S 414.12 | ‘H-NMR (CDC13,400 MHz): δ 8.70 (s, 1H), 7.77 (d, J= 8.4 Hz, 1H), 7.63-7.60 (m, 2H), 7.51 (s, 1H), 7.45 (d, J = 9.6 Hz, 1H), 7.35 (d,J= 10.0 Hz, 1H), 6.07 (t, J= 6.0 Hz, 1H), 3.483.43 (m, 2H), 1.73-1.45 (m, 8H), 1.30-1.14 (m, 3H), 1.000.91 (m, 2H); |
203
1540 | F if^l NH 0 s \=/ N N hr | A, 28, 212 (75 mg) | 15 | 381.0 (MM); | C19H43FN4 o2s 380.07 | ‘H NMR (DMSO-iZd, 400 MHz): δ 10.94 (brs, 1H), 9.20 (t, J= 5.7 Hz, 1H), 9.08 (s, 1H), 8.75 (s, 2H), 7.75-7.60 (m, 3H), 7.537.46 (m, 1H), 7.41 (dd, 7= 7.8, 0.9 Hz, 1H), 7.32-7.28 (m, 1H), 4.47 (d, 7= 5.6 Hz, 2H); |
1541 | F 0 ôrNH ° S \=/ N-\ „ Al | A, 28,213 | 22 | 385.9 (MM); | C18H12FN3 O2s2 385.04 | ‘H NMR (DMSO-76,400 MHz): δ 10.95 (s, 1H), 9.25 (t, 7= 5.7 Hz, 1H), 8.96 (s, 1H), 7.80 (s, 1H), 7.71-7.65 (m, 2H), 7.60 (dd,7 = 8.0,2.0 Hz, 1H), 7.52-7.46 (m, 1H), 7.40 (d, 7= 7.7 Hz, 1H), 7.34-7.28 (m, 1H), 4.65 (d, 7=5.7 Hz, 2H); |
1542 | F 0 ÂA~nh o S \=/ N^. „ M N | A, 28,214 | 31 | 370.0 (MM); | C18H12FN3 O3S 369.06 | ‘H NMR (DMSO-Jî, 400 MHz): δ 10.95 (s, 1H), 9.09 (t, 7= 5.4 Hz, 1H), 8.27 (s, 1H), 7.72-7.65 (m, 2H), 7.61 (dd, 7 = 8.0,1.9 Hz, 1H), 7.53-7.46 (m, 1H), 7.40 (d, 7= 7.2 Hz, 1H), 7.34-7.27 (m, 1H), 7.03 (s, 1H), 4.51(d, 7= 5.4 Hz, 2H); |
204
1543 | F ?\ l!^As ν | A, 28, 215 | 22 | 370.0 (^+1); | c20hi5fn4 O2S 394.09 | ‘H NMR (DMSO-de, 400 MHz): δ 10.96 (s, 1H), 9.01 (s, 1H), 8.69-8.60 (m, 3H), 7.66 (d, J =8.0 Hz, 1H), 7.62 (s, 1H), 7.51 (dd, J = 8.2.2.0 Hz, 1H), 7.49-7.46 (m, 1H), 7.40 (d,J=7.8Hz, 1H), 7.28-7.33 (m, 1H), 3.53 (q, .7= 6.4 Hz, 2H), 2.84 (t,J= 6.6 Hz, 2H); |
1471 | F 0 /ks/'NH ί'Ύ % —4 J N-7 | A, 28, 216 | 22 | 393.9 (MN-i); | c21h16fn3 O2S 393.09 | ‘H NMR (DMSO-4,400 MHz): δ 10.96 (s, 1H), 8.63 (t, J= 5.5 Hz, 1H), 8.52-8.47 (m, 1H), 7.71-7.64 (m, 3H), 7.55 (dd,J=8.2,1.8 Hz, 1H), 7.517.49 (m, 1H), 7.40 (d, .7=7.4 Hz, 1H), 7.31 (t, .7=9.2 Hz, 1H), 7.25 (d, J = 7.7 Hz, 1H), 7.23-7.19 (m, lH),3.59(q,J = 6.8 Hz, 2H), 2.96 (t, J= 7.3 Hz, 2H); |
1555 | F O xAsG^-NH p | A, 28, 217 | 20 | 393.9 (MN-1); | C2iH16FN3 o2s 393.09 | Ή NMR (DMS0-<4 400 MHz): δ 10.97 (s, 1H), 8.64 (t, J= 5.5 Hz, 1H), 8.43 (s, 1H), 8.40 (dd,J= 4.8,1.6 Hz, 1H), 7.68-7.61 (m, 3H), 7.53 (dd, .7=8.0,2.0 Hz, 1H), 7.517.46 (m, 1H), 7.40 (d, .7=7.8, |
205
Hz, 1H), 7.347.27 (m, 2H), 3.49 (q, .7=7.0 Hz, 2H), 2.84 (t, 2= 7.0 Hz, 2H); | ||||||
1490 | F | A, 28,218 | 27 | 393.9 (M++l); | c20h14fn3 O2S 379.08 | ‘H NMR (DMSO-20, 400 MHz): δ 10.96 (s, 1H), 9.15 (t, J= 5.7 Hz, 1H), 8.52 (s, 1H), 8.45 (dd,2= 4.7,1.4 Hz, 1H), 7.73-7.66 (m, 3H), 7.63 (dd, 2=8.2,1.8 Hz, 1H), 7.547.44 (m, 1H), 7.40 (d, J =7.3 Hz, 1H), 7.367.28 (m, 2H), 4.46 (d, 2=5.6 Hz, 2H); |
1463 | F Q\ \Knh /9 | A, 28, 185 | 39 | 365.9 (M++1); | C19Hi2FN3 O2S 365.06 | *H NMR (DMSO-X, 400 MHz): δ 11.04 (s, 1H), 10.63 (s, 1H), 8.48 (d, 2= 6.0 Hz, 2H), 7.80-7.69 (m, 5H), 7.43 (d, 2 = 7.6 Hz, 2H), 7.33 (t, 2= 9.1 Hz, 1H); |
1472 | F 9\ Y/-nh P Cx /Υνλλ | A, 28,186 | 13 | 440.9 (Nf+i); | C26H17FN2 O2S 440.10 | ‘H NMR (DMSO-X 400 MHz): δ 11.04 (s, 1H), 10.38 (s, 1H), 8.078.04 (m, 1H), 7.82-7.72 (m, 4H), 7.67-7.61 (m, 2H), 7.557.30 (m, 8H); |
1580 | F R \/-NH P | A, 28, 347 | 9 | 384.0 (M*+i); | Ci9Hi4FN3 O3S 383.07 | ‘H NMR (DMSO-d6,400 MHz): δ 10.98 (s, 1H), 8.68 (t, 2= 5.6 Hz, 1H), 8.22 (s, 1H), 7.69-7.64 (m, |
206
2H), 7.55 (dd, J = 8.0,1.9 Hz, 1H), 7.53-7.46 (m, 1H), 7.40 (dd, .7=7.6, 0.9 Hz, 1H), 7.36- 7.28 (m, 1H), 6.92 (s, 1H), 3.49 (q, .7=6.2 Hz, 2H), 2.90 (t,J= 6.7 Hz, 2H); | ||||||
1598 | F Y/NH /? | A, 28, 352 | 29 | 399.9 (M%1); | cI9h14fn3 O2S2 399.05 | ‘H NMR (DMSO-î/î, 400 MHz): δ 10.98 (brs, 1H), 8.91 (s, 1H), 8.70 (t, J= 5.6 Hz, 1H), 7.68 (d,J=7.9 Hz, 3H), 7.57 (dd, .7=8.0,1.9 Hz, 1H), 7.53- 7.47 (m, 1H), 7.41 (d, .7=7.1 Hz, 1H), 7.357.29 (m, 1H), 3.48 (q,J=5.9 Hz, 2H), 3.10 (1,.7= 6.7 Hz, 2H); |
1465 | è^NH ° | A, 28, 219 | 30 | 469.0 (M++l); | C28H21FN2 O2S 468.13 | ‘H NMR (DMSO-rf6,400 MHz): δ 10.97 (s, 1H), 8.66 (t, J= 5.3 Hz, 1H), 7.77-7.24 (m, 15H), 3.50 (q, J = 7.0 Hz, 2H), 2.86 (t, .7= 7.0 Hz, 2H); |
1477 | F R\ k / NH /? Ο Μχχ f^ysOjNlCHjh AJ / N \M\ // | A, 28,406 | 12 | 500.1 (Mkl); | C24H22FN3 O4S2 499.10 | ‘H NMR (DMSO-rk 400 MHz): δ 10.97 (s, 1H), 8.63 (t, J= 5.5 Hz, 1H), 7.69-7.61 (m, 4H), 7.54-7.46 (m, 4H), 7.40 (d, .7= 7.0 Hz, 1H), 7.34-7.28 (m, 1H), 3.563.46 (m, 2H), 2.93 (t, J =7.0 |
207
Hz, 2H), 2.54 (s, 6H); | ||||||
1308 | 0 θ S \=/ N-W | Α, 35,212 | 39 | 380.9 (MM); | C19H13FN4 O2S 380.07 | ‘H-NMR (DMSO-A, 400 MHz): δ 10.89 (s, 1H), 9.16 (t, J= 5.6 Hz, 1H), 9.07 (s, 1H), 8.74 (s, 2H), 7.71-7.66 (m, 2H), 7.64-7.58 (m, 2H), 7.47 (dd,7=9.2,2.8 Hz, 1H), 7.37 (dt, 7=11.6, 3.2 Hz, 1H), 4.47 (d,7=5.6 Hz, 2H); |
1309 | 0 χο Ν | Β, 35, 213 | 21 | 385.9 (Μ++1); | c18h12fn3 O2S2 385.04 | ‘H-NMR (DMSO-A, 400 MHz): δ 10.89 (brs, 1H), 9.24 (t, 7=5.6 Hz, 1H), 8.95 (brs, 1H), 7.80 (brs, 1H), 7.70-7.65 (m, 2H), 7.617.57 (m, 2H), 7.47 (d, 7=6.4 Hz, 1H), 7.397.37 (m, 1H), 4.64 (d,7=5.6 Hz, 2H); |
1310 | 0 F\/A< ΝΗ s-OA-^-^Q | Α, 35,216 | 44 | 393.9 (W+1); | c21h16fn3 O2S 393.09 | ‘H-NMR (DMSO-A, 400 MHz): δ 10.89 (s, 1H), 8.62 (t, 7= 5.6 Hz, 1H), 8.47 (d,7=8.0 Hz, 1H), 7.707.61 (m, 3H), 7.59-7.54 (m, 2H), 7.48 (dd, 7 = 9.2,2.8 Hz, 1H), 7.36 (dt, J = 11.6, 3.2 Hz, 1H), 7.24 (d, 7 = 8.0 Hz, 1H), 7.22-7.19 (m, 1H), 3.61-3.50 (m, 2H), 2.96 (t, 7= 7.2 Hz, 2H); |
208
1311 | 0 y~~C N | A, 35, 214 | 35 | 369.9 (Nf+l); | C18H12FN3 O3S 369.06 | ‘H-NMR (DMSO-7tf, 400 MHz): δ 10.89 (brs, 1H), 9.07 (t, 7= 5.2 Hz, 1H), 8.27 (s, 1H), 7.70 (s, 1H), 7.66 (d, 7 = 8.0 Hz, 1H), 7.62-7.57 (m, 2H), 7.48 (dd, 7 = 9.2,2.8 Hz, 1H), 7.37 (dt, J = 11.6,3.2 Hz, 1H), 7.03 (s, 1H), 4.50 (d, 7 = 5.2 Hz, 2H); |
1312 | 0 F-χΧ^Α-ΝΗ Il 1 V-x o /-\ h'^-O | A, 35,215 | 11 | 395.2 (M++l); | C2oH15FN4 O2S 394.09 | ‘H-NMR (DMSO-7d, 400 MHz): δ 10.89 (brs, 1H), 9.01 (s, 1H), 8.658.62 (m, 3H), 7.65-7.35 (m, 6H), 3.52 (t, 7= 6.4 Hz, 2H), 2.84 (t, 7= 6.4 Hz, 2H); |
1313 | FYÎ5q'N\L· o H X-OH | A, 35,220 | 69 | 465.2 (M++l); | C26H25FN2 O3S 464.16 | ‘H-NMR (DMS O-f/,;, 400 MHz): δ 10.88 (s, 1H), 8.72 (d, 7= 8.0 Hz, 1H), 7.70 (s, 1H), 7.66 (s, 2H), 7.62-7.58 (m, 1H), 7.47 (dd, 7 = 8.8,2.8 Hz, 1H), 7.37 (dt, 7 = 11.6,3.2 Hz, 1H), 7.32-7.25 (m, 4H), 5.01- 4.95 (m, 1H), 4.86 (t, 7= 6.0 Hz, 1H), 3.68- 3.57 (m, 2H), 1.24 (s, 9H); |
1316 | Cl | A, 35, 221 | 50 | 382.8 (Nf+l) | C20H12F2N 2O2S 382.06 | ‘H-NMR (DMSO-7d) 400 MHz): δ 10.96 (s, 1H), 10.35 (s, 1H), 7.767.72 (m, 5H), |
209
7.63-7.60 (m, 1H), 7.50 (dd, J = 9.2,2.8 Hz, 1H), 7.41-7.36 (m, 1H), 7.19 (t, 7= 8.8 Hz, 2H); | ||||||
1321 | Ο /9 /==\ ri AXs-X·' H | A, 35, 222 | 51 | 398.9 (M*+l) | C20H12CIF N2O2S 398.03 | ‘H-NMR (DMSO-7d, 400 MHz): δ 10.94 (s, 1H), 10.40 (s, 1H), 7.787.70 (m, 5H), 7.63-7.60 (m, 1H), 7.50 (dd, 7 = 9.2,3.2 Hz, 1H), 7.41-7.37 (m, 3H); |
1320 | 0 Fx/JxZ~NH US^_( | A, 35, 359 | 7 | 471.0 (M*+l) | C26H19FN4 02s 470.12 | ‘H-NMR (DMSO-76,400 MHz): δ 10.90 (s, 1H), 9.15 (s, lH),9.11(s, 1H), 8.64 (t, 7= 5.2 Hz, 1H), 7.73 (d, 7=8.0 Hz, 2H), 7.677.61 (m, 2H), 7.59-7.55 (m, 2H), 7.48 (dd, 7 = 9.2,2.8 Hz, 1H), 7.40-7.34 (m, 2H), 3.50 (q, 2H),2.89(t, 7= 7.2 Hz, 2H); |
1343 | 0 XsAV H | A, 35, 367 | 49 | 471.4 (MX1); | C26H19FN4 O2S 470.12 | ‘H-NMR (DMSO-7d, 400 MHz): δ 10.88 (s, 1H), 8.75 (s, 2H), 8.64 (t, 7= 6.0 Hz, 1H), 8.36-8.34 (m, 2H), 7.65-7.63 (m, 2H), 7.607.57 (m, 2H), 7.55-7.45 (m, 4H), 7.39-7.34 (m, 1H), 3.56 (q, 7= 6.4 Hz, 2H), 2.88 (t, 7= 6.8 Hz, 2H); |
210
1314 | Ο | A, 35, 372 | 13 | 457.0 (Mfl-l) | C25H17FN4 o2s 456.11 | ‘H-NMR (DMS0-dtf, 400 MHz): δ 10.91 (s, 1H), 9.20 (t, J= 6.0 Hz, 1H), 9.17 (s, 1H), 9.11 (s, 2H), 7.77-7.74 (m, 3H), 7.67 (s, 2H), 7.62-7.58 (m, 1H), 7.507.40 (m, 3H), 7.38 (td, J= 11.6, 3.2 Hz, 1H), 4.50 (d, J = 6.0 Hz, 2H); |
1315 | Ο AAsA=/ hA% Q | A, 35, 377 | 32 | 456.9 (M-+1); | C25Hi7FN4 O2S 456.11 | ‘H-NMR (DMSO-dd, 400 MHz): δ 10.89 (s, 1H), 9.17 (t, J= 5.6 Hz, 1H), 8.84 (s, 2H), 8.38-8.35 (m, 2H), 7.72 (s, 1H), 7.69-7.60 (m, 2H), 7.597.58 (m, 1H), 7.52-7.51 (m, 3H), 7.49-7.46 (m, 1H), 7.37 (td, J= 11.6, 2.8 Hz, 1H), 4.50 (d, .7=6.0 Hz, 2H); |
1317 | ο, F __^-ΝΗ Ο Η | A, 35, 223 | 30 | 382.9 (MXi); | C20HI2F2N 2O2S 382.06 | ‘H-NMR (DMS0-<4, 400 MHz): δ 10.96 (s, 1H), 10.46 (s, 1H), 7.767.68 (m, 4H), 7.64-7.60 (m, 1H), 7.52-7.49 (m, 2H), 7.417.35 (m, 2H), 6.93 (dt, J= 10.0,1.6 Hz, 1H); |
1334 | 0. F Αα-νη 9 %=χ c, f'~CxXVn-O' | A, 35, 224 | 14 | 417.6 (MXl); | C20HnClF2 N2O2S 416.02 | ‘H-NMR (DMSO-dd, 400 MHz): δ 10.94 (s, 1H), 10.26 (s, 1H), 7.78 (s, 1H), 7.75-7.70 |
211
(m, 2H), 7.64- 7.60 (m, 2H), 7.54-7.51 (m, 2H), 7.39 (dt,7 = 11.6,3.2 Hz, 1H), 7.31 (dd, J = 8.8,1.2 Hz, 1H); | ||||||
1322 | Q c _JZnh O H | A, 35, 225 | 15 | 382.9 (M++l); | C2oHi2F2N 2θ2^ 382.06 | ‘H-NMR (DMSO-7tf, 400 MHz): δ 10.94 (s, 1H), 10.18 (s, 1H), 7.78 (s, 1H), 7.75-7.74 (m, 2H), 7.647.55 (m, 2H), 7.50 (dd, 7= 9.2, 2.8 Hz, 1H), 7.39 (dt, 7 = 8.8,2.8 Hz, 1H), 7.31-7.26 (m, 2H), 7.247.19 (m, 1H); |
1323 | ox _Vnh o Cl | C, 35, 226 | 21 | 417.7 (tf+l) | C20HnClF2 N2O2S 416.02 | ‘H-NMR (DMSO-75,400 MHz): δ 10.94 (s, 1H), 10.16 (s, 1H), 7.80 (s, 1H), 7.77-7.72 (m, 2H), 7.637.60 (m, 1H), 7.57-7.53 (m, 2H), 7.50 (dd, 7 = 9.2,2.8 Hz, 1H), 7.39 (td, 7 = 11.2,2.8 Hz, 1H), 7.27 (td, 7 = 11.2, 2.8 Hz, 1H); |
1324 | θν F J p VA'S-'XZ h^> | A, 35, 227 | 7 | 419.2 (M*+l) | C2oHioF4N 2O2S 418.04 | ‘H-NMR (DMSO-7(î, 400 MHz): δ 10.98 (brs, 1H), 10.60 (br s, 1H), 7.77-7.66 (m, 5H), 7.637.60 (m, 1H), 7.51 (dd,7= 9.2, 2.8 Hz, 1H), 7.41-7.37 (m, 1H); |
212
1318 | A P Z~NH O r Ί | A, 35, 228 | 67 | 401.2 (MM), | c20hhf3n 2O2S 400.05 | ‘H-NMR (DMSO-7d, 400 MHz): δ 10.93 (s, 1H), 10.19 (s, 1H), 7.78 (s, 1H), 7.73 (s, 2H), 7.63-7.48 (m, 3H), 7.417.32 (m, 2H), 7.11 (t, 7=8.8 Hz, 1H); |
1319 | o. _>-NH 0 f'€a=Xj'n-V | A, 35,179 | 53 | 364.9 OVT+1); | C2oHi3FN2 02S 364.07 | ‘H-NMR (DMSO-7d, 400 MHz): δ 10.95 (s, 1H), 10.29 (s, 1H), 7.76 (s, 1H), 7.73-7.72 (m, 4H), 7.647.60 (m, 1H), 7.51 (dd,7= 9.2,2.8 Hz, 1H), 7.40 (dd, 7 = 8.4,2.8 Hz, 1H), 7.37-7.32 (m, 2H), 7.10 (t, 7= 7.6 Hz, 1H); |
1328 | 0 _/~nh o M | A, 35,229 | 5 | 366.9 (W+l), | C18HnFN4 02S 366.06 | ‘H-NMR (DMSO-7,, 400 MHz): δ 10.99 (s, 1H), 10.69 (s, 1H), 9.13 (s, 2H), 8.93 (s, 1H), 7.80 (s, 1H), 7.77 (s, 2H), 7.64-7.60 (m, 1H), 7.51 (dd,7= 9.2,3.2 Hz, 1H), 7.39 (dt, 7=11.2, 2.8 Hz, 1H); |
1344 | c 7 n^.m fΆλ FM· J! P | C, 35,230 | 8 | 367.5 (Mf+1); | CISHnFN4 O2S 366.06 | ‘H NMR (DMSO-7d, 400 MHz): δ 11.29 (s, 1H), 10.94 (s, 1H), 8.95 (s, 1H), 8.72 (d, 7 = 5.8 Hz, 1H), 8.17 (d, 7= 5.7 Hz, 1H), 7.837.76 (m, 2H), 7.75-7.67 (m, 1H), 7.62 (dd, J = 8.5,5.1 Hz, |
213
1H), 7.51 (dd, J = 9.1,2.8 Hz, 1H), 7.39 (t,J= 8.0 Hz, 1H); | ||||||
1329 | Ο Vnh 0 H N | A, 35, 231 | 28 | 371.9 (M*+l) | C17H10FN3 O2S2 371.02 | *H-NMR (DMSO-dfo 400 MHz): δ 12.70 (br s, 1H), 10.98 (s, 1H), 7.87-7.86 (m, 2H), 7.72 (d, J = 8.4 Hz, 1H), 7.63-7.60 (m, 1H), 7.51 (dt,J = 9.2,2.8 Hz, 2H), 7.41-7.37 (m, 1H), 7.287.25 (m, 1H); |
1335 | 0 /—nh p | A, 35, 380 | 17 | 371.8 (mM; | C17H10FN3 O2S2 371.02 | ‘H-NMR (DMSO-iZd, 400 MHz): δ 11.79 (brs, 1H), 10.98 (s, 1H), 8.62 (s, 1H), 7.79-7.73 (m, 2H), 7.61-7.58 (m, 2H), 7.507.47 (m, 1H), 7.47 (d, J= 9.2, 2.8 Hz, 1H), 7.37(td,J= 11.2,3.2 Hz, 1H); |
1353 | 0 /—NH p _ ύϊΓ iwç | A, 35, 232 | 4 | 355.8 (MU-1), | C17HI0FN3 O3S 355.04 | ‘H-NMR (DMSO-<4,400 MHz): δ 11.62 (brs, 1H), 10.94 (brs, 1H), 7.95-7.85 (m, 1H), 7.817.69 (m, 3H), 7.63-7.59 (m, 1H), 7.50 (d, J = 6.4 Hz, 1H), 7.40-7.37 (m, 1H), 7.20 (brs, 1H); |
1330 | 0 >-NH p | C, 35,185 | 20 | 365.8 (M%1), | cI9h12fn3 O2S 365.06 | ‘H-NMR (DMSO-<4 400 MHz): δ 10.97 (s, 1H), 10.63 (s, 1H), 8.48- |
214
8.47 (m, 2H), 7.77-7.73 (m, 5H), 7.64-7.60 (m, 1H), 7.51 (dd, 7= 9.2,2.8 Hz, 1H), 7.39 (td,7= 11.2, 2.8 Hz, 1H); | ||||||
1336 | C, 35,233 | 30 | 383.9 (M+l)+, | CI9H11F2 n3o2s 383.05 | ‘H-NMR (DMSO-7tf, 400 MHz): δ 10.98 (s, 1H), 10.93 (s, 1H), 8.398.35 (m, 1H), 8.17 (dd, 7= 9.2,4.0 Hz, 1H), 7.82-7.77 (m, 3H), 7.69 (d, 7= 8.0 Hz, 1H), 7.63-7.60 (m, 1H), 7.50 (dd,7=9.2,2.8 Hz, 1H), 7.38 (td, 7= 11.6, 3.2 Hz, 1H); | |
1337 | 0 | B, 35, 234 | 14 | 383.9 (MU-1), | Ci9HnF2N 3o2s 383.05 | ‘H-NMR (DMSO-A, 400 MHz): δ 10.98 (brs, 1H), 10.73 (brs, 1H), 8.74 (s, 1H), 8.34 (s, 1H), 8.16 (d, 7 = 9.2 Hz, 1H), 7.78 (s, 1H), 7.76 (s, 2H), 7.64-7.60 (m, 1H), 7.51 (dd, 7 = 9.2,3.2 Hz, 1H), 7.39 (dt, 7 = 11.6,3.2 Hz, 1H); |
1338 | ΧλυΛ'Ο'01 | C, 35, 235 | 12 | 400.5 (M+l)+, | Ci9HhC1F n3o2s 399.02 | ‘H-NMR (DMSO-A, 400 MHz): δ 11.01 (brs, 2H), 8.43 (brs, 1H), 8.18 (d, 7= 8.8 Hz, 1H), 7.95 (d, 7 = 8.4 Hz, 1H), 7.80-7.77 (m, 2H), 7.69 (d, 7 = 7.6 Hz, 1H), |
215
7.61-7.60 (m, 1H), 7.50 (d,J = 9.2 Hz, 1H), 7.38 (t,J= 8.0 Hz, 1H); | ||||||
1345 | 0 NH^C) iN\ | C, 35, 236 | 6 | 400.5 (NT+i), | CI9HhC1F n3o2s 399.02 | ‘H-NMR (DMSO-dg, 400 MHz): δ 10.97 (brs, 1H), 10.71 (brs, 1H), 8.82 (brs, 1H), 8.36 (d, J = 7.6 Hz, 2H), 7.78-7.76 (m, 3H), 7.62 (t,J= 7.6 Hz, 1H), 7.51 (d,J=8.0 Hz, 1H), 7.39 (t, J= 7.2 Hz, 1H); |
1331 | q. ,°~a | A, 35, 237 | 21 | 406.6 (KT+l), | c2Ih12fn3 O3S 405.06 | ‘H-NMR (DMSO-ds, 400 MHz): δ 10.97 (s, 1H), 10.55 (s, 1H), 8.68 (s, 1H), 8.31 (s, 1H), 7.79-7.75 (m, 4H), 7.607.61 (m, 2H), 7.51 (dd,J= 9.2,2.8 Hz, 1H), 7.39 (dt, J = 11.6,3.2 Hz, 1H); |
1354 | 0e, 35,238 (o= Et3N, DMAP) | 14 | 405.9 (Af+l), | C2iH12FN3 O3S 405.06 | ‘H-NMR DMSO-rf6,400 MHz): δ 12.44 (brs, 1H), 10.94 (s, 1H), 7.92 (brs, 1H), 7.86-7.84 (m, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.62-7.60 (m, 2H), 7.55-7.49 (m, 2H), 7.407.30 (m, 3H); | |
1325 | q, /s~n | A, 35, 239 | 25 | 422.0 (M++l); | c21h12fn3 O2S2 421.04 | ‘H-NMR (DMSO-dtf, 400 MHz): δ 10.97 (s, 1H), 10.56 (s, 1H), 9.30 (s, |
216
1H), 8.65 (s, 1H), 8.05 (d, J = 8.8 Hz, 1H), 7.79-7.73 (m, 4H), 7.64-7.61 (m, 1H), 7.51 (dd, J= 9.2,2.8 Hz, 1H), 7.39 (dt, 7=11.2, 2.8 Hz, 1H); | ||||||
1339 | 0 >-NH p 5_/=φ xy» aP | A, 35,240 | 28 | 422.3 (ΜΦ1), | C21H12FN3 O2S2 421.04 | ‘H-NMR (DMSO-iZtf, 400 MHz): δ 12.09 (brs, 1H), 10.98 (s, 1H), 8.00 (d,7=8.0 Hz, 1H), 7.937.91 (m, 2H), 7.79-7.74 (m, 2H), 7.64-7.60 (m, 1H), 7.537.44 (m, 2H), 7.41-7.32 (m, 2H); |
1332 | Q. ΐ 7~NH 0 _/=V h N | C, 35, 241 | 13 | 439.9 (M+l)+, | czlHnFZN 3O2S2 439.03 | ‘H-NMR (DMSO-φ, 400 MHz): δ 12.91 (brs, 1H), 10.96 (s, 1H), 7.93-7.90 (m, 2H), 7.78 (d, J = 6.8 Hz, 1H), 7.68-7.59 (m, 3H), 7.50 (dd, J = 9.2,2.8 Hz, 1H), 7.38 (td, J = 11.6, 3.2 Hz, 1H), 7.23-7.17 (m, 1H); |
1340 | o. zCi T~NH ,9 sVy M^s^V h N | C, 35, 242 | 5 | 455.9 (M*4-l) | C2IHhC1F N3O2S2 455.00 | ‘H-NMR (DMSO-φ, 400 MHz): δ 13.01 (brs, 1H), 11.00 (s, 1H), 8.16 (s, 1H), 7.91 (d,7=8.0 Hz, 2H), 7.797.70 (m, 2H), 7.64-7.60 (m, 1H), 7.53-7.47 (m, 2H), 7.39 (td, 7= 8.4,3.2 |
217
Hz, 1H); | ||||||
1326 | 0 | A, 35, 243 | 46 | 441.5 (M++l); | c26h17fn2 O2S 440.10 | ‘H-NMR (DMSO-76, 400 MHz): δ 10.96 (s, 1H), 10.39 (s, 1H), 7.84 (d, 7= 8.8 Hz, 2H), 7.78 (s, 1H), 7.74 (s, 2H), 7.68-7.61 (m, 4H), 7.51 (dd,7 = 9.2,2.8 Hz, 1H), 7.47-7.45 (m, 1H), 7.437.32 (m, 4H); |
1333 | _ YNH P 'ïIJtnV | A, 35, 186 | 46 | 441.4 (MM); | c26h17fn2 O2S 440.10 | ‘H NMR (400 MHz, DMSOd6) δ 10.97 (s, 1H), 10.38 (s, 1H), 8.05 (s, 1H), 7.83-7.73 (m, 4H), 7.68 7.61 (m, 3H), 7.52 - 7.37 (m, 7H); |
1376 | Ox >~NH P r==\ FvYÎ JPj’n^^'Ç-n M'S'M' H | A, 35, 217 | 59 | 393.9 (M++l); | c2Ih16fn3 O2S 393.09 | ‘H NMR (DMSO-A, 400 MHz): δ 10.91 (s, 1H), 8.62 (t, 7= 5.5 Hz, 1H), 8.44-8.38 (m, 2H), 7.67-7.57 (m, 4H), 7.54 (dd, 7=8.2,1.8 Hz, 1H), 7.48 (dd, 7=9.2,2.9 Hz, 1H), 7.37 (dt,7=8.5,2.9 Hz, 1H), 7.29 (dd, 7=7.7,4.8 Hz, 1H), 3.543.44 (m, 2H), 2.84 (t, 7= 7.0 Hz, 2H); |
1417 | 0 _Xnh 0 F-n XY n-M? H 0 | B, 35, 347 | 12 | 383.9 (M++l); | C19HI4FN3 O3S 383.07 | ‘H NMR (DMSO-A, 400 MHz): δ 10.90 (brs, 1H), 8.66 (t,7= 5.5 Hz, 1H), 8.21 (s, 1H), 7.68-7.63 (m, 2H), 7.60 |
218
(dd, J= 8.6, 5.3 Hz, 1H), 7.55 (dd,/=8.2,1.7 Hz, 1H), 7.48 (dd, /= 9.2,2.9 Hz, 1H), 7.37 (dt,/=8.5,3.0 Hz, 1H), 6.92 (s, 1H), 3.49 (q, 2H), 2.90 (t,/= 6.7 Hz, 2H); | ||||||
1418 | 0. r~NH .0 lAsAA | B, 35, 352 | 36 | 399.9 (M^+l); | Ci9H14FN3 O2S2 399.05 | ‘H NMR (DMSO-X 400 MHz): δ 10.92 (brs, 1H), 8.91 (brs, 1H), 8.70 (brs, 1H), 7.737.54 (m, 5H), 7.49 (d,/=7.2 Hz, 1H), 7.427.36 (m, 1H), 3.52-3.45 (m, 2H), 3.13-3.10 (m, 2H); |
1364 | 'VAs-'U' hPA) | A, 35, 218 | 38 | 380.0 (M++1); | C20H14F N3O2S 379.08 | 1H NMR (400 MHz, DMSOd6): δ 10.89 (s, 1H), 9.15 (t, J = 5.4 Hz, 1H), 8.52 (s, 1H), 8.45 (dd, J = 4.8,1.5 Hz, 1H), Ί.Τ5-Ί.5Ί (m, 5H), 7.48 (dd, J = 9.2,2.9 Hz, 1H), 7.41- 7.36 (m, 1H), 7.34 (dd, J = 7.9,4.9 Hz, 1H), 4.46 (d, J = 5.9 Hz, 2H); |
1370 | o . z-y NH /? ) À X / | A, 35,219 | 31 | 469.7 (M++1); | C28H21F N2O2S 468.13 | 1HNMR (DMSO-d6,400 MHz): δ 10.91 (s, 1H), 8.65 (t, J = 5.4 Hz, 1H), 7.69-7.53 (m, 8H), 7.50-7.41 (m, 3H), 7.407.28 (m, 4H), 3.50 (q, J =6.7 Hz, 2H), 2.86 (t, J = 7.2 Hz, |
219
2H); | ||||||
1384 | q Κνη θ fW ru ryso2N(CH3)2 WV H | A, 35,406 | 29 | 499.9 (M++1) | C24H22F N3O4S2 499.10 | 1HNMR (DMSO-d6,400 MHz): δ 10.91 (brs, 1H), 8.62 (t, J = 5.6 Hz, 1H), 7.67-7.62 (m, 4H), 7.59 (dd, J =8.6, 5.3 Hz, 1H), 7.53 (dd,J = 8.2,1.7 Hz, 1H), 7.517.46 (m, 3H), 7.37 (td, J =8.5, 3.0 Hz, 1H), 3.51 (q, J = 6.6 Hz, 2H), 2.93 (t, J =7.0 Hz, 2H), 2.54 (s, 6H); |
1385 | 0 XP'sXP H^Xn | A, 35, 244 | 40 | 441.9 (M++1); | C25H16F N3O2S 441.09 | Ή NMR (400 MHz, DMSOd6): δ 10.98 (br s, 1H), 10.44 (s, 1H), 8.68 (d, J = 5.1 Hz, 1H), 8.50 (s, 1H), 7.94-7.89 (m, 2H), 7.87-7.84 (m, 1H), 7.837.77 (m, 3H), 7.76-7.72 (m, 1H), 7.63 (dd, J = 8.6,5.3 Hz, 1H), 7.52 (dd, J = 9.1,2.7 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.43-7.35 (m, 2H); |
1400 | O y^~y~Ny^yX z <0 | A, 35,245 | 21 | 441.9 (M++1); | C25H16F N3O2S 441.09 | Ή NMR (400 MHz, DMSOde): δ 10.98 (s, 1H), 10.42 (s, 1H), 8.85 (brs, 1H), 8.59 (d, J = 3.7 Hz, 1H), 8.08 (s, 1H), 8.03 (d, J=8.0 Hz, 1H), 7.857.72 (m, 4H), 7.63 (dd, J = 8.5, 5.2 Hz, |
220
1H), 7.54-7.45 (m, 4H), 7.40 (td, J = 8.4,2.9 Hz, 1H); | ||||||
1401 | 0 NH /? | A, 35, 246 | 33 | 442.0 (M++1); | C25H16F N3O2S 441.09 | ‘H NMR (400 MHz, DMSOde): δ 10.99 (s, 1H), 10.46 (s, 1H), 8.66 (d, J = 6.0 Hz, 2H), 8.18-8.16 (m, 1H), 7.85 (dt, J = 7.6,1.6 Hz, 1H), 7.81-7.78 (m, 1H), 7.777.74 (m, 2H), 7.68-7.61 (m, 3H), 7.56-7.49 (m, 3H), 7.40 (td, J =8.5,2.5 Hz, 1H); |
1386 | 0 NH /? /====^ Ainxa Xî^'s'X^ h ^yo V | A, 35,247 | 34 | 431.9 (MM); | c23hI4fn3 O3S 431.07 | ‘H NMR (400 MHz, DMSOd6): δ 10.98 (s, 1H), 10.44 (s, 1H), 8.46 (s, 1H), 8.16 (s, 1H), 7.83-7.69 (m, 4H), 7.697.59 (m, 2H), 7.55-7.43 (m, 3H), 7.40 (td, J = 8.5,3.0 Hz, 1H); |
1424 | f C02Et VAsAA hAtx | F, 35, 248 | 32 | 452.0 (MM); | C23H18FN3 O4S 451.10 | ‘H NMR (400 MHz, DMSOd6): 10.89 (s, 1H), 9.20 (d, J = 7.3 Hz, 1H), 8.57-8.54 (m, 1H), 7.84 (td, J = 7.7,1.8 Hz, 1H), 7.74 (s, 1H), 7.70-7.64 (m, 2H), 7.60 (dd, J= 8.6, 5.3 Hz, 1H), 7.53 (d, .7= 7.9 Hz, 1H), 7.48 (dd, J = 9.2,2.9 Hz, 1H), 7.43-7.33 (m, 2H), 5.77 (d, .7=7.3 Hz, |
221
1H), 4.16-4.09 (m, 2H), 1.14 (t, J= 7.1 Hz, 3H); | ||||||
1405 | F CO2Et xX/1 | F, 35, 249 | 28 | 451.9 (MY1); | C23H48FN3 O4S 451.10 | ‘H NMR (400 MHz, DMSOde): δ 10.90 (s, 1H), 9.38 (d, J = 7.5 Hz, 1H), 8.58 (d,J= 5.0 Hz, 2H), 7.73 (s, 1H), 7.717.65 (m, 2H), 7.61 (dd,J= 8.6, 5.2 Hz, 1H), 7.52-7.44 (m, 3H), 7.38 (td, J= 8.4,3.0 Hz, 1H), 5.71 (d, .7=7.4 Hz, 1H), 4.19-4.10 (m, 2H), 1.15 (t, .7=7.1 Hz, 3H); |
1442 | c 7 N-N W^sAZ h s | F, 35, 250 | 31 | 372.8 (M++l); | c16h9fn4 O2S2 372.02 | ‘H NMR (400 MHz, DMSOdfi): δ 10.91 (s, 1H), 8.87 (br s, 1H), 7.94 (s, 1H), 7.87 (dd, J = 8.0,1.7 Hz, 1H), 7.61 (d, J = 9.0 Hz, 1H), 7.59-7.56 (m, 1H), 7.48 (dd, J = 9.2,2.9 Hz, 1H), 7.35 (td, J = 8.5,3.0 Hz, 1H); |
1537 | c JÏ n-n ΥΊ -XX/' nA? | F, 35, 251 | 16 | 357.0 (NT+1); | c16h9fn4 O3S 356.04 | ‘H NMR (400 MHz, DMSOdû) δ 12.26 (br s, 1H), 10.97 (brs, 1H), 9.02 (s, 1H), 7.847.71 (m, 3H), 7.62 (dd, .7= 8.4, 5.3 Hz, 1H), 7.51 (dd,J = 9.2,2.7 Hz, 1H), 7.39 (td, J = 8.4,2.9 Hz, 1H); |
222
1503 | c J « ϊλΧ/rV'0» | Fa, 35,252 (« = Microwave 100 °C temp, lh) | 39 | 371.0 (M^l); | C17HhFN4 O3S 370.05 | ‘H MMR (400 MHz, DMSOdg): δ 11.95 (br s, 1H), 10.97 (brs, 1H), 7.85- 7.70 (m, 3H), 7.62 (dd,7= 8.6, 5.2 Hz, 1H), 7.50 (dd, J = 9.2,2.8 Hz, 1H), 7.39 (td, J = 8.5,2.9 Hz, 1H), 2.45 (s, 3H); |
1443 | 0 / NH /9 N UOH | F, 35,253 | 17 | 405.9 (M++l); | C17H9C1F N3O2S2 404.98 | ‘HNMR (400 MHz, DMSOd6): δ 12.97 (br s, 1H), 11.00 (brs, 1H), 7.86 (brs, 2H), 7.73 (d, 7= 8.2 Hz, 1H), 7.60 (brs, 2H), 7.51 (d, 7 = Ί.Ί Hz, 1H), 7.43-7.35 (m, 1H); |
1440 | 0 / NH P /^=\ H | A, 35,383 | 34 | 443.0 (M++l); | C24H15FN4 O2S 442.09 | ‘HNMR (DMSO-76.400 MHz): δ 10.99 (s, 1H), 10.47 (s, 1H), 9.21 (s, 1H), 9.09 (s, 2H), 8.13-8.11 (m, 1H), 7.887.85 (m, 1H), 7.80 (s, 1H), 7.77-7.75 (m, 2H), 7.63 (dd,7 = 8.6, 5.3 Hz, 1H), 7.56-7.50 (m, 3H), 7.40 (td, 7= 8.5,3.0 Hz, 1H); |
1451 | 0 V-mh 9 | A, 35, 386 | 26 | 443.0 (M++1); | c24h15fn4 O2S 442.09 | ‘HNMR (400 MHz, DMSOdfi): δ 10.99 (s, 1H), 10.52 (s, 1H), 9.27 (s, 1H), 8.88 (d,7 = 5.3 Hz, 1H), 8.66-8.63 (m, 1H), 8.04 (dd, 7 = 5.4,1.3 Hz, |
223
1H), 7.98-7.91 (m, 2H), 7.837.73 (m, 3H), 7.63 (dd,7= 8.6, 5.3 Hz, 1H), 7.58-7.49 (m, 2H), 7.40 (td, 7= 8.5,3.0 Hz, 1H); | ||||||
1441 | 0 F~fx ΧΑ Άλ | A, 35, 389 | 32 | 448.0 (MM); | c23hI4fn3 O2S2 447.05 | ‘H NMR (400 MHz, DMSOde): δ 10.99 (s, 1H), 10.42 (s, 1H), 9.10 (s, 1H), 8.27 (s, 1H), 8.06 -8.04 (m, 1H), 7.827.71 (m, 4H), 7.63 (dd, 7= 8.6, 5.2 Hz, 1H), 7.57-7.35 (m,4H); |
1453 | O _ /“NH /? /^X Al JVVO ^OH | B, 35,392 | 10 | 457.0 (MM); | c26h17fn2 03s 456.09 | ‘H NMR (DMSO-A.400 MHz): δ 10.99 (brs, 1H), 10.33 (s, 1H), 9.57 (s, 1H), 7.96 (s, 1H), 7.79 (s, 1H), 7.75-7.74 (m, 2H), 7.68 (d, 7 = 8.7 Hz, 1H), 7.63 (dd,7= 8.6, 5.3 Hz, 1H), 7.52 (dd, 7 = 9.2,2.9 Hz, 1H), 7.45 (d,7 = 8.7 Hz, 2H), 7.43-7.36 (m, 2H), 7.33-7.29 (m, 1H), 6.86 (d, 7= 8.7 Hz, 2H); |
1480 | 0 / NH H f'CasO^Ai <AsAJ | F*, 35,396 (Z> = EDC solvent) | 32 | 432.4 (MM) | c23h14fn3 O3S 431.07 | ‘H NMR (400 MHz, DMSOd6): δ 11.78(br s, 1H), 10.96 (brs, 1H), 7.907.45 (m, 10H), 7.44-7.33 (m, 2H); |
224
1454 | /? N ΡΊί1 Γτ HÏ KAsAA h v | A, 35,429 | 37 | 471.0 (MAI); | c23h14fn3 03s 431.07 | ‘H NMR (DMSO-rftf, 400MHz): δ 10.98 (s, 1H), 10.37 (s, 1H), 8.02 (s, 1H), 7.83-7.70 (m, 4H), 7.63 (dd, 7 = 8.6, 5.3 Hz, 1H), 7.52 (dd, J = 9.2,2.9 Hz, 1H), 7.47-7.36 (m, 4H), 7.20 (d, 7= 7.8 Hz, 1H), 7.16-7.14 (m, 1H), 6.96 (dd, 7= 8.0, 2.2 Hz, 1H), 3.82 (s, 3H); |
1481 | 0 Ah o | Fc, 35, 397 (c = CH3CN solvent, Mw, 100 °C, 2h | 43 | 448.4 (M*+l) | c23h14fn3 O2S2 447.05 | ‘H NMR (400 MHz, DMSOd6): δ 12.82 (br s, 1H), 11.01 (s, 1H), 7.97 (s, 1H), 7.93-7.85 (m, 2H), 7.76- 7.71 (m, 1H), 7.68-7.60 (m, 3H), 7.52 (dd, J = 9.2,2.9 Hz, 1H), 7.47-7.37 (m, 3H), 7.35- 7.30 (m, 1H); |
1397 | 0 FyAxH LA Αλα0 am% s<AA3 | B, 35, 401 (Reaction time 5 h) | 31 | 439.0 (ΝΓ+1) | c22hI9fn4 O3S 438.12 | Ή NMR (DMSO-7d, 400 MHz): δ 10.87 (s, 1H), 8.96 (s, 1H), 8.64 (s, 2H), 8.41 (d,7 = 8.7 Hz, 1H), 7.64 (d, 7= 8.0 Hz, 1H), 7.62 7.57 (m, 2H), 7.51 (dd,7= 8.1,1.8 Hz, 1H), 7.47 (dd, 7 = 9.1,3.0 Hz, 1H), 7.37 (dt, 7 = 8.5, 3.0 Hz, 1H), 4.42-4.29 (m, 1H), 3.43 (d, 7= 6.1 Hz, 2H), 3.28 (s, |
225
3H), 2.94 (dd, J = 14.0,4.1Hz, 1H), 2.74 (dd, J = 14.0,10.1, Hz, 1H); | ||||||
1347 | Ο /X/·' ΝΗ | Α, 42, 212 | 46 | 380.9 (ΐνΓ+ΐ) | C19H13FN4 02S 380.07 | ‘H NMR (DMSO-d6>400 MHz): δ 10.81 (s, 1H), 9.17 (t, J= 5.6 Hz, 1H), 9.08 (s, 1H), 8.75 (s, 2H), 7.79-7.59 (m, 4H), 7.45 (dd, J = 8.5 Hz, 2.5 Hz, 1H), 7.32 (td,/=8.6,2.6 Hz, 1H), 4.48 (d,/=5.6 Hz, 2H); |
1356 | 0 χΧΝΗ ρΛΑ^2Η° Ν | F, 42, 213 | 13 | 385.8 (Μ++1) | Ci8Hi2FN3 O2S2 385.04 | ‘H NMR (DMSO-A 400 MHz): δ 10.81 (s, 1H), 9.25 (t, /= 5.9 Hz, 1H), 8.96 (s, 1H), 7.80 (s, 1H), 7.75 (dd,/= 8.7, 5.9 Hz, 1H), 7.71-7.70 (m, 1H), 7.687.65 (m, 1H), 7.63-7.58 (m, 1H), 7.45 (dd,/ = 8.5,2.6 Hz, 1H), 7.32 (td,/ = 8.5,2.6 Hz, 1H), 4.65 (d,/ = 5.7 Hz, 2H); |
1348 | 0 ΑΧ ΝΗ χΧΚ-ί F Ν-7 | Α, 42, 216 | 41 | 394.6 (MX) | c21h16fn3 02S 393.09 | ‘H NMR (DMSO-Jÿ, 400 MHz): δ 10.81 (s, 1H), 8.62 (t, /=5.5 Hz, 1H), 8.49 (dd,/= 0.8,4.0 Hz, 1H), 7.75 (dd,/ = 8.7,6.0 Hz, 1H), 7.71-7.61 (m, 3H), 7.55 (dd,/= 1.8, 8.1 Hz, 1H), 7.45 (dd,/=8.5 Hz, |
226
2.6 Hz, 1H), 7.32 (dt, J= 8.5, 2.6 Hz, 1H), 7.25 (d, J = 7.8 Hz, 1H), 7.22-7.19 (m, 1H), 3.67-3.50 (m, 2H), 2.96 (t, J= 7.3 Hz, 2H); | ||||||
1349 | 0 N | A, 42,214 | 47 | 369.9 (M+l) | C18H42FN3 O3S 369.06 | ‘H NMR (DMSO-dd, 400 MHz): δ 10.79 (brs, 1H), 9.08 (t,J=5.5Hz, 1H), 8.27 (s, 1H), 7.91-7.89 (m, 1H), 7.75 (dd, J= 8.7, 6.0 Hz, 1H), 7.687.60 (m, 2H), 7.45 (dd,J= 8.5, 2.5 Hz, 1H), 7.32 (td, J = 8.5,2.6 Hz, 1H), 7.03 (s, 1H), 4.51 (d, J = 5.4 Hz, 2H); |
1362 | 0 F ' | A, 42, 215 | 26 | 395.0 (NT+i) | C20H15FN4 O2S 394.09 | ‘H NMR (DMSO-îZî 400 MHz): δ 10.81 (s, 1H), 9.01 (s, 1H), 8.68-8.60 (m, 3H), 7.75 (dd, J= 8.7, 6.0 Hz, 1H), 7.677.59 (m, 2H), 7.52 (dd,J= 8.0,1.8 Hz, 1H), 7.44 (t,J= 6.4 Hz, 1H), 7.32 (dt,J= 8.5, 2.5 Hz, 1H), 3.52 (q,J = 6.4 Hz, 2H), 2.84 (t, J= 6.6 Hz, 2H); |
1377 | O _^y-NH J AZVVh^Vn F | A, 42, 217 | 34 | 393.9 (M+l) | C2iHI6FN3 O2S 393.09 | ‘H NMR (DMSO-^,400 MHz): δ 10.82 (s, 1H), 8.62 (t, .7= 5.5 Hz, 1H), 8.43-8.42 (m, 1H), 8.40 (d, J |
227
= 5.0 Hz, 1H), 7.75 (t, J= 6.7 Hz, 1H), 7.68- 7.60 (m, 3H), 7.54 (dd,7= 8.0,1.8 Hz, 1H), 7.45 (dd, J = 8.6,2.6 Hz, 1H), 7.38-7.24 (m, 2H), 3.573.42 (m, 2H), 2.84 (t, J= 7.0 Hz, 2H); | ||||||
1402 | 0 Jy-NH ο | A, 42, 347 | 23 | 383.9 (M*+l) | c19h14fn3 o3s 383.07 | ‘H NMR (DMS0-7d, 400MHz): δ 10.82 (s, 1H), 8.66 (t, J= 5.6 Hz, 1H), 8.21 (s, 1H), 7.75 (dd, 7= 8.7, 6.0 Hz, 1H), 7.697.62 (m, 2H), 7.55 (dd, 7= 8.1,1.7 Hz, 1H), 7.45 (dd, 7 = 8.5,2.5 Hz, 1H), 7.32 (td, 7 = 8.5, 2.5 Hz, 1H), 6.92 (s, 1H), 3.58-3.42 (m, 2H), 2.91 (t, 7= 6.7 Hz, 2H); |
1403 | ο NH 9 F | A, 42,352 | 14 | cI9h14fn3 O2S2 399.05 | ‘H NMR (DMS0-7d, 400 MHz): δ 10.83 (s, 1H), 8.91 (s, 1H), 8.69 (t, 7= 5.4 Hz, 1H), 7.76 (dd,7= 8.6, 5.9 Hz, 1H), 7.71-7.63 (m, 3H), 7.58 (d, 7= 8.2 Hz, 1H), 7.45 (dd, 7 = 8.5, 2.5 Hz, 1H), 7.33 (td, 7 = 8.6,2.5 Hz, 1H), 3.48(q, 7 = 6.4 Hz, 2H), 3.10 (t, 7= 6.7 Hz, 2H); |
228
1365 | Ο >-ΝΗ χΧοF | 0 η | A, 42,218 | 53 | 379.9 (M*+l) | C20H14FN3 O2S 379.08 | ‘H NMR (DMSO-ik 400 MHz): δ 10.81 (s, 1H), 9.15 (t, J= 6.1 Hz, 1H), 8.56-8.49 (m, 1H), 8.45 (dd, J = 4.7,1.4 Hz, 1H), 7.78-7.60 (m, 5H), 7.45 (dd, .7=8.6,2.5 Hz, 1H), 7.397.27 (m, 2H), 4.47 (d, J = 5.7 Hz, 2H); |
1371 | 0 F | A, 42,219 | 25 | 469.8 (W+1); | C28H21FN2 O2S 468.13 | ‘H NMR (DMSO-î4, 400 MHz): δ 10.82 (s, 1H), 8.65 (t, J= 5.5 Hz, 1H), 7.76 (t,J= 6.9 Hz, 1H), 7.697.54 (m, 7H), 7.49-7.39 (m, 3H), 7.38-7.26 (m, 4H), 3.573.35 (m, 2H), 2.86 (t,J= 7.2 Hz, 2H); | |
1387 | 0 / ΝΗ /? Q lYR F | rVsOzNÎC^z AJ | A, 42, 406 | 23 | 499.9 (MN-1) | C24H22FN3 O4S2 499.10 | ‘H-NMR (DMSO-i7d, 400 MHz): δ 10.82 (s, 1H), 8.62 (t, J= 5.6 Hz, 1H), 7.76 (dd,J= 8.7, 6.0 Hz, 1H), 7.66-7.62 (m, 4H), 7.557.43 (m, 4H), 7.33(td,J= 8.6, 2.6 Hz, 1H), 3.54-3.48 (m, 2H), 2.93 (t, J= 7.1 Hz, 2H), 2.57-2.52 (m, 6H); |
1366 | 0 Vnh ίΧΧ> F | 0__ Jl / n H | A, 42,185 | 24 | 365.9 (Mkl); | C19H12FN3 O2S 365.06 | ‘H NMR (DMSO-rf6,400 MHz): δ 10.89 (s, 1H), 10.64 (s, 1H), 8.48 (d, J= 5.2 Hz, 2H), 7.84-7.67 (m, |
229
6H), 7.48 (dd, J = 8.5,2.6 Hz, 1H), 7.34 (t, 7= 8.3 Hz, 1H); | ||||||
1358 | 0 _/-nh /? | A, 42,186 | 46 | 441.6 (M+l) | C26H17FN2 02S 440.10 | Ή NMR (DMS0-7d, 400 MHz): δ 10.89 (s, 1H), 10.38 (s, 1H), 8.05 (s, 1H), 7.82-7.71 (m, 5H), 7.63 (d, 7= 7.2 Hz, 2H), 7.54-7.31 (m, 7H); |
1398 | 0 )-NH 0 SO2N(CH3)2 | A, 42,410 | 20 | 514.0 (M*+l); | C25H24FN3 O4S2 513.12 | ‘H NMR (DMSO-d6,400 MHz): δ 10.81 (s, 1H), 8.55 (t, 7= 5.7 Hz, 1H), 7.76 (dd,7= 8.7, 6.0 Hz, 1H), 7.70-7.63 (m, 4H), 7.58 (dd, 7=8.0,1.7 Hz, 1H), 7.537.42 (m, 3H), 7.33 (td, 7= 8.6, 2.6 Hz, 1H), 3.28-3.23 (m, 2H), 2.72 (t, 7= 7.6 Hz, 2H), 2.57 (s, 6H), 1.99-1.78 (m, 2H); |
1390 | 0 if^i NH 0 F o | A, 50,212 | 61 | 380.9 (M“+l) | ci9h13fn4 02S 380.07 | ‘H NMR (DMSO-7d, 400 MHz): δ 10.88 (s, 1H), 9.17 (t, 7= 5.7 Hz, 1H), 9.08 (s, 1H), 8.74 (s, 2H), 7.71 (dd,7= 4.9 Hz, 3.1 Hz, 2H), 7.67-7.59 (m, 1H), 7.547.43 (m, 3H), 4.47 (d,7=5.7 Hz, 2H); |
230
1407 | 0 | A, 50,213 | 30 | 385.9 (M+l) | C18H12FN3 O2S2 385.04 | ‘H NMR CDMSO-i/tf, 400 MHz): δ 10.89 (s, 1H), 9.25 (t, J= 5.7 Hz, 1H), 8.96 (s, 1H), 7.80 (s, 1H), 7.71 (dd, J= 4.8, 3.1 Hz, 2H), 7.60 (dd, J = 8.1,1.8 Hz, 1H), 7.54-7.45 (m, 3H), 4.65 (d, 2= 5.6 Hz, 2H); |
1408 | 0 | A, 50,214 | 23 | 369.9 (M*+l) | C18H12FN3 O3S 369.06 | ‘H NMR (DMSO-2&400 MHz): δ 10.88 (s, 1H), 9.08 (t, 2= 5.5 Hz, 1H), 8.27 (s, 1H), 7.75-7.66 (m, 2H), 7.61 (dd, 2 = 8.0,1.5 Hz 1H), 7.54-7.44 (m, 3H), 7.03 (s, lH),4.51(d, 2= 5.3 Hz, 2H); |
1409 | O F h*X—-4. // M V-N | A, 50,215 | 29 | 395.8 (M++1); | C2oH15FN4 O2S 394.09 | ‘H NMR (DMSO-2d, 400 MHz): δ 10.89 (s, 1H), 9.01 (s, 1H), 8.68-8.61 (m, 3H), 7.69 (d, 2= 8.0 Hz, 1H), 7.63 (s, 1H), 7.55-7.45 (m, 4H), 3.553.49 (m, 2H), 2.84 (t, 2= 6.6 Hz, 2H); |
1383 | O x^szAnH f| 1 À“\ P N*7 | A, 50,216 | 30 | 393.9 (M+l) | C2iH16FN3 O2S 393.09 | ‘H NMR (DMSO-rftf, 400 MHz): δ 10.89 (s, 1H), 8.63 (t, 2= 5.3 Hz, 1H), 8.50-8.47 (m, 1H), 7.72-7.63 (m, 3H), 7.55 (dd, 2=8.1,1.8 Hz, 1H), 7.537.44 (m, 3H), 7.25 (d, 2=7.8 |
231
Hz, 1H), 7.23- 7.18 (m, 1H), 3.62-3.55 (m, 2H), 2.96 (t,J= 7.3 Hz, 2H); | ||||||
1391 | 0 ίι 1 p | A, 50,217 | 44 | 393.9 (My+l) | C2iH16FN3 O2S 393.09 | ‘H NMR (DMSO-ik 500 MHz): δ 10.88 (s, 1H), 8.61 (t, .7= 5.4 Hz, 1H), 8.44-8.36 (m, 2H), 7.67 (d, J = 8.1 Hz, 1H), 7.65-7.59 (m, 2H), 7.54-7.43 (m, 4H), 7.28 (dd, J= 7.4, 5.1 Hz, 1H), 3.47 (q, J= 6.7 Hz, 2H), 2.82 (t,J= 6.9 Hz, 2H); |
1392 | 0 rrNH ° F ~ Fp | A, 50,218 | 22 | 379.9 (KT+l); | C2oH|4FN3 o2s 379.08 | ‘H NMR (DMSO-dtf, 400 MHz): δ 10.88 (s, 1H), 9.15 (t, .7= 5.8 Hz, 1H), 8.56-8.49 (m, 1H), 8.45 (d,J = 5.2 Hz, 1H), 7.74-7.67 (m, 3H), 7.65-7.62 (m, 1H), 7.547.43 (m, 3H), 7.34 (dd,J= 7.7,4.9 Hz, 1H), 4.46 (d, J = 5.7 Hz, 2H); |
1393 | 0 Vnh p (X jyvgn F | A, 50,185 | 12 | 365.9 (Nf+1) | c19h12fn3 O2S 365.06 | ‘H NMR (DMSO-eZtf, 400 MHz): δ 10.97 (s, 1H), 10.63 (s, 1H), 8.48 (d, J= 5.3 Hz, 2H), 7.82-7.76 (m, 2H), 7.76-7.71 (m, 3H), 7.567.47 (m, 3H); |
1410 | O 'y- nh p «ssx ÇmPnP-X | A, 50,186 | 19 | 440.9 (M*+l) | c26hI7fn2 O2S 440.10 | ‘H NMR (DMSO-îA 400 MHz): δ 10.97 (s, 1H), 10.38 (s, 1H), 8.05 (s, |
232
1H), 7.85-7.70 (m, 4H), 7.63 (d, 7= 7.2 Hz, 2H), 7.57-7.36 (m, 8H); | ||||||
1487 | Ο | Α, 50, 347 | 22 | 383.9 GvT+i) | cI9h14fn3 O3S 383.07 | ‘H NMR (DMSO-70,500 MHz): 10.88 (s, 1H), 8.65 (t, 7= 5.5 Hz, 1H), 8.20 (s, 1H), 7.68 (d,7=8.1 Hz, 1H), 7.64 (s, 1H), 7.577.43 (m, 4H), 6.90 (s, 1H), 3.47 (q,7=6.7 Hz, 2H), 2.89 (t, 7= 6.8 Hz, 2H); |
1528 | 0 ΝΗ ο | Α, 50, 352 | 43 | 399.8 (ΚΤ+1) | C19H14FN3 O2S2 399.05 | ‘H NMR (DMSO-7tf,400 MHz): δ 10.92 (brs, 1H), 8.91 (s, 1H), 8.71 (t, 7= 5.4 Hz, 1H), 7.74-7.67 (m, 3H), 7.57 (dd, 7 = 8.1,1.8 Hz, 1H), 7.54-7.44 (m, 3H), 3.48 (q, 7= 6.5 Hz, 2H), 3.10 (t,7= 6.7 Hz, 2H); |
1466 | ο | Α, 50,219 | 50 | 469.0 (Μ-+1) | C28H21FN2 O2S 468.13 | ‘H NMR (DMSO-7dj400 MHz): δ 10.90 (s, 1H), 8.66 (t, 7= 5.6 Hz, 1H), 7.72-7.67 (m, 2H), 7.65-7.61 (m, 2H), 7.607.56 (m, 3H), 7.54-7.42 (m, 5H), 7.36-7.29 (m, 3H), 3.49 (q, 7= 6.8 Hz, 2H), 2.86 (t, 7= 7.3 Hz, 2H); |
233
1488 | 0 pA NH θ T s yA-so^lCHah * H | A, 50,406 | 34 | 500.0 (MAI) | C24H22FN3 O4S2 499.10 | ‘H NMR (DMSO-76, 400 MHz) δ 10.90 (s, 1H), 8.63 (t, 7= 5.6 Hz, 1H), 7.71-7.61 (m, 4H), 7.56-7.44 (m, 6H), 3.583.45 (m, 2H), 2.92 (t, 7= 7.0 Hz, 2H), 2.54 (s, 6H); |
1428 | 0 nh >? O-^yy br | A, 55,212 | 23 | 381.0 (M*+l) | C19H13FN4 O2S 380.07 | Ή NMR (DMSO-7tf400 MHz): δ 10.70 (s, 1H), 9.09 (s, 1H), 8.99(1,7= 5.1 Hz, 1H), 8.74 (s, 2H), 7.69 (d,7=6.5 Hz, 1H), 7.59 (d, 7= 9.5 Hz, 1H), 7.56-7.45 (m, 4H), 4.48 (d, 7= 5.6 Hz, 2H); |
1429 | 0 NH J F II f N | A, 55, 213 | 30 | 385.8 (M++i); | C18H12FN3 O2S2 385.04 | ‘H NMR (DMSO-76.400 MHz): δ 10.71 (s, 1H), 9.03 (t, 7= 5.1 Hz, 1H), 8.98 (s, 1H), 7.79 (s, 1H), 7.69 (dd,7= 7.4,1.4 Hz, 1H), 7.58 (d, 7 = 9.5 Hz, 1H), 7.56-7.47 (m, 3H), 7.46-7.42 (m, 1H), 4.64 (d, 7= 5.7 Hz, 2H); |
1430 | 0 z^Z NH /? OXC< ηΛα F ? N | A, 55,214 | 24 | 369.9 (M++l); | c18h12fn3 O3S 369.06 | ‘H NMR (DMSO-7tf,400 MHz): δ 10.71 (s, 1H), 8.89 (t, 7= 5.1 Hz, 1H), 8.29 (s, 1H), 7.69 (dd,7= 7.4,1.5 Hz, 1H), 7.58 (d, 7 = 9.4 Hz, 1H), 7.56-7.45 (m, |
234
3H), 7.43 (d, J = 6.5 Hz, 1H), 7.02 (s, 1H), 4.50 (d, .7=5.5 Hz, 2H); | ||||||
1411 | 0 F | A, 55,215 | 37 | 394.9 (MM); | c20h15fn4 02S 394.09 | ‘H NMR (DMSO-<Zd>400 MHz): δ 10.73 (s, 1H), 9.02 (s, 1H), 8.67 (s, 2H), 8.44 (t,J= 5.1 Hz, 1H), 7.69 (d, .7=6.9 Hz, 1H), 7.587.45 (m, 4H), 7.34 (d,J=6.5 Hz, 1H), 3.52 (q, 2H), 2.82 (t, J= 6.6 Hz, 2H); |
1394 | Ο Ny^\-A | A, 55, 216 | 44 | 393.9 (M%1) | C2iH16FN3 02S 393.09 | ‘H NMR (DMSO-ds,400 MHz): δ 10.73 (brs, 1H), 8.538.46 (m, 1H), 8.45-8.39 (m, 1H), Ί.Ί2-Ί.6Ί (m, 2H), 7.577.45 (m, 4H), 7.40 (d, J = 6.6 Hz, 1H), 7.26 (d, J =7.7 Hz, 1H), 7.24-7.22 (m, 1H), 3.58 (q, 2H), 2.94 (t, J= 7.2 Hz, 2H); |
1395 | Ο /^λ~ Ny^\-A F | A, 55, 217 | 51 | 393.9 (M*+l) | c21h16fn3 O2S 393.09 | ‘H NMR (DMSO-di.400 MHz): δ 10.74 (s, 1H), 8.42 (d, J= 8.7 Hz, 3H), 7.69 (d, J =7.0 Hz, 1H), 7.64 (d, J =7.8 Hz, 1H), 7.60-7.44 (m, 4H), 7.36 (d, .7= 6.5 Hz, 1H), 7.30 (dd, J = 7.5,4.9 Hz, 1H), 3.48 (q, 2H), 2.81 (t, J= 6.8 Hz, 2H); |
235
1396 | 0 NH 0 U-sAXJTp. | A, 55,218 | 46 | 379.9 (NT+l); | c20h14fn3 O2S 379.08 | Ή NMR (DMSO-Jtf, 400 MHz): δ 10.70 (brs, 1H), 8.95 (t, 7= 5.1 Hz, 1H), 8.52 (s, 1H), 8.46 (d, 7 = 3.9 Hz, 1H), 7.75-7.64 (m, 2H), 7.59 (d, 7 = 9.5 Hz, 1H), 7.56-7.44 (m, 4H), 7.35 (dd, 7 = 7.7,4.9 Hz, 1H), 4.46 (d, 7 = 6.0 Hz, 2H); |
1557 | 0 NH P | A, 55, 347 | 38 | 383.9 (MM) | CI9Hi4FN3 03s 383.07 | ‘H NMR (DMSO-7d400 MHz): δ 10.73 (s, 1H), 8.46 (t, 7= 4.9 Hz, 1H), 8.22 (s, 1H), 7.71-7.67 (m, 1H), 7.58-7.45 (m, 4H), 7.39 (d, 7=6.5 Hz, 1H), 6.92 (s, 1H), 3.48(q, 7 = 6.6 Hz, 2H), 2.89 (t, 7=6.7 Hz, 2H); |
1558 | 0 'f- NH P CUCtA^ | A, 55,352 | 33 | 400.0 (MM) | c19h14fn3 O2S2 399.05 | ‘H NMR (DMSO-7tf>400 MHz): δ 10.75 (s, 1H), 8.93 (s, 1H), 8.49 (t, 7= 4.5 Hz, 1H), 7.72-7.64 (brs, 2H), 7.59-7.44 (m, 4H), 7.41 (d, 7= 6.5 Hz, 1H), 3.47(q, 7 = 6.4 Hz, 2H), 3.08 (t, 7=6.6 Hz, 2H); |
1491 | 0 F | A, 55, 219 | 87 | 469.0 (MM); | C28H2iFN2 o2s 468.13 | ‘H NMR (DMSO-A.400 MHz): δ 10.75 (s, 1H), 8.45 (t, 7= 4.5 Hz, 1H), 7.69 (dd,7= 7.4,1.3 Hz, 1H), 7.64(d, 7 |
236
= 7.3 Hz, 2H), 7.61-7.42 (m, 8H), 7.40 (d, J = 6.5 Hz, 1H), 7.37-7.30 (m, 3H), 3.48 (q, J = 6.8 Hz, 2H), 2.84 (t,J= 7.2 Hz, 2H) | ||||||
1507 | 0 / NH /? LTsAX. h ''XJ F | A, 55,406 | 47 | 499.9 (KT+1); | c24h22fn3 O4S2 499.10 | ‘HNMR (DMSO-di.400 MHz): δ 10.75 (s, 1H), 8.42 (t, J= 5.1 Hz, 1H), 7.71-7.63 (m, 3H), 7.57-7.45 (m, 6H), 7.35 (d, J= 6.5 Hz, lH),3.50(q, J = 6.7 Hz, 2H), 2.91 (t, J =6.9 Hz, 2H), 2.56 (s, 6H); |
1508 | 0 S F H | A, 55,185 | 32 | 365.9 (M+l) | Ci9H12FN3 O2S 365.06 | ‘HNMR (DMSO-<4.400 MHz): δ 10.79 (s, 2H), 8.48 (d, J= 6.0 Hz, 2H), 7.73-7.66 (m, 2H), 7.62 (d, J = 6.3 Hz, 2H), 7.59-7.45 (m, 4H); |
1509 | 0 ÏAnh /? | A, 55,186 | 53 | 441.0 (MM) | c26h17fn2 O2S 440.10 | ‘HNMR (DMSO-<7di400 MHz): δ 10.79 (s, 1H), 10.51 (s, 1H), 7.98 (s, 1H), 7.71 (dd, J = 7.4,15 Hz, 1H), 7.68-7.59 (m, 4H), 7.587.44 (m, 6H), 7.43-7.35 (m, 3H); |
1518 | Q. F ^-nhJ 9 N^7 | B, 62,212 | 39 | 398.9 (NT+1) | Ci9HI2F2N 4O2S 398.06 | ‘HNMR (DMSO-d6,400 MHz): δ 10.68 (s, 1H), 9.38 (t, J= 6.0 Hz, 1H), 9.10 (s, 1H), 8.73 (s, 2H), |
237
7.72-7.68 (m, 1H), 7.59-7.46 (m, 4H), 4.50 (d, .7= 5.9 Hz, 2H); | ||||||
1545 | Q. p hXs> F < N | B, 62,213 | 25 | 403.9 (JvT+i) | C18HhF2N 3O2S2 403.03 | ‘H NMR (DMSO-i/e, 400 MHz): δ 10.66 (s, 1H), 9.39 (t, J= 5.9 Hz, 1H), 9.00 (s, 1H), 7.79 (s, 1H), 7.72-7.68 (m, 1H), 7.59-7.45 (m, 4H), 4.66 (d, .7= 5.7 Hz, 2H); |
1530 | Q\ F NbJ j? xZsZsAhXt0, F L f N | B, 62, 214 | 30 | 387.9 (ΚΓ+1) | Ci8HhF2N 3O3S 387.05 | ‘H NMR (DMSO-Jô, 400 MHz): δ 10.66 (s, 1H), 9.26 (t, J= 5.6 Hz, 1H), 8.31 (s, 1H), 7.73-7.66 (m, 1H), 7.58-7.46 (m, 4H), 7.02 (s, lH),4.51(d, J= 5.5 Hz, 2H); |
1562 | Q\ p z^î NiMxA n F | B, 62, 215 | 25 | 413.0 (ΝΓ+1) | C20Hi4F2N 4O2S 412.08 | ‘H NMR (DMSO-<76,400 MHz): δ 10.66 (s, 1H), 9.03 (s, 1H), 8.80 (t,J= 5.9 Hz, 1H), 8.67 (s, 2H), 7.78-7.62 (m, 1H), 7.58-7.43 (m, 4H), 3.53 (q, 2H), 2.81 (t, J= 6.5 Hz, 2H); |
1519 | Q. f nh/o X^-S^\=Af h x n> | B, 62,216 | 25 | 411.9 (Nf+l) | C21HISF2N 3O2S 411.09 | ‘H NMR (DMSO-î76, 400 MHz): δ 10.64 (s, 1H), 8.78 (t, J= 5.5 Hz, 1H), 8.49 (d, .7=4.2 Hz, 1H), 7.777.62 (m, 2H), 7.59-7.41 (m, 4H), 7.35-7.13 (m, 2H), 3.58 (q, 2H), 2.92 (t, |
238
J= 7.2 Hz, 2H); | ||||||
1531 | Ο MM | B, 62,217 | 57 | 411.9 (MM) | C2iH15F2N 3O2S 411.09 | ‘H NMR (DMSO-A,400 MHz): δ 10.66 (s, 1H), 8.80 (t, J= 5.6 Hz, 1H), 8.51-8.34 (m, 2H), 7.72-7.68 (m, 1H), 7.65 (td, J= 1.9, 7.8 Hz, 1H), 7.577.45 (m, 4H), 7.31 (dd, J= 7.7.4.8 Hz, 1H), 3.49 (q, 2H), 2.80 (t,J= 6.8 Hz, 2H); |
1563 | cWm | B, 62, 352 | 28 | 418.0 (MM) | c19h13f2n 3O2S2 417.04 | ‘H NMR (DMSO-rf6,400 MHz): δ 10.66 (s, 1H), 8.94 (s, 1H), 8.88 (t,J= 5.5 Hz, 1H), 7.72-7.69 (m, 1H), 7.68 (s, 1H), 7.58-7.46 (m, 4H), 3.48 (q, 2H),3.06(t, J= 6.6 Hz, 2H); |
1546 | Q\ F o | B, 62, 218 | 46 | 398.0 (MM) | C2oH13F2N 3O2S 397.07 | ‘H NMR (DMSO-î/6,400 MHz): δ 10.67 (s, 1H), 9.31 (t, J= 6.0 Hz, 1H), 8.52 (s, 1H), 8.48 (dd,J= 4.8,1.6 Hz, 1H), 7.74-7.64 (m, 2H), 7.587.46 (m, 4H), 7.39-7.36 (m, 1H), 4.48 (d, J = 5.9 Hz, 2H); |
1497 | θ' p S F | B, 62,219 | 15 | 487.0 (MM); | C28H2oF2N 2O2S 486.12 | ‘H NMR (DMSO-J6i400 MHz): δ 10.63 (s, 1H), 8.81 (t, J= 5.9 Hz, 1H), 7.71-7.65 (m, 1H), 7.63- 7.60 (m, 2H), 7.58- |
239
7.50 (m, 3H), 7.50-7.40 (m, 5H), 7.35-7.28 (m, 3H), 3.46 (q, 2H), 2.80 (t, 7= 7.1 Hz, 2H); | ||||||
1272 | 0 | A, 70, 261 | 55 | 412.8 (NT+l); | C23H26N2O 3S 410.17 | ‘H-NMR (DMSO-dtf, 400 MHz): δ 10.74 (s, 1H), 8.42 (t, J= 6.4 Hz, 1H), 7.64-7.60 (m, 2H), 7.54 (s, 1H), 7.43 (d, 7 = 8.8 Hz, 1H), 7.18 (s, 1H), 7.05 (d, 7=8.8 Hz, 1H), 3.76 (s, 3H), 3.243.21 (m, 2H), 1.70-1.58 (m, 5H), 1.40-1.35 (m,2H), 1.261.09 (m,4H), 0.91-0.83 (m, 2H); |
1287 | 0 S ο H 1 | A, 76, 261 | 46 | 411.9 (M+l); | C23H26N2O 3S 410.17 | ‘H-NMR (DMS0-<7d, 400 MHz): δ 10.55 (s, 1H), 8.08 (t, 7= 5.6 Hz, 1H), 7.67 (t, 7= 5.6 Hz, 1H), 7.547.43 (m, 4H), 7.27 (s, 1H), 3.85 (s, 3H), 3.26-3.21 (m, 2H), 1.70-1.59 (m, 5H), 1.391.33 (m, 2H), 1.29-1.12 (m, 4H), 0.93-0.85 (m,2H); |
1286 | ο | A, 82, 261 | 20 | 395.6 (M+l) | C23H26N2O 2S 394.17 | ‘H-NMR (DMS0-rfd, 400 MHz): δ 10.69 (s, 1H), 8.37 (t, 7= 5.6 Hz, 1H), 7.68-7.59 (m, 3H), 7.53-7.43 (m, 3H), 3.253.20 (m, 2H), 2.55 (s, 3H), |
240
1.70-1.58 (m, 5H), 1.40-1.35 (m, 2H), 1.261.14 (m,4H), 0.91-0.85 (m, 2H); | ||||||
1275 | 0 | A, 88,261 | 35 | 395.8 (M+l) | C23H26N2O 2S 394.17 | ‘H-NMR (DMSO-Jd, 400 MHz): δ 10.66 (brs, 1H), 8.20 (brs, 1H), 7.66 (d, 7= 7.2 Hz, 1H), 7.53-7.44 (m,4H), 7.10 (s, 1H), 3.223.17 (m, 2H), 2.22 (s, 3H), 1.70-1.58 (m, 5H), 1.37-1.09 (m, 6H), 0.900.82 (m, 2H); |
1641 | 0 nh o O^sOy' hX^n V | A, 88, 212 | 61 | 377.3 (M*+l) | C20H16N4O 2s 376.10 | *HNMR (DMSO-7d,400 MHz): δ 10.62 (s, 1H), 9.10 (s, 1H), 8.91 (t, 7= 5.7 Hz, 1H), 8.75 (s, 2H), 7.67 (dd,7= 1.6,7.4,1.6 Hz, 1H), Ί.5Ί-ΊΑ2 (m, 4H), 7.23 (s, 1H), 4.44 (d, 7= 5.9 Hz, 2H), 2.23 (s, 3H) |
1642 | 0 NH /? iji, -Λ/Ν-Χ-s N | A, 88, 213 | 34 | 381.9 (M*+i) | C19HI5N3O 2s2 381.06 | ‘H NMR (DMSO-7d,400 MHz): δ 10.63 (s, 1H), 9.008.95 (m, 2H), 7.79 (s, 1H), 7.66 (dd,7= 7.5,1.5 Hz, 1H), 7.54-7.41 (m, 4H), 7.15 (s, 1H), 4.61(d, 7= 5.7 Hz, 2H), 2.23 (s, 3H); |
241
1643 | 0 __Λ“ΝΗ /9 CUOzi-γκ tr | A, 88,218 | 75 | 376.0 (M*+l) | C21H47N3O 2S 375.10 | ‘H NMR (DMSO-dà,400 MHz): δ 10.63 (s, 1H), 8.87 (t, J= 5.9 Hz, 1H), 8.53 (s, 1H), 8.47 (dd,J= 4.8,1.5 Hz, 1H), 7.74-7.65 (m, 2H), 7.567.41 (m, 4H), 7.36 (dd, J= 7.4, 5.1 Hz, 1H), 7.20 (s, 1H), 4.42 (d, J = 6.0 Hz, 2H), 2.23 (s, 3H) |
1478 | 0 9 OuVn, N^7 | A, 97, 212 (Reaction time 18 h) | 45 | 376.9 (M^+l) | C20H16N4O 2s 376.10 | ‘H NMR (DMSO-d6,400 MHz): δ 10.24 (s, 1H), 9.09 (s, 1H), 8.93 (t, J= 5.9 Hz, 1H), 8.75 (s, 2H), 7.69-7.59 (m, 1H), 7.56-7.39 (m, 4H), 7.14 (d, .7= 7.9 Hz, 1H), 4.44 (d, J = 5.7 Hz, 2H), 2.26 (s, 3H); |
1513 | 0 _/^nh/ 9 N | A, 97, 213 | 28 | 382.2 çmF+1) | Ci9H15N3O 2S2 381.06 | 'H NMR (DMSO-d6>400 MHz): δ 10.23 (s, 1H), 9.01 (t, J= 5.9 Hz, 1H), 8.98 (s, 1H), 7.79 (s, 1H), 7.71-7.59 (m, 1H), 7.55-7.48 (m, 2H), ΊΑΊ7.40 (m, 2H), 7.06 (d,J=7.9 Hz, 1H), 4.61 (d, .7= 5.7 Hz, 2H), 2.27 (s, 3H); |
1514 | 0 _/“nh / 9 VAsAJ/ H^-q N | B, 97, 214 | 55 | 365.8 (MM) | C19H15N3O 3s 365.08 | ‘H NMR (DMSO-d6,400 MHz): δ 10.21 (s, 1H), 8.83 (t, .7= 5.7 Hz, 1H), 8.26 (s, 1H), |
242
7.83-7.56 (m, 1H), 7.56-7.36 (m, 4H), 7.06 (d, 7= 7.9 Hz, 1H), 7.01 (s, 1H), 4.44 (d, 7 = 5.6 Hz, 2H), 2.24 (s, 3H); | ||||||
1529 | îTa. /? | A, 97,215 | 25 | 390.9 (M-+1) | c21hisn4o 2S 390.12 | ‘H NMR (DMSO-76.400 MHz): δ 10.20 (s, 1H), 9.03 (s, 1H), 8.68 (s, 2H), 8.38 (t, 7= 5.3 Hz, 1H), 7.69-7.60 (m, 1H), 7.53-7.39 (m, 4H), 6.96 (d, 7= 7.9 Hz, 1H), 3.51 (q, 2H), 2.81 (t, 7= 6.6 Hz, 2H), 2.13 (s, 3H); |
1459 | 0 z^\ Νγ^χ-Λ VZ-s-AsV H Ά | A, 97,216 | 58 | 390.0 (M*+l) | C22H19N3O 2S 389.12 | ‘H NMR (DMSO-76,400 MHz): δ 10.20 (s, 1H), 8.48 (d, 7= 4.0 Hz, 1H), 8.34 (br s, 1H), 7.76-7.58 (m, 2H), 7.55-7.35 (m, 4H), 7.26 (d, 7= 7.8 Hz, 1H), 7.23-7.18 (m, 1H), 7.00 (d, 7= 7.8 Hz, 1H), 3.55(d, 7 = 5.5 Hz, 2H), 2.93 (t, 7= 7.1 Hz, 2H), 2.19 (s, 3H); |
1467 | 0 /λ~ ΝΥχ-Α | A, 97,217 | 29 | 390.0 (NT+i) | C22H19N3O 2S 389.12 | ‘H NMR (DMSO-76,500 MHz): δ 10.20 (s, 1H), 8.468.39 (m, 2H), 8.36 (t, 7= 5.4 Hz, 1H), 7.65 (td, 7= 6.2,3.0 Hz, 2H), 7.587.38 (m, 4H), 7.31 (dd,7= 7.7,4.8 Hz, |
243
1H), 6.96 (d, J = 8.1 Hz, 1H), 3.47 (d,7=5.5 Hz, 2H), 2.80 (t, 7= 6.8 Hz, 2H), 2.15 (s, 3H); | ||||||
1560 | 0 /-nh / 9 | A, 97, 347 | 21 | 379.9 (M*+l) | C20H47N3O 3S 379.10 | ‘HNMR (DMSO-7640° MHz): δ 10.22 (s, 1H), 8.41 (t, 7= 5.7 Hz, 1H), 8.22 (s, 1H), 7.72- 7.58 (m, 1H), 7.56-7.35 (m, 4H), 7.01 (d, 7= 7.9 Hz, 1H), 6.92 (s, lH),3.45(d,7 = 6.2 Hz, 2H), 2.98-2.81 (m, 2H), 2.22 (s, 3H); |
1561 | 0 _7~nh/ 9 OOM | A, 97,352 | 34 | 396.0 (MAI) | C20H17N3O 2S2 395.08 | ‘HNMR (DMSO-761400 MHz): δ 10.22 (s, 1H), 8.93 (s, 1H), 8.44 (t, 7= 5.9 Hz, 1H), 7.68 (s, 1H), 7.67-7.63 (m, 1H), 7.54-7.47 (m, 2H), 7.467.42 (m, 2H), 7.02 (d, 7= 7.9 Hz, 1H), 3.45 (q, 2H),3.07(t, 7= 6.6 Hz, 2H), 2.21 (s, 3H); |
1515 | 0 | A, 97,218 | 40 | 376.0 (Nf+l) | CziHnNjO 2S 375.10 | ‘HNMR (DMSO-76,400 MHz): δ 10.24 (s, 1H), 8.90 (t, 7= 6.1 Hz, 1H), 8.54-8.51 (m, 1H), 8.46 (d, 7 = 5.3 Hz, 1H), 7.70 (dt,7= 7.8,1.9 Hz, 1H), 7.67-7.63 (m, 1H), 7.547.40 (m, 4H), 7.36 (dd, 7= |
244
7.5, 5.1 Hz, 1H), 7.12 (d, J = 7.9 Hz, 1H), 4.42 (d,J= 6.0 Hz, 2H), 2.27 (s, 3H); | ||||||
1495 | 0 Ca<τθ | A, 97, 219 | 41 | 465.0 (MA1) | C29H24N2O 2s 464.16 | Ή NMR (DMSO-J6i400 MHz): δ 10.20 (s, 1H), 8.37 (t, J= 5.1 Hz, 1H), 7.64 (d,J=7.2 Hz, 3H), 7.59 (d, .7= 8.0 Hz, 2H), 7.53-7.40 (m, 6H), 7.397.26 (m, 3H), 7.00 (d, .7=7.9 Hz, 1H), 3.48 (q, 2H),2.83(t, J= 6.9 Hz, 2H), 2.19 (s, 3H); |
1516 | 0 | B, 97,185 | 34 | 361.9 (MAI) | C20H15N3O 2S 361.09 | ‘H NMR (DMSO-J6,400 MHz): δ 10.73 (brs, 1H), 10.34 (br s, 1H), 8.45 (d, J = 4.6 Hz, 2H), 7.71-7.53 (m, 5H), 7.50-7.44 (m, 2H), 7.26 (d, J =7.9 Hz, 1H), 2.34 (s, 3H); |
1517 | 0 / NHJ /° H ïVv fV0» « /A A / N VA // | B, 97,406 | 50 | 496.0 (M+l) | C25H25N3O 4S2 495.13 | ‘H NMR (DMSO-<4,400 MHz): δ 10.21 (s, 1H), 8.36 (t, J= 5.6 Hz, 1H), 7.69-7.62 (m, 3H), 7.57-7.40 (m, 6H), 6.96 (d, .7=7.9 Hz, 1H), 3.50 (d, J = 5.3 Hz, 2H), 2.90 (t, J= 6.7 Hz, 2H), 2.58 (s, 6H), 2.14 (s, 3H); |
245
1496 | Ο 'f- νη/ 9 | Β, 97,186 | 37 | 437.0 (MX) | C27H20N2O 2s 436.12 | Ή NMR (DMSO-de 400 MHz): δ 10.42 (s, 1H), 10.31 (s, 1H), 8.00 (s, 1H), 7.70-7.63 (m, 2H), 7.627.53 (m, 4H), 7.51-7.43 (m, 4H), 7.43-7.35 (m, 3H), 7.26 (d,/=7.9 Hz, 1H), 2.37 (s, 3H); |
1276 | 0 νη νη2 η | Α, 135,261 | 40 | 424.8 (MX); | C23H25N3O 3S 423.16 | ‘H-NMR (DMSO-A 500 MHz): δ 10.86 (brs, 1H), 8.458.44 (m, 1H), 8.14 (s, 1H), 8.00 (s, 1H), 7.89 (d,/=8.0 Hz, 1H), 7.75 (d,/=8.0Hz, 1H), 7.65 (d,/ = 8.5 Hz, 1H), 7.57 (d, /= 8.5 Hz, 2H), 3.243.23 (m, 2H), 1.70-1.58 (m, 5H), 1.37 (t,/= 6.5 Hz, 2H), 1.18-1.09 (m, 5H), 0.86 (t,/= 6.5 Hz, 2H); |
1200 | 0. /ΐ ΝΗ __ 0 «0 | Α, 140,211 | 73 | 375.1 (MX); | C22H18N2O 2S 374.11 | ‘H-NMR (DMSO-/d, 400 MHz): δ 10.85 (s, 1H), 8.60 (t, /= 4.8 Hz, 1H), 8.01 (s, 1H), 7.78 (d,/=8.4 Hz, 1H), 7.69 (d,/=8.4Hz, 1H), 7.54-7.44 (m, 3H), 7.307.17 (m, 6H), 3.47-3.42 (m, 2H), 2.82 (t,/= 7.6 Hz, 2H); |
246
1207 | σ | A, 145, 3cyclohexylp ropanoic acid | 35 | 381.1 (Μ*+1) | C22H24N2O 2s 380.16 | 'H-NMR (DMSO-7d, 400 MHz): δ 10.67 (s, 1H), 10.03 (s, 1H), 7.66 (d ,7= 7.2 Hz, 1H), 7.60 (s, 1H), 7.50-7.40 (m, 4H), 7.31 (d,7=8.4 Hz, 1H), 2.32-2.27 (m, 2H), 1.691.60 (m, 5H), 1.48-1.43 (m, 2H), 1.18-1.13 (m, 4H), 0.900.85 (m, 2H); |
1644 | 0 | A, 150,261 | 54 | 381.4 (MM) | C22H24N2O 2S 380.16 | ‘H-NMR (DMSO-70, 400 MHz): δ 10.77 (brs, 1H), 8.588.54 (m, 1H), 8.12 (s, 1H), 7.90 (d, 7=8.0 Hz, 1H), 7.627.56 (m, 2H), 7.38-7.34 (m, 1H), 7.23 (d, 7 = 8.0 Hz, 1H), 7.16 (t, 7= 6.8 Hz, 1H), 3.273.24 (m, 2H), 1.72-1.58 (m, 5H), 1.26-1.11 (m, 5H), 0.960.82 (m, 2H); |
1645 | ο | B, 155, 3cyclohexylp ropanoic acid | 6 | 381.2 (M+l); | C22H24N2O 2s 380.16 | ‘H-NMR (DMSO-7d, 400 MHz): δ 10.64 (s, 1H), 10.08 (s, 1H), 7.95 (s, 1H), 7.68-7.65 (m, 1H), 7.53 (d, 7= 7.2 Hz, 1H), 7.43 (d,7 = 8.4 Hz, 1H), 7.34 (t, 7= 8.0 Hz, 1H), 7.22 (d, 7= 7.2 Hz, 1H), 7.13(1,7= 7.6 Hz, 1H), 2.32-2.27 (m, 2H), 1.69-1.60 |
247
(m, 4H), 1.491.41 (m, 2H), 1.28-1.13 (m, 4H), 0.90-0.85 (m, 3H); | ||||||
1373 | 0 ρΑ™ ° 0 Q | Α, 156,212 (Reaction time24 h) | 21 | 378.9 (M%1) | C19H14N4O 3s 378.08 | ‘H NMR (DMSO-76, 500 MHz): δ 11.03 (brs, 1H), 9.21 (t,7= 5.4 Hz, 1H), 9.06 (s, 1H), 8.73 (s, 2H), 7.88 (d, J = 8.1 Hz, 1H), 7.83-7.76 (m, 2H), 7.74-7.67 (m, 3H), 7.637.59 (m, 1H), 4.46 (d,7=4.9 Hz, 2H); |
1388 | 0 ° - «Μ N | A, 156,213 | 21 | 383.9 (W+l) | C18H13N3O 3S2 383.04 | ‘H NMR (DMSO-i/e, 400MHz): δ 11.05 (s, 1H), 9.31 (t, 7=6.3 Hz, 1H), 8.96 (s, 1H), 7.887.60 (m, 8H), 4.65 (d, 7=5.6 Hz, 2H); |
1381 | 0 ΝΗ ° J '=' Ν-Χ „ X; | A, 156,214 | 23 | 367.9 (M+l) | C18H43N3O 4S 367.06 | ‘H NMR (DMSO-76,400 MHz): δ 11.05 (s, 1H), 9.14 (t, 7= 5.6 Hz, 1H), 8.27 (s, 1H), 7.88 (dd,7= 8.2,1.5 Hz, 1H), 7.84-7.78 (m, 2H), 7.767.67 (m, 3H), 7.63 (dd, 7= 7.7,1.0 Hz, 1H), 7.04 (s, 1H), 4.51 (d,7 = 5.5 Hz, 2H); |
1423 | ο χ^Υ-ΝΗ Η 1 V-X Ρ Yks Ν ο - γ-α | B, 156,215 | 32 | 393.0 (Nf+1) | C20H16N4O 3S 392.09 | Ή NMR (DMSO-d6i400 MHz): δ 11.06 (s, 1H), 9.01 (s, 1H), 8.69 (t, 7= 5.6 Hz, 1H), |
248
8.66 (s, 2H), 7.84-7.77 (m, 3H), 7.74 (d, J = 7.0 Hz, 1H), 7.67 (d, 7=8.2 Hz, 1H), 7.657.60 (m, 2H), 3.53 (q, 7=6.3 Hz, 2H), 2.84 (t, 7= 6.6 Hz, 2H); | ||||||
1374 | Ο ί η ο Ν-7 | Α, 156,216 | 44 | 391.9 (Nf+1) | C2IHI7N3O 3S 391.10 | ‘H NMR (DMSO-76j400 MHz): δ 11.06 (s, 1H), 8.69 (t, 7= 5.6 Hz, 1H), 8.51-8.47 (m, 1H), 7.85-7.78 (m, 3H), 7.74 (d, 7= 6.9 Hz, 1H), 7.71-7.60 (m, 4H), 7.25 (d, 7= 7.7 Hz, 1H), 7.23-7.18 (m, 1H), 3.59 (q, 7= 6.5 Hz, 2H), 2.96 (t, 7= 7.3 Hz, 2H); |
1389 | 0 x^s/'NH ί jT . Ο ° ηΧ-Ο | Α, 156,217 | 21 | 391.9 (MAI) | C21H17N3O 3s 391.10 | ‘HNMR (DMSO-76>400 MHz): δ 11.06 (s, 1H), 8.69 (t, 7= 5.2 Hz, 1H), 8.44-8.37 (m, 2H), 7.84-7.72 (m, 4H), 7.707.60 (m, 4H), 7.29 (dd, 7= 7.5, 5.0 Hz, lH),3.49(q,7 = 6.5 Hz, 2H), 2.83 (t, 7= 7.0 Hz, 2H); |
1382 | 0 η Ί ρ IÎjA Ζ=\ AA/MJ 0 Η | Α, 156,185 | 8 | 363.9 (Μ+1) | c19h13n3o 3S 363.07 | ‘HNMR (DMSO-76,400 MHz): δ 11.13 (brs, 1H), 10.69 (s, 1H), 8.53-8.43 (m, 2H), 7.99 (dd, 7 = 8.1,1.5 Hz, 1H), 7.86-7.75 (m, 5H), 7.75- |
249
7.70 (m, 2H), 7.67-7.62 (m, 1H); | ||||||
1375 | Ο | Α, 156,186 | 33 | 439.5 (Μ*+1) | C26H18N2O 3S 438.10 | ‘H NMR (DMSO-J6,400 MHz): δ 11.13 (s, 1H), 10.44 (s, 1H), 8.077.98 (m, 2H), 7.87-7.72 (m, 6H), 7.68-7.60 (m, 3H), 7.527.35 (m, 5H); |
1427 | 0 ΝΗ Ρ kAsηΑγ^ν 0 X-sJ | Α, 156,218 | 19 | 377.9 (MY1); | C20H45N3O 3S 377.08 | Ή NMR (DMSO-d6,400 MHz): δ 11.05 (s, 1H), 9.21 (t, .7=5.9 Hz, 1H), 8.53 (s, 1H), 8.45 (dd,J= 4.7,1.4 Hz, 1H), 7.90 (dd, J = 8.2,1.5 Hz, 1H), 7.85-7.68 (m, 6H), 7.63 (td, .7=7.5,1.3 Hz, 1H), 7.34 (dd, J= Ί.1, 4.8 Hz, 1H), 4.47 (d, .7= 5.2 Hz, 2H); |
1485 | 0 _/~ΝΗ Ρ 0θ0Λ^ξ> ό | Α, 156,347 | 18 | 381.9 (Μ%1) | CiçHijNsO 4S 381.08 | ‘H NMR (DMSO-<4,400 MHz): δ 11.06 (s, 1H), 8.73 (t, J= 5.6 Hz, 1H), 8.21 (s, 1H), 7.85 -7.78 (m, 3H), 7.74 (dd, J = 9.5,2.7 Hz, 1H), 7.68 (d, J = 8.4 Hz, 2H), 7.63 (td, .7= 10.1,1.1 Hz, 1H), 6.92 (s, 1H), 3.53-3.46 (m, 2H), 2.90 (t, J= 6.7 Hz, 2H); |
1527 | 0 _/-ΝΗ 0 CmOR^ II ° 0 | Α, 156,352 | 24 | 397.8 (κΓ+ΐ) | C19HisN3O 3S2 397.06 | ‘H NMR (DMSO-tZ6,400 MHz): δ 11.07 (brs, 1H), 8.90 |
250
(s, 1H), 8.76 (t, 2= 5.5 Hz, 1H), 7.877.78 (m, 3H), 7.75 (d, 2 = 7.3 Hz, 1H), 7.71-7.67 (m, 3H), 7.66-7.60 (m, 1H), 3.523.45 (m, 2H), 3.10(1,2=6.7 Hz, 2H); | ||||||
1476 | δ | A, 156,219 | 29 | 467.0 (MM) | C28H22N2O 3S 466.14 | ‘H NMR (DMSO-26j400 MHz): δ 11.07 (s, 1H), 8.72 (t, 2= 5.4 Hz, 1H), 7.87-7.78 (m, 3H), 7.76-7.73 (m, 1H), 7.717.67 (m, 2H), 7.65-7.60 (m, 3H), 7.58 (d, 2 = 8.2 Hz, 2H), 7.47-7.41 (m, 2H), 7.36-7.29 (m, 3H), 3.50 (q, 2= 6.7 Hz, 2H), 2.86 (t, 2= 7.2 Hz, 2H); |
1486 | 0 NH 0 Γχ II 0 | A, 156,406 | 17 | 498.0 (M*+l) | C24H23N3O 5S2 497.11 | ‘H NMR (DMSO-X.400 MHz): δ 11.06 (s, 1H), 8.68 (t, 2= 5.5 Hz, 1H), 7.85-7.77 (m, 3H), 7.76-7.73 (m, 1H), 7.687.61 (m, 5H), 7.48 (d,2=8.4 Hz, 2H), 3.613.45 (m, 2H), 2.92 (t, 2= 7.0 Hz, 2H), 2.53 (s, 6H); |
1575 | 0, N H P Qs^ NH2 II 0 | B, 156,133 | 48 | 286.8 (M-+1) | Ci4H10N2O 3S 286.04 | ‘H-NMR DMSO-26,400 MHz): δ 11.05 (brs, 1H), 8.06 (brs, 1H), 7.937.58 (m, 7H), 7.52 (brs, 1H); |
251
1446 | 0 ΝΗ P 0 0 < hr | A, 159,212 | 38 | 395.0 (M*+l) | C19H14N4O 4S 394.07 | ‘H NMR (DMSO-<76,400 MHz): δ 11.51 (s, 1H), 9.34 (t, J= 5.8 Hz, 1H), 9.08 (s, 1H), 8.76 (s, 2H), 8.06 (d,J=8.2 Hz, 1H), 8.017.95 (m, 2H), 7.92-7.80 (m, 4H), 4.50 (d, J = 5.6 Hz, 2H); |
1455 | 0 -Χ- NH P pxppPh^\'s x ào y | A, 159,213 | 27 | 399.9 (Nf+1) | C18HI3N3O 4S2 399.03 | ‘H NMR (DMSO-tA 400 MHz): δ 11.50 (s, 1H), 9.42 (t, .7= 5.9 Hz, 1H), 8.97 (s, 1H), 8.05 (d,J=8.3 Hz, 1H), 7.98 (td, .7=7.4,1.1 Hz, 2H), 7.90 (td, J =7.5,1.4 Hz, 1H), 7.877.77 (m, 4H), 4.67 (d, .7=5.6 Hz, 2H); |
1456 | 0 VPsr'PP' hPt°\ â'o < υ u | A, 159,214 | 23 | 384.0 (ivrt+i) | C1SH13N3O 5S 383.06 | ‘H NMR (DMSO-<76,400 MHz): δ 11.51 (brs, 1H), 9.26 (t, J= 5.6 Hz, 1H), 8.29 (s, 1H), 8.05 (d, J = 8.3 Hz, 1H), 8.01-7.95 (m, 2H), 7.90 (td, J = 7.5,1.5 Hz, 1H), 7.88-7.78 (m, 3H), 7.06 (s, 1H), 4.53(d, J= 5.3 Hz, 2H); |
1457 | PPPPF^PLn 'zx' 0 0 | A, 159,215 | 32 | 409.0 (mU-1) | C20H16N4O 4S 408.09 | ‘H NMR (DMSO-îZ6, 400 MHz): δ 11.51 (s, 1H), 9.01 (s, 1H), 8.80 (t,J= 5.7 Hz, 1H), 8.67 (s, 2H), 8.03 (d, J= 8.2 Hz, 1H), 8.017.96 (m, 2H), |
252
7.94-7.82 (m, 2H), 7.76 (s, 1H), 7.71 (dd,J = 8.3,1.6 Hz, 1H), 3.55 (q, J = 6.3 Hz, 2H), 2.86 (t,J= 6.6 Hz, 2H); | ||||||
1447 | 0 Ο 0 | A,159,216 | 30 | 408.0 (MM) | C21H17N3O 4S 407.09 | Ή NMR (DMSO-îZ6, 400 MHz): δ 11.51 (s, 1H), 8.80 (t, J= 5.5 Hz, 1H), 8.51-8.48 (m, 1H), 8.03 (d, J = 8.3 Hz, 1H), 8.00-7.96 (m, 2H), 7.93-7.83 (m, 2H), 7.797.78 (m, 1H), 7.74 (dd,J= 8.3,1.6 Hz, 1H), 7.69 (td, J = 7.7,1.8 Hz, 1H), 7.26 (d, J = 7.7 Hz, 1H), 7.23-7.19 (m, 1H), 3.64-3.57 (m, 2H), 2.97 (t, J= 7.3 Hz, 2H); |
1448 | 0 _/-νη 9 VAs'A^'h^-'V-n 2>\' 0 0 | A, 159,217 | 22 | 407.9 (MM) | C^lHnNjO 4S 407.09 | ‘H NMR (DMSO-î?6, 400 MHz): δ 11.52 (s, 1H), 8.81 (t, J =5.6 Hz, 1H), 8.48-8.36 (m, 2H), 8.03 (d, J = 8.3 Hz, 1H), 8.01-7.95 (m, 2H), 7.93-7.83 (m, 2H), 7.797.78 (m, 1H), 7.73 (dd,J= 8.3,1.5 Hz, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.29 (dd, .7= 7.8,4.7 Hz, 1H), 3.51 (q, J = 6.5 Hz, 2H), 2.85 (t, J= 7.0 Hz, 2H); |
253
1449 | 0 _/“NH /? 0 0 \ J hr | A,159,218 | 15 | 393.9 (M*+l) | C20H15N3O 4S 393.08 | Ή NMR (DMSO-d6,400 MHz): δ 11.49 (brs, 1H), 9.33 (t, 7= 5.5 Hz, 1H), 8.60-8.39 (m, 2H), 8.05 (d, 7= 8.2 Hz, 1H), 8.02-7.94 (m, 2H), 7.937.81 (m, 4H), 7.70 (d, 7=7.7 Hz, 1H), 7.34 (dd,7=7.6,4.8 Hz, 1H), 4.49 (d, 7= 5.5 Hz, 2H); |
1462 | 0 H 0 0 | A, 159,185 | 15 | 379.9 (M*+l) | cI9hI3n3o 4S 379.06 | ‘H NMR (DMSO-φ, 400 MHz): δ 11.60 (s, 1H), 10.80 (s, 1H), 8.50 (d, 7= 6.1 Hz, 2H), 8.13 (d, 7= 8.2 Hz, 1H), 8.01 (td, 7=7.9,1.0 Hz, 2H), 7.967.84 (m, 4H), 7.73 (d, 7=6.3 Hz, 2H); |
1458 | 0 NH /? ζΓ/Ν-χΙ VVV H oo θ | A, 159,186 | 33 | 455.0 (ΜΑ-l) | C26H18N2O 4S 454.10 | ‘H NMR (DMSO-d6,400 MHz): δ 11.57 (s, 1H), 10.53 (s, 1H), 8.10 (d, 7= 8.2 Hz, 1H), 8.04- 7.96 (m, 3H), 7.95-7.82 (m, 4H), 7.73 (d, 7= 7.6 Hz, 1H), 7.66-7.56 (m, 2H), 7.507.33 (m, 5H); |
1616 | 0 / NH /9 (Xda^On fj 'k 0 0 | A, 159, 347 | 9 | 398.0 (MAI) | c19hI5n3o 5S 397.07 | ‘H NMR (DMSO-70,400 MHz): δ 11.52 (s, 1H), 8.84 (t, 7= 5.7 Hz, 1H), 8.22 (s, 1H), 8.04 (d, 7=8.2 Hz, 1H), 8.007.96 (m, 2H), 7.91 (dd,7= |
254
7.4,1.5 Hz, 1H), 7.89-7.79 (m, 2H), 7.74 (dd, 7=8.3,1.5 Hz, 1H), 6.92 (s, 1H), 3.51 (q, 7= 6.5 Hz, 2H), 2.92 (t, 7= 6.8 Hz, 2H). | ||||||
1617 | 0 >-ΝΗ 0 0 0 | A, 159,352 | 44 | 414.0 (M*+l) | c19h15n3o 4S2 413.05 | ‘H NMR (DMSO-7d,400 MHz): δ 11.53 (s, 1H), 8.91 (s, 1H), 8.87 (t, 7= 5.5 Hz, 1H), 8.05 (d,7=8.3 Hz, 1H), 8.017.96 (m, 2H), 7.92-7.83 (m, 2H), 7.81 (s, 1H), 7.76 (dd, 7 = 8.3,1.4 Hz, 1H), 7.69 (s, lH),3.50(q,7 = 6.0 Hz, 2H), 3.11 (t, 7= 6.6 Hz, 2H); |
1618 | H 0 0 | B, 159,219 ( Reaction time 24 h) | 50 | 481.1 (MM) | C28H22N2O 4S 482.13 | ‘H NMR (DMSO-7d>400 MHz): δ 11.49 (brs, 1H), 8.83 (t, 7= 5.4 Hz, 1H), 8.04 (d, 7 = 8.3 Hz, 1H), 8.00-7.95 (m, 2H), 7.93-7.80 (m, 3H), 7.76 (dd,7=8.3,1.4 Hz, 1H), 7.647.61 (m, 2H), 7.58 (d, 7= 8.3 Hz, 2H) 7.44 (t, 7= 7.6 Hz, 2H), 7.36-7.30 (m, 3H), 3.52 (q, 7 = 6.5,2H), 2.87 (t, 7= 7.1 Hz, 2H); |
1619 | 0 / NH /? η H Ά 0 0 | A, 159,406 | 25 | 514.0 (Μ*+1) | C24H23N3O 6¾ 513.10 | ‘H NMR (DMSO-7d,400 MHz): δ 11.52 (brs, 1H), 8.80 (t, 7= 5.2 Hz, |
255
1H), 8.03 (d, J = 8.2 Hz, 1H), 8.01-7.96 (m, 2H), 7.93-7.82 (m, 2H), 7.77 (s, lH),7.72(d, J= 8.2 Hz, 1H), 7.65 (d, 7=8.2 Hz, 2H), 7.49 (d, 7= 8.2 Hz, 2H), 3.59-3.49 (m, 2H), 2.94 (t, 7= 6.8 Hz, 2H), 2.54 (s, 6H). | ||||||
1620 | 0 NH /? 0 0 | A, 159, 254 | 39 | 392.9 (MM) | C21Hi6N2O 4S 392.08 | ‘H NMR (DMSO-A.400 MHz): δ 11.44 (brs, 1H), 9.27 (t,7=5.9 Hz, 1H), 8.05 (d, 7 = 8.2 Hz, 1H), 7.98 (td, 7= 7.7,1.4, Hz, 2H), 7.93-7.82 (m, 4H), 7.357.28 (m, 4H), 7.27-7.21 (m, 1H), 4.47 (d, 7 = 6.1 Hz, 2H); |
1621 | 0 NH /? 0 0 \-/ | A, 159,255 | 42 | 406.9 (MM) | C22H18N2O 4S 406.10 | ‘H NMR (DMSO-7i,400 MHz): δ 11.45 (brs, 1 H), 9.24 (t, 7= 5.9 Hz, 1H), 8.05 (d, 7 = 8.2 Hz, 1H), 7.98 (td,7= 7.7,1.1 Hz, 2H), 7.93-7.81 (m, 4H), 7.227.18 (m, 1H), 7.13-7.04 (m, 3H), 4.43 (d, J = 5.6 Hz, 2H), 2.27 (s, 3H); |
1622 | O V-NH o O O < J | A, 159,256 | 29 | 411.0 (MM) | C2iHi5FN2 O4S 410.07 | ‘H NMR (DMSO-<4400 MHz): δ 11.26 (brs, 1H), 9.31 (t, 7= 6.0 Hz, 1H), 8.06 (d, 7 = 8.2 Hz, 1H), 7.98 (td, 7= |
256
7.8,1.3 Hz, 2H), 7.93-7.83 (m, 4H), 7.36 (td, .7=7.8, 6.3 Hz, 1H), 7.167.04 (m, 3H), 4.48 (d, .7=6.0 Hz, 2H); | ||||||
1623 | 0 P 0 0 \=S=Z F | A, 159,257 | 43 | 411.0 (M*+l) | c2Ih15fn2 o4s 410.07 | ‘H NMR (DMSO-^,400 MHz): δ 11.49 (brs, 1H), 9.26 (t, J= 5.9 Hz, 1H), 8.04 (d,J = 8.3 Hz, 1H), 8.00-7.94 (m, 2H), 7.92-7.78 (m, 4H), 7.34 (dd, J= 8.7, 5.6 Hz, 2H), 7.187.10 (m, 2H), 4.44 (d, .7=5.9 Hz, 2H); |
1624 | 0 /Ί~ΝχΧ hAtMocf3 0 0 Xssy | A, 159,258 | 21 | 476.9 (M*+l) | c22h15f3n 2OsS 476.07 | ‘H NMR (DMSO-rfd, 400 MHz): δ Π.52 (s, 1H), 9.34 (t, J= 5.9 Hz, 1H), 8.07 (d, .7=8.2 Hz, 1H), 8.017.96 (m, 2H), 7.93-7.82 (m, 4H), 7.46 (t,J= 7.9 Hz, 1H), 7.33 (d, .7=7.7 Hz, 1H), 7.307.22 (m, 2H), 4.51 (d,J=5.9 Hz, 2H) |
1634 | 0 / NH /9 ς XA'sAA H N 0 0 | G, 159,231 | 11 | 385.8 (MM) | C17HnN3O 4S2 385.02 | ‘H NMR (DMSO-A.400 MHz): δ 12.90 (brs, 1H), 11.61 (s, 1H), 8.12-7.98 (m, 5H), 7.96-7.84 (m, 2H), 7.58 (d, .7= 3.7 Hz, 1H), 7.31 (d,J = 3.0 Hz, 1H); |
257
1635 | Ο _/-ΝΗ /? ο Ο \ —/ Ό | A, 159, 377 | 32 | 471.0 (IVT+l) | C25HI8N4O 4S 470.10 | ‘HNMR (DMSO-iZd,500 MHz): δ 11.51 (s, 1H), 9.35 (t, J= 5.7 Hz, 1H), 8.85 (s, 2H), 8.39-8.35 (m, 2H), 8.06 (d, J = 8.2 Hz, 1H), 8.01-7.95 (m, 2H), 7.92-7.81 (m, 4H), 7.547.49 (m, 3H), 4.53 (d, .7=5.5 Hz, 2H); |
1646 | J’ 9°2'β%=\ ΑΟΛ-Η) //V 0 0 | A, 159,259 | 36 | 505.3 (M-l)+ | C27H26N2O 6S 506.15 | ‘HNMR (DMSO-dd,4°0 MHz): δ 11.52 (s, 1H), 8.99 (br s, 1H), 8.05 (d, J= 8.5 Hz, 1H), 8.01-7.96 (m, 2H), 7.93-7.83 (m, 2H), 7.797.73 (m, 2H), 7.26 (d, .7=4.8 Hz, 4H), 7.217.16 (m, 1H), 4.54 (brs, 1H), 3.14-2.98 (m, 2H), 1.34 (s, 9H); |
1625 | 0 _Jr- ΝΗ ο d'b θ | A, 159,176 | 18 | 423.0 (M*+l) | C22Hi8N2O 5S 422.09 | ‘HNMR (DMSO-dtf ,400 MHz): δ 11.48 (brs, 1H), 8.94 (t, 7= 5.4 Hz, 1H), 8.04 (d, J = 8.3 Hz, 1H), 8.01-7.95 (m, 2H), 7.93-7.78 (m,4H), 7.317.24 (m, 2H), 6.97-6.89 (m, 3H), 4.10 (t, 7= 5.7 Hz, 2H), 3.63 (q,7=5.6 Hz, 2H); |
1647 | 0 _Jr-NH P Qs^^o. °° | A, 159,265 | 29 | 440.9 (M+l) | C22H]7FN2 O5S 440.08 | ‘HNMR (DMSO-7d,400 MHz): δ 1’1.51 (s, 1H), 8.92 (s, 1H), 8.04 (d,7 |
258
= 8.2 Hz, 1H), 7.98 (td, J= 7.5, 0.9 Hz, 2H), 7.93-7.77 (m,4H), 7.10 (t, J= 9.3 Hz, 2H), 7.00-6.91 (m, 2H), 4.08 (t, 7= 5.5 Hz, 2H), 3.61 (q, 7=5.6 Hz, 2H); | ||||||
1648 | ο. /~NH ,9 ς ZCI CQOAA 0 0 | A, 159, 253 | 18 | 419.8 (M*+l) | c17h10cin 3O4S2 418.98 | ‘H NMR (DMSO-7d400 MHz): δ 13.19 (brs, 1H), 11.62 (s, 1H), 8.10 (d, 7= 8.2 Hz, 1H), 8.077.97 (m, 4H), 7.95-7.85 (m, 2H), 7.63 (s, 1H); |
1627 | 0 _/“NH /? QsjOÎrQ ry tx | A, 159, 372 | 16 | 471.0 (M+l) | C25H1SN4O 4S 470.10 | ‘hnmr (DMSO-7d 400 MHz): δ 11.52 (s, 1H), 9.34 (t, J= 5.9 Hz, 1H), 9.17 (s, 1H), 9.12 (s, 2H), 8.07 (d,7=8.2 Hz, 1H), 7.99 (td, 7=7.8,1.1 Hz, 2H), 7.947.83 (m, 4H), 7.77 (d, 7=8.3 Hz, 2H), 7.46 (d, 7= 8.2 Hz, 2H), 4.53 (d, 7 = 5.7 Hz, 2H); |
1637 | Q. c >-NH P rx .xyMjG 0 0 | H, 159, 241 | 47 | 453.9 (M+l) | C21H12FN3 C>4S2 453.03 | ‘HNMR (DMSO-7d>400 MHz): δ 13.22 (brs, 1H), 11.63 (s, 1H), 8.15-8.08 (m, 2H), 8.06-7.98 (m, 3H), 7.987.84 (m, 3H), 7.79 (dd, 7= 7.9,4.8 Hz, 1H), 7.33 (td,7 = 8.9,2.4 Hz, |
259
1H); | ||||||
1649 | ΧΧχχΡ rvci XX, -Ajn Xi-® 0 0 | C, 159, 235 | 27 | 413.8 (JVf+l) | CI9Hi2C1N 3O4S 413.02 | Ή NMR (DMSO-îÎ5,400 MHz): δ 11.56 (brs, 1H), 11.26 (brs, 1H), 8.46 (brs, 1H), 8.20 (d, J = 8.7 Hz, 1H), 8.10-7.83 (m, 8H); |
1628 | 0 _/- NH o (X --O*Xa /c°2CH3 db H θ | A, 159, 519 | 32 | 513.0 (nT+i) | C28H20N2O 6S 512.10 | ‘H NMR (DMSO-7tf,400 MHz): δ 1’1.57 (brs, 1H), 10.54 (s, 1H), 8.11 (d, 7=8.3 Hz, 1H), 8.00 (td, 7=9.0,1.0 Hz, 2H), 7.957.84 (m, 4H), 7.76- 7.72 (m, 3H), 7.64 (td, 7 = 9.1,1.5 Hz, 1H), 7.50 (td, 7 = 7.6,1.3 Hz, 1H), 7.46- 7.39 (m, 2H), 7.087.03 (m, 1H), 3.61 (s, 3H); |
1629 | 0 NXxf /55^ z Λ h^<3n | A, 159,246 (Reaction time RT-18 h) | 31 | 455.9 (Nf+1) | C2SHI7N3O 4S 455.09 | ‘H NMR (DMSO-7s,400 MHz): δ 1’1.60 (s, 1H), 10.60 (s, 1H), 8.86 (br s, 1H), 8.60 (d, 7= 3.7 Hz, 1H), 8.13 (d, 7=8.3 Hz, 1H), 8.08 (s, 1H), 8.067.98 (m, 3H), 7.97-7.85 (m, 4H), 7.81 (d,7 = 6.7 Hz, 1H), 7.55-7.48 (m, 3H); |
1520 | 0 _Ρ“ΝΗ /9 CXXuηΛ^ν ch3 | A, 164,212 | 25 | 360.2 (Kf+1) | C2oHI7N50 2 359.14 | ‘H NMR (DMSO-76,400 MHz): δ 10.28 (s, 1H), 9.07 (s, 1H), 9.01 (t, 7= 5.7 Hz, 1H), |
260
8.74 (s, 2H), 7.66-7.60 (m, 2H), 7.56 (s, 1H), 7.53-7.47 (m, 1H), 7.26 (d, 7= 8.6 Hz, 1H), 7.20 (d,7 = 8.0 Hz, 1H), 7.10 (t, 7= 7.2 Hz, 1H), 4.47 (d, 7= 5.6 Hz, 2H), 3.29 (s, 3H); | ||||||
1581 | 0 h~Ats\ Au O ϋΠ3 | A,164,213 | 10 | 365.0 (ΝΓ+1) | CijHieNiO 2s 364.10 | 'HNMR (DMSO-76>500 MHz): δ 10.26 (s, 1H), 9.05 (t, 7= 5.7 Hz, 1H), 8.93 (s, 1H), 7.77 (s, 1H), 7.66-7.44 (m, 4H), 7.20 (dd, 7 = 18.1, 8.2 Hz, 2H), 7.08 (t, 7= 7.4 Hz, 1H), 4.62 (d,7=5.6 Hz, 2H), 3.28 (s, 3H); |
1547 | 0 Z A | A, 164,214 | 25 | 348.9 (&Γ+1) | C19H16N4O 3 348.12 | ); ‘HNMR (DMSO-76,400 MHz): δ 10.28 (s, 1H), 8.90 (t, 7= 5.6 Hz, 1H), 8.27 (s, 1H), 7.66-7.59 (m, 2H), 7.55 (s, 1H), 7.52-7.47 (m, 1H), 7.24 (d, 7= 8.5 Hz, 1H), 7.20 (d, 7 = 7.9 Hz, 1H), 7.10 (t, 7= 7.5 Hz, 1H), 7.02 (s, lH),4.50(d, 7= 5.3 Hz, 2H), 3.30 (s, 3H); |
1548 | MpAA h ch3 | A, 164,215 | 29 | 374.0 (MX1) | C2iH19N5O 2 373.15 | ‘HNMR (DMSO-<76,400 MHz): δ 10.28 (s, 1H), 9.01 (s, 1H), 8.65 (s, 2H), 8.46 (t,7= 5.7 Hz, 1H), |
261
7.63 (dd,7= 7.7.1.6 Hz, 1H), 7.53-7.47 (m, 3H), 7.21 (dd, 7=11.2, 8.3 Hz, 2H), 7.10 (t, 7= 7.5 Hz, 1H), 3.52 (q, 7= 6.4 Hz, 2H), 3.29 (s, 3H), 2.85 (t, 7= 6.6 Hz, 2H); | ||||||
1498 | 0 NH 0 N H NX ch3 | A, 164, 216 | 21 | 373.0 (Nf+1) | C22H20N4O 2 372.16 | ‘H NMR (DMSO-7<5,4°0 MHz): δ 10.29 (s, 1H), 8.50 (d, 7= 4.0 Hz, 1H), 8.46 (t, 7= 5.4 Hz, 1H), 7.69 (td, 7=7.6,1.9 Hz, 1H), 7.64 (dd, 7=7.7,1.7 Hz, 1H), 7.577.47 (m, 3H), 7.27-7.18 (m, 4H), 7.10 (t, 7= 7.2 Hz, 1H), 3.57 (q, 7=7.0 Hz, 2H), 3.30 (s, 3H), 2.96 (t, J= 7.3 Hz, 2H); |
1549 | 0 0 | A, 164,217 | 27 | 373.0 (M*+l) | C22H20N4O 2 372.16 | ‘H NMR (DMSO-76,400 MHz): δ 10.29 (s, 1H), 8.488.42 (m, 2H), 8.40 (dd, 7= 4.7,1.5 Hz, 1H), 7.63 (dd, 7 = 7.7,1.6 Hz, 2H), 7.57 -7.45 (m, 3H), 7.29 (dd,7=7.7,4.8 Hz, 1H), 7.21 (dd,7=11.0, 8.4 Hz, 2H), 7.10 (t, 7= 7.4 Hz, 1H), 3.48 (q, 7=7.1 Hz, 2H), 3.30 (s, 3H), 2.84 (t, 7= 7.0 Hz, 2H); |
262
1532 | Ο ✓-U'ΝΗ /? Ci ch3 | A, 164,352 | 24 | 378.0 (MY1); | c20h18n4o 2S 378.12 | ‘H NMR (DMSO-îZ6>400 MHz): δ 10.30 (s, 1H), 8.91 (s, 1H), 8.53 (t,J= 5.7 Hz, 1H), 7.69 (s, 1H), 7.64 (dd, J= 7.7.1.7 Hz, 1H), 7.57 (dd, J = 8.4,2.0 Hz, 1H), 7.54-7.47 (m, 2H), 7.22 (dd, .7=16.5, 8.1 Hz, 2H), 7.10 (t, J= 7.1 Hz, 1H), 3.47 (q, J— 6.8 Hz, 2H), 3.31 (s, 3H),3.10(t,J= 6.7 Hz, 2H); |
1499 | 0 ™3 v | A, 164,218 | 30 | 358.9 (M*+l) | c2Ih18n4o 2 358.14 | ‘H NMR (DMSO-6/6,400 MHz): δ 10.29 (s, 1H), 8.98 (t, J= 5.8 Hz, 1H), 8.51 (s, 1H), 8.44 (dd,J= 4.8,1.6 Hz, 1H), 7.68 (tt, J = 7.9,1.9 Hz, 1H), 7.63 (tt, J = 8.0,1.9 Hz, 2H), 7.57 (s, 1H), 7.53-7.47 (m, 1H), 7.34 (dd, J= 7.3,4.8 Hz, 1H), 7.25 (d, .7=8.5 Hz, lH),7.20(d,J = 8.0 Hz, 1H), 7.10 (t,J= 7.1 Hz, 1H), 4.46 (d, .7=5.9 Hz, 2H), 3.30 (s, 3H); |
1521 | cz^~ ch3 | A, 164,219 | 36 | 448.1 (M*+i) | 029Η25Ν3Ο 2 447.19 | ‘H NMR (DMSO-d6,500 MHz): δ 10.28 (s, 1H), 8.47 (t, J= 5.4 Hz, 1H), 7.65-7.54 (m, 6H), 7.52 (s, |
263
1H), 7.48 (t, 7= 7.8 Hz, 1H), 7.43 (t,7=7.7 Hz, 2H), 7.357.28 (m, 3H), 7.20 (dd, 7= 16.8, 8.4 Hz, 2H), 7.08 (t, 7= 7.5 Hz, 1H), 3.47 (q, 7=6.4 Hz, 2H), 3.28 (s, 3H), 2.84 (t, 7= 7.2 Hz, 2H); | ||||||
1533 | ο CAnPJ/ ηΑγ^ν | Ac, 167,212 (c = Reaction Time 12 hRT) | 19 | 373.9 (M'Ai); | c21h19n5o 2 373.15 | ‘H NMR (DMSO-76>400 MHz): δ 10.29 (s, 1H), 9.07 (s, 1H), 9.02 (t,7= 5.7 Hz, 1H), 8.74 (s, 2H), 7.65-7.55 (m, 3H), 7.52-7.46 (m, 1H), 7.25 (d, J =8.5 Hz, 1H), 7.20 (d, J = 8.2 Hz, 1H), 7.11 (t, .7=7.4 Hz, 1H), 4.46 (d, 7= 5.6 Hz, 2H), 3.83-3.75 (m, 2H), 1.12 (t, J= 6.9 Hz, 3H); |
1534 | 0 _/-νη /? à | Ae, 167,213 | 22 | 378.9 (MAi) | C20H18N4O 2S 378.12 | ‘H NMR (DMSO-76j400 MHz): δ 10.29 (s, 1H), 9.07 (t, 7= 5.9 Hz, 1H), 8.95 (s, 1H), 7.79 (s, 1H), 7.63-7.54 (m, 3H), 7.52-7.46 (m, 1H), 7.24 (d, 7= 8.5 Hz, 1H), 7.20 (d, 7 = 8.0 Hz, 1H), 7.10 (t, 7= 7.2 Hz, 1H), 4.64 (d, 7= 5.7 Hz, 2H), 3.84-3.75 (m, 2H), 1.12 (t, 7= 7.0 Hz, 3H); |
264
1564 | 0 /? à V | Ac, 167,214 | 31 | 363.0 (M%1) | C20H18N4O 3 362.14 | ‘HNMR (DMSO-d6i400 MHz): δ 10.29 (s, 1H), 8.90 (t, J= 5.6 Hz, 1H), 8.27 (s, 1H), 7.63-7.55 (m, 3H), 7.52-7.47 (m, 1H), 7.24 (d, J =8.5 Hz, 1H), 7.20 (d,7 = 8.2 Hz, 1H), 7.11 (t, 7=7.3 Hz, 1H), 7.01 (s, 1H), 4.50 (d, 7= 5.4 Hz, 2H), 3.83-3.76 (m, 2H), 1.12 (t, 7= 7.0 Hz, 3H); |
1565 | Èt | Ac, 167, 215 | 36 | 388.0 (M++l) | C22H21N5O 2 387.17 | ‘HNMR (DMSO-76,500 MHz): δ 10.27 (s, 1H), 8.99 (s, 1H), 8.64 (s, 2H), 8.44 (t, 7= 5.4 Hz, 1H), 7.58 (d,7=6.7 Hz, 1H), 7.527.45 (m, 3H), 7.19 (dd, 7= 14.6, 8.2 Hz, 2H), 7.08(1,7= 7.5 Hz, 1H), 3.81-3.72 (m, 2H), 3.50 (q, 7 = 6.1 Hz, 2H), 2.83 (t, 7= 6.7 Hz, 2H), 1.10 (t,7= 6.9 Hz, 3H); |
1522 | 0 CXm-C/ü'^O Et | Ac, 167,216 | 29 | 387.0 (MM) | C23H22N4O 2 386.17 | 'HNMR (DMSO-76,400 MHz): δ 10.29 (s, 1H), 8.49 (d, 7= 4.1 Hz, 1H), 8.45 (t, 7= 5.3 Hz, 1H), 7.69 (td, 7=7.7,1.8 Hz, 1H), 7.60 (dd, 7= 7.7,1.6 Hz, 1H), 7.577.47 (m, 3H), 7.27-7.18 (m, |
265
4H), 7.10(1,/= 7.4 Hz, 1H), 3.83-3.74 (m, 2H),3.57(q,/ = 6.9 Hz, 2H), 2.96 (t,/= 7.3 Hz, 2H), 1.12 (t,/= 6.9 Hz, 3H); | ||||||
1523 | Ο ΝΗ χ έΛ^-χ-Q | Ae, 167,217 | 36 | 387.0 (MX) | C23H22N4O 2 386.17 | ‘H NMR (DMSO-/6,500 MHz): δ 10.28 (s, 1H), 8.478.34 (m, 3H), 7.65-7.56 (m, 2H), 7.54-7.45 (m, 3H), 7.28 (dd, /= 7.5,4.9 Hz, 1H), 7.19 (dd,/= 13.7, 8.2 Hz, 2H), 7.09 (t,/=7.2 Hz, 1H), 3.76 (brs, 2H), 3.46 (q,/=6.7Hz, 2H), 2.82(1,/= 7.1Hz, 2H), 1.10(1,/=6.9 Hz, 3H); |
1566 | ο / ΝΗ /? ΓΧ ΧνΧ Η Et | Ac, 167,352 | 36 | 393.1 (MX) | C21H20N4O 2s 392.13 | ‘H NMR (DMSO-/6,500 MHz): δ 10.29 (s, 1H), 8.89 (s, 1H), 8.51 (t,/= 5.4 Hz, 1H), 7.67 (s, 1H), 7.61-7.43 (m, 4H), 7.22 (d,/ = 8.4 Hz, 1H), 7.18 (d,/= 8.1 Hz, 1H), 7.09 (t,/= 7.4 Hz, 1H), 3.82-3.74 (m, 2H), 3.45 (q,/= 6.5 Hz, 2H), 3.08 (t,/= 6.7 Hz, 2H), 1.11(1,/=6.8 Hz, 3H); |
266
1550 | 0 /? ει V | Ac, 167,218 | 30 | 373.1 CvT+1) | C22H20N4O 2 372.16 | 'HNMR (DMSO-de 400 MHz): δ 10.29 (s, 1H), 8.98 (t, 7= 5.9 Hz, 1H), 8.52 (s, 1H), 8.44 (dd,7= 4.7,1.6 Hz, 1H), 7.68 (dt, J = 7.9,1.8 Hz, 1H), 7.65-7.56 (m, 3H), 7.49 (td, 7= 7.7,1.7 Hz, 1H), 7.367.32 (m, 1H), 7.25 (d,7=8.5 Hz, 1H), 7.20 (d, 7= 7.9 Hz, 1H), 7.10 (td, 7 = 7.5, 0.8 Hz, 1H), 4.46 (d, 7 = 5.7 Hz, 2H), 3.82-3.75 (m, 2H), 1.12 (t, 7= 7.0 Hz, 3H); |
1524 | cz^- Et | Ac, 167,219 | 15 | 462.1 (M*+l) | C30H27N3O 2 461.21 | ‘HNMR (DMSO-rffii400 MHz): δ 10.30 (s, 1H), 8.48 (t, 7= 5.5 Hz, 1H), 7.68-7.41 (m, 10H), 7.36-7.29 (m, 3H), 7.21 (dd, 7= 13.5, 8.3 Hz, 2H), 7.10 (t, 7= 7.5 Hz, 1H), 3.823.75 (m, 2H), 3.48 (q,7=6.9 Hz, 2H), 2.86 (t,7= 7.2 Hz, 2H), 1.12 (t, 7= 6.9 Hz, 3H); |
1482 | O NH J W'nAt'nJpN έη V | A, 170,212 | 36 | 436.1 (Nf+1) | C26H21N5O 2 435.17 | ‘HNMR (DMSO-76 500 MHz): δ 10.36 (s, 1H), 9.06 (s, 1H), 8.97 (t, 7= 5.8 Hz, 1H), 8.72 (s, 2H), 7.61 (dd,7= 7.7,1.3 Hz, 1H), 7.57-7.51 |
267
(m, 2H), 7.47- 7.39 (m, 3H), 7.33 (d, .7=8.4 Hz, 1H), 7.30- 7.23 (m, 3H), 7.15 (t, .7= 7.8 Hz, 1H), 7.08 (t, J= 7.4 Hz, 1H), 5.03 (s, 2H), 4.44 (d,J = 5.5 Hz, 2H); | ||||||
1510 | 0 h^)Ts\ έ„ y | A, 170, 213 | 20 | 441.1 (mM) | c23h20n4o 2s 440.13 | Ή NMR (DMSO-d6,400 MHz): δ 10.37 (s, 1H), 9.04 (t, J= 5.8 Hz, 1H), 8.94 (s, 1H), 7.77 (s, 1H), 7.61 (dd,J= 7.7,1.6 Hz, 1H), 7.56 (s, 1H), 7.50 (dd, J = 8.5,1.9 Hz, 1H), 7.47-7.39 (m, 3H), 7.32 (d, .7= 8.6 Hz, 1H), 7.29-7.22 (m, 3H), 7.14 (t, J= 7.2 Hz, 1H), 7.08 (t,J= 7.3 Hz, 1H), 5.03 (s, 2H), 4.61 (d, J= 5.6 Hz, 2H); |
1492 | O V^N-Âss^iTArQ If | A, 170,214 | 35 | 425.1 (MM) | C2sH2oN40 3 424.15 | ‘H NMR (DMSO-d6,400 MHz): δ 10.37 (s, 1H), 8.87 (t, J= 5.6 Hz, 1H), 8.25 (s, 1H), 7.61 (dd, J= 7.7,1.6 Hz, 1H), 7.55 (s, 1H), 7.51 (dd, J = 8.4,2.0 Hz, 1H), 7.47-7.39 (m, 3H), 7.32 (d, .7= 8.5 Hz, 1H), 7.30-7.23 (m, 3H), 7.177.12 (m, 1H), 7.08 (t,J= 7.2 Hz, 1H), 7.00 (s, 1H), 5.03 (s, |
268
2H), 4.47 (d, J = 5.4 Hz, 2H); | ||||||
1464 | 0 μη P N A A A/ n'vX 1 Bn | A, 170,215 | 16 | 450.1 (MM) | C27H23N5O 2 449.19 | ‘H NMR (DMSO-26>400 MHz): δ 10.36 (s, 1H), 9.01 (s, 1H), 8.64 (s, 2H), 8.42 (t, 2= 5.5 Hz, 1H), 7.60 (dd, 2= 7.7,1.6 Hz, 1H), 7.49-7.38 (m, 5H), 7.337.21 (m, 4H), 7.15 (t, 2= 7.1 Hz, 1H), 7.08 (t, 2= 7.4 Hz, 1H), 5.02 (s, 2H), 3.49 (q, J = 6.4 Hz, 2H), 2.82 (t, 2= 6.7 Hz, 2H); |
1474 | 0 NH P CanXjSi^^O Bn | A, 170,216 | 38 | 449.1 (ivT+i) | C28H24N4O 2 448.19 | Ή NMR (DMSO-26.500 MHz): δ 10.35 (s, 1H), 8.47 (d, 2= 3.8 Hz, 1H), 8.41 (t, 2=5.4 Hz, 1H), 7.687.64 (m, 1H), 7.59 (d, 2= 7.8 Hz, 1H), 7.527.49 (m, 1H), 7.47-7.37 (m, 4H), 7.31-7.17 (m, 6H), 7.167.11 (m, 1H), 7.07 (t, 2= 7.2 Hz, 1H), 5.01 (s, 2H), 3.53 (q, 2= 6.7 Hz, 2H), 2.92 (t, 2= 7.2 Hz, 2H); |
1475 | 0 Bn h\—Q | A, 170, 217 | 38 | 449.1 (IVC+l) | C28H24N4O 2 448.19 | ‘H NMR (DMSO-26i500 MHz): δ 10.36 (s, 1H), 8.438.39 (m, 2H), 8.37 (dd,2= 4.6,1.2 Hz, 1H), 7.75-7.54 (m, 2H), 7.49 (s, 1H), 7.46- |
269
7.36 (m, 4H), 7.33-7.21 (m, 5H), 7.18-7.10 (m, 1H), 7.06 (t, 7= 7.4 Hz, 1H), 5.01 (s,2H), 3.47-3.41 (m, 2H), 2.80 (t, 7= 6.9 Hz, 2H); | ||||||
1559 | ο CL ΧΎΆ-Π ΖΖ ίΖ H 'rZ Bn | A, 170,347 | 20 | 439.1 (M++l) | C26H22N4O 3 438.17 | ‘HNMR (DMSO-î4,4°0 MHz): δ 10.37 (s, 1H), 8.47 (t, 7= 5.6 Hz, 1H), 8.20 (s, 1H), 7.61 (dd,7= 7.7,1.6 Hz, 1H), 7.51 (s 1H), 7.47-7.40 (m, 4H), 7.337.23 (m, 4H), 7.18-7.12 (m, 1H), 7.08 (t, 7= 7.4 Hz, 1H), 6.90 (s, 1H), 3.46 (q, 7=6.6 Hz, 2H), 2.88 (t,7= 6.8 Hz, 2H); |
1511 | 0 5^NH /? cl Vnx ZJ H '-'S- Bn | A, 170, 352 | 32 | 455.0 (M+l) | C26H22N4O 2S 454.15 | ‘HNMR (DMSO-76,500 MHz): δ 10.37 (s, 1H), 8.89 (s, 1H), 8.49 (t, 7= 5.5 Hz, 1H), 7.66 (s, 1H), 7.60 (dd, 7= 7.7,1.3 Hz, 1H), 7.52 (s, 1H), 7.49-7.38 (m, 4H), 7.31 (d, 7= 8.7 Hz, 1H), 7.28-7.22 (m, 3H), 7.14 (t, 7= 7.2 Hz, 1H), 7.07 (t, 7= 7.4 Hz, 1H), 5.02 (s, 2H), 3.43 (q, 7= 6.5 Hz, 2H), 3.06 (t, 7= 6.7 Hz, 2H); |
270
1493 | 0 X-nh P Bn | A, 170,218 | 16 | 434.1 (M*+l) | C27H22N4O 2 434.17 | ‘H NMR (DMSO-76j400 MHz): δ 10.37 (s, 1H), 8.95 (t, 7= 5.9 Hz, 1H), 8.51-8.49 (m, 1H), 8.43 (dd, 7 = 4.8,1.6 Hz, 1H), 7.66 (td, 7 = 7.5,1.7 Hz, 1H), 7.61 (dd, 7 = 7.7,1.7 Hz, 1H), 7.58-7.52 (m, 2H), 7.477.38 (m, 3H), 7.35-7.22 (m, 5H), 7.18-7.12 (m, 1H), 7.08 (t, 7= 7.1 Hz, 1H), 5.03 (s, 2H), 4.43 (d, 7= 5.7 Hz, 2H); |
1483 | 0 lAnX 1 Bn | A, 170,219 | 20 | 524.3 (MM) | C35H29N3O 2 523.23 | ‘H NMR (DMSO-76.500 MHz): δ 10.38 (s, 1H), 8.45 (t, 7= 5.5 Hz, 1H), 7.66-7.52 (m, 6H), 7.51-7.39 (m, 6H), 7.377.23 (m, 7H), 7.18-7.13 (m, 1H), 7.08 (t, 7= 7.4 Hz, 1H), 5.03 (s, 2H), 3.49-3.43 (m, 2H), 2.84 (t, 7= 7.2 Hz, 2H); |
1494 | 0 N H Bn | A, 170,185 | 16 | 421.1 (MM) | C26H20N4O 2 420.16 | ); ‘H NMR (DMSO-A.400 MHz): δ 10.45 (d, 7= 4.4 Hz, 2H), 8.53-8.38 (m, 2H), 7.747.70 (m, 2H), 7.67-7.62 (m, 3H), 7.50-7.39 (m,4H), 7.31 (d, 7= 8.0 Hz, 1H), 7.27 (t, 7= 7.6 Hz, 2H), 7.20-7.08 (m, 2H), 5.07 (s, |
271
2H); | ||||||
1512 | 0 NH B O AWW \ A J! N \__k UNM h U 1 Bn | A, 170,406 | 18 | 555.1 (tf+1) | c31h30n4o 4S 554.20 | Ή NMR (DMSO-J6,400 MHz): δ 10.35 (s, 1H), 8.40 (t, 7= 5.6 Hz, 1H), 7.68-7.53 (m, 3H), 7.52-7.36 (m, 7H), 7.317.18 (m,4H), 7.13 (t, 7=7.3 Hz, 1H), 7.06 (t, 7= 7.4 Hz, 1H), 5.00 (s, 2H), 3.49-3.41 (m, 2H), 2.88 (t, 7= 7.0 Hz, 2H), 2.51 (s, 6H); |
1484 | 0 __YNH /? Λ=^\ H rx Bn \ j | A, 170,186 | 7 | 496.2 (M*+l) | C33H25N3O 2 495.19 | ‘H NMR (DMSO-76>400 MHz): δ 10.44 (s, 1H), 10.20 (s, 1H), 8.058.03 (m, 1H), 7.75 (d, 7=8.4 Hz, 1H), 7.697.58 (m, 5H), 7.51-7.35 (m, 9H), 7.34-7.24 (m, 3H),7.17(t, 7= 7.7 Hz, 1H), 7.11 (t,7=7.5 Hz, 1H), 5.07 (s, 2H); |
1468 | 0 / NH /9 /^=\ ΤλΙηΛΐ s H Xv°h | A, 35,413 | 15 | 456.9 (MM) | c26h17fn2 03S 456.09 | ‘H NMR (400 MHz, DMSOdfi): δ 10.97 (s, 1H), 10.36 (s, 1H), 9.53 (s, 1H), 8.03-8.01 (m, 1H), 7.81 7.71 (m, 4H), 7.63 (dd,7= 8.6, 5.3 Hz, 1H), 7.51 (dd,7 = 9.2,2.9 Hz, 1H), 7.45-7.36 (m, 2H), 7.357.32 (m, 1H), 7.26 (t, 7= 7.8 Hz, 1H), 7.067.00 (m, 2H), 6.79- 6.75 (m, |
272
1H); | ||||||
1452 | 0 'Φνη /? /^\ S Η ^^AVoMe | Α, 35,412 | 37 | 471.0 (Μ*+1) | C27H19FN2 o3s 470.11 | ‘Η NMR (DMSO-Jî, 400MHz): δ 10.98 (s, 1H), 10.37 (s, 1H), 8.02 (s, 1H), 7.83-7.70 (m, 4H), 7.63 (dd, J = 8.6, 5.3 Hz, 1H), 7.52 (dd, J = 9.2,2.9 Hz, 1H), 7.47-7.36 (m, 4H), 7.20 (d, 7= 7.8 Hz, 1H), 7.16-7.14 (m, 1H), 6.96 (dd, 7= 8.0, 2.2 Hz, 1H), 3.82 (s, 3H); |
1636 | 0 VXsjAYfAA/ '/χ' ο ο | Α, 159,415 | 50 | 400.9 (Nf+l) | C20H20N2O 5S 400.11 | ‘H NMR (DMSO-7d>400 MHz): δ 11.50 (s, 1H), 8.69 (t, 7= 5.4 Hz, 1H), 8.03 (d, 7=8.3 Hz, 1H), 8.017.96 (m, 2H), 7.93-7.82 (m, 2H), 7.80 - 7.76 (m, 2H), 3.813.71 (m, 2H), 3.61-3.54 (m, 1H), 3.45-3.40 (m, 1H). 3.293.25 (m, 1H), 2.00-1.90 (m, 1H), 1.86-1.73 (m, 2H), 1.68 (q, 7= 7.0 Hz, 2H), 1.46-1.35 (m, 1H); |
1626 | 0 / ΝΗ /? Ν=\ (Γη Κ’Ά ZVN’- <? ! Λ Λ / ν^Α\ // Ν UXV Η W 0 0 | Α, 159,421 | 14 | 474.0 (M+l) | c24hI9n5o 4S 473.12 | ‘H NMR (DMSO-76i400 MHz): δ 11.52 (s, 1H), 8.81 (t, 7= 5.5 Hz, 1H), 8.09 (s, 2H), 8.04 (d,7=8.3 Hz, 1H), 8.007.82 (m, 6H), 7.80-7.72 (m, 2H), 7.42 (d, 7 |
273
= 8.6 Hz, 2H), 3.57-3.49 (m, 2H), 2.90 (t, J= 7.0 Hz, 2H); | ||||||
1650 | 0 / NH ? /N Y\A CÇo WJW A NHCbz 0 0 | A, 159,427 | 51 | 628.1 (M*+l) | c34h33n3o 7S 627.20 | ‘H NMR (DMSO-7tf,400 MHz): δ 11.52 (s, 1H), 8.76 (t, 7= 5.5 Hz, 1H), 8.03 (d,7=8.3 Hz, 1H), 8.007.96 (m, 2H), 7.92-7.83 (m, 2H), 7.79 (s, 1H), 7.75 (dd, J = 8.2,1.4 Hz, 1H), 7.44-7.22 (m,6H), 7.11 (d, 7=8.6 Hz, 2H), 6.82 (d, J = 8.5 Hz, 2H), 5.00 (s, 2H), 3.90 (t, 7= 6.2 Hz, 2H), 3.43 (q, 7= 6.7 Hz, 2H), 3.04 (q, J = 6.7 Hz, 2H), 2.74 (t, 7= 7.3 Hz, 2H), 1.711.63 (m, 2H), 1.58-1.49 (m, 2H); |
274
Example 27: Synthesis of Compounds 1268 and 1269
Synthesis of methyl 2-cyano-2-phenylacetate (432): To a stirred solution of sodium hydride (60%,
2.5 g, 63.82 mmol) in anhydrous toluene (50 mL) under argon atmosphère was added 2-phenyl acetonitrile 430 (5 g, 42.55 mmol) at 0 °C and stiired for 30 min. To this dimethyl carbonate 431 (5.74 g, 63.82 mmol) in anhydrous toluene (30 mL) was added drop wise for 10 min and stirred at 0
O
C for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with saturated ammonium chloride (20 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with brine (50 mL), dried over sodium sulphate, 10 filtered and concentrated in vacuo to obtain the crude. The crude compound was purifîed through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 432 (4.8 g, 64%) as colorless syrup. TLC: 30% EtOAc/hexanes (Rf. 0.7);1 H-NMR (CDC13, 400 MHz): δ 7.47-7.39 (m, 5H), 4.74 (s, 1H), 3.81 (s, 3H).
275
Synthesis of methyl 3-amino-2-phenyIpropanoate (433): To a stirred solution of compound 432 (1 g, 5.71 mmol) in MeOH (50 mL) under argon atmosphère were added Boc-anhydride (2.49 g, 11.42 mmol), nickel dichloride hexahydrate (135 mg, 0.57 mmol) and sodium borohydride (1.5 g, 39.99 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with MeOH (30 mL), filtered through celite and the filtrate was concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 30% EtOAc/ Hexanes to afford racemic compound 433 (550 mg, 36%) as an off white solid. TLC: 20% EtOAc/ hexanes (Rf. 0.4); 'H-NMR (DMSO-i/ÿ, 500 MHz): δ 7.34 (t, J= 7.0 Hz, 2H), 7.30-7.25 (m, 3H), 6.93 (t, J= 6.0 Hz, 1H), 3.85 (t, J= 7.5 Hz, 1H), 3.60 (s, 3H), 3.28-3.23 (m,lH), 1.34 (s, 9H). The racemic compound 433 was purified through chiral préparative HPLC to afford compound 434 Fr-I (120 mg) and compound 435 Fr-II (90 mg) as off-white solids.
Compound 434 Fr-I analytical data:
Chiral HPLC: 99.27%, Rt= 9.58 min (Chiralcel AD-H, 250 x 4.6 mm, 5 pm); mobile phase (A) 0.1% DEA in w-Hexane (B) EtOH (A: B: 98: 2); Flow Rate: 1.0 mL/min).
Compound 435 Fr-II analytical data:
Chiral HPLC: 99.29%, Rt=10.87 min (Chiralcel AD-H, 250 x 4.6 mm, 5 pm); mobile phase (A) 0.1% DEA in n-Hexane (B) EtOH (A: B: 98: 2); Flow Rate: 1.0 mL/min).
Synthesis of methyl (2?)-2-phenyl-3-((2, 2, 2-trifluoroacetyl)-X4-azanyl) propanoate (436): To a stirred solution of compound 434 (Fr-I) (50 mg, 0.17 mmol) in CH2CI2 (2 mL) under inert atmosphère was added trifluoroacetic acid (0.026 mL, 0.35 mmol) at 0 C; warmed to RT and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude compound 436 (20 mg, TFA sait) as off-white solid. TLC: 70% EtOAc/ hexanes (Rf. 0.2); ‘H-NMR (DMSO-î/6, 400 MHz): δ 8.10 (br s, 2H), 7.41-7.28 (m, 5H), 4.03 (t, 7= 6.0 Hz, 1H), 3.63 (s, 3H), 3.48 (t, J= 9.2 Hz, 1H), 3.12-3.08 (m, 1H).
Synthesis of methyl (Æ)-3-(ll-oxo-10,11-dihydrodibenzo \b, f[ [1, 4] thiazepine-8carboxamido)-2-phenylpropanoate (437): To a stirred solution of compound 6 (70 mg, 0.25 mmol) in DMF (5 mL) under argon atmosphère were added EDCI.HC1 (73.9 mg, 0.38 mmol), HOBt (30 mg, 0.38 mmol), compound 436 (70 mg, 0.38 mmol), diisopropyl ethyl amine (0.09 mL, 0.51 276 ο
mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2x10 mL). The combined organic extracts were dried over sodium sulphate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 90% EtOAc/ Hexanes to afford compound 437 (70 mg, 63%) as colorless syrup. TLC: 5% MeOH/ CH2C12 (Rf. 0.5);1 H-NMR (DMS0-76 400 MHz): δ 10.75 (s, 1H), 8.65 (t, 7= 5.6 Hz, 1H), 7.68 (d, J= 7.2 Hz, 2H), 7.67-7.60 (m, 4H), 7.54-7.49 (m, 2H), 7.49-7.44 (m, 3H), 7.35-7.25 (m, 1H), 4.02 (t, 7= 7.2 Hz, 1H), 3.80-3.73 (m, 1H), 3.55 (t, 7= 6.4 Hz, 1H), 3.47 (s, 3H).
Synthesis of (Z?)-3-(ll-oxo-10,11-dihydrodibenzo [b,j\ [1, 4] thiazepine-8-carboxamido)-2phenylpropanoic acid (1268): To a stirred solution of compound 437 (40 mg, 0.092 mmol) in THF: H2O (4: 1, 2.5 mL) was added LiOH.H2O (7.7 mg, 0.18 mmol) at 0 C; warmed to RT and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, diluted with water (5 mL), pH was adjusted to ~ 6 using 1 N HCl and extracted with EtOAc (2x10 mL). The combined organic extracts were dried over sodium sulphate, filtered and concentrated in vacuo to afford 1268 (25 mg, 65%) as white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.5); 1 H-NMR (DMSO-rifi, 400 MHz): δ 12.49 (br s, 1H), 10.76 (s, 1H), 8.62 (t, 7= 5.6 Hz, 1H), 7.68 (d, 7= 7.2 Hz, 1H), 7.66-7.61 (m, 2H), 7.54-7.42 (m, 4H), 7.34-7.23 (m, 5H), 3.92 (t, 7= 7.6 Hz, 1H), 3.77-3.72 (m, 1H), 3.57-3.50 (m, 1H); LC-MS: 90.53%; 419.4 (M^+l); (column; X-bridge C-18, (50 x 3.0 mm, 3.5 pm); RT 3.76 min. 0.05% TFA (Aq) : ACN; 0.8 mL/min); UPLC (purity): 93.78%; (column : Acquity BEH C-18 (50 x 2.1 mm, 1.7 μ); RT 2.04 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
Synthesis of methyl (5)-2-plienyl-3-((2, 2, 2-trifluoroacetyl)-X4-azanyl) propanoate (438): To a stirred solution of compound 435 (Fr-II) (90 mg, 0.32 mmol) in CH2C12 (3 mL) under inert atmosphère was added trifluoroacetic acid (0.073 mL, 0.64 mmol) at 0 C; warmed to RT and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude compound 438 (90 mg, TFA sait) as an off-white solid. TLC: 70% EtOAc/ Hexanes (Rf. 0.2); *H-NMR (DMSO-J6, 400 MHz): δ 8.10 (br s, 2H), 7.41-7.28 (m, 5H), 4.03 (t, 7= 6.0 Hz, 1H), 3.63 (s, 3H), 3.48 (t, 7= 9.2 Hz, 1H), 3.12-3.08 (m, 1H).
Synthesis of methyl (5)-3-(1 l-oxo-10,11-dihydrodibenzo [b,j\ [1, 4] thiazepine-8carboxamido)-2-phenylpropanoate (439): To a stirred solution of compound 6 (70 mg, 0.25 mmol) in DMF (5 mL) under argon atmosphère were added EDCI.HC1 (73.9 mg, 0.38 mmol), HOBt 277 (52 mg, 0.38 mmol), compound 438 (70 mg, 0.38 mmol), diisopropyl ethyl amine (0.09 mL, 0.51 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2x10 mL). The combined organic extracts were dried over sodium sulphate, filtered and concentrated in vacuo to obtain the crude. The crude was purifîed through silica gel column chromatography using 80% EtOAc/ hexanes to afford compound 439 (70mg, 63%) as an off-white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.5); *H-NMR (DMSO-î/6, 400 MHz): δ 10.77 (s, 1H), 8.65 (t, J= 5.6 Hz, 1H), 7.69 (d, 7.2 Hz, 1H), 7.65-7.61 (m, 2H), 7.55-7.45 (m, 4H), 7.37-7.34 (m,
2H), 7.31-7.27 (m, 3H), 4.02 (t, J= 7.2 Hz, 1H), 3.80-3.74 (m, 1H), 3.59 (s, 3H), 3.56-3.53 (m,lH).
Synthesis of (5)-3-(ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-carboxamido)-2phenylpropanoic acid (1269): To a stirred solution of compound 439 (40 mg, 0.09 mmol) in THF : H2O (4: 1, 2.5 mL) was added lithium hydroxide monohydrate (7.7 mg, 0.18 mmol) at 0 C; warmed to RT and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, diluted with water (5 mL), the pH was adjusted to ~ 6 using 1 N HCl and extracted with EtOAc (2 x 10 mL). The combined organic extracts were dried over sodium sulphate, filtered and concentrated in vacuo to afford 1269 (25 mg, 65%) as white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.3); ^-NMR (DMSO-t/ô, 400 MHz): δ 12.51 (br s, 1H), 10.76 (s, 1H), 8.62 (t, J= 5.6 Hz, 1H), 7.68 (d, J =7.2 Hz, 1H), 7.66-7.61 (m, 2H), 7.54-7.43 (m, 4H), 7.34-7.23 (m, 5H), 3.92 (t, J= 7.6 Hz, 1H), 3.77-3.72 (m, 1H), 3.57-3.50 (m, 1H); LC-MS: 96.04%; 417.8 (M-l)+; (column; X-select C-18, (50 x 3.0 mm,
3.5 pm); RT 2.38 min. 5.0 mMNRiOAc : ACN; 0.8 mL/min); UPLC (purity): 96.12%; (column : Acquity BEH C-18 (50 x 2.1 mm, 1.7 p); RT 2.03 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
278
Example 28: Synthesis of Compound 1239
Synthesis of te/ï-butyl (2-cyanophenyI) carbamate (441): To a stirred solution of 2aminobenzonitrile 440 (1 g, 8.47 mmol) in CH2CI2 (15 mL) under argon atmosphère were added
Boc-anhydride (1.84 g, 4.76 mmol) and triethyl amine (0.83 mL, 5.96 mmol), DMAP (0.1 mg, catalytic amount) at 0 C; warmed to RT and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 30% EtOAc/ hexanes to afford compound 441 (500 mg, 28%) as white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.8); Tl-NMR (DMSO-4, 400 MHz): δ 9.25 (br s, 1H), 7.85 (d, J= 7.6 Hz, 1H), 7.73 (t, J= 7.6 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.45 (t, J= 7.6 Hz, 1H), 1.35 (br s, 9H).
Synthesis of teri-butyl (2-cyanophenyl) (methyl) carbamate (442): To a stirred solution of compound 441 (500 mg, 2.29 mmol) in DMF (10 mL) under argon atmosphère were added sodium hydride (60%, 55 mg, 2.29 mmol), methyl iodide (325 mg, 2.29 mmol) at 0 C; warmed to RT and 15 stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with ice cold water (10 mL), extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over sodium sulphate, fîltered and concentrated in vacuo to
279 obtain the crude. The crude was purified through silica gel column chromatography using 40% EtOAc/ hexanes to afford compound 442 (480 mg, 88%) as white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.5); 'H-NMR (DMSO-7d, 400 MHz): δ 7.85 (d, J= 7.6 Hz, 1H), 7.73 (t, 7= 7.6 Hz, 1H), 7.53 (d, J= 7.6 Hz, 1H), 7.45 (t, J= 7.6 Hz, 1H), 3.18 (s, 3H), 1.35 (br s, 9H).
Synthesis of teri-butyl (2-(aminomethyl) phenyl) (methyl) carbamate (443): To a stirred solution of compound 442 (50 mg, 0.21 mmol) in MeOH (3 mL) under argon atmosphère was added Raney Nickel (20 mg), methanolic ammonia (1.5 mL) at RT and stirred under hydrogen atmosphère (balloon pressure) for 6 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite, washed with MeOH (2x5 mL) and the fîltrate was concentrated in vacuo to obtain the crude. The crude was washed with diethyl ether (2x10 mL) and dried in vacuo to afford compound 443 (40 mg, 80%) as white solid. TLC: 50% EtOAc/ hexanes (Rf. 0.2); 'H-NMR (DMSO-7tf, 400 MHz): δ 7.52 (d, 7= 7.2 Hz, 1H), 7.28-7.20 (m, 2H), 7.12 (t, 7=
5.6 Hz, 1H), 3.60-3.57 (m, 2H), 3.14 (br s, 3H), 1.25 (s, 9H).
Synthesis of tert-butyl methyl (2-((ll-oxo-10,11-dihydrodibenzo [b,f\ [1, 4] thiazepine-8carboxamido) methyl) phenyl) carbamate (444): To a stirred solution of compound 6 (40 mg, 0.14 mmol) in DMF (3 mL) under argon atmosphère were added EDCI.HC1 (42 mg, 0.22 mmol), HOBt (30 mg, 0.22 mmol), compound 443 (37.6 mg, 0.16 mmol), diisopropyl ethyl amine (0.05 mL, 0.29 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice-cold water (20 mL). The precipitate was filtered and the obtained solid was dried in vacuo to afford compound 444 (40 mg, 55%) as white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.5); LC-MS: 93.49%; 390.3 (M^+l) (DesBoc).
Synthesis of 7V-(2-(inethylainino) benzyl)-ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-
8-carboxamide (1239): A stirred solution of compound 444 (40 mg, 0.08 mmol) in 4 N HCl in 1, 4dioxane (2 mL) under argon atmosphère at 0-5 C was stirred for 1 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with saturated NaHCO3 solution (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (15 mL), dried over sodium sulphate, filtered and concentrated in vacuo to afford 1239 (10 mg, 32%) as white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.4); 'H-NMR (DMSO-76, 400 ΜΗζ):δ 10.74 (s, 1H), 8.96 (t, 7= 6.0 Hz, 1H), 7.72-7.60 (m, 4H), 7.55-7.43 (m, 3H), 7.08 (t, 7= 280
7.6 Hz, 1H ), 7.02 (d, J= 7.2 Hz, 1H), 6.53 (t, J= 7.2 Hz, 2H), 5.38-5.37 (m, 1H), 4.29 (d, J= 7.2 Hz, 2H), 2.72 (d, J= 4.8 Hz, 3H); LC-MS: 93.74%; 390.3 (MM); (column; X-select CSH C-18, (50 x 3.0 mm, 3.5 pm); RT 3.44 min. 0.05% TFA (Aq) : ACN; 0.8 mL/min); UPLC (purity): 94.35%; (column : Acquity UPLC BEH C-18 (2.1 x 50 mm, 1.7 μ); RT 1.87 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
Example 29: Synthesis of Compound 1244
Synthesis of tert-butyl 4-(cyanomethylene) piperidine-l-carboxylate (447): To a stirred solution of diethyl (cyanomethyl) phosphonate 445 (978 mg, 5.52 mmol) in anhydrous THF (10 mL) under argon atmosphère was added LiHMDS (1 mL, 5.52 mmol, IM in THF) was added drop wise for 10 min at -78 °C. To this was added ZerAbutyl 4-oxopiperidine-l-carboxylate 446 (1 g, 5.01 mmol) in THF (2 mL) dropwise for 10 min and stirred for 3 h at the same température. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with saturated ammonium chloride solution (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 15% EtOAc/ hexanes to afford compound 447 (900 mg, 82%) as white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.5); JH NMR (CDCl3,400 MHz) δ 5.19 (s, 1H), 3.54-3.49 (m, 4H), 2.56 (t, J= 5.8 Hz, 2H), 2.33 (t, J= 5.6 Hz, 2H), 1.48 (s, 9H);
Synthesis of to'Z-butyl 4-(2-aminoethyl) piperidine-l-carboxylate (448): To a stirred solution of 447 (100 mg, 0.45 mmol) in AcOH (5 mL) under argon atmosphère was added 10% Pd/C (50 mg) at
281
RT and stirred under hydrogen atmosphère (balloon pressure) for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mass was fîltered through celite and washed with EtOAc (3x15 mL) and the volatiles were removed in vacuo to afford compound 448 (70 mg, mixture of isomers) as pale brown syrup. TLC: 6% MeOH/ CH2C12 (Rf. 0.2); ’H-NMR (DMSO-îZ6, 400 MHz): δ 3.89 (d, J= 12.4 Hz, 2H), 2.70-2.68 (m, 2H), 1.68-1.65 (m, 2H), 1.59 (d, J= 12.0 Hz, 1H), 1.38 (s, 9H), 1.33-1.28 (m, 4H), 0.99-0.89 (m, 2H).
Synthesis of ter/-butyl 4-(2-(1 l-oxo-10,11-dihydrodibenzo \b, f\ [1, 4] thiazepine-8carboxamido) ethyl) piperidine-l-carboxylate (449): To a stirred solution of compound 6 (40 mg, 0.14 mmol) in DMF (3 mL) under argon atmosphère were added EDCI.HC1 (42 mg, 0.22 mmol), HOBt (30 mg, 0.22 mmol), compound 448 (40 mg, 0.17 mmol), diisopropyl ethyl amine (0.05 mL, 0.29 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was triturated with EtOAc: H2O (1: 5, 12 mL), fîltered and the precipitate was dried in vacuo to afford compound 449 (36 mg, 51%) as white solid. TLC: 7% MeOH/ CH2C12 (Rf. 0.7); ’H-NMR (DMSOd6, 400 MHz): δ 10.76 (s, 1H), 8.47 (br s, 1H), 7.69-7.63 (m, 3H), 7.57-7.53 (m, 2H), 7.47 (t, J= 8.8 Hz, 2H), 3.89 (d, J= 10.8 Hz, 2H), 3.26-3.25 (m, 2H), 2.67 (s, 3H), 1.64 (d, J= 10.8 Hz, 2H), 1.42-1.41 (m, 2H), 1.37 (s, 9H), 0.97-0.95 (m, 2H).
Synthesis of ll-oxo-7V-(2-(piperidin-4-yI) ethyl)-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8carboxamide (1244): To a stirred solution of compound 449 (36 mg, 0.07 mmol) in CH2C12 (3 mL) under argon atmosphère was added trifluoro acetic acid (0.03 mL, 0.37 mmol) at 0 C; warmed to RT and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was neutralized with 10% NaHCO3 solution (15 mL) and extracted with EtOAc (3x15 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to afford 1244 (15 mg, 53%) as an off-white solid. TLC: 7% MeOH/ CH2C12 (Rf. 0.2); *H-NMR (DMSO-r/6, 400 MHz): δ 10.77 (br s, 1H), 8.48 (t, J= 5.6 Hz, 1H), 7.69-7.64 (m, 3H), 7.57-7.43 (m, 4H), 3.26-3.25 (m, 3H), 3.16-3.12 (m, 2H), 2.68 (t, J= 10.0 Hz, 2H), 1.77-1.74 (m, 2H), 1.44 (t, J= 6.8 Hz, 3H); 1.23-1.13 (m, 2H); LC-MS: 90.01%; 382.4 (MP'+l); (column; X-select CSH C-18, (50 x 3.0 mm, 3.5 pm); RT 2.97 min. 0.05% TFA (Aq) : ACN; 0.8 mL/min); UPLC (purity): 92.90%; (column : Acquity UPLC BEH C-18 (2.1 x 50 mm, 1.7 p); RT 1.60 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
282
Example 30: Synthesis of Compounds 1651 and 1652
Synthesis of A-methoxy-IV-methylthiazole-5-carboxamide (451): To a stirred solution of thiazole5-carboxylic acid 378 (1.5 g, 11.61 mmol) in CH2CI2 (30 mL) under argon atmosphère were added
EDCI.HC1 (2.45 g, 12.78 mmol), HOBt (785 mg, 135.13 mmol), 7V,O-dimethyl hydroxylamine
O hydrochloride 450 (1.36 g, 97.6 mmol) and diisopropyl ethyl amine (10 mL, 58.09 mmol) at 0 C;
warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (50 mL) and extracted with CH2C12 (3 x 50 mL). The combined organic extracts were washed with 1 N HCl (20 mL), saturated NaHCO3 solution (30 mL), brine (50 mL) and dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through combi flash chromatography using 30-40% EtOAc/ hexanes to afford compound 451 (1.2 g, 60%) as colorless syrup. TLC: 5% MeOH/ CH2C12 (Rf. 0.6); *H NMR (DMSO-rf6,400 MHz): 9.32 (s, 1H), 8.52 (s, 1H), 3.77 (s, 3H), 3.30 (s, 3H).
Synthesis of l-(thiazol-5-yl) ethan-l-one (452): To a stirred solution of compound 451 (1.2 g, 6.97 15 mmol) in THF (20 mL) under argon atmosphère was added methyl magnésium bromide (3.2
283 mL,10.46 mmol, 3 M solution in Et20) dropwise for 10 min at -10 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with saturated ammonium chloride (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through combi flash chromatography using 25-30% EtOAc/ hexanes to afford compound 452 (800 mg, 90%) as white solid. TLC: 50% EtOAc/ hexanes (Rf. 0.6); 'HNMR (DMSO-<Zd,400 MHz): δ 9.40 (s, 1H), 8.71 (s, 1H), 2.60 (s, 3H).
Synthesis of l-(thiazol-5-yl) ethan-l-one oxime (453): To a stirred solution of compound 452 (800 mg, 6.29 mmol) in MeOH (20 mL) under inert atmosphère was added hydroxyl amine
O hydrochloride (875 mg, 12.59 mmol) and pyridine (2 mL) dropwise for 5 min at 0 C warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo diluted with water (50 mL) and stirred for 30 min. The precipitated solid was filtered dried in vacuo to afford compound 453 (800 mg, 90%) as white solid. TLC: 40% EtOAc/ hexanes (Rf. 0.4, 0.6); JH NMR (DMSO-<Ztf> 400 MHz) (Mixture of E/Z isomers): δ 11.86 (s, 1H), 11.41 (s, 0.6 H), 9.19 (s, 1H), 9.01 (s, 0.56 H), 8.35 (s, 1H), 8.15 (s, 0.65 H), 2.31 (s, 3H), 2.21 (s, 2H).
Synthesis of l-(thiazol-5-yl) ethan-l-amine (454): To a stirred solution of compound 453 (800 mg, 5.63 mmol) in MeOH: acetic acid (1: 1, 20 mL) under inert atmosphère were zinc powder (2.2 g, 33.80 mmol) at RT; heated at 50 °C and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite washed with MeOH (3 x 10 mL). The fîltrate were removed in vacuo, the residue was diluted with water (20 mL), basified with aqueous ammonia (15 mL) and extracted with EtOAc (3 x 50 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude compound 454 (racemic) (700 mg, 92%) as brown syrup. TLC: 5% MeOH/ CH2CI2 (Rf. 0.4, 0.6); XH NMR (DMSO-^,400 MHz): δ 8.90 (s, 1H), 7.71 (s, 1H), 4.33-4.28 (m, 1H), 3.38 (t, J= 6.4 Hz, 1H), 1.87 (s, 3H).
Synthesis of ll-oxo-A’-(l-(thiazol-5-yl) ethyl)-10,11-dihydrodibenzo [b, f\ [1, 4] thiazepine-8carboxamide (455 Racemic): Using Procedure A the title compound was prepared with DBT-Acid (150 mg, 0.55 mmol) and compound 454 racemic (109 mg, 0.66) to afford compound 455 (Racemic) (100 mg, 48%); TLC: 5% MeOH/ CH2C12 (Rf 0.5); 'H NMR (DMSO-/Zd, 400 MHz): δ
284
10.87 (br s, 1H), 9.14 (d, J= 8.0 Hz, 1H), 8.95 (s, 1H), 7.79 (d, J= 3.6 Hz, 2H), 7.70-7.58 (m, 3H), 7.56-7.42 (m, 3H), 5.48-5.41 (m, 1H), 1.60 (s, 3H); LC-MS: 98.31%; 381.9 (M*+l); (column; Ascentis Express Cl8, (50 x 3.0 mm, 2.7 pm); RT 2.03 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min); HPLC (purity): 97.68%; (colunrn; Eclipse XDB C-18 (150 x
4.6 mm, 5.0 pm); RT 7.58 min. ACN : 0.05% TFA (Aq); 1.0 mL/min) (IP14012554); Chiral HPLC: 35.10%, Rt= 9.01 min (Chiralpak-IA, 250 x 4.6 mm, 5 pm); mobile phase (A) 0.1% DEA in π-Hexane (B) CH2C12: MeOH (50: 50) (A: B:: 63: 35); Flow Rate: 1.0 mL/min).
The racemic compound 455 (100 mg) was separated by préparative HPLC using a CHIRALPAK-IC column (250 x 20 mm x 5 pm) (10 mg loading; mobile phase (A) 0.1% DEA in zz-Hexane (B) CH2C12: MeOH: DMF (65: 35: 05) (A: B:: 75: 25) to afford 1651 (10 mg) and 1652 (15 mg) as an off-white solids.
Analytical Data of 1651:
TLC: 5% MeOH/ CH2C12 (Rf 0.5); *H NMR (DMSO-A, 400 MHz): δ 10.75 (s, 1H), 9.02 (d, J= 7.8 Hz, 1H), 8.95 (s, 1H), 7.79 (s, 1H), 7.72-7.64 (m, 3H), 7.62-7.58 (m, 1H), 7.56-7.41 (m, 3H), 5.45 (t, J= 7.0 Hz, 1H), 1.57 (d, J= 6.8 Hz, 3H); LC-MS: 96.06%; 381.8 (NTT!); (column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 2.03 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min); HPLC (purity): 95.02%; (column; Zorbax SB C-18 (150 x 4.6 mm, 3.5 pm); RT 7.79 min. ACN : 0.05% TFA (Aq); 1.0 mL/min) (IP15010530); Chiral HPLC: 96.24%, Rt- 14.33 min (Chiralpak-IA, 250 x 4.6 mm, 5 pm); mobile phase (A) 0.1% DEA in nHexane (B) CH2C12: MeOH: DMF (65: 35: 05) (A: B:: 75: 25); Flow Rate: 1.0 mL/min). Note: Altematively the racemic compound 454 was resolved and one fraction had led to 1651.
Analytical Data of 1652:
TLC: 5% MeOH/ CH2C12 (Rf 0.5); *H NMR (DMSO-</6,400 MHz): δ 10.75 (s, 1H), 9.03 (d, J= 8.3 Hz, 1H), 8.95 (s, 1H), 7.79 (s, 1H), 7.71-7.63 (m, 3H), 7.62-7.58 (m, 1H), 7.56-7.42 (m, 3H), 5.48-5.47(m, 1H), 1.57 (d, J= 6.9 Hz, 3H); LC-MS: 96.65%; 381.9 (M++l); (column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 2.68 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min); HPLC (purity): 98.53%; (column; Zorbax SB C-18 (150 x 4.6 mm, 3.5 pm); RT 7.76 min. ACN : 0.05% TFA (Aq); 1.0 mL/min) (IP15010229). Chiral HPLC:
285
99.87%, Rt= 16.90 min (Chiralpak-IA, 250 x 4.6 mm, 5 pm); mobile phase (A) 0.1% DEA in nHexane (B) CH2C12: MeOH: DMF (65: 35: 05) (A: B:: 75: 25); Flow Rate: 1.0 mL/min).
Example 31: Synthesis of Compounds 1653 and 1633
Synthesis of teri-butyl 2-((ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-carboxamido) methyl) pyrrolidine-l-carboxylate (457): Using Procedure A the title compound was prepared with compound 6 (300 mg, 1.10 mmol), fôrAbutyl 2-(aminomethyl) pyrrolidine-l-carboxylate 456 (0.24 mL, 1.21 mmol) and was obtained in 50% yield as an off-white solid; TLC: 10% MeOH/ CH2C12 (Rf. 0.7); *H NMR (DMSO-d<i,400 MHz): δ 10.76 (br s, 1H), 8.53 (t, J= 5.5 Hz, 1H), 7.717.63 (m, 3H), 7.56-7.43 (m, 4H), 3.95-3.79 (m, 1H), 3.52-3.35 (m, 1H), 3.26-3.19 (m, 3H), 1.861.71 (m, 4H), 1.38 (s, 9H).
Synthesis of ll-oxo-7V-(pyrrolidin-2-ylmethyl)-10,11-dihydrodibenzo [/>,/] [1,4] thiazepine-8carboxamide hydrochloride (1633): To a stirred solution of compound 457 (250 mg, 0.55 mmol) in CH2C12 (5 mL) under argon atmosphère was added 4 N HCl in 1, 4-dioxane (1 mL) at 0 C; warmed to RT and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to afford compound 1633 (150 mg, 77%; HCl sait) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.1); *H NMR (DMSO-d6,400 MHz): δ 10.82 (br s, 1H), 8.88 (br s, 3H), 7.74-7.62 (m, 4H), 7.56-7.43 (m, 3H), 3.67-3.57 (m, 1H), 3.56-3.46 (m, 2H), 3.24-3.07 (m, 2H), 2.07-1.95 (m, 1H), 1.95-1.78 (m, 2H), 1.68-1.59 (m, 1H); LC-MS: 96.49%; 354.0 (Mf+1) (-HC1); (column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 1.64 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min); HPLC (purity):
286
96.28%; (column; Zorbax SB C-18 (150 x 4.6 mm, 3.5 pm); RT 6.64 min. ACN : 0.05% TFA (Aq); 1.0 mL/min).
Synthesis of A-((l-acetylpyrrolidin-2-yl) methyl)-ll-oxo-10,11-dihydrodibenzo [b,j\ [1, 4] thiazepine-8-carboxamide (1653): To a stirred solution of compound 1633 (100 mg, 0.25 mmol) in CH2CI2 (5 mL) under argon atmosphère were added triethylamine (0.12 mL, 0.77 mmol), acetyl chloride (0.02 mL, 0.30 mmol) at 0 C; warmed to RT, stirred for 12 h. The reaction was monitored by TLC; after completion the reaction, the reaction the volatiles were removed in vacuo', the residue was basified with saturated NaHCO3 solution and extracted with CH2CI2 (2 x 50 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 5% MeOH/ CH2CI2 to afford 1653 (20 mg, 20%) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.6); ^NMRtDMSO-AdOO MHz): δ 10.84-10.73 (m, 1H), 8.87-8.55 (m, 1H), 7.72-7.63 (m, 3H),
7.60-7.43 (m, 4H), 4.17-3.94 (m, 1H), 3.53-3.33 (m, 3H), 3.32-3.30 (m, 0.5H), 3.20-3.09 (m, 0.5H), 2.08-1.92 (m, 3H), 1.88-1.70 (m, 4H); LC-MS: 99.36%; 396.4 (MA1); (column; X-Select C-18, (50 x 3.0 mm, 3.5 pm); RT 3.34 min, 0.77 min. 5 mM Aq.NHfiOAc: ACN 0.8 mL/min). HPLC (purity): 98.67%; (column; Eclipse XDB C-18 (150 x 4.6 mm, 5.0 pm); RT 7.28 min. ACN: 5 mM Aq. NH4OAc; 1.0 mL/min).
Example 32: Synthesis of Compounds 1615 and 1608
Synthesis of tert-butyl 3-((1 l-oxo-10,11-dihydrodibenzo [b,f] [1, 4] thiazepine-8-carboxamido) methyl) pyrrolidine-l-carboxylate (459): Using Procedure A the title compound was prepared
287 with 6 (300 mg, 1.10 mmol), iert-butyl 3-(aminomethyl) pyrrolidine-l-carboxylate 458 (0.24 mL, 1.21 mmol) and was obtained in 60% yield as an off-white solid; TLC: 10% MeOH/ CH2CI2 (Rf. 0.5); XH NMR (DMSO-î/6,400 MHz): δ 10.76 (s, 1H), 8.61 (t, J= 5.0 Hz, 1H), 7.72-7.63 (m, 3H),
7.60- 7.42 (m, 4H), 3.34-3.18 (m, 1H), 3.28-3.13 (m, 4H), 2.99-2.92 (m, 1H), 2.42-2.34 (m, 1H), 1.94-1.82 (m, 1H), 1.64-1.50 (m, 1H), 1.37 (s, 9H).
Synthesis of ll-oxo-7V-(pyrroIidin-3-ylmethyl)-10,11-dihydrodibenzo [b, J] [1, 4] thiazepine-8carboxamide hydrochloride (1608): To a stirred solution of compound 459 (300 mg, 0.66 mmol) in CH2CI2 (5 mL) under argon atmosphère was added 4 N HCl in 1, 4-dioxane (1 mL) at 0 C; warmed to RT and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to afford compound 1608 (200 mg, 78%; HCl sait) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.1); ‘H-NMR (DMSO-J6, 400 MHz): δ 10.78 (s, 1H), 8.88 (br s, 2H), 8.70 (t, J= 5.7 Hz, 1H), 7.71-7.65 (m, 3H), 7.59 (dd, J= 8.2, 2.0 Hz, 1H), 7.56-7.43 (m, 3H), 3.27-3.15 (m, 5H), 3.15-3.04 (m, 1H), 2.94-2.80 (m, 1H), 2.04-1.92 (m, 1H), 1.69-1.56 (m, 1H); LC-MS: 98.04%; 353.9 (M++l) (-HC1); (column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 1.64 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min); UPLC (purity): 97.21%; (column; Acquity UPLC BEH C-18 (50 x 2.1 mm, 1.7 p); RT 1.55 min. ACN : 0.025% TFA (Aq); 0.5 mL/min) (IP14120205).
Synthesis of 7V-((l-acetyIpyrrolidin-3-yl) methyl)-ll-oxo-10,11-dihydrodibenzo [b,f\ [1, 4] thiazepine-8-carboxamide (1615): To a stirred solution of compound 1608 (100 mg, 0.28 mmol) in CH2CI2 (5 mL) under argon atmosphère were added triethylamine (0.12 mL, 0.84 mmol), acetyl chloride (0.02 mL, 0.33 mmol) at 0 C; warmed to RT, stirred for 12 h. The reaction was monitored by TLC; after completion the reaction, the reaction the volatiles were removed in vacuo', the residue was basified with saturated NaHCO3 solution and extracted with CH2CI2 (2x30 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 5% MeOH/ CH2CI2 to afford 1615 (30 mg, 26%) as an off-white solid. TLC: 10% MeOH/ CH2CI2 (Rf. 0.6); 'HNMR (DMSO-<Z6,400 MHz): δ 10.71 (m, 1H), 8.69 -8.58 (m, 1H), 7.72-7.63 (m, 3H),
7.61- 7.41 (m, 4H), 3.55-3.34 (m, 3H), 3.29-3.19 (m, 2H), 3.17-3.13 (m, 0.5H), 3.00 (dd, J= 11.8, 7.3 Hz, 0.5H), 2.41-2.34 (m, 1H), 2.02-1.84 (m, 4H), 1.73-1.49 (m, 1H); LC-MS: 95.89%; 396.0 (M^+l); (column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 1.87 min. 0.025% Aq. TFA +
288
5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min); HPLC (purity): 97.29%; (column; Eclipse
XDB C-18 (150 x 4.6 mm, 5.0 pm); RT 7.05 min. ACN: 5 mM Aq. NH4OAc; 1.0 mL/min).
Example 33: Synthesis of Compound 1654
Synthesis of toŸ-butyl 3-((ll-oxo-10,11-dihydrodibenzo \b, f\ [1, 4] thiazepine-8-carboxamido) methyl) azetidine-l-carboxylate (461): To a stirred solution of compound 6 (600 mg, 2.21 mmol) in DMF (5 mL) under argon atmosphère were added EDCI.HC1 (634 mg, 3.32 mmol), HOBt (435 mg, 3.32 mmol), tert-butyl 3-(aminomethyl) azetidine-l-carboxylate 460 (453 mg, 2.43 mmol) and diisopropyl ethyl amine (1.14 mL, 6.64 mmol) at RT and stirred for 12 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (25 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 5% MeOH/ CH2CI2 to afford compound 461 (600 mg, 61%) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.6); ’HNMR (DMSO-î/6,400 MHz): δ 10.76 (s, 1H), 8.64 (t, J= 5.6 Hz, 1H), 7.71-7.64 (m, 3H), 7.59-7.43 (m, 4H), 3.84 (t, J= 7.0 Hz, 2H), 3.663.50 (m, 2H), 3.41 (t, J= 6.3 Hz, 2H), 2.72-2.64 (m, 1H), 1.33 (s, 9H).
Synthesis of ll-oxo-7V-((l-(2, 2, 2-trifluoroacetyl)-114-azetidin-3-yl) methyl)-10,11dihydrodibenzo \b,f\ [1, 4] thiazepine-8-carboxamide (1654): To a stirred solution of 461 (350 mg, 0.79 mmol) in CH2CI2 (10 mL) under argon atmosphère were added BF3.Et2O (0.18 mL, 1.59 mmol), molecular sieves (20 mg) at 0 °C; warmed to RT and stirred for 1 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (25
289 mL) and extracted with CH2CI2 (2 x 25 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified using préparative HPLC purification to afford compound 1654 (20 mg, 7%) as an off-white solid. TLC: 10% MeOH/ CH2CI2 (Rf. 0.6); *H NMR (DMSO-<Zà,400 MHz): δ 10.79 (s, 1H), 8.70 (t, J= 5.6 Hz, 1H), 8.62-8.39 (m, 1H), 7.73-7.66 (m, 3H), 7.59 (dd, J= 8.1, 1.7 Hz, 1H), 7.57-7.43 (m, 3H), 3.993.88 (m, 2H), 3.80-3.69 (m, 2H), 3.45 (t, J= 6.1 Hz, 2H), 3.04-2.94 (m, 1H); LC-MS: 99.41%; 339.9 (M++l); (column; Ascentis Express Cl8, (50 x 3.0 mm, 2.7 pm); RT 1.70 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min); HPLC (purity): 98.60%; (column; Zorbax SB C-18 (150 x 4.6 mm, 3.5 pm); RT 6.54 min. ACN : 0.05% TFA (Aq); 1.0 mL/min).
Synthesis of tert-butyl 4-((ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-carboxamido) methyl) piperidine-l-carboxylate (463): Using Procedure A the title compound was prepared with compound 6 (200 mg, 0.73 mmol), teri-butyl 4-(aminomethyl) piperidine-l-carboxylate 462 (0.17 mL, 0.81 mmol) and was obtained in 86% yield as pale brown solid; TLC: 5% MeOH/ CH2CI2 (Rf. 0.5); JH NMR (DMSO-<Z6,400 MHz): δ 10.75 (br s, 1H), 8.52 (t, J= 5.6 Hz, 1H), 7.72-7.61 (m, 3H), 7.60-7.42 (m, 4H), 3.93-3.88 (m, 2H), 3.12 (t, J= 6.0 Hz, 2H), 2.71-2.59 (m, 2H), 1.74-1.57 (m, 3H), 1.38 (s, 9H), 1.06-0.92 (m, 2H)
Synthesis of ll-oxo-/V-(piperidin-4-ylmethyl)-10,11-dihydrodibenzo \b, f\ [1,4] thiazepine-8carboxamide hydrochloride (1609): To a stirred solution of compound 463 (300 mg, 0.64 mmol)
290 in CH2CI2 (5 mL) under argon atmosphère was added 4 N HCl in 1, 4-dioxane (1 mL) at 0 C; warmed to RT and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to afford compound 1609 (200 mg, 85%; HCl sait) as pale brown solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.2); ’ïï-NMR (DMSO-îZ* 400 MHz): δ 10.77 (s, 1H), 8.67-8.58 (m, 2H), 8.32 (br s, 1H), 7.71 -7.64 (m, 3H), 7.61-7.43 (m, 4H), 3.27-3.20 (m, 2H), 3.18-3.12 (m, 2H), 2.89-2.76 (m, 2H), 1.82-1.72 (m, 3H), 1.38-1.23 (m, 2H); LC-MS: 98.23%; 368.0 (M++l) (-HC1); (column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 1.67 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min); UPLC (purity): 97.67%; (column; Acquity UPLC BEH C-18 (50 x 2.1 mm, 1.7 p); RT 1.59 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
Synthesis of 7V-((l-acetylpiperidin-4-yl) methyl)-ll-oxo-10,11-dihydrodibenzo [b,j\ [1, 4] thiazepine-8-carboxamide (1601): To a stirred solution of compound 1609 (100 mg, 0.24 mmol) in CH2CI2 (5 mL) under argon atmosphère were added triethylamine (0.1 mL, 0.74 mmol), acetyl chloride (0.02 mL, 0.29 mmol) at 0 C; warmed to RT, stirred for 12 h. The reaction was monitored by TLC; after completion the reaction, the reaction the volatiles were removed in vacuo', the residue was basifîed with saturated NaHCO3 solution and extracted with CH2CI2 (2x15 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purifîed through silica gel column chromatography using 1% MeOH/ CH2CI2 to afford 1601 (20 mg, 20%) as an off-white solid. TLC: 10% MeOH/ CH2CI2 (Rf. 0.5); ^-NMR (DMSO-^, 400 MHz): δ 10.75 (s, 1H), 8.53 (t, J= 5.5 Hz, 1H), 7.71-7.63 (m, 3H),
7.61-7.43 (m, 4H), 4.36-4.29 (m, 1H), 3.81-3.73 (m, 1H), 3.19-3.06 (m, 2H), 3.00-2.91 (m, 1H), 2.53-2.46 (m, 1H), 1.96 (s, 3H), 1.82-1.58 (m, 3H), 1.14-0.89 (m, 2H); LC-MS: 99.33%; 410.0 (M++l); (column; Ascentis Express Cl8, (50 x 3.0 mm, 2.7 pm); RT 1.99 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min); UPLC (purity): 99.57%; (column; Acquity UPLC BEH C-18 (50 x 2.1 mm, 1.7 p); RT 1.79 min. ACN: 0.025% TFA (Aq); 0.5 mL/min).
291
Example 35: Synthesis of Compounds 1357,1655, and 1367
Synthesis of methyl ll-oxo-10,11-dihydrodibenzo \b,f] [1, 4] thiazepine-8-carboxylate (474): To a stirred solution of compound 6 (500 mg, 1.84 mmol) in MeOH: CH2CI2 (1: 1, 20 mL) under argon atmosphère was added CH2N2 (insitu prepared using N-nitrosomethyl urea (0.95 g, 9.2 mmol) + KOH (0.51 g, 9.22 mmol) ) at 0 °C; warmed to RT and stirred for 1 h. The reaction was monitored by TLC; afiter completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 474 (450 mg, 86%) as white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.5);1 H-NMR (DMSO-rftf, 500 MHz): δ 10.82 (s, 1H), 7.82 (s, 1H), 7.75-7.69 (m, 3H), 7.58-7.63 (m, 3H), 3.82 (s, 3H).
Synthesis of 8-(hydroxymethyl) dibenzo \b,f\ [1, 4] thiazepin-ll(10//)-one (474-A): To a stirred solution of compound 474 (500 mg, 1.75 mmol) in dry THF (3 mL) under argon atmosphère was added diisobutylaluminium hydride (1 M sol. in Toluene, 5 mL, 5.26 mmol) dropwise for 5 min at 15 25 °C; warmed to RT and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was cooled to 0 °C, quenched with saturated sodium potassium tartrate solution (10 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude, which was titurated with MeOH: diethyl ether (1: 4, 5 mL) to afford 474-A (300 mg, 66%) as an off-white
292 solid. TLC: 70% EtOAc/ hexanes (Rf. 0.4); *H NMR (DMSO-76, 400 MHz): δ 10.66 (s, 1H), 7.67 (dd, 7= 7.5,1.6 Hz, 1H), 7.55-7.38 (m, 4H), 7.19 (s, 1H), 7.07 (dd, 7= 7.9, 1.7 Hz, 1H), 5.26 (t, 7= 5.7 Hz, 1H), 4.44 (d, 7= 5.6 Hz, 2H); LC-MS: 97.26%; 257.8 (M*+l); (column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 1.94 min. 0.025% Aq. TFA + 5% ACN: ACN +; 5% 0.025% Aq. TFA, 1.2 mL/min); UPLC (purity): 96.65%; (column; Acquity BEH C-18 (50 x 2.1 mm, 1.7 μ); RT 1.80 min. ACN: 0.025% TFA (Aq); 0.5 mL/min).
Synthesis of ll-oxo-10,11-dihydrodibenzo \h, f\ [1, 4] thiazepine-8-carbaldehyde (475): To a stirred solution of compound 474-A (60 mg, 0.23 mmol) in CH2CI2 (5 mL) under argon atmosphère was added Dess-Martin periodinane (300 mg, 0.70 mmol) at 0 C; warmed to RT and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with CH2CI2 (50 mL) and washed with saturated hypo solution (20 mL). The organic extract was dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified using silicagel column chromatography using 30% EtOAc/ hexanes to afford compound 475 (41 mg, 68%) as an off-white solid. TLC: 70% EtOAc/ hexanes (Rf. 0.8); *H NMR (DMSO-Tî, 400 MHz): δ 10.89 (s, 1H), 9.96 (s, 1H), 7.81 (d, 7= 7.6 Hz, 1H), 7.73-7.66 (m, 3H), 7.59-7.45 (m, 3H).
Synthesis of 8-((phenethylamino) methyl) dibenzo [b,f\ [1, 4] thiazepin-ll(10/7)-°ne (1357): To a stirred solution of compound 475 (100 mg, 0.39 mmol) in MeOH (4 mL) under argon atmosphère were added 2-phenylethan-l-amine 211 (57 mg, 0.47 mmol) and acetic acid (1 mL) at RT and
O stirred for 1 h. To this was added sodium cyanoborohydride (72 mg, 1.16 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water with EtOAc (100 mL), washed with saturated sodium bicarbonate solution (20 mL) and water (20 mL). The organic extract was dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified using silicagel column chromatography using 2% MeOH/ CH2CI2 to afford compound 1357 (25 mg, 18%) as an off-white solid. TLC: 100% EtOAc (Rf. 0.3); JH NMR (DMSO-76, 400 MHz): δ 10.65 (s, 1H), 7.67 (dd, 7= 7.4, 1.6 Hz, 1H), 7.54-7.39 (m, 4H), 7.28-7.23 (m, 2H), 7.21-7.14 (m, 4H), 7.10 (d, 7= 7.2 Hz, 1H), 3.70 (br s, 2H), 2.72 (br s, 4H); LC-MS: 95.70%; 361.0 (M*+l); (column; X-select CSH C18, (50 x 3.0 mm, 3.5 pm); RT 2.65 min. 0.05% Aq. TFA: ACN; 0.8
293 mL/min); UPLC (purity): 95.01%; (column; Acquity BEH C-18 (50 x 2.1 mm, 1.7 μ); RT 1.87 min. ACN: 0.025% TFA (Aq); 0.5 mL/min).
Synthesis of7V-((ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepin-8-yl) methyl)-2V-phenethyl acetamide (1367): To a stirred solution of compound 1357 (40 mg, 0.11 mmol) in CH2CI2 (2 mL) under argon atmosphère were added pyridine (0.013 mL, 0.16 mmol), acetic anhydride (0.011 mL, 0.12 mmol) at 0-5 C; warmed to RT and stirred for 2 h. The reaction was monitored by TLC; after completion the reaction, the reaction mixture was diluted with CH2CI2 (20 mL) washed with 1 N HCl (5 mL) and brine (10 mL). The organic extract was dried over sodium sulfate, fïltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 5% EtOAc/ hexanes to afford 1367 (25 mg, 57%) as an off-white solid.
TLC: 70% EtOAc/ hexanes (Rf. 0.8); JH NMR (DMSO-îZ6, 500 MHz): δ 10.62-10.60 (m, 1H), 7.67-7.64 (m, 1H), 7.57-7.38 (m, 4H), 7.29-6.94 (m, 7H), 4.45 (d, J= 9.8 Hz, 2H), 3.41-3.35 (m, 2H), 2.82-2.66 (m, 2H), 1.97-1.87 (m, 3H); LC-MS: 92.67%; 403.5 (VT+l); (column; X-select CSH C18, (50 x 3.0 mm, 3.5 pm); RT 4.37 min. 5 mM AqJSffifiOAc: ACN; 0.8 mL/min); UPLC (purity): 93.63%; (column; Acquity BEH C-18 (50 x 2.1 mm, 1.7 μ); RT 2.41 min. ACN: 0.025% TFA (Aq); 0.5 mL/min).
Example 36: Synthesis of Compound 1501
294
Synthesis of 8-(hydroxymethyl)-10-(4-methoxybenzyl) dibenzo [b,f\ [1,4] thiazepin-ll(lOH)one (476): To a stirred solution of 1655 (1 g, 3.89 mmol) in THF (50 mL) were added Benzyltriéthylammonium chloride (88 mg, 0.38 mmol), 50% aqueous sodium hydroxide solution (4 mL) at 0-5 C and stirred for 20 min. To this was added 4-methoxybenzy chloride (0.52 mL, 3.89
O mmol) at 0-5 C and heated to reflux for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice water (40 mL) and extracted with EtOAc (2 x 100 mL). The combined organic extracts was dried over sodium sulfate, fiitered and concentrated in vacuo to obtain the crude. The crude was purified using silicagel column chromatography using 2% MeOH/ CH2CI2 to afford compound 476 (800 mg, 57%) as white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.6); *H NMR (DMSO-î/6, 500 MHz): δ 7.64-7.59 (m, 1H), 7.53 (s, 1H), 7.51-7.44 (m, 2H), 7.41-7.35 (m, 2H), 7.22 (d, J= 8.7 Hz, 2H), 7.06 (d, 7.8 Hz, 1H), 6.81 (d, J= 8.7 Hz, 2H), 5.67 (d, J= 15.3 Hz, 1H), 5.21 ( br s, 1H), 4.85 (d, J= 15.3 Hz, 1H), 4.41 (s, 2H), 3.68 (s, 3H).
Synthesis of 8-(bromomethyl)-10-(4-methoxybenzyl) dibenzo \b,f\ [1,4] thiazepin-l Î (10Z/)-one (477): To a stirred solution of compound 476 (800 mg, 2.12 mmol) in CH2CI2 (20 mL) under argon
O atmosphère were added triphenyl phosphine (1.1 g, 4.24 mmol), CBr4 (0.3 mL, 3.18 mmol) at 0 C; warmed to RT and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 50% EtOAc/ hexanes to afford compound 477 (600 mg, 66%) as an off-white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.8); *H NMR (DMSO-J6, 500 MHz): δ 7.73 (s, 1H), 7.63 (dd, J= 7.1, 1.9 Hz, 1H), 7.53-7.44 (m, 2H), 7.43-7.36 (m, 2H), 7.22-7.15 (m, 3H), 6.79 (d, J= 8.7 Hz, 2H), 5.77-5.71 (m, 1H), 4.80 (d, J= 15.0 Hz, 1H), 4.60 (s, 2H), 3.67 (s, 3H).
Synthesis of 10-(4-methoxybenzyl)-8-(phenethoxymethyl)dibenzo \b,f\ [1,4] thiazepinll(10H)-one (479): To a stirred solution of 2-phenylethan-l-ol 477 (100 mg, 0.81 mmol) in THF (10 mL) inert atmosphère was added was added sodium hydride (60%, 49 mg, 2.5 mmol) under portion wise for 5 min at 0 °C; warmed to RT and stirred for 2 h. To this was added compound 478 (359 mg, 0.81 mmol) at RT; heated to 65 °C and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice-cold water (20 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over sodium
295 sulfate, filtered and concentrated in vacuo to obtain the crude compound 479 (150 mg) as yellow solid. TLC: 70% EtOAc/ hexanes (Rf. 0.5); LC-MS: 58.75%; 482.0 (NL+l); (column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 3.25 min. 0.025% Aq. TFA + 5% ACN: ACN +; 5% 0.025% Aq. TFA, 1.2 mL/min).
Synthesis of 8-(phenethoxymethyl) dibenzo \b,f\ [1, 4] thiazepin-l l(10//)-one (1501): A mixture of compound 479 (140 mg, crude) and trifluoro acetic acid (2 mL) under inert atmosphère at RT was heated to 80 C and stirred for 6 h in a sealed tube. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo, the residue was quenched with 20% aqueous sodium bicarbonate solution (10 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts was dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified using silicagel column chromatography using 70% EtOAc/ hexanes to afford compound 1501 (35 mg, 33%) as white solid. TLC: 70% EtOAc/ hexanes (Rf. 0.4); *H NMR (DMSO-J6, 400 MHz): δ 10.65 (s, 1H), 7.67 (dd, J= 7.5, 1.6 Hz, 1H), 7.54-7.40 (m, 4H), 7.29-7.13 (m, 6H), 7.04 (dd, J= 7.9, 1.7 Hz, 1H), 4.44 (s, 2H), 3.63 (t, J= 6.9 Hz, 2H), 2.84 (t, J= 6.9 Hz, 2H); LC-MS: 96.49%; 361.9 (WT+l); (column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 2.79 min. 0.025% Aq. TFA + 5% ACN: ACN +; 5% 0.025% Aq. TFA, 1.2 mL/min); HPLC (purity): 96.59%; (column; Eclipse XDB-C-18 (150 x 4.6 mm, 5.0 pm); RT 10.25 min. ACN: 0.025% TFA (Aq); 1.0 mL/min).
Example 37: Synthesis of lO-methyl-ll-oxo-10,11-dihydrodibenzo [Z>, /1 fl, 41 thiazepine-8carboxylic acid (486) - a common intermediate
To a stirred solution of compound 6 (500 mg, 1.84 mmol) in DMF (10 mL) was added sodium hydride (60%, 442 mg, 18.45 mmol) under inert atmosphère at 0 °C and stirred for 1 h. To this was methyl iodide (1.14 mL, 18.45 mmol) at 0-5 °C, warmed to RT and stirred for 1.5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and washed with EtOAc (2 x 20 mL). The aqueous layer was separated and the pH was adjusted to ~2 with 4 N HCl. The precipitated solid was filtered, washed with n-hexane (10 mL) and 296 dried in vacuo to obtain the compound 486 (400 mg, 76%) a white solid. TLC: 10% MeOH/ CH2CI2 (Rf. 0.2); ’H-NMR (DMSO-J6, 500 MHz): δ 13.31 (br s, 1H), 7.99 (s, 1H), 7.75-7.68 (m, 2H), 7.65-7.61 (m, 1H), 7.54-7.49 (m, 1H), 7.44-7.39 (m, 2H), 3.53 (s, 3H).
Example 38: Synthesis of compounds from compound 486 and various commercially available amines
Compound 486 was converted to final products using commercially available amines or by employing Procedure A and the results are captured in the Table 2:
Table 2: Synthesis of compounds from compound 486 and various commercially available amines
,/ΑΚαα'·' AnoA Z’s.'f'AU·/':'·:1:î | Structure } s ; *·. / ? - * -·:ί ·Τ^ί< ' ·* | : Procedure,;· ; : .......- ...-À!: Intermediate, Amine | LRx. j Yield (%) -'.J.*·; i.J.ïî·.,' | IVIass ·,. Spec. Found | 'Mass-Spéc/λ Calculated | ' /. ifHrNMR·'‘t’;;' zyzz-.L'y |
1573 | M ? | A, 486, 213 | 36 | 382.0 (Mf+1) | 381.06 for C19H15N3O2 s2 | lH-NMR (DMSO-Jtf, 400 MHz): δ 9.27 (t, J= 5.7 Hz, 1H), 8.96 (s, 1H), 7.96 (s, 1H), 7.82 (s, 1H), 7.74-7.70 (m, 1H), 7.68-7.61 (m, 2H), 7.547.49 (m, 1H), 7.45-7.38 (m, 2H), 4.67 (t,J= 5.4 Hz, 2H), 3.54 (s, 3H); |
1553 | °W ' r\ n P H | A,486,218 | 30 | 376.1 (Mf+l) | 375.10 for C2]Hi7N3O2 S | ‘H-NMR (DMSO-iZd, 400 MHz): δ 9.16 (t, J= 5.7 Hz, 1H), 8.54 (s, 1H), 8.45 (dd,J= 4.6,1.3 Hz, 1H), 7.98 (s, 1H), 7.75-7.61 |
297
(m, 4H), 7.557.49 (m, 1H), 7.46-7.38 (m, 2H), 7.33 (dd, J = 7.3,4.8 Hz, 1H), 4.55-4.41 (m, 2H), 3.55 (s, 3H); | ||||||
1574 | A, 486,212 | 36 | 376.9 (MAI); | 376.10 for C20H16N4O2 S | ‘H-NMR (DMSO-<7d, 400 MHz): δ 9.19 (t, J= 5.7 Hz, 1H), 9.08 (s, 1H), 8.76 (s, 2H), 7.98 (s, 1H), 7.73 (d, .7=8.4 Hz, 1H), 7.687.60 (m, 2H), 7.55-7.49 (m, 1H), 7.46-7.38 (m, 2H), 4.57 4.39 (m, 2H), 3.55 (s, 3H); | |
1133 | ο / Q OH | D, 486 | 70 | 405.127 2 | 405.1273 for C23H21N2O3 S | ‘H NMR (400 MHz, DMSOd6) δ 9.25 (s, 1H), 8.63 (t,J = 5.6 Hz, 1H), 7.88 (d, J= 1.8 Hz, 1H), 7.73 - 7.56 (m, 3H), 7.55-7.47 (m, 1H), 7.47-7.36 (m, 2H), 7.05 (t, J =7.7 Hz, 1H), 6.60 (td, J =9.2, 7.1 Hz, 3H), 3.53 (s, 3H), 3.46-3.38 (m, 2H), 2.71 (t, J = 7.4 Hz, 2H). |
298
Example 39: Synthesis of Compounds 1342 and 1361
Synthesis of methyl (Z)-2-((tert-butoxycarbonyl) amino)-3-(pyrimidin-5-yl) acrylate (507): To a stirred solution of methyl 2-((tert-butoxycarbonyl) amino)-2-(dimethoxyphosphoryl) acetate 506 (3.3 g, 11.11 mmol) in CH2CI2 (15 mL) under inert atmosphère was added potassium Abutoxide (13.8 mL, 13.88 mmol, IM solution in THF), portion wise for 15 min at -30 °C. To this was added o pyrimidine-5-carbaldehyde 505 (1 g, 9.25 mmol) in CH2CI2 (5 mL) drop wise for 10 min at -30 C, stirred for 2 h; warmed to 0 °C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (50 mL) and extracted with
CH2CI2 (2 x 100 mL). The combined organic extracts were washed with water (100 mL), dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 50% EtOAc/ hexanes to afford compound 507 (1.8 g, 72%) as an off-white solid. TLC: 70% EtOAc/ hexanes (Rf. 0.8); XH NMR (500MHz, DMSOd6): δ 9.11 (s, 1H), 9.02 (brs, 1H), 8.98 (s, 2H), 6.46 (s, 1H), 3.76 (s, 3H), 1.42-1.38 (m, 9H).
Synthesis of methyl 2-((terAbutoxycarbonyl) amino)-3-(pyrimidin-5-yl) propanoate (508): To a stirred solution of compound 507 (1.8 g, 6.45 mmol) in MeOH (25 mL) under inert atmosphère was added 5% Pd/C (500 mg) at RT and stirred under hydrogen atmosphère (at 100 psi) for 16 h in a steel bomb. The reaction was monitored by TLC; after completion of the reaction, the reaction
299 mixture was filtered through celite and washed with 10% MeOH/ CH2CI2 (2 x 50 mL). The filtrate was concentrated in vacuo to obtain the crude compound 508 (1.3 g, 72%) as colorless syrup. TLC: 5% MeOH/ CH2CI2 (Rf. 0.5); 'H NMR (DMSO-</d, 500 MHz): δ 9.03 (s, 1H), 8.68 (s, 2H), 7.40 (d, J= 7.8 Hz, 1H), 4.33-4.25 (m, 1H), 3.65 (s, 3H), 3.09 (dd, J= 14.4, 4.4 Hz, 1H), 2.89-2.81 (m, 1H), 1.33-1.22 (m, 9H).
Synthesis of methyl 2-amino-3-(pyrimidin-5-yl) propanoate hydrochloride (509): To a stirred solution of compound 508 (1.3 g, 4.62 mmol) in CH2CI2 (5 mL) under argon atmosphère was added 4 N HCl in 1, 4-dioxane (5 mL) at 0 °C; warmed to RT and stirred for 3.5 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to afford compound 509 (850 mg) as an off-white solid. TLC: 5% MeOH/ CH2CI2 (Rf. 0.2); 'H NMR (DMSO-rfd, 400 MHz): δ 9.15-9.08 (m, 1H), 8.75 (s, 4H), 4.45-4.44 (m, 1H), 3.73 (s, 3H), 3.22 (dd, J =6.6, 2.4 Hz, 2H).
Synthesis of methyl 2-(2-fluoro-ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8carboxamido)-3-(pyrimidin-5-yl) propanoate (1342): Using Procedure B the title compound was prepared with compound 35 (200 mg, 0.69 mmol), compound 509 (165 mg, 0.76 mmol) and was obtained in 67% yield as an off-white solid; TLC: 5% MeOH/ CH2CI2 (Rf 0.5); JH NMR (DMSOrf6,500 MHz): δ 10.89 (s, 1H), 8.99 (t, J= 4.0 Hz, 2H), 8.69 (s, 2H), 7.66 (d, J= 8.1 Hz, 1H), 7.617.56 (m, 2H), 7.52 (dd, J= 8.1, 1.4 Hz, 1H), 7.46 (dd, J= 9.1, 2.7 Hz, 1H), 7.36 (td, J= 8.4, 2.9 Hz, 1H), 4.81-4.70 (m, 1H), 3.64 (s, 3H), 3.22 (dd, J= 14.2, 4.9 Hz, 1H), 3.05 (dd, J= 14.0, 10.6 Hz, 1H); LC-MS: 98.59%; 453.4 (M++l); (column; X-select CSH C18, (50 x 3.0 mm, 3.5 pm); RT 3.45 min. 0.05% Aq. TFA: ACN; 0.8 mL/min); UPLC (purity): 99.40%; (column; Acquity BEH C-18 (50 x 2.1 mm, 1.7 p); RT 1.89 min. ACN: 0.025% TFA (Aq); 0.5 mL/min).
Synthesis of 2-fluoro-7V-(l-hydroxy-3-(pyrimidin-5-yl) propan-2-yl)-ll-oxo-10,11dihydrodibenzo [Λ,./] [1,4] thiazepine-8-carboxamide (1361): To a stirred solution of 1342 (200 mg, 0.44 mmol) in MeOH (5 mL) under inert atmosphère was added sodium borohydride (65 mg, 1.76 mmol) at 0 °C; warmed to RT and stirred for 6 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was quenched with ice cold water (25 mL) and extracted with 5% MeOH/ CH2CI2 (5 x 25 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 8% MeOH/ CH2CI2 to afford compound 1361 (140 300 mg, 75%) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.4); 2H NMR (DMSO-</6,400 MHz): δ 10.87 (s, 1H), 8.96 (s, 1H), 8.64 (s, 2H), 8.30 (d, J= 8.7 Hz, 1H), 7.66-7.63 (m, 1H), 7.617.57 (m, 2H), 7.53 (dd, J= 8.1, 1.8 Hz, 1H), 7.47 (dd, J= 9.2, 2.9 Hz, 1H), 7.37 (td, J= 8.5, 3.0 Hz, 1H), 4.93 (t, J= 5.6 Hz, 1H), 4.22-4.11 (m, 1H), 3.53-3.40 (m, 2H), 2.98 (dd, J= 13.9, 4.2 Hz, 1H), 2.73 (dd, J= 14.0, 10.1 Hz, 1H); LC-MS: 99.82%; 425.4 (M*+l); (column; X-select CSH Cl8, (50 x 3.0 mm, 3.5 pm); RT 3.68 min. 0.05% Aq. TFA: ACN; 0.8 mL/min); UPLC (purity): 99.77%;
(column; Acquity BEH C-18 (50 x 2.1 mm, 1.7 p); RT 1.65 min. ACN: 0.025% TFA (Aq.); 0.5 mL/min).
Example 40: Synthesis of Compound 1346
Synthesis of 2-(2-fluoro-ll-oxo-10,11-dihydrodibenzo [b,j\ [1,4] thiazepine-8-carboxamido)3-(pyrimidin-5-yl) propanoic acid (510): To a stirred solution of compound 1342 (150 mg, 0.33 mmol) in a mixture of THF: H2O (4: 1,5 mL) was added lithium hydroxide monohydrate (35 mg, 0.82 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (3 mL) and the pH was adjusted to ~5 with 1 N HCl. The precipitated solid was filtered and dried in vacuo to afford compound 510 (75 mg, 52%) as white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.2); 1H NMR (DMSO ¢(¢,400 MHz): δ 10.90 (s, 1H), 8.98 (s, 1H), 8.78 (d, J= 7.6 Hz, 1H), 8.68 (s, 2H), 7.66 (d, J= 8.0 Hz, 1H), 7.62-7.57 (m, 2H), 7.53 (dd, J= 8.1, 1.7 Hz, 1H), 7.47 (dd, J= 9.2, 2.9 Hz, 1H), 7.37 (dt, J= 8.5, 2.9 Hz, 1H), 7.40-7.34 (m, 1H), 4.69-4.58 (m, 1H), 3.23 (dd, J= 14.1, 4.6 Hz, 1H), 3.03 (dd, J= 14.0, 10.3 Hz, 1H).
301
Synthesis of teri-butyl 2-(2-fluoro-ll-oxo-10,11-dihydrodibenzo [b,f\ [1, 4] thiazepine-8carboxamido)-3-(pyrimidin-5-yl) propanoate (1346): To a stirred solution of compound 510 (70 mg, 0.15 mmol) in Abutanol (4 mL) under inert atmosphère were added Boc-anhydride (0.11 mL, 0.47 mmol) and DMAP (30 mg, 0.03 mmol) at 5 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (10 mL) and extracted with CH2CI2 (2 x 25 mL). The combined organic extracts were dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through préparative TLC (50% EtOAc/ hexanes) to afford 1346 (25 mg, 32%) as an offwhite solid. TLC: 70% EtOAc/ hexanes (Rf. 0.4); JH NMR (DMSO-^, 400 MHz): δ 10.91 (s, 1H),
9.01 (s, 1H), 8.89 (d, J= 7.8 Hz, 1H), 8.71 (s, 2H), 7.67 (d, J= 8.0 Hz, 1H), 7.64-7.58 (m, 2H), 7.55 (dd, J= 8.0, 1.9 Hz, 1H), 7.48 (dd, J= 9.2, 2.9 Hz, 1H), 7.38 (td, J= 8.5, 2.9 Hz, 1H), 4.65-4.59 (m, 1H), 3.21-3.13 (m, 1H), 3.09-2.99 (m, 1H), 1.39-1.31 (m, 9H); LC-MS: 98.60%; 495.6 (MM); (column; X-select CSH C18, (50 x 3.0 mm, 3.5 pm); RT 3.91 min. 0.05% Aq. TFA: CAN; 0.8 mL/min); UPLC (purity): 98.29%; (column; Acquity BEH C-18 (50 x 2.1 mm, 1.7 p); RT 2.15 min. CAN: 0.025% TFA (Aq); 0.5 mL/min).
302
Example 41: Synthesis of Compounds 1420 and 1419
Synthesis of methyl 3'-nitro-[l, l'-biphenyI]-4-carboxylate (512): To a stirred solution of methyl 4-bromobenzoate 511 (2.5 g, 14.97 mmol) and (3-nitrophenyl) boronic acid 382 (3.8 g, 17.96 mmol) in Toluene (20 mL) under inert atmosphère were added sodium carbonate (3.17 g, 29.96 mmol in 25 mL of H2O) at RT and purged under argon atmosphère for 20 min. To this was added Pd(PPh3)4 (691 mg, 0.59 mmol) and heated to 80 C for 5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with EtOAc (200 mL). The organic extract was dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 10% EtOAc/ hexanes to afford compound 512 (800 mg, 21%) as yellow liquid. TLC: 15% EtOAc/ hexanes (Rf. 0.5); 1H NMR (400 MHz, CD3OD): δ 8.54-8.52 (m, 1H), 8.29-8.26 (m, 1H), 8.15 (d, J= 8.7 Hz, 2H), 8.12-8.09 (m, 1H), 7.84 (d, J= 8.6 Hz, 2H), 7.74 (t, J= 8.0 Hz, 1H), 3.94 (s, 3H).
Synthesis of methyl 3'-amino-[l, l'-biphenyl]-4-carboxylate (513): To a stirred solution of compound 512 (800 mg, 3.11 mmol) in EtOH (50 mL) under inert atmosphère was added 10% Pd/C (500 mg, wet) under argon atmosphère and stirred under H2 atmosphère (balloon pressure) for 5 h.
303
After completion of the reaction, the reaction mixture was fïltered through celite, washed with 50% MeOH/ CH2CI2 (150 mL). The filtrate was concentrated in vacuo to obtain the crude which was purified through silicagel column chromatography in 5% MeOH/ CH2CI2 to afford compound 513 (600 mg, 67%) as an off-white solid. The crude was carried for next step without further purification. TLC: 5% MeOH/ CH2C12 (Rf. 0.4).
Synthesis of methyl 3'-(2-fluoro-ll-oxo-10,11-dihydrodibenzo [b,j\ [1,4] thiazepine-8carboxamido)-[l, l'-biphenyl]-4-carboxylate (1420): Using Procedure A the title compound was prepared with 35 (50 mg, 0.17 mmol), compound 513 (43 mg, 0.19 mmol) and was obtained in 58% yield as white solid; TLC: 5% MeOH/ CH2C12 (Rf. 0.5); JH NMR (DMSO-76,400 MHz): δ 10.99 (s, 1H), 10.43 (s, 1H), 8.14 (s, 1H), 8.07 (d, J= 7.9 Hz, 2H), 7.85-7.72 (m, 6H), 7.63 (dd, J= 8.6, 5.3 Hz, 1H), 7.54-7.45 (m, 3H), 7.40 (td, J= 8.5, 3.0 Hz, 1H), 3.88 (s, 3H); LC-MS: 98.86%; 498.1 (M*+l); (column; X-select CSH C18, (50 x 3.0 mm, 3.5 pm); RT 4.15 min. 0.05% Aq. TFA: ACN; 0.8 mL/min); UPLC (purity): 95.09%; (column; Acquity BEH C-18 (50 x 2.1 mm, 1.7 p); RT 2.75 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
Synthesis of 3'-(2-fIuoro-ll-oxo-10,11-dihydrodibenzo [b,f\ [1,4] thiazepine-8-carboxamido)[1, l’-biphenyl]-4-carboxylic acid (1419): To a stirred solution of 1420 (50 mg, 0.10 mmol) in MeOH: H2O (3:1,8 mL) was added potassium hydroxide (56 mg, 1.00 mmol) at RT in a sealed tube and heated to 90 °C and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the pH of the reaction mixture was acidified with 4 N HCl to pH ~2. The obtained solid was fïltered, triturated with 10% EtOAc/ hexanes (10 mL) and dried in vacuo and to afford compound 1419 (20 mg, 41%) as an off-white solid. TLC: 70% EtOAc/ hexanes (Rf. 0.2); ’H NMR (400 MHz, DMSO-dô): δ 12.98 (brs, 1H), 11.00 (s, 1H), 10.51 (s, 1H), 8.15 (s, 1H), 8.04 (d, J= 8.4 Hz, 2H), 7.87-7.70 (m, 6H), 7.63 (dd, J= 8.6, 5.3 Hz, 1H), 7.54-7.46 (m, 3H), 7.40 (td, J= 8.5,2.9 Hz, 1H); LC-MS: 91.15%; 485.0 (M++l); (column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 2.48 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min); UPLC (purity): 93.75%; (column; Acquity BEH C-18 (50 x 2.1 mm, 1.7 p); RT 2.43 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
304
Example 42: Synthesis of Compounds 1422 and 1421
Synthesis of methyl 3'-nitro-[l, l'-biphenyl]-3-carboxylate (515): To a stirred solution of methyl 3-bromobenzoate 514 (2.5 g, 14.99 mmol) and (3-nitrophenyl) boronic acid 382 (3.8 g, 17.99 mmol) in toluene (20 mL) under inert atmosphère were added sodium carbonate (3.17 g, 29.99 mmol in 20 mL of H2O) at RT and purged under argon atmosphère for 20 min. To this was added Pd(PPh3)4 (693 mg, 0.59 mmol) and heated to 80 C for 5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with EtOAc (200 mL). The organic extract was dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 10% EtOAc/ hexanes to afford compound 515 (1 g, 26%) as yellow liquid. TLC: 15% EtOAc/ hexanes (Rf. 0.5); *H NMR (400 MHz, DMSO-rf6): δ 8.48-8.46 (m, 1H), 8.30-8.25 (m, 2H), 8.22-8.18 (m, 1H), 8.11-8.07 (m, 1H), 8.04 (dt, J= 7.8, 1.3 Hz, 1H), 7.80 (t, J= 8.0 Hz, 1H), 7.69 (t, J= 7.8 Hz, 1H), 3.91 (s, 3H).
Synthesis of methyl 3'-amino-[l, l'-biphenyl]-3-carboxy!ate (516): To a stirred solution of compound 515 (1 g, 3.89 mmol) in EtOH (100 mL) under inert atmosphère was added 10% Pd/C (600 mg, wet) under argon atmosphère and stirred under H2 atmosphère (balloon pressure) for 16 h. After completion of the reaction, the reaction mixture was filtered through celite and the celite pad
305 was washed with 50% MeOH/ CH2CI2 (150 mL). The fïltrate was evaporated in vacuo to obtain the crude which was purified through silicagel column chromatography in 20% EtOAc/ hexanes to afford compound 516 (600 mg, 67%) as an off-white solid. TLC: 40% EtOAc/ hexanes (Rf. 0.3); 'H NMR (400 MHz, DMSO-76): δ 8.15- 8.08 (m, 1H), 7.92 (d, J= 7.7 Hz, 1H), 7.84 (d, 7= 8.2 Hz, 1H), 7.59 (t, 7= 7.7 Hz, 1H), 7.13 (t, 7= 7.8 Hz, 1H), 6.90-6.87 (m, 1H), 6.81 (d, 7= 7.6 Hz, 1H), 6.60 (dd, 7= 8.0, 1.4 Hz, 1H), 5.22 (s, 2H), 3.32 (s, 3H).
Synthesis of methyl 3'-(2-fluoro-ll-oxo-10,11-dihydrodibenzo [b, J\ [1, 4] thiazepine-8carboxamido)-[l, l'-biphenyl]-3-carboxylate (1422): Using Procedure A the title compound was prepared with compound 35 (70 mg, 0.24 mmol), compound 516 (55 mg, 0.24 mmol) and was obtained in 41% yield as white solid; TLC: 5% MeOH/ CH2C12 (Rf. 0.5); *H NMR (400 MHz, DMSO-7tf): δ 10.99 (s, 1H), 10.43 (s, 1H), 8.12-8.19 (m, 1H), 8.10-8.08 (m, 1H), 7.96 (dd, 7= 12.8, 7.9 Hz, 2H), 7.85 (dt, 7= 7.1, 1.8 Hz, 1H), 7.81-7.73 (m, 3H), 7.69-7.59 (m, 2H), 7.54-7.45 (m, 3H), 7.40 (td, 7= 8.5, 2.9 Hz, 1H), 3.90 (s, 3H); LC-MS: 99.82%; 499.0 (M+l)+; (column; X-select CSH C18, (50 x 3.0 mm, 3.5 pm); RT 4.10 min. 0.05% Aq. TFA: ACN; 0.8 mL/min); UPLC (purity): 98.72%; (column; Acquity BEH C-18 (50 x 2.1 mm, 1.7 μ); RT 2.78 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
Synthesis of 3'-(2-fIuoro-ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-carboxamido)[1, l'-biphenyl]-3-carboxylic acid (1421): To a stirred solution of 1422 (35 mg, 0.07 mmol) in MeOH: H2O (3:1,5 mL) under inert atmosphère was added potassium hydroxide (40 mg, 0.70 mmol) at RT in a sealed tube and heated to 80 °C and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the pH of the reaction mixture was acidified with 4 N HCl to pH ~2 and extracted with EtOAc (2x10 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The obtained solid was filtered, dried in vacuo and triturated with 10% EtOAc/ hexanes (10 mL) to afford compound 1421 (20 mg, 58%) as white solid. TLC: 70% EtOAc/ hexanes (Rf. 0.2); *H NMR (400 MHz, DMSOd6): δ 12.99 (br s, 1H), 10.98 (s, 1H), 10.43 (s, 1H), 8.21-8.19 (m, 1H), 8.11-8.09 (m, 1H), 7.96 (d, J = 7.7 Hz, 1H), 7.87 (dd, 7= 19.5, 7.3 Hz, 2H), 7.82-7.73 (m, 3H), 7.66-7.58 (m, 2H), 7.54-7.44 (m, 3H), 7.40 (td,7= 8.5, 2.9 Hz, 1H); LC-MS: 99.07%; 484.9 (MT+1); (column; X-select CSH C18, (50 x 3.0 mm, 3.5 pm); RT 3.73 min. 0.05% Aq. TFA: ACN; 0.8 mL/min); UPLC (purity):
306
96.90%; (column; Acquity BEH C-18 (50 x 2.1 mm, 1.7 μ); RT 2.46 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
Example 43: Synthesis of Compounds 1436 and 1435
Synthesis of methyl 3’-nitro-[l, l'-biphenyl]-2-carboxylate (518): To a stirred solution of methyl 2-bromobenzoate 517 (2.5 g, 14.97 mmol) and (3-nitrophenyl) boronic acid 382 (3.8 g, 17.96 mmol) in toluene (20 mL) under inert atmosphère were added sodium carbonate (3.17 g, 29.94 mmol in 20 mL of H2O) at RT and purged under argon atmosphère for 20 min. To this was added Pd(PPh3)4 (691 mg, 0.59 mmol) and heated to 80 °C for 6 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with EtOAc (200 mL). The organic extract was dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 15% EtOAc/ hexanes to afford compound 518 (600 mg, 17%) as yellow solid. TLC: 30% EtOAc/ hexanes (Rf 0.6); 1H NMR (400 MHz, DMSO-iZtf): δ 8.27-8.23 (m, 1H), 8.11-8.09 (m, 1H), 7.89 (dd, 7= 7.7, 1.3 Hz, 1H), 7.79-7.67 (m, 3H), 7.59 (td, J= 7.6, 1.1 Hz, 1H), 7.52 (dd, J= 7.6, 0.6 Hz, 1H), 3.31 (s, 3H).
Synthesis of methyl 3'-amino-[l, l'-biphenyl]-2-carboxylate (519): To a stirred solution of compound 518 (600 mg, 2.33 mmol) in EtOH (50 mL) under inert atmosphère was added 10% Pd/C
307 (300 mg, wet) under argon atmosphère and stirred under H2 atmosphère (balloon pressure) for 16 h. After completion of the reaction, the reaction mixture was filtered through celite and the celite pad was washed with 50% MeOH/ CH2CI2 (100 mL). The filtrate was evaporated in vacuo to afford compound 519 (500 mg, 87%) as an off-white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.6); *H NMR (400 MHz, DMSO-d6): δ 7.63 (dd, J= Ί.Ί, 1.0 Hz, 1H), 7.56 (td, J= 9.0, 1.8 Hz, 1H), 7.43 (td, J= Ί.6,1.1 Hz, 1H), 7.37 (dd, J= 7.7, 0.8 Hz, 1H), 7.03 (t, J= 7.7 Hz, 1H), 6.57-6.52 (m, 1H), 6.526.49 (m, 1H), 6.39 (d, J= 7.5 Hz, 1H), 5.14 (br s, 2H), 3.59 (s, 3H).
Synthesis of methyl 3'-(2-fluoro-ll-oxo-10,11-dihydrodibenzo \b.f\ [1, 4] thiazepine-8carboxamido)-[l, l'-biphenyl]-2-carboxylate (1436): Using Procedure A the title compound was prepared with compound 35 (100 mg, 0.34 mmol), compound 519 (78 mg, 0.34 mmol) and was obtained in 35% yield as white solid; TLC: 5% MeOH/ CH2C12 (Rf. 0.5); Tl NMR (400 MHz, DMSO-^): δ 10.97 (s, 1H), 10.37 (s, 1H), 7.78-7.72 (m, 6H), 7.66-7.60 (m, 2H), 7.54-7.48 (m, 2H), 7.46-7.36 (m, 3H), 7.04 (d, J= 7.3 Hz, 1H), 3.61 (s, 3H); LC-MS: 93.05%; 499.0 (M/^-t-l); (column; Ascentis Express Cl8, (50 x 3.0 mm, 2.7 pm); RT 2.74 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min); UPLC (purity): 91.54%; (column; Acquity BEH C-18 (50 x 2.1 mm, 1.7 p); RT 2.72 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
Synthesis of 3'-(2-fluoro-ll-oxo-10,11-dihydrodibenzo \b,j\ [1, 4] thiazepine-8-carboxamido)[1, l'-biphenyl]-2-carboxy!ic acid (1435): To a stirred solution of 1436 (35 mg, 0.07 mmol) in MeOH: H2O (3:1,8 mL) was added potassium hydroxide (40 mg, 0.70 mmol) at RT in a sealed tube and heated to 80 °C and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the pH of the reaction mixture was acidified with 4 N HCl to pH ~2 and extracted with EtOAc (2x10 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The obtained solid was filtered, triturated with 10% EtOAc/ hexanes (5 mL) and dried in vacuo to afford compound 1435 (20 mg, 58%) as white solid.
TLC: 70% EtOAc/ hexanes (Rf. 0.2); *H NMR (400 MHz, DMSO-d6): δ 11.00 (br s, 1H), 10.36 (s, 1H), 7.81-7.69 (m, 5H), 7.67-7.59 (m, 2H), 7.54-7.48 (m, 2H), 7.44-7.31 (m, 4H), 7.07 (d, J= 7.8 Hz, 1H); LC-MS: 91.40%; 484.9 (ΜΤΤ); (column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 2.49 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min); UPLC (purity): 92.47%; (column; Acquity BEH C-18 (50 x 2.1 mm, 1.7 p); RT 2.36 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
308
Example 44: Synthesis of ll-oxo-10,11-dihydrodibenzo [b, f\ [1, 41 thiazepine-8-suIfonamide
To a stirred solution of compound 491 (80 mg, 0.26 mmol) in DMSO (1.5 mL) under inert atmosphère were added potassium metabisulfate (116 mg, 0.52 mmol), tetraethyl ammonium bromide (60 mg, 0.28 mmol), sodium formate (40 mg, 0.57 mmol), palladium acetate (18 mg, 0.026 mmol) and 1, 10-phenanthroline (14 mg, 0.078 mmol) at RT in a microwave vial and purged under argon atmosphère for 10 min; heated to 90 °C for 4 h. The reaction was monitored by TLC; after completion of the reaction, the crude compound was carried forward to next step. TLC: 30% EtOAc/ hexanes (Rf. 0.4).
The above crude compound and commercially available amines were converted to corresponding sulfonamide employing the Procedure L and the results are captured in the Table 3.
Procedure L:
To a stirred solution of above crude compound (100 mg, crude) in THF (2 mL) under argon atmosphère were added piperidine 521 (0.05 mL, 0.54 mmol) in THF (1 mL), 7V-bromosuccinimide (96 mg, 0.54 mmol) in THF (1 mL) at 0 °C; warmed to RT and stirred for 12 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with brine (20 mT,) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purifîed through silica gel column chromatography to afford the desired compound.
309
Commercially available amines used for the préparation of compounds:
Ό | “0 | HN-\ kz~0H | HN—i A | |
521 | 522 | 275 | 523 | 524 |
h2n^ | ...x> | OL/NH2 | η2νΆΗ | |
254 | 257 | |||
525 | 179 | 221 | ||
h2n s-^ | ||||
212 | 213 |
Table 3: Synthesis of compounds from compound 520 and various commercially available amines
No. | . Structure . : | Procedure, Intermediate, Amine ' | Rx. Yîeld (%) | Mass Spec. Found | Mass Spec/ Calculated· | 'll-NMR . i ’ - 1 |
1399 | 0 H °< *° XPo | L, 521 (RT 18 h) | 15 | 374.9 (M+l) | 374.08 for C18H18N2O 3s2 | ‘HNMR (DMSO-iZe, 400 MHz): δ 10.86 (s, 1H), 7.80 (d, 7=8.0 Hz, 1H), 7.72 (dd, 7=7.6,1.4 Hz, 1H), 7.597.55 (m, 2H), 7.54-7.43 (m, 3H), 2.93-2.84 (m, 4H), 1.571.48 (m, 4H), 1.42-1.31 (m, 2H); |
1431 | M | L, 522 | 19 | 390.9 (M*+l) | 390.07 for C[8Hi8N2O 4S2 | ‘HNMR (DMSO-7d, 400 MHz): δ 10.87 (s, 1H), 7.81 (d, 7=8.2 Hz, 1H), 7.72 (dd,7=7.4,1.4 Hz, 1H), 7.607.53 (m, 3H), 7.52-7.45 (m, |
310
2H), 4.66 (d, J = 4.0 Hz, 1H), 3.53-3.49 (m, 1H), 3.19-3.12 (m, 2H), 2.762.69 (m, 2H), 1.77-1.68 (m, 2H), 1.49-1.35 (m,2H); | ||||||
1432 | 0 H %'/° ,S. ΛΠυ v/s | L, 275 | 20 | 360.8 (M*+l) | 360.06 for c17h16n2o 3S2 | ‘H NMR (DMSO-φ, 400 MHz): δ 10.85 (s, 1H), 7.79 (d, 7=8.0 Hz, 1H), 7.747.70 (m, 1H), 7.63 (s, 1H), 7.60-7.45 (m, 4H), 3.16-3.11 (m, 4H), 1.751.56 (m,4H); |
1433 | / ΥΎ n-\ /=\ A> C^0H VjAs | L, 523 | 19 | 376.9 (ΝΓ+1) | 376.06 for C17H16N2O 4S2 | ‘H NMR (DMSO-φ, 400 MHz): δ 10.83 (s, 1H), 7.78 (d, 7= 8.0 Hz, 1H), 7.747.68 (m, 1H), 7.63 (s, 1H), 7.59-7.45 (m, 4H), 4.86 (d, 7 = 3.4 Hz, 1H), 4.17-4.14 (m, 1H), 3.27-3.18 (m, 3H), 3.102.93 (m, 1H), 1.81-1.69 (m, 1H), 1.68-1.58 (m, 1H); |
1434 | x XJ U OH | L, 524 | 20 | 362.8 (JVF+l) | 362.04 for Ci6HI4N2O 4S2 | ‘H NMR (DMSO-di, 400 MHz): δ 10.90 (s, 1H), 7.86 (d, 7= 8.2 Hz, 1H), 7.73 (dd,7=7.5,1.5 Hz, 1H), 7.647.62 (m, 1H), 7.60-7.47 (m, 4H), 5.71 (d, 7 = 6.3 Hz, 1H), 4.30-4.22 (m, 1H), 3.89 (dd, 7 |
311
= 8.5, 6.8 Hz, 2H), 3.40-3.34 (m, 2H); | ||||||
1450 | 0 H d-Ax | L, 525 | 16 | 348.9 (M*+l) | 348.06 for C^Hie^O 3S2 | ‘HNMR (DMSO-7d, 400 MHz): δ 10.89 (s, 1H), 7.77 (d, 7=8.2 Hz, 1H), 7.737.68 (m, 2H), 7.65-7.63 (m, 1H), 7.57-7.44 (m, 4H), 3.273.16 (m, 1H), 0.94 (d, J =6.5 Hz, 6H); |
1412 | O^s | L, 179 | 15 | 382.9 (Nf+1) | 382.04 for C19H44N2O 3S2 | ‘HNMR (DMSO-7d, 400 MHz): δ 10.90 (s, 1H), 10.42 (s, 1H), 7.73 (d,7=8.2 Hz, 1H), 7.68 (dd, 7=6.9,15. Hz, 1H), 7.657.63 (m, 1H), 7.55-7.43 (m, 4H), 7.24-7.18 (m, 2H), 7.087.04 (m, 2H), 7.01 (t, 7=7.7 Hz, 1H); |
1413 | 0. H 0 „0 y^yF VNYV 'nAJ | L, 221 | 23 | 400.9 (M%1) | 400.04 for C19HI3FN2 O3S2 | ‘HNMR (DMS0-<4 400 MHz): 10.90 (s, 1H), 10.37 (s, 1H), 7.74 (d,7=8.3 Hz, 1H), 7.69 (dd,7=6.9,1.5 Hz, 1H), 7.607.56 (m, 1H), 7.55-7.45 (m, 3H), 7.43 (dd, J = 8.2,2.0 Hz, 1H), 7.09-7.04 (m,4H); |
1414 | Afro W~~s | L, 254 | 23 | 396.9 (M++l) | 396.06 for C2oH16N20 3S2 | ‘HNMR (DMSO-7d, 400 MHz): δ 10.83 (s, 1H), 8.28 (t, 7= 6.3 |
312
Hz, 1H), 7.74 (dd,7= 6.8,1.5 Hz, 1H), 7.69 (d, J= 8.2 Hz, 1H), 7.59-7.49 (m, 4H), 7.47 (dd, 7= 8.2,2.0 Hz, 1H), 7.157.10 (m, 2H), 7.06 (t, 7=7.4 Hz, 2H), 7.026.96 (m, 1H), 3.99 (d, 7= 6.3 Hz, 2H); | ||||||
1415 | jvIm θ'^^ΧΧ O~s x | L, 257 | 22 | 414.9 (κΓ+i) | 414.05 for C20H15FN2 O3S2 | ‘HNMR (DMSO-iZtf, 400 MHz): δ 10.86 (s, 1H), 8.28 (t, 7= 6.2 Hz, 1H), 7.767.67 (m, 2H), 7.63-7.60 (m, 1H), 7.58-7.44 (m, 4H), 7.18 (dd,7=8.6, 5.6 Hz, 2H), 6.92 (t,7= 8.9 Hz, 2H), 4.04-3.92 (m, 2H); |
1473 | A ΥΎ Ad O~5 x | L, 212 | 19 | 399.0 (M*+l) | 398.05 for C18H14N4O 3S2 | ‘HNMR (DMSO-rZg, 400 MHz): δ 10.86 (s, 1H), 8.76 (s, 1H), 8.59 (s, 2H), 8.43 (brs, 1H), 7.78-7.70 (m, 2H), 7.60-7.54 (m, 3H), 7.547.48 (m, 2H), 4.07 (s, 2H); |
313
Synthesis of 8-(benzylthio) dibenzo [b,j\ [1,4] thiazepin-ll(10H)-one (527): To a stirred solution of compound 491 (1 g, 3.26 mmol) in 1, 4-dioxane (20 mL) under argon atmosphère were added phenylmethanethiol 526 (0.4 mL, 3.59 mmol), CS2CO3 (921 mg, 3.92 mmol) at RT, purged under argon atmosphère for 20 min. To this were added Pd2(dba)3 (75 mg, 0.081 mmol), Xantphos (94 mg, 1.06 mmol) at RT and heated to 110-120 C and stirred for 12 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered and the fîltrate was removed in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 5-40% EtOAc/ hexanes to afford compound 527 (700 mg, 61 %) as pale yellow solid. TLC: 30% EtOAc/ hexanes (Rf. 0.4); XH NMR (DMSO-^, 400 MHz): δ 10.63 (s, 1H), 7.68-7.65 (m, 1H), 7.53-7.41 (m, 4H), 7.39-7.34 (m, 2H), 7.32-7.20 (m, 3H), 7.17 (s, 1H), 7.10 (dd, J= 8.2, 2.1 Hz, 1H), 4.24 (s, 2H).
Synthesis of ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-sulfonyl chloride (520): To a stirred solution of 527 (700 mg, 2.00 mmol) in acetic acid: H2O (3: 1, 16 mL) under was addedNchlorosuccinimide (668 mg, 5.61 mmol) at 0 °C; warmed to RT and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (100 mL) and extracted with diethyl ether (2 x 100 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to afford crude compound 520 (700 mg) as yellow solid. The crude compound was carried forward for next step without further purification. TLC: 20% EtOAc/ hexanes (Rf. 0.6); LC-MS: 68.55%; 325.9 (NC+l); column; Ascentis Express
314
C18, (50 x 3.0 mm, 2.7 gm); RT 2.51 min. 0.025% Aq. TFA + 5% ACN: ACN +; 5% 0.025% Aq. TFA, 1.2 mL/min).
Example 45: Synthesis of compounds from compound 520 and various commercîally available amines
Compound 520 and commercially available amines were converted to corresponding sulfonamides employing Procedure M and the results are captured in Table 4.
Procedure M:
To a stirred solution of 2, 4-difluoroaniline 228 (100 mg, 0.77 mmol) in CH2CI2 (5 mL) under argon 10 atmosphère were added compound 6 (252 mg, crude), pyridine (3.87 mL, 5.26 mmol) at 0 C;
warmed to RT and stirred for 12 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with CH2CI2 (2 x 50 mT,). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography to 15 afford the desired compound.
Commercially available amines used for the synthesis of compounds
Table 4: Synthesis of compounds from compound 520 and various commercially available amines
No.'i | Structure v : ·: - .y ·> 1 *·’ | Procedure, Intermediate, 'Amine Il 1 | Rx. Yield (%) | Mass Spec. Found , i | T MaskSpe'c^· Calculated | '! Tl-NMR I J i |
315
1526 | °κ Η °v° ZVF Ρ ΪΥη Γ O^s χ F | Μ, 520,228 | 8 | 418.8 (Μ%1) | 418.03 for C19H12F2N2 O3S2 | Ή NMR (DMSO-i/g, 400 MHz): δ 10.89 (s, 1H), 10.25 (s, 1H), 7.77 (d, .7= 8.2 Hz, 1H), 7.70 (dd,J=7.5,1.2 Hz, 1H), 7.587.45 (m, 4H), 7.43 (dd,J= 8.2, 2.0 Hz, 1H), 7.25-7.17 (m, 2H), 7.066.98 (m, 1H) |
1544 | y^jp'01 | Μ, 520, 224 | 10 | 435.1 (MUl) | 434.00 for C19H12C1F n2o3s2 | ‘H NMR (DMSO-/4, 400 MHz): δ 10.90 (s, 1H), 10.43 (s, 1H), 7.77 (d, J= 8.2 Hz, 1H), 7.70 (d, J =7.0 Hz, 1H), 7.61-7.43 (m, 5H), 7.427.37 (m, 1H), 7.26-7.18 (m, 2H); |
1505 | CXs χ | Μ, 520, 229 | 6 | 385.1 (ΜΕί) | 384.04 for C17H12N4O 382 | ‘H NMR (DMSO-rftf, 400 MHz): δ 11.02 (brs, 1H), 10.90 (s, 1H), 8.90 (s, 1H), 8.52 (s, 2H), 7.78 (d, J = 8.2 Hz, 1H), 7.71-7.64 (m, 2H), 7.57-7.44 (m,4H); |
1506 | 0 ΝΗ Ο( ιι ν *ζ 0 | Μ, 520,229 (excess equiv. ofNCS) | 6 | 400.8 (NC+1) | 400.03 for c17h12n4o 4s2 | ‘H NMR (DMSO-rf6, 400 MHz): δ 11.15 (s, 1H), 11.08 (brs, 1H), 8.91 (s, 1H), 8.52 (s, 2H), 7.86-7.77 (m, 4H), 7.73 (d, .7= 7.0 Hz, 1H), 7.68 (s, 1H), 7.66-7.61 |
316
(m, 1H); | ||||||
1556 | VyAAj” /=/ IH h s-^ | M, 520,213 | 9 | 403.9 (MM) | 403.01 for C17H13N3O 3S3 | ‘H NMR (DMSO-iZtf, 400 MHz): δ 10.86 (s, 1H), 8.76 (s, 1H), 8.44 (t, 2= 6.0 Hz, 1H), 7.76 (d, 2= 8.2 Hz, 1H), 7.74-7.71 (m, 1H), 7.66 (s, 1H), 7.62 (s, 1H), 7.59-7.47 (m, 4H), 4.25 (d, 2= 5.9 Hz, 2H); |
1597 | T ji j N | M, 520,215 | 5 | 412.9 (M*+l) | 412.07 for C19Hi6N4O 3S2 | ‘H NMR (DMSO-26, 400 MHz): δ 10.87 (brs, 1H), 8.91 (s, 1H), 8.59 (s, 2H), 7.90-7.85 (m, 1H), 7.787.70 (m, 2H), 7.61-7.44 (m, 5H), 3.10-3.03 (m, 2H), 2.762.63 (m, 2H); |
317
Synthesis of 4-chloro-7V-(2-cyclohexylethyl)-3-nitrobenzenesuIfonamide (529): To a stirred solution of 2-cyclohexylethan-l-amine 261 (500 mg, 3.93 mmol) in CH2CI2 (10 mL) under inert atmosphère were added pyridine (0.9 mL), 4-chloro-3-nitrobenzenesulfonyl chloride 528 (1 g, 3.93 mmol) at 0 °C; warmed to RT and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with CH2CI2 (2x30 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 15% EtOAc/ hexanes to afford compound 529 (1.36 g, 52%) as yellow solid. TLC: 30% EtOAc/ hexanes (Rf. 0.6); ’H-NMR (CDCI3, 400 MHz): δ 8.33 (s, 1H), 7.97 (d, J= 8.4 Hz, 1H), 7.71 (d, J= 8.4 Hz, 1H), 4.52 (t, J= 5.6 Hz, 1H), 3.03 (q, 2H), 1.69-1.56 (m, 4H), 1.401.35 (m, 2H), 1.28-1.08 (m, 5H), 0.89-0.83 (m, 2H).
Synthesis of methyl 2-((4-(ZV-(2-cyclohexylethyl) sulfamoyl)-2-nitrophenyI) thio) benzoate (530): To a stirred solution of compound 529 (200 mg, 0.57 mmol) in DMF (4 mL) under inert atmosphère was added césium carbonate (281 mg, 0.86 mmol) at RT; heated to 40 C, then added methyl thio salicylate (106 mg, 0.63 mmol) and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted
318 with EtOAc (2 x 30 mL). The combined organic extracts were washed with water (20 mL), dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 530 (210 mg, 76%) as yellow syrup. TLC: 30% EtOAc/ hexanes (Rf. 0.4); ’H-NMR (CDC13, 400 MHz): δ 8.67 (s, 1H), 7.99-7.97 (m, 1H), 7.73 (d, J= 8.4 Hz, 1H), 7.65-7.59 (m, 3H), 6.97 (d, J= 8.8 Hz, 1H), 4.44 (t, J= 6.0 Hz, 1H), 3.81 (s, 3H), 3.03-2.98 (m, 2H), 1.67-1.58 (m, 5H), 1.42-1.33 (m, 3H), 1.29-1.09 (m, 3H), 0.91-0.87 (m, 2H).
Synthesis of methyl 2-((2-ainino-4-(A-(2-cyclohexylethyl) sulfamoyl) phenyl) thio) benzoate (531): To a stirred solution of compound 530 (200 mg, 0.41 mmol) in MeOH (10 mL) under inert atmosphère was added 10% Pd/ C (60 mg) at RT and stirred under hydrogen atmosphère (balloon pressure) for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite and the fîltrate was concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 10% EtOAc/ Hexanes to afford compound 531 (120 mg, 64%) as an off-white solid. TLC: 30% EtOAc/ Hexanes (Rf. 0.3); *H-NMR (CDC13, 400 MHz): δ 8.03 (d, J= 7.6 Hz, 1H), 7.59 (d, J= 8.4 Hz, 1H), 7.307.29 (m, 2H), 7.21-7.16 (m, 2H), 6.71 (d, J= 8.0 Hz, 1H), 4.36 (br s, 1H), 3.97 (s, 3H), 3.04 (t, J=
6.4 Hz, 2H), 1.68-1.61 (m, 5H), 1.39-1.35 (m, 2H), 1.29-1.13 (m, 4H), 0.90-0.84 (m, 2H).
Synthesis of 2-((2-amino-4-(ZV-(2-cycIohexylethyl) sulfamoyl) phenyl) thio) benzoic acid (532): To a stirred solution of compound 531 (110 mg, 0.24 mmol) in THF: H2O (2: 1,6 mL) was added lithium hydroxide monohydrate (20 mg, 0.49 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (15 mL), acidified with dil. HCl. The obtained precipitate was filtered, washed with ether (2x5 mL) and dried in vacuo to afford compound 532 (85 mg, 80%) as white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.2); ’H-NMR (DMSO-î/ô, 400 MHz): δ 13.19 (br s, 1H), 7.94 (d, J= 7.6 Hz, 1H), 7.50-7.47 (m, 2H), 7.34 (t, J= 7.2 Hz, 1H), 7.24-7.18 (m, 2H), 6.94 (d, 8.0 Hz, 1H), 6.61 (d, J= 8.0 Hz, 1H), 5.82 (br s, 2H), 2.85-2.80 (m, 2H), 1.59-1.52 (m, 5H),
1.27-1.23 (m, 3H), 1.16-1.11 (m, 3H), 0.83-0.78 (m, 2H).
Synthesis of/V-(2-cyclohexyIethyl)-ll-oxo-10,11-dihydrodibenzo [A,./] [1,4] thiazepine-8sulfonamide (1228): To a stirred solution of compound 532 (80 mg, 0.18 mmol) in THF (5 mL) under inert atmosphère was added CDI (89 mg, 0.55 mmol) at 0 C; warmed to RT and stirred for 16
319
h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (20 mL), acidified with dil.HCl. The obtained precipitate was filtered, washed with ether (2x5 mL) and dried in vacuo to afford 1228 (35 mg, 46%) as white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.6); ’H-NMR (DMSO-^, 400 MHz): δ 10.89 (s, 1H), 7.77 (d, J= 8.0 Hz, 1H), 7.71-7.69 (m, 1H), 7.64-7.62 (m, 2H), 7.56-7.45 (m, 4H), 2.782.73 (m, 2H), 1.48-1.42 (m, 5H), 1.19-1.07 (m, 6H), 0.71-0.66 (m, 2H); LC-MS: 98.00%; 417.6 (M++l); (column; X-Select CSH C-18, (50 x 3.0 mm, 3.5 pm); RT 4.76 min. 0.05% TFA (Aq) : ACN; 0.8 mL/min); UPLC (purity): 95.34%; (column : Acquity BEH C-18 (50 x 2.1 mm, 1.7 μ); RT 2.74 min. ACN : 0.025% TFA (Aq.); 0.5 mL/min).
Example 47: Synthesis of Compound 1289
Synthesis of 4-chloro-3-nitro-7V-phenethyIbenzenesulfonamide (533): To a stirred solution of 2phenylethan-1-amine 211 (250 mg, 2.06 mmol) in CH2C12 (5 mL) under inert atmosphère were added 4-chloro-3-nitrobenzenesulfonyl chloride 528 (528 mg, 2.06 mmol), pyridine (0.5 mL) at 0 15 °C; warmed to RT and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with CH2C12 (2 x 30 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 320
15% EtOAc/ hexanes to afford compound 533 (410 mg, 58%) as colorless syrup. TLC: 30% EtOAc/ hexanes (Rf. 0.6); ’H-NMR (CDC13j400 MHz): δ 8.21 (s, 1H), 7.85 (d, 8.4 Hz, 1H),
7.64 (d, J= 8.4 Hz, 1H), 7.27 (s, 1H), 7.25-7.22 (m, 2H), 7.08 (d, J= 8.0 Hz, 2H), 4.59 (t, J= 6.0 Hz, 1H), 3.32 (q, 2H), 2.81 (t, J= 6.8 Hz, 2H).
Synthesis of methyl 2-((2-nitro-4-(A?-phenethylsulfamoyl) phenyl) thio) benzoate (534): To a stirred solution of compound 533 (100 mg, 0.29 mmol) in DMF (3 mL) under inert atmosphère were added methyl thio salicylate (54 mg, 0.32 mmol), césium carbonate (143 mg, 0.44 mmol) at RT; heated to 40 °C and stirred for 2 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (15 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (20 mL), dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purifîed through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 534 (90 mg, 65%) as yellow solid. TLC: 30% EtOAc/ hexanes (Rf. 0.4);1 H-NMR (CDC13, 400 MHz): δ 8.56 (s, 1H), 7.98 (t, J= 6.8 Hz, 1H), 7.64-7.60 (m, 4H), 7.23-7.20 (m, 3H), 7.07 (d, 8.4 Hz, 2H), 6.91 (d, J=
8.4 Hz, 1H), 4.50 (t, 6.0 Hz, 1H), 3.80 (s, 3H), 3.28 (q, 2H), 2.79 (t, J= 6.8 Hz, 2H).
Synthesis of methyl 2-((2-amino-4-(7V-phenethylsulfamoyl) phenyl) thio) benzoate (535): To a stirred solution of compound 534 (330 mg, 0.69 mmol) in MeOH (15 mL) under inert atmosphère was added 10% Pd/ C (100 mg) at RT and stirred under hydrogen atmosphère (balloon pressure) for 12 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was filtered through celite, washed with CH2CI2 (2x5 mL) and the filtrate was concentrated in vacuo to obtain the crude. The crude was purifîed through silica gel column chromatography using 15% EtOAc/ hexanes to afford compound 535 (210 mg, 68%) as an off-white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.3); *H-NMR (CDC13, 400 MHz): δ 8.03 (d, J= 8.0 Hz, 1H), 7.56 (d, J= 8.0 Hz, 1H), 7.28 (d, J= 8.0 Hz, 3H), 7.25-7.23 (m, 1H), 7.19-7.11 (m, 5H), 6.69 (d, J= 8.0 Hz, 1H), 4.37 (t, J=
6.4 Hz, 1H), 4.12 (q, 1H), 3.97 (s, 3H), 3.31 (q, 2H), 2.81 (t, J= 6.8 Hz, 2H), 2.04 (s, 1H).
Synthesis of 2-((2-amino-4-(/V-phenethylsulfamoyl) phenyl) thio) benzoic acid (536): To a stirred solution of compound 535 (200 mg, 0.45 mmol) in THF: H2O (2: 1,6 mL) was added lithium hydroxide monohydrate (38 mg, 0.90 mmol) at RT and stirred for 16 h; heated to 40 C and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (15 mL), acidified with dil. HCl. The
321 obtained precipitate was filtered, washed with ether (2x5 mL) and dried in vacuo to afford compound 536 (130 mg, 67%) as white solid. TLC: 40% EtOAc/ hexanes (Rf. 0.2); ’H-NMR (DMSO-î/6, 400 MHz): δ 7.93 (d, J= 7.6 Hz, 1H), 7.68 (t, J= 6.0 Hz, 1H), 7.47 (d, J= 8.0 Hz, 1H), 7.32-7.25 (m, 4H), 7.21-7.16 (m, 4H), 6.95 (d, J= 8.0 Hz, 1H), 6.60 (d, J= 8.4 Hz, 1H), 5.81 (br s,
2H), 3.03 (q, 2H), 2.70 (t, J= 8.0 Hz, 2H).
Synthesis of ll-oxo-A-phenethyl-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-sulfonamide (1289): To a stirred solution of compound 536 (100 mg, 0.23 mmol) in THF (5 mL) under inert atmosphère was added CDI (113 mg, 0.70 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (20 mL), acidified with IN HCl. The obtained precipitate was filtered, washed with ether (2x5 mL) and dried in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 3-5% MeOH/ CH2CI2 to afford 1289 (35 mg, 37%) as white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.6); ’H-NMR (DMSO-dtf, 400 MHz): δ 10.86 (s, 1H), 7.81 (br s, 1H), 7.73 (d, J= 8.0 Hz, 2H), 7.71 (s, 1H), 7.59-7.45 (m, 4H), 7.18-7.14 (m, 2H), 7.11-7.07 (m, 3H), 2.97 (q, 2H), 2.64 (t, J= 7.6 Hz, 2H); LC-MS: 97.83%; 411.5 (M*+l);
(column; X-Select CSH C-18, (50 x 3.0 mm, 3.5 pm); RT 4.33 min. 0.05% TFA (Aq): ACN; 0.8 mL/min); UPLC (purity): 98.00%; (column: Acquity BEH C-18 (50 x 2.1 mm, 1.7 μ); RT 2.43 min. ACN: 0.025% TFA (Aq); 0.5 mL/min).
322
Example 48: Synthesis of Compounds 1277 and 1282
Synthesis of 3-(methoxycarbonyl)-ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8carboxylic acid (537): To a stirred solution of dimethyl 2-((2-amino-4-(tert-butoxycarbonyl) phenyl) thio) terephthalate 130 (200 mg, 0.47 mmol) in 1, 2-dichloro ethane (10 mL) under inert atmosphère was added trifluoro acetic acid (1.09 g, 9.59 mmol) at RT; heated to 80 °C and stirred for 24 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 6% MeOH/ CH2CI2 to afford compound 537 (60 mg, 38%) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.3); ’H-NMR (DMSO-d6, 400 MHz): δ 13.17 (br s, 1H), 10.99 (s, 1H), 8.02 (s, 1H), 7.97 (d, J= 8.0 Hz, 1H), 7.82 (d, J= 8.0 Hz, 1H), 7.79 (s, 1H), 7.70-7.65 (m, 2H), 3.86 (s, 3H).
Synthesis of methyl 8-((2-cyclohexyIethyl) carbamoyl)-ll-oxo-10,11-dihydrodibenzo \b,f\ [1,
4] thiazepine-3-carboxylate (538): To a stirred solution of compound 537 (60 mg, 0.18 mmol) in
DMF (2.4 mL) under inert atmosphère were added 2-cyclohexylethan-l-amine 261 (28 mg, 0.21 mmol), HOBt (37 mg, 0.27 mmol), EDCI. HCl (52 mg, 0.27 mmol), diisopropyl ethyl amine (0.08 mL, 0.36 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL). The obtained solid was filtered 323 and dried in vacuo to afford compound 538 (45 mg, 56%) as an off-white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.6); ’H-NMR (DMSO-X 400 MHz): δ 10.94 (s, 1H), 8.46-8.45 (m, 1H), 8.02 (s, 1H), 7.97 (d, 7= 8.0 Hz, 1H), 7.81 (d, 7= 8.0 Hz, 1H), 7.68 (d, 7= 7.6 Hz, 2H), 7.57 (d, 7= 8.4 Hz, 1H), 3.87 (s, 3H), 3.26-3.21 (m, 2H), 1.70-1.62 (m, 5H), 1.40-1.35 (m, 2H), 1.26-1.09 (m, 4H), 0.91-0.83 (m,2H).
Synthesis of 8-((2-cyclohexylethyI) carbamoyl)-ll-oxo-10,11-dihydrodibenzo {b,f\ [1, 4] thiazepine-3-carboxylic acid (1282): To a stirred solution of compound 538 (125 mg, 0.28 mmol) in THF: H2O (4: 1, 5 mL) was added lithium hydroxide monohydrate (59.9 mg, 1.42 mmol) at RT and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude. The crude was diluted with water (20 mL), neutralized with HCl, the obtained solid was filtered and dried in vacuo to afford 1282 (90 mg, 74%) as white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.3); ’H-NMR (DMSO-7tf, 400 MHz): δ 13.44 (br s, 1H), 10.92 (s, 1H), 8.45 (t, 7= 5.6 Hz, 1H), 8.00 (s, 1H), 7.95 (d, 7= 8.0 Hz, 1H), 7.79 (d, 7= 8.0 Hz, 1H), 7.68-7.66 (m, 2H), 7.58-7.56 (m, 1H), 3.26-3.21 (m, 2H), 1.70-1.58 (m, 5H), 1.40-1.35 (m, 2H), 1.30-1.22 (m, 4H), 0.91-0.83 (m, 2H). LC-MS: 99.29%; 425.9 (M*+l); (column; X-Select CSH C-18, (50 x 3.0 mm, 3.5 pm); RT 4.40 min. 0.05% TFA (Aq) : ACN; 0.8 mL/min); UPLC (purity): 98.94%; (column : Acquity BEH C-18 (50 x 2.1 mm, 1.7 p); RT 2.32 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
Synthesis of Az8-(2-cyclohexylethyl)-A^-methyl-ll-oxo-10,11-dihydrodibenzo [b, J] [1,4] thiazepine-3, 8-dicarboxamide (1277): To a stirred solution of 1282 (30 mg, 0.07 mmol) in DMF (1.2 mL) under inert atmosphère were added methyl amine 306 (2 M in THF, 0.07 mL, 0.14 mmol), HATU (54.7 mg, 0.14 mmol), diisopropyl ethyl amine (0.05 mL, 0.28 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice water (10 mL). The obtained solid was filtered, washed with EtOAc (2x5 mL) and dried in vacuo to afford 1277 (11 mg, 35%) as white solid. TLC: 7% MeOH/ CH2C12 (Rf. 0.8); 1H-NMR (DMSO-76, 400 MHz): δ 10.86 (s, 1H), 8.63-8.62 (m, 1H), 8.44 (t, 7= 5.2 Hz, 1H), 7.95 (s, 1H), 7.85 (d, 7= 8.0 Hz, 1H), 7.75 (d, 7= 8.4 Hz, 1H), 7.65 (d, 7= 8.4 Hz, 2H), 7.58-7.55 (m, 1H), 3.26-3.21 (m, 2H), 2.77 (s, 3H), 1.70-1.58 (m, 5H), 1.40-1.35 (m, 2H), 1.26-1.14 (m, 4H), 0.91-0.83 (m, 2H); LC-MS: 94.12%; 438.8 (MM); (column; X-Select CSH C18, (50 x 3.0 mm, 3.5 pm); RT 4.05 min. 0.05% TFA (Aq) : ACN; 0.8 mL/min); UPLC (purity):
324
98.69%; (column : Acquity BEH C-18 (50 x 2.1 mm, 1.7 μ); RT 2.28 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
Example 49: Synthesis of Compound 1278
Synthesis of7V8-(2-cyclohexylethyl)-7V3,7V3-dimethyl-ll-oxo-10,11-dihydrodibenzo \b,j\ [1, 4] thiazepine-3, 8-dicarboxamide (1278): To a stirred solution of 1282 (40 mg, 0.09 mmol) in DMF (2 mL) under inert atmosphère were added dimethylamine hydrochloride (23 mg, 0.28 mmol), HATU (73 mg, 0.18 mmol), diisopropyl ethyl amine (0.09 mL, 0.47 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (15 mL). The obtained solid was filtered, triturated with EtOAc (2x5 mL) and dried in vacuo to afford 1278 (19 mg, 48%) as an off-white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.6); 'H-NMR (DMSO-4, 400 MHz): δ 10.84 (s, 1H), 8.44 (t, 7= 5.2 Hz, 1H), 7.72 (d, 7= 8.0 Hz, 1H), 7.67-7.63 (m, 2H), 7.58-7.47 (m, 2H), 7.45 (d, 7= 8.0 Hz, 1H), 3.27-3.22 (m, 2H), 2.96 (s, 3H), 2.88 (s, 3H), 1.70-1.58 (m, 5H), 1.41-1.35 (m, 2H), 1.28-1.26 (m, 1H), 1.2515 1.14 (m, 3H), 0.91-0.83 (m, 2H); LC-MS: 98.41%; 452.7 (MM); (column; X-Select CSH C-18, (50 x 3.0 mm, 3.5 pm); RT 4.11 min. 0.05% TFA (Aq) : ACN; 0.8 mL/min); UPLC (purity): 99.60%; (column : Acquity BEH C-18 (50 x 2.1 mm, 1.7 p); RT 2.33 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
325
Example 50: Synthesis of Compounds 1280 and 1281
Synthesis of methyl ll-oxo-8-(phenethylcarbamoyl)-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-3-carboxylate (539): To a stirred solution of compound 537 (75 mg, 0.22 mmol) in
DMF (3 mL) under inert atmosphère were added 2-phenylethan-l -amine 211 (30 mg, 0.25 mmol), HOBt (46 mg, 0.34 mmol), EDCI. HCl (65 mg, 0.34 mmol), diisopropyl ethyl amine (0.08 mL, 0.45 mmol) at 0 °C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice water (20 mL). The obtained solid was filtered, washed with 20% EtOAc/ Hexanes (2x5 mL) and dried in vacuo to afford compound 539 (80 mg, 81%) as white solid. TLC: 7% MeOH/ CH2CI2 (Rf. 0.8); ’H-NMR (DMSOd6, 400 MHz): δ 10.96 (s, 1H), 8.61 (t, J= 5.6 Hz, 1H), 8.02 (s, 1H), 7.97 (d, J= 8.0 Hz, 1H), 7.82 (d, J= 8.4 Hz, 1H), 7.68 (d, J= 8.0 Hz, 2H), 7.57-7.54 (m, 1H), 7.29-7.25 (m, 2H), 7.22-7.16 (m, 3H), 3.87 (s, 3H), 3.47-3.42 (m, 2H), 2.80 (t, J= 7.2 Hz, 2H).
Synthesis of ll-oxo-8-(phenethylcarbamoyl)-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-315 carboxylic acid (540): To a stirred solution of compound 539 (80 mg, 0.18 mmol) in THF: H2O (4: 1, 3 mL) was added lithium hydroxide monohydrate (39 mg, 0.92 mmol) at RT and stirred for 5 h.
The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (15 mL), acidified with HCl, the obtained solid was
326 filtered, washed with 20% EtOAc/ hexanes (2x5 mL) and dried in vacuo to afford compound 540 (65 mg, 84%) as white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.2); ’H-NMR (DMSO-Jtf, 400 MHz): δ 13.44 (br s, 1H), 10.94 (s, 1H), 8.62 (t, J= 5.6 Hz, 1H), 8.00 (s, 1H), 7.95 (d, J= 8.0 Hz, 1H), 7.79 (d, J= 8.0 Hz, 1H), 7.68 (d, J= 8.0 Hz, 2H), 7.57-7.54 (m, 1H), 7.29-7.25 (m, 2H), 7.227.16 (m, 3H), 3.47-3.42 (m, 2H), 2.80 (t, J= 7.2 Hz, 2H).
Synthesis of A^-inethyl-ll-oxo-A^-phenethyl-lO, 11-dihydrodibenzo \b,f\ [1, 4] thiazepine-3, 8dicarboxamide (1280): To a stirred solution of compound 540 (35 mg, 0.08 mmol) in DMF (2 mL) under inert atmosphère were added methyl amine (2 M in THF, 0.24 mL, 0.50 mmol), HATU (130 mg, 0.32 mmol), diisopropyl ethyl amine (0.10 mL, 0.50 mmol) at 0 °C; warmed to RT and stirred for 44 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with ice water (15 mL). The obtained solid was filtered, washed with EtOAc (2x5 mL) and dried in vacuo to afford 1280 (12 mg, 28%) as white solid. TLC: 10% MeOH/ CH2C12 (Rf. 0.4); ’H-NMR (DMSO-î/s, 400 MHz): δ 10.89 (s, 1H), 8.63-8.60 (m, 2H), 7.96 (s, 1H), 7.85 (d, J= 8.0 Hz, 1H), 7.76 (d, J= 8.0 Hz, 1H), 7.66-7.65 (m, 2H), 7.56-7.54 (m, 1H), 7.29-7.26 (m, 2H), 7.227.16 (m, 3H), 3.47-3.42 (m, 2H), 2.88-2.73 (m, 5H); LC-MS: 95.22%; 432.6 (M++l); (column; XSelect CSH C-18, (50 x 3.0 mm, 3.5 pm); RT 3.61 min. 0.05% TFA (Aq) : ACN; 0.8 mL/min); UPLC (purity): 94.66%; (column : Acquity BEH C-18 (50 x 2.1 mm, 1.7 pm); RT 1.97 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
Synthesis of N3, A^-diniethyl-l l-oxo-'X-phenethyl-lO, 11-dihydrodibenzo \b,f\ [1, 4] thiazepine-3, 8-dicarboxamide (1281): To a stirred solution of 540 (30 mg, 0.07 mmol) in DMF (2 mL) under inert atmosphère were added dimethyl amine hydrochloride 310 (17.5 mg, 0.21 mmol), HATU (55.5 mg, 0.14 mmol), diisopropyl ethyl amine (0.07 mL, 0.35 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (10 mL). The obtained solid was filtered, washed with EtOAc (2x5 mL) and dried in vacuo to afford 1281 (17 mg, 53%) as an off-white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.6); *H-NMR (DMSO-^, 400 MHz): δ 10.86 (s, 1H), 8.61 (t, 5.2 Hz, 1H),
7.72 (d, J= 8.0 Hz, 1H), 7.67-7.64 (m, 2H), 7.57-7.53 (m, 2H), 7.46 (d, J= 8.0 Hz, 1H), 7.29-7.26 (m, 2H), 7.20-7.16 (m, 3H), 3.48-3.43 (m, 2H), 2.96 (s, 3H), 2.86 (s, 3H), 2.82-2.79 (m, 2H); LCMS: 97.11%; 446.7 (M++l); (column; X-Select CSH C-18, (50 x 3.0 mm, 3.5 pm); RT 3.68 min.
327
0.05% TFA (Aq) : ACN; 0.8 mL/min); UPLC (purity): 98.02%; (column : Acquity BEH C-18 (50 x 2.1 mm, 1.7 μ); RT 2.03 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
Example 51: Synthesis of Compounds 1225 and 1224
Synthesis of phenyl (ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepin-8-yl) carbamate (542):
To a stirred solution of compound 145 (40 mg, 0.16 mmol) in CH2CI2 (3 mL) under inert atmosphère were added diisopropyl ethyl amine (0.06 mL, 0.33 mmol), phenyl carbonochloridate 541 (28 mg, 0.18 mmol) at 0 °C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (15 mL) and extracted with CH2CI2 (2 x 25 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was triturated with 15% EtOAc/ hexanes to afford compound 542 (50 mg, 83%) as an off-white solid. TLC: 70% EtOAc/ Hexanes (Rf. 0.8); 'H-NMR (DMSO-4, 400 MHz): δ 10.73 (s, 1H), 10.45 (s, 1H), 7.68-7.65 (m, 1H), 7.527.40 (m, 7H), 7.28-7.24 (m, 2H), 7.21 (d, J = 7.6 Hz, 2H).
Synthesis of l-(2-cycIohexylethyI)-3-(ll-oxo-10,11-dihydrodibenzo \b,f\ [1,4] thiazepin-8-yl) urea (1225): To a stirred solution of compound 542 (50 mg, 0.13 mmol) in DMSO (3 mL) under inert atmosphère were added 2-cyclohexylethan-l-amine 161 (21 mg, 0.16 mmol), triethyl amine (0.04 mL, 0.27 mmol) at 0 °C; warmed to RT and stirred for 5 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (15 mL). The obtained solid was filtered, washed with EtOAc (2x5 mL) and dried in vacuo to afford 1225 (17
328 mg, 31%) as white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.5); ’H-NMR (DMSO-rf6, 500 MHz): δ 10.58 (s, 1H), 8.58 (s, 1H), 7.64 (d, J= 7.5 Hz, 1H), 7.48-7.40 (m, 3H), 7.34 (d, J= 7.5 Hz, 2H), 7.13-7.11 (m, 1H), 6.10-6.07 (m, 1H), 3.08-3.04 (m, 2H), 1.67-1.57 (m, 5H), 1.31-1.11 (m, 6H), 0.86-0.84 (m, 2H); LC-MS: 95.28%; 396.4 (M^+l); (column; X-Bridge C-18, (50 x 3.0 mm, 3.5 pm); RT 3.76 min. 0.05% TFA (Aq) : ACN; 0.8 mL/min); UPLC (purity): 96.65%; (column : Acquity UPLC BEH C-18 (2.1 x 50 mm, 1.7 p); RT 2.65 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
In a similar manner 1224 (l-(ll-oxo-10,ll-dihydrodibenzo[b,f][l,4]thiazepin-8-yl)-3phenethylurea) was prepared. Yield: 27% LC-MS: 390.3 (M^+l); *H-NMR (DMSO-ifo 400
MHz): δ 10.59 (s, 1H), 8.69 (s, 1H), 7.65 (d, J= 7.2 Hz, 1H), 7.49-7.41 (m, 3H), 7.35 (d, J= 7.6 Hz,
2H), 7.29 (d, J= 7.2 Hz, 2H), 7.22-7.13 (m, 4H), 6.14 (t, J= 6.0 Hz, 1H), 3.30 (s, 2H), 2.73 (t, J= 6.8 Hz, 2H).
Example 52: Synthesis of Compounds 1535 and 1536
The racemic compound of 1388 (18 mg) was separated using a CHIRALPAK-IC column (250 x 20 mm x 5 pm) (10 mg loading; 0.1% DEA in n-hexane: CH2C12: MeOH (50: 50) (A: B = 25: 75) as mobile phase) HPLC to afford 1535 (2.5 mg) and 1536 (2.5 mg) as off-white solids.
Compound 1535 analytical data (Fr-I):
LC-MS: 99.81%; 383.9 (M++l); (column; Ascentis Express C-18, (50 x 3.0 mm, 2.7 pm); RT 1.69 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min). UPLC (purity):
329
96.76%; (column; Acquity UPLC BEH C-18 (50 x 2.1 mm, 1.7 μ); RT 1.49 min. ACN: 0.025% TFA (Aq); 0.5 mL/min). Chiral HPLC: 99.16%, Rt= 99.16 min (Chiralpak-IC, 250 x 4.6 mm, 5 pm); mobile phase (A) 0.1% DEA in n-Hexane (B) CH2CI2: MeOH (50: 50) (A: B:: 25: 75); Flow Rate: 1.0 mL/min).
Compound 1536 analytical data (Fr-II):
LC-MS: 99.39%; 383.9 (MU-l); (column; Ascentis Express C-18, (50 x 3.0 mm, 2.7 pm); RT 1.70 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min). UPLC (purity): 99.56%; (column; Acquity UPLC BEH C-18 (50 x 2.1 mm, 1.7 μ); RT 1.49 min. ACN: 0.025% TFA (Aq); 0.5 mL/min). Chiral HPLC: 98.30%, Rt= 13.33 min (Chiralpak-IC, 250 x 4.6 mm, 5 pm); mobile phase (A) 0.1% DEA in n-Hexane (B) CH2C12: MeOH (50: 50) (A: B:: 25: 75); Flow Rate: 1.0 mL/min).
Example 53: Synthesis of Compound 1206
Synthesis of A-(2-cyclohexylethyl)-ll-oxo-10,11-dihydrodibenzo [b,f\ [1,4] thiazepine-8carboxamide (545): To a stirred solution of 6 (100 mg, 0.36 mmol) in DMF (6 mL) under argon atmosphère were added EDCI.HCI (105 mg, 0.54 mmol), HOBt (74 mg, 0.54 mmol), 2cyclohexylethan-1-amine 261 (56 mg, 0.44 mmol), and diisopropyl ethyl amine (95 mg, 0.73 mmol) at 0-5 °C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo. The residue was diluted with water (20 mL), filtered and washed with water (2x5 mL) to obtain the crude. The crude was triturated with EtOAc (2x5 mL) to afford 545 (70 mg, 50%) as white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.5); 'H-NMR (DMSO-îZî, 400 MHz): δ 10.75 (s, 1H), 8.43 (t, J= 5.6 Hz, 1H), 7.69-7.62 (m, 3H), 7.56-7.43 (m,
330
4H), 3.26-3.21 (m, 2H), 1.70-1.58 (m, 5H), 1.40-1.35 (m, 2H), 1.28-1.09 (m, 4H), 0.91-0.83 (m, 2H).
Synthesis of 2V-(2-cyclohexyIethyl)-ll-oxo-10,11-dihydrodibenzo [b,f\ [1,4] thiazepine-8carboxamide 5, 5-dioxide (1206): To a stirred solution of 545 (40 mg, 0.10 mmol) in chloroform (20 mL) under inert atmosphère was added m-chloro perbenzoic acid (36.3 mg, 0.21 mmol) at RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with saturated sodium bicarbonate solution (15 mL) and extracted with CH2CI2 (2 x 20 mL). The combined organic extracts were washed with water (20 mL), dried over sodium sulfate, fîltered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 30% EtOAc/ hexanes to afford 1206 (16 mg, 37%) as white solid. TLC: 5% MeOH/ CH2C12 (Rf. 0.4); ’ïï-NMR (DMSO-rftf, 400 MHz): δ 11.49 (s, 1H), 8.63 (t, J= 4.8 Hz, 1H), 8.04-7.96 (m, 3H), 7.91-7.83 (m, 2H), 7.77 (t, J= 6.4 Hz, 2H), 3.253.24 (m, 2H), 1.71-1.58 (m, 5H), 1.42-1.37 (m, 2H), 1.28-1.14 (m, 4H), 0.92-0.84 (m, 2H); LC-MS: 97.31%; 413.2 (MAI); (column; X-bridge C-18, (50 x 3.0 mm, 3.5 pm); RT 3.78 min. 0.05% TFA in water: ACN; 0.8 mL/min); UPLC (purity): 96.73%; (column : Acquity UPLC BEH C-18 (2.1 x 50 mm, 1.7 p); RT 2.52 min. ACN : 0.025% TFA (Aq); 0.5 mL/min).
331
Example 54: Synthesis of Compound 1656
Synthesis of tert-butyl (4-bromophenethyl) carbamate (547): To a stirred solution of 2-(4bromophenyl) ethan-l-amine 546 (500 mg, 2.50 mmol) in CH2CI2 (5 mL) under argon atmosphère were added Boc-anhydride (594 mg, 2.75 mmol), diisopropyl ethyl amine (1 mL, 7.50 mmol) at RT and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (25 mL) and extracted with CH2CI2 (2x35 mL). The combined organic extracts were washed with water (25 mL), dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude was purified through silica gel column chromatography using 5-8% EtOAc/ hexanes to afford compound 547 (500 mg, 65%) as white solid. TLC: 10% EtOAc/ hexanes (Rf. 0.5); ’H-NMR (DMSO-76, 400 MHz): δ 7.46 (d, J= 8.0 Hz, 2H), 7.12 (d, J= 8.0 Hz, 2H), 6.86-6.82 (m, 1H), 3.12-3.08 (m, 2H), 2.68-2.64 (m, 2H), 1.32 (s, 9H).
Synthesis of terAbutyl (4-((trimethylsilyl) ethynyl) phenethyl) carbamate (548): To a stirred solution of compound 547 (500 mg, 1.66 mmol) in DMF (10 mL) under argon atmosphère were
332 added ethynyltrimethylsilane (1.8 mL, 16.66 mmol), triethyl amine (2.32 mL, 16.66 mmol) and purged under argon for 15 min. To this were added Pd(PPh3)2C12 (118 mg, 0.16 mmol), copper iodide (33 mg, 0.16 mmol) and purged under argon for 15 min; heated to 70 C and stirred for 48 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude which was purified through silica gel column chromatography using 10% EtOAc/ hexanes to afford compound 548 (500 mg, 95%) as brown syrup. TLC: 10% EtOAc/ hexanes (Rf. 0.6); 1 H-NMR (DMSO-d6,400 MHz): δ 7.38 (d, J= 8.0 Hz, 2H), 7.18 (d, J= 8.0 Hz, 2H), 6.85 (t, 7= 7.2 Hz, 1H), 3.16-3.11 (m, 2H), 2.70-2.66 (m, 2H), 1.34 (s, 9H), 0.23 (s, 9H).
Synthesis of tert-butyl (4-ethynylphenethyl) carbamate (549): To a stirred solution of compound 548 (500 mg, 1.70 mmol) in THF (5 mL) under argon atmosphère was added TBAF (2.08 mL, 2.08 mmol) in THF (3 mL) at RT and stirred for 4 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude which was purified through silica gel column chromatography using 5-10% EtOAc/ hexanes to afford compound 549 (450 mg, 95%) as brown syrup. TLC: 10% EtOAc/ hexanes (Rf. 0.4); 1H-NMR (DMSO-di, 500 MHz): δ 7.39 (d, J= 7.5 Hz, 2H), 7.20 (d, J= 7.5 Hz, 2H), 6.87-6.85 (m, 1H), 4.10 (s, 1H), 3.15-3.12 (m, 2H), 2.71-2.69 (m, 2H), 1.30 (s, 9H).
Synthesis of tert-butyl (4-(l-benzyl-17/-l, 2, 3-triazol-5-yl) phenethyl) carbamate (551): To a stirred solution of compound 549 (200 mg, 0.82 mmol) in MeOH: DMF (1: 1, 20 mL) under argon atmosphère were added (azidomethyl) benzene 550 (410 mg, 3.06 mmol), copper iodide (202 mg, 1.02 mmol) at RT; heated to reflux and stirred for 18 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude which was purified through silica gel column chromatography using 30% EtOAc/ hexanes to afford compound 551 (200 mg, 68%) as white solid. TLC: 30% EtOAc/ hexanes (Rf. 0.3); *H-NMR (DMSO-4 500 MHz): δ 8.59 (s, 1H), 7.75 (d, J= 8.5 Hz, 2H), 7.41-7.34 (m, 5H), 7.25 (d, J= 8.0 Hz, 2H), 6.906.88 (m, 1H), 5.64 (s, 2H), 3.17-3.13 (m, 2H), 2.70 (t, J= 7.5 Hz, 2H), 1.36 (s, 9H).
Synthesis of 2-(4-(l-benzyl-LHr-l, 2, 3-triazol-5-yl) phenyl) ethan-l-amine (552): To a stirred solution of compound 551 (190 mg, 0.50 mmol) in CH2C12 (4 mL) under argon atmosphère was added trifluoro acetic acid (1 mL) at RT and stirred for 3 h. The reaction was monitored by TLC; after completion of the reaction, the volatiles were removed in vacuo to obtain the crude to obtain compound 552 (180 mg, crude) as dark brown syrup which was carried to the next step without any 333 purification. TLC: 100% EtOAc (Rf. 0.2); ’H-NMR (DMSO-î/6, 400 MHz): δ 8.61 (s, 1H), 7.81 (d, J= 8.0 Hz, 2H), 7.78-7.76 (m, 3H), 7.39-7.32 (m, 6H), 5.64 (s, 2H), 3.09-3.04 (m, 2H), 2.87 (t, J= 7.6 Hz, 2H).
Synthesis of 7V-(4-(l-benzyl-LHr-l, 2,3-triazol-5-yl) phenethyl)-ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-carboxamide 5, 5-dioxide (553): To a stirred solution compound 552 (200 mg, 0.66 mmol) in DMF (10 mL) under argon atmosphère were added EDCI. HCl (189 mg, 0.98 mmol), HOBt (189 mg, 0.98 mmol), compound 6 (297 mg, 0.79 mmol), diisopropyl ethyl amine (0.35 mL, 1.98 mmol) at 0 C; warmed to RT and stirred for 16 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with EtOAc (2 x 50 mL) washed with water (50 mL), brine, dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude compound was purified through column chromatography using 2% MeOH/ CH2CI2 to afford compound 553 (180 mg, 49%) as an off-white solid. TLC: 5% MeOH/ CH2CI2 (Rf 0.5); *H NMR (DMSO-^400 MHz): δ 11.46 (br s, 1H), 8.80 (t, J= 5.5 Hz, 1H), 8.56 (s, 1H), 8.03 (d, J= 8.3 Hz, 1H), 8.00-7.95 (m, 2H), 7.92-7.83 (m, 2H), 7.79 (s, 1H), 7.75 (d, J= 8.2 Hz, 3H), 7.42-7.31 (m, 5H), 7.29 (d, J= 8.3 Hz, 2H), 5.63 (s, 2H), 3.50 (q, J= 6.8 Hz, 2H), 2.85 (t, J= 7.2 Hz, 2H).
Synthesis of 2ν-(4-(1Η-1, 2, 3-triazol-5-yl) phenethyl)-ll-oxo-10,11-dihydrodibenzo \b,f\ [1, 4] thiazepine-8-carboxamide 5, 5-dioxide (1656): To a stirred solution of compound 553 (180 mg, 0.31 mmol) in DMSO (10 mL) under argon atmosphère was added potassium tertiary butoxide (1 M in THF, 2.5 mL, 2.55 mmol) at RT. The reaction mixture was stirred under oxygen atmosphère (balloon pressure) for 24 h. The reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (5 mL) and extracted with EtOAc (3 x 50 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude. The crude compound was purified through column chromatography using 2% MeOH/ CH2CI2, lyophilized and washed EtOAc (5 mL), filtered, washed with n-pentane (5 mL)and dried in vacuo to afford 1656 (20 mg, 13%) as white solid. TLC: 5% MeOH/ CH2CI2 (Rf. 0.3); XH NMR (DMSO-Jî, 400 MHz): δ 14.91 (br s, 1H), 11.52 (br s, 1H), 8.81 (t, J= 5.5 Hz, 1H), 8.21 (br s, 1H), 8.04 (d, J= 8.3 Hz, 1H), 8.01-7.95 (m, 2H), 7.92-7.85 (m, 2H), 7.82-7.73 (m, 4H), 7.31 (d, J = 7.9 Hz, 2H), 3.51 (q, J= 6.6 Hz, 2H), 2.86 (t, J= 7.1 Hz, 2H); LC-MS: 96.04%; 473.9 QVf+l); (column; Ascentis Express C-18, (50 x 3.0 mm, 2.7 pm); RT 2.01 min. 0.025% Aq. TFA + 5%
334
ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min). HPLC (purity): 95.54%; (column; Zorbax SB C-18 (150 x 4.6 mm, 3.5 pm); RT 7.59 min. ACN: 0.05% TFA (Aq); 1.0 mL/min).
Example 55: Synthesis of compounds from compound 575 using various commercially available amines
Readily available acids similar to 575, 576 and 577 were converted to the desired compounds using commercially available amines employing Procedures A and B and the results are captured in Tables 5 and 6.
Carbon bridged compounds:
Table 5: Synthesis of compounds from compound 575 using various commercially available amines
• f/·· / •V A' | • Structure | Procedure, Intermediate, Amine | Rx. Yield '(%) | Mass Spec. . Found · | Mass Spec.: Calculatèd - t | V Tl-NMR t 1 |
1591 | A, 575,218 (RT 12 h) | 44 | 343.9 (M+l) | 343.13 for C2IH17N3O 2 | ‘H-NMR (DMSO-dft 400 MHz): δ 9.27 (t, J= 5.7 Hz, 1H), 8.96 (s, 1H), 7.96 (s, 1H), 7.82 (s, 1H), 7.74-7.70 (m, 1H), 7.687.61 (m, 2H), 7.54-7.49 (m, 1H), 7.45-7.38 (m, 2H), 4.67 (t, 2= 5.4 Hz, 2H), 3.54 (s, 3H); | |
1198 | 0 λΑνΙΙ | A, 575 | 64 | 363.2 (MX1); | (DMSO-X 400 MHz): δ 10.51 (s, 1H), 8.30-8.29 (m, 1H), 7.70 (d, 2 = 8.0 Hz, 1H), |
335
7.56 (s, 1H), 7.51-7.46 (m, 2H), 7.41-7.31 (m, 3H), 3.94 (s, 2H), 3.23 (d, J= 6.4 Hz, 2H), 1.70-1.62 (m, 5H), 1.391.37 (m,2H), 1.26-1.14 (m, 4H), 0.91-0.86 (m,2H); | ||||||
1576 | 0 /? (Μην, V | A, 575,212 (RT 12 h) | 44 | 344.9 (M*+l) | 344.13 for C20H16N4O 2 | ‘H-NMR (DMSO-î/î, 400 MHz): δ 10.52 (s, 1H), 9.10-9.01 (m, 2H), 8.74 (s, 2H), 7.70 (d,J = 7.5 Hz, 1H), 7.62 (s, 1H), 7.57 (d,J=7.9 Hz, 1H), 7.517.43 (m, 2H), 7.38 (d, J =7.3 Hz, 1H), 7.33 (t, J= 7.5 Ηζ,ΙΗ), 4.46 (d, J =5.5 Hz, 2H), 3.96 (s, 2H); |
1577 | 0 < à N | A, 575,213 | 26 | 350.0 (M%1) | 349.09 for Ci9H15N3O 2s | 'H-NMR (DMSO-ίή,, 400 MHz): δ 10.52 (s, 1H), 9.10 (t, J= 5.8 Hz, 1H), 8.95 (s, lH),7.79(s, 1H), 7.70 (dd, J = 7.7,1.1 Hz, 1H), 7.61 (s, 1H), 7.54 (dd, J = 7.9,1.6 Hz, 1H), 7.48 (td, J = 8.8,1.8 Hz, 1H), 7.43 (d,J = 7.9 Hz, 1H), 7.38 (d, J =6.9 Hz, 1H), 7.33 (td, .7=7.6,1.6 Hz, 1H), 4.64 (d, J =5.7 Hz, 2H), 3.96 (s, |
336
2H); |
Oxygen-bridged compounds:
Table 6: Synthesis of compounds from compound 576 and various commercially available amines
No. t t | Structure | Procedure, Intermediate, Amine | Rx. Yield (%) | Mass Spec. Found. | Mass Spec. Calculated, | ) 11 ‘H-NMR ' |
1593 | o _ NH P / !J\ R N | B, 576, 213 | 38 | 351.9 (M++l) | 351.07 for c18h13n3o3 S | ‘H-NMR (DMSO-7d, 400 MHz): δ 10.63 (s, 1H), 9.17 (t, 7=5.8 Hz, 1H), 8.96 (s, 1H), 7.827.76 (m, 2H), 7.68 (s, 1H), 7.66-7.59 (m, 2H), 7.42 (d, J = 8.4 Hz, 1H), 7.38-7.31 (m, 2H), 4.65 (d, J = 5.6 Hz, 2H) |
1594 | 0 NH o | A, 576,218 | 55 | 345.9 (MM) | 345.11 for C20H15N3O3 | ‘H-NMR (DMSO-7d, 400 MHz): δ 10.62 (s, 1H), 9.07 (t, 7=5.8 Hz, 1H), 8.53 (s, 1H), 8.45 (d, 7= 4.1 Hz, 1H), 7.78 (dd, J = 7.7,1.6 Hz, 1H), 7.72-7.60 (m, 4H), 7.43 (d, 7= 8.4 Hz, 1H), 7.39-7.31 (m, 3H), 4.47 (d,7=5.7 Hz, 2H) |
337
346.9 (Μ*+1)
346.11 for
C19IL4N4O3
Ή-NMR (DMS0-7d, 400 MHz): δ 10.62 (s, 1H), 9.13-9.05 (m, 2H), 8.75 (s, 2H), 7.78 (dd, J = 7.7,1.6 Hz, 1H), 7.68 (s, 1H), 7.66-7.60 (m, 2H), 7.43 (d, 7=8.4 Hz, 1H), 7.39-7.30 (m, 2H), 4.48 (d, 7= 5.6 Hz, 2H)
Nitrogen-bridged compounds:
Synthesis of ll-oxo-jV-(thiazol-5-ylmethyl)-10, ll-dihydro-SH-dibenzo {b, e] [1, 4] diazepine-85 carboxamide (1602): Using Procedure A the title compound was prepared using compound 577 (35 mg, 0.13 mmol) and thiazol-5-ylmethanamine hydrochloride 213 (20 mg, 0.13 mmol) and diisopropyl ethyl amine (0.05 mL, 0.27 mmol) and was obtained in 31% yield as an off-white solid; TLC: 5% MeOH/ CH2C12 (Rf 0.5); ’H-NMR (DMSO-7d, 400 MHz): δ 9.89 (s, 1H), 8.99-8.94 (m, 2H), 8.15 (s, 1H), 7.79 (s, 1H), 7.69 (dd, 7= 7.8, 1.3 Hz, 1H), 7.50 -7.42 (m, 2H), 7.38-7.32 (m,
1H), 7.00 (dd, 7= 10.9, 8.3 Hz, 2H), 6.91 (t, 7= 7.4 Hz, 1H), 4.63 (d, 7= 5.6 Hz, 2H); LC-MS:
93.15%; 351.0 (M^+l); column; Ascentis Express C18, (50 x 3.0 mm, 2.7 pm); RT 1.76 min. 0.025% Aq. TFA + 5% ACN: ACN + 5% 0.025% Aq. TFA, 1.2 mL/min); UPLC (purity): 93.21%; (column; Acquity BEH C-18 (50 x 2.1 mm, 1.7 p); RT 1.57 min. ACN: 0.025% TFA (Aq); 0.5 mL/min).
Example 56: Assay Measuring Activity of Compounds on Viral Production in and on Viability of AD38 Cells
338
AD38 cells grown in a 175 cm flask with “Growth Medium” (DMEM/F12 (1:1) (cat# SH30023.01, Hyclone, IX Pen/step (cat#: 30-002-CL, Mediatech, Inc), 10% FBS (cat#: 101, Tissue Culture Biologics), 250 pg/mL G418 (cat#: 30-234-CR, Mediatech, Inc), 1 pg/mL Tétracycline (cat#: T3325, Teknova)) were detached with 0.25% trypsin. Tetracycline-free “treatment medium” (15 mL DMEM/F12 (1:1) (cat# SH30023.01, Hyclone, lx Pen/step (cat#: 30-002-CL, Mediatech, Inc), with 2% FBS, Tet-system approved (cat#: 631106, Clontech) were then added to mix and spun at 1300 rpm for 5 min. Pelleted cells were then re-suspended/washed with 50 mL of IX PBS 2 times and 10 mL Treatment Medium one time. AD38 cells were then re-suspended with 10 mL of Treatment Medium and counted. Wells of a collagen coated 96-well NUNC microtiter plate were seeded at 50,000/well in 180 pL of Treatment Medium, and 20 pL of in treatment media with either 10% DMSO (Control) or a 10X solution of compound in 10% DMSO was added. Plates were incubated for 6 days at 37 °C.
Viral load production was assayed by quantitative PCR of the core sequence. Briefly, 5 pL of clarified supematant was added to a PCR reaction mixture that contained forward primers HBV-f 5'CTGTGCCTTGGGTGGCTTT-3', Reverse primers HBV-r 5’AAGGAAAGAAGTCAGAAGGCAAAA-3' and Fluorescent TaqMan™ Probes HBV-probe 5FAM/AGCTCCAAA/ZEN/TTCTTTATAAGGGTCGATGTCCATG/3IABkFQ -3' in Quanta Biosciences PerfeCTa® qPCR Toughmix®, and was subsequently on an Applied Biosystems VIIA7 in a final volume of 20 pL. The PCR mixture was incubated at 45 °C for 5 minutes, then 95 °C for 10 min, followed by 40 cycles of 10 seconds at 95 °C and 20 seconds at 60 °C. Viral load was quantitated against known standards by using ViiA™ 7 Software. Viral load in the supematant from wells with treated cells were compared against viral load in supematant from DMSO control wells (> 3 per plate).
At the end of compound treatment period cell viability was assessed using a Promega CellTiter-Glo protocol. Ail supematant was removed the previously treated 96-well microtiter plate, and 50 pL Tetracycline-free treatment medium (DMEM/F12 (1:1), lx Pen/step (cat#: 30-002-CL, Mediatech, Inc), with 2% FBS, Tet-system approved (cat#: 631106, Clontech), and 1% DMSO was added back to each well. Another 50 pL of CellTiter-Glo reagent solution (Promega, G7573) was then added at room température and the contents mixed for 2 minutes on an orbital shaker to induce cell lysis. This was followed by incubation at room température for 10 minutes to stabilize the luminescent
339 signal. The luminescence was recorded for 0.2 seconds per well on a Tecan multimode platereader (Infinité Ml 000 pro). The luminescent signal from each well was normalized against that of untreated (DMSO) control wells. Ail results were reported percent viability (with controls being 100%).
Table 7
J J Compound No. | AD38 Viral Load (CpAM/DMSO %) àt 10 pM | AD38 Viability Normalized Resuit * (CPAM/DMSO %) at 10 ,pM |
1101 | 15 | 107 |
1102 | 1 | 100 |
1103 | 2 | 87 |
1104 | 1 | 85 |
1105 | 1 | 101 |
1107 | 2 | 106 |
1108 | 1 | 105 |
1109 | 6 | 99 |
1110 | 2 | 119 |
1111 | 2 | 89 |
1112 | 4 | 73 |
1113 | 1 | 99 |
1114 | 1 | 104 |
1115 | 1 | 106 |
1117 | 67 | 108 |
1118 | 61 | 95 |
1120 | 7 | 94 |
1121 | 6 | 109 |
1122 | 21 | 86 |
1123 | 62 | 95 |
1124 | 80 | 99 |
340
1125 | 20 | 108 |
1127 | 22 | 94 |
1130 | 2 | 101 |
1133 | 94 | 99 |
1149 | 5 | 118 |
1150 | 1 | 22 |
1151 | 1 | 50 |
1152 | 1 | 45 |
1154 | 90 | 50 |
1155 | 18 | 103 |
1156 | 16 | 106 |
1157 | 1 | 48 |
1158 | 37 | 120 |
1159 | 8 | 92 |
1160 | 2 | 105 |
1161 | 1 | 99 |
1162 | 61 | 99 |
1163 | 3 | 104 |
1164 | 27 | 103 |
1165 | 5 | 82 |
1166 | 10 | 119 |
1167 | 57 | 124 |
1168 | 10 | 117 |
1169 | 39 | 107 |
1170 | 1 | 95 |
1171 | 49 | 103 |
1172 | 51 | 107 |
1173 | 39 | 105 |
341
1174 | 35 | 109 |
1175 | 30 | 123 |
1176 | 2 | 104 |
1177 | 47 | 118 |
1182 | 13 | 55 |
1183 | 2 | 36 |
1184 | 1 | 0 |
1185 | 1 | 0 |
1186 | 1 | 39 |
1187 | 1 | 73 |
1188 | 4 | 83 |
1189 | 1 | 85 |
1190 | 1 | 70 |
1191 | 14 | 121 |
1192 | 3 | 81 |
1193 | 4 | 90 |
1194 | 1 | 45 |
1195 | 0 | 48 |
1196 | 2 | 95 |
1197 | 1 | 88 |
1198 | 3 | 60 |
1199 | 19 | 109 |
1200 | 18 | 125 |
1201 | 1 | 50 |
1202 | 7 | 107 |
1203 | 3 | 89 |
1204 | 2 | 97 |
1205 | 2 | 89 |
342
1206 | 10 | 106 |
1207 | 24 | 99 |
1208 | 11 | 103 |
1209 | 1 | 102 |
1210 | 25 | 116 |
1211 | 1 | 106 |
1212 | 1 | 72 |
1213 | 2 | 55 |
1214 | 2 | 94 |
1216 | 1 | 125 |
1217 | 1 | 37 |
1218 | 12 | 104 |
1219 | 5 | 100 |
1220 | 2 | 94 |
1221 | 19 | 106 |
1222 | 32 | 100 |
1223 | 2 | 28 |
1224 | 3 | 65 |
1225 | 10 | 87 |
1226 | 1 | 80 |
1227 | 10 | 92 |
1228 | 22 | 101 |
1229 | 45 | 76 |
1230 | 46 | 102 |
1231 | 12 | 93 |
1232 | 42 | 94 |
1233 | 1 | 93 |
1234 | 3 | 79 |
343
1235 | 6 | 61 |
1237 | 4 | 66 |
1238 | 26 | 104 |
1239 | 33 | 106 |
1240 | 26 | 92 |
1241 | 12 | 86 |
1242 | 91 | 78 |
1243 | 20 | 118 |
1244 | 14 | 103 |
1245 | 1 | 101 |
1246 | 6 | 96 |
1247 | 8 | 103 |
1248 | 3 | 106 |
1249 | 34 | 108 |
1250 | 14 | 113 |
1251 | 8 | 99 |
1252 | 14 | 94 |
1253 | 15 | 103 |
1256 | 1 | 102 |
1257 | 26 | 113 |
1258 | 12 | 105 |
1259 | 11 | 84 |
1260 | 8 | 100 |
1264 | 8 | 104 |
1266 | 1 | 74 |
1267 | 77 | 93 |
1268 | 77 | 106 |
1269 | 63 | 107 |
344
1270 | 1 | 94 |
1271 | 6 | 100 |
1272 | 24 | 102 |
1273 | 6 | 96 |
1274 | 11 | 88 |
1275 | 3 | 93 |
1276 | 24 | 89 |
1277 | 43 | 89 |
1278 | 3 | 88 |
1279 | 55 | 84 |
1280 | 74 | 94 |
1281 | 29 | 86 |
1282 | 102 | 105 |
1283 | 1 | 97 |
1285 | 3 | 108 |
1286 | 36 | 114 |
1287 | 11 | 96 |
1288 | 5 | 49 |
1289 | 40 | 96 |
1290 | 33 | 94 |
1291 | 1 | 102 |
1293 | 95 | 97 |
1308 | 1 | 99 |
1309 | 1 | 107 |
1310 | 1 | 89 |
1311 | 8 | 95 |
1312 | 5 | 83 |
1313 | 17 | 108 |
345
1314 | 69 | 101 |
1315 | 4 | 103 |
1316 | 32 | 89 |
1317 | 50 | 95 |
1318 | 14 | 70 |
1319 | 16 | 83 |
1320 | 43 | 93 |
1321 | 15 | 74 |
1322 | 28 | 94 |
1323 | 96 | 60 |
1324 | 10 | 24 |
1325 | 26 | 90 |
1326 | 23 | 95 |
1328 | 54 | 105 |
1329 | 62 | 109 |
1330 | 41 | 109 |
1331 | 43 | 88 |
1332 | 70 | 103 |
1333 | 20 | 73 |
1334 | 33 | 83 |
1335 | 87 | 104 |
1336 | 70 | 90 |
1337 | 77 | 91 |
1338 | 70 | 118 |
1339 | 113 | 70 |
1340 | 64 | 116 |
1342 | 113 | 95 |
1343 | 8 | 91 |
346
1344 | 96 | 102 |
1345 | 115 | 93 |
1346 | 105 | 97 |
1347 | 3 | 94 |
1348 | 0 | 107 |
1349 | 12 | 102 |
1353 | 50 | 97 |
1354 | 98 | 70 |
1356 | 3 | 101 |
1357 | 39 | 115 |
1358 | 15 | 72 |
1361 | 79 | 113 |
1362 | 19 | 98 |
1364 | 1 | 102 |
1365 | 2 | 105 |
1366 | 12 | 93 |
1367 | 33 | 88 |
1370 | 5 | 94 |
1371 | 6 | 94 |
1372 | 60 | 103 |
1373 | 10 | 100 |
1374 | 1 | 98 |
1375 | 11 | 89 |
1376 | 3 | 63 |
1377 | 5 | 65 |
1381 | 40 | 93 |
1382 | 47 | 117 |
1383 | 1 | 87 |
347
1384 | 4 | 79 |
1385 | 26 | 51 |
1386 | 61 | 95 |
1387 | 2 | 78 |
1388 | 5 | 71 |
1389 | 15 | 89 |
1390 | 2 | 92 |
1391 | 2 | 71 |
1392 | 2 | 85 |
1393 | 41 | 87 |
1394 | 55 | 94 |
1395 | 64 | 79 |
1396 | 63 | 95 |
1397 | 73 | 95 |
1398 | 5 | 60 |
1399 | 105 | 92 |
1400 | 34 | 105 |
1401 | 31 | 79 |
1402 | 12 | 81 |
1403 | 15 | 82 |
1405 | 14 | 94 |
1407 | 3 | 103 |
1408 | 17 | 94 |
1409 | 4 | 83 |
1410 | 35 | 50 |
1411 | 66 | 91 |
1412 | 48 | 87 |
1413 | 92 | 78 |
348
1414 | 39 | 89 |
1415 | 27 | 77 |
1417 | 11 | 75 |
1418 | 12 | 73 |
1419 | 113 | 89 |
1420 | 29 | 86 |
1421 | 78 | 95 |
1422 | 64 | 95 |
1423 | 37 | 91 |
1424 | 65 | 96 |
1427 | 7 | 85 |
1428 | 28 | 93 |
1429 | 38 | 90 |
1430 | 56 | 92 |
1431 | 115 | 92 |
1432 | 79 | 91 |
1433 | 82 | 94 |
1434 | 85 | 96 |
1435 | 77 | 99 |
1436 | 10 | 104 |
1440 | 71 | 91 |
1441 | 28 | 90 |
1442 | 65 | 99 |
1443 | 64 | 95 |
1444 | 6 | 65 |
1445 | 24 | 38 |
1446 | 3 | 84 |
1447 | 1 | 85 |
349
1448 | 3 | 85 |
1449 | 2 | 86 |
1450 | 73 | 94 |
1451 | 30 | 92 |
1452 | 15 | 62 |
1453 | 48 | 97 |
1454 | 27 | 95 |
1455 | 3 | 89 |
1456 | 15 | 101 |
1457 | 28 | 92 |
1458 | 12 | 49 |
1459 | 4 | 92 |
1462 | 35 | 99 |
1463 | 31 | 97 |
1464 | 49 | 98 |
1465 | 39 | 106 |
1466 | 7 | 88 |
1467 | 1 | 92 |
1468 | 76 | 97 |
1471 | 16 | 97 |
1472 | 37 | 95 |
1473 | 81 | 97 |
1474 | 51 | 101 |
1475 | 47 | 107 |
1476 | 1 | 86 |
1477 | 67 | 16 |
1478 | 2 | 94 |
1480 | 72 | 95 |
350
1481 | 46 | 100 |
1482 | 46 | 98 |
1483 | 65 | 98 |
1484 | 26 | 100 |
1485 | 30 | 96 |
1486 | 53 | 94 |
1487 | 15 | 96 |
1488 | 84 | 97 |
1490 | 7 | 79 |
1491 | 39 | 80 |
1492 | 39 | 79 |
1493 | 51 | 80 |
1494 | 115 | 60 |
1495 | 9 | 77 |
1496 | 2 | 18 |
1497 | 9 | 49 |
1498 | 1 | 82 |
1499 | 2 | 84 |
1501 | 37 | 71 |
1503 | 40 | 87 |
1505 | 81 | 85 |
1506 | 72 | 85 |
1507 | 11 | 96 |
1508 | 31 | 81 |
1509 | 15 | 29 |
1510 | 62 | 82 |
1511 | 38 | 85 |
1512 | 27 | 99 |
351
1513 | 2 | 82 |
1514 | 13 | 84 |
1515 | 2 | 82 |
1516 | 30 | 82 |
1517 | 2 | 78 |
1518 | 67 | 85 |
1519 | 73 | 81 |
1520 | 1 | 81 |
1521 | 1 | 22 |
1522 | 1 | 82 |
1523 | 1 | 70 |
1524 | 2 | 18 |
1525 | 78 | 85 |
1526 | 57 | 92 |
1527 | 19 | 116 |
1528 | 4 | 85 |
1529 | 12 | 111 |
1530 | 70 | 93 |
1531 | 53 | 96 |
1532 | 17 | 112 |
1533 | 2 | 105 |
1534 | 5 | 109 |
1535 | 108 | 85 |
1536 | 2 | 120 |
1537 | 36 | 98 |
1540 | 12 | 87 |
1541 | 11 | 117 |
1542 | 34 | 95 |
352
1543 | 72 | 90 |
1544 | 40 | 97 |
1545 | 59 | 88 |
1546 | 65 | 89 |
1547 | 16 | 90 |
1548 | 28 | 85 |
1549 | 7 | 109 |
1550 | 1 | 87 |
1551 | 51 | 91 |
1552 | 64 | 93 |
1553 | 86 | 93 |
1555 | 36 | 81 |
1556 | 67 | 86 |
1557 | 54 | 86 |
1558 | 51 | 88 |
1559 | 68 | 92 |
1560 | 13 | 92 |
1561 | 8 | 118 |
1562 | 25 | 89 |
1563 | 41 | 93 |
1564 | 10 | 119 |
1565 | 4 | 103 |
1566 | 31 | 91 |
1567 | 1 | 109 |
1568 | 1 | 100 |
1569 | 1 | 114 |
1570 | 2 | 115 |
1571 | 35 | 117 |
353
1572 | 5 | 116 |
1573 | 46 | 126 |
1574 | 78 | 109 |
1575 | 90 | 108 |
1576 | 8 | 108 |
1577 | 6 | 120 |
1578 | 33 | 100 |
1580 | 59 | 89 |
1581 | 3 | 97 |
1582 | 8 | 112 |
1583 | 41 | 121 |
1584 | 52 | 95 |
1585 | 66 | 87 |
1586 | 23 | 112 |
1587 | 78 | 92 |
1588 | 0 | 98 |
1589 | 1 | 85 |
1590 | 1 | 96 |
1591 | 13 | 111 |
1592 | 50 | 102 |
1593 | 3 | 133 |
1594 | 4 | 109 |
1595 | 3 | 108 |
1597 | 64 | 87 |
1598 | 61 | 93 |
1599 | 72 | 101 |
1600 | 12 | 108 |
1601 | 62 | 106 |
354
1602 | 38 | 116 |
1603 | 6 | 91 |
1604 | 0 | 105 |
1605 | 25 | 106 |
1606 | 7 | 104 |
1607 | 14 | 93 |
1608 | 63 | 103 |
1609 | 68 | 99 |
1611 | 0 | 130 |
1612 | 0 | 112 |
1613 | 0 | 122 |
1614 | 2 | 45 |
1615 | 32 | 123 |
1616 | 5 | 115 |
1617 | 1 | 118 |
1618 | 0 | 44 |
1619 | 12 | 122 |
1620 | 3 | 111 |
1621 | 1 | 117 |
1622 | 0 | 120 |
1623 | 1 | 128 |
1624 | 1 | 136 |
1625 | 2 | 111 |
1626 | 0 | 118 |
1627 | 5 | 115 |
1628 | 17 | 138 |
1629 | 3 | 95 |
1631 | 9 | 112 |
355
1632 | 2 | 122 |
1633 | 66 | 124 |
1634 | 45 | 125 |
1635 | 1 | 93 |
1636 | 0 | 111 |
1637 | 32 | 123 |
INCORPORATION BY REFERENCE
Ail publications and patents mentioned herein, including those items listed below, are hereby incorporated by reference in their entirety for ail purposes as if each individual publication or patent 5 was specifically and individually incorporated by reference. In case of conflict, the présent application, including any définitions herein, will control.
EQUIVALENTS
While spécifie embodiments of the subject invention hâve been discussed, the above spécification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this spécification. The fu.ll scope of the invention should be determined by reference to the daims, along with their full scope of équivalents, and the spécification, along with such variations.
Unless otherwise indicated, ail numbers expressing quantifies of ingrédients, reaction conditions, and so forth used in the spécification and daims are to be understood as being modified in ail instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in this spécification and attached daims are approximations that may vary depending upon the desired properties sought to be obtained by the présent invention.
Claims (69)
- Claims1. A compound represented by:Formula 1 wherein:T is selected from the group consisting of-C(O)-, -CH2-C(O)-, -N(C(O)-CH3)-, -NH-, -O-, and -S(O)Z-, where z is 0, 1 or 2;Y is C(Rn)2 , S(O)y, NRy and O wherein y is 0, 1, or 2;Ry is selected from the group consisting of H, methyl, ethyl, propyl, phenyl and benzyl;Rl is selected from the group consisting of H, methyl, and -C(O)-Ci.3alkyl;L is a bond or Cm straight chain alkylene optionally substituted by one or two substituents each independently selected from the group consisting of methyl (optionally substituted by halogen or hydroxyl), ethenyl, hydroxyl, NR’R”, phenyl, heterocycle, and halogen and wherein the Cm straight chain alkylene may be interrupted by an -O-;R2 is selected from the group consisting of H, phenyl or naphthyl (wherein the phenyl or naphthyl may be optionally substituted with one, two , three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci-ôalkyl, C2-6alkenyl, C2.6alkynyl, Ci.galkoxy, NR’R”, -C(O)-NR’R”, -C(O)-Ci_ 6alkyl, -C(O)-Ci-6alkoxy, phenyl (optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, cyano, Ci„6alkyl, C2. 6alkenyl, C2.6alkynyl, Ci_6alkoxy,NR’R”, C(O)-NR’R”, -C(O)-Ci_6alkyl, -C(O)-Ci_6alkoxy, StOXv-CMôalkyl (where w is 1, 2 or 3), S(O)W-NR’R” (where w is 1, 2 or 3),-NR’-S(O)w, and S(O)W-NR’R”(where w is 1, 2 or 3)), heteroaryl (optionally substituted by one, two or three357 substituents each independently selected from the group consisting of halogen, hydroxyl, Ci_6alkyl, C2.6alkenyl, C2.6alkynyl, Ci_6alkoxy, NR’R”, C(O)-NR’R”, -C(O)-Ci_6alkyl, -C(O)-Ci_6alkoxy, S(O)w-Ci_6alkyl (where w is 1, 2 or 3), NR’-S(O)W, and -S(O)w-NR’R”(where w is 1, 2 or 3)), C3_ ôcycloalkyl, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -S(O)W-NR’R” (where w is 1, 2 or 3), and NR’-S(O)W, (where w is 1, 2 or 3)),5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from O, N and S (wherein the 5-6 membered heteroaryl may be optionally substituted on a carbon with one, two , three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, C2_6alkenyl, C2_6alkynyl, Ci-ôalkoxy, phenyl (optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci-galkyl, C2_6alkenyl, C2_6alkynyl, Ci-6alkoxy, NR’R”, C(O)- NR’R”, -C(O)-Ci_6alkyl, C(O)-OH, -C(O)-Ci_6alkoxy, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -NR’-S(O)W, and -S(O)WNR’R”(where w is 1, 2 or 3)), heteroaryl, heterocycle, NR’R”, -C(O)- NR’R”, -C(O)-Ci_6alkyl, C(O)-Ci-6alkoxy, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -NR’-S(O)W, and -S(O)W-NR’R”(where w is 1, 2 or 3), and on a nitrogen by R’),Ci-ôalkyl, Cj-éalkoxy, C2_6alkenyl, C3_iocycloalkyl (optionally substituted with one, two , three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, NR’R”, -C(O)- NR’R”, =CNR’, Ci_6alkyl, Ci_6alkoxy, -C(O)-Ci_6alkyl, and -C(O)-Ci_ ôalkoxy, and wherein the C3_iocycloalkyl may optionally be a bridged cycloalkyl)), and a 4-6 membered heterocycloalkyl having one or two heteroatoms each independently selected from O, N and S (wherein the 4-6 membered heterocycloalkyl may be optionally substituted with one, two , three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, NR’R”, -C(O)- NR’R”, Cj.6alkyl, Ci_6alkoxy, -C(O)-Ci_6alkyl, and -C(O)-Ci_6alkoxy);R’ is selected, independently for each occurrence, from H, methyl, ethyl, propyl, phenyl, and benzyl;R” is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, carboxybenzyl, -C(O)-methyl and -C(O)-ethyl, or R’ and R” taken together may form a 4-6 membered heterocycle;358 each of moieties R4, R5, R6, R7, R8, R9, R10, and R11 are independently selected for each occurrence from the group consisting of hydrogen, Ci_6alkyl, C2-6alkenyl, C2-6alkynyl, halogen, hydroxyl, nitro, cyano, NR’R”, -C(O)- NR’R”, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -NR’S(O)Wj and -S(O)W-NR’R”(where w is 0, 1 or 2), Ci_6alkoxy,-C(O)-OH, -C(O)-Ci-6alkyl, and C(O)-Ci-6alkoxy;wherein for each occurrence, Ci_6alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C2-6alkenyl, C2-6alkynyl, Ci_6alkoxy, phenyl, NR’R”, -C(O)- NR’R”, S(O)w-methyl (where w is 1, 2 or 3), -NR’-S(O)W; and S(O)W-NR’R”(where w is 0, 1 or 2); Ci_6alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, phenyl, NR’R”, -C(O)-NR’R”, S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -NR’-S(O)Wj and S(O)W-NR’R” (where w is 0, 1 or 2); and C3_6cycloalkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Cj-ealkyl, Ci_6alkoxy, -C(O)-Ci^alkyl, -C(O)-Ci_6alkoxy, andNR’R”; and pharmaceutically acceptable salts thereof.
- 2. The compound of claim 1, wherein L is -CH2-.
- 3. The compound of claim 1, wherein L is C2-3alkylene.
- 4. The compound of claim 1, wherein L is selected from the group consisting of-CH2-CH2-, -CH2(CH2)-CH2-, -CH2-CH2(OH)-, -CH2-CH2(CH3OH)-, and-CH2-CH2(OH)-CH2-.
- 5. The compound of claim 1, wherein L is a bond.
- 6. The compound of claim 1, wherein L is - C2-3alkylene-O-.
- 7. The compound of claim 1, wherein L is -O-.
- 8. The compound of any one of daims 1-7, wherein Y is S(O)y or NRy.
- 9. The compound of any one of daims 1-8, wherein Y is S(O)y.
- 10. The compound of any one of daims 1-9, wherein Y is S.
- 11. The compound of any one of daims 1-10, wherein R2 is phenyl or 5-6 membered heteroaryl.359
- 12. The compound of any one of claims 1-11, wherein R2 is phenyl.
- 13. The compound of any one of claims 1-12, wherein R2 is phenyl substituted by one or two substituents each selected from the group consisting of fluorine, chlorine, Ci^alkyl (optionally substituted by one, two or three fluorines), Ci_6alkoxy (optionally substituted by5 one, two or three fluorines), hydroxyl, NR’R”, -S(O)2-NR’R”, heteroaryl, and phenyl (optionally substituted by halogen or hydroxyl).
- 14. The compound of claim 12, wherein R2 is phenyl substituted by an 5-6 membered heteroaryl selected from the group consisting of:10
- 15. The compound of claim 14, wherein R2 is phenyl substituted by
- 16. The compound of any one of claims 1-11, wherein R2 is a 5-6 membered heteroaryl.
- 17. The compound of claim 16, wherein R2 is selected from the group consisting of:360J. NR' >C-NR'
- 18. The compound of claim 16 or 17 wherein R2 is selected from the group consisting of:R32, and whereinR32 is selected from the group consisting of H, halogen, phenyl, and Ci_6alkyl (optionally substituted by one, two or three halogens);R52 is selected from the group consisting of H, halogen, phenyl, and Cj^alkyl (optionally substituted by one, two or three halogens);R42 is selected from the group consisting of H, halogen, phenyl, CAalkyl (optionally substituted by one, two or three halogens), Ci_6alkoxy (optionally substituted by one, two or three halogens), NH2, -OCH3, NHCH3, and N(CH3)2.
- 19. The compound of claim 18, wherein R42 is independently selected for each occurrence from the group consisting of H, methyl, ethyl, propyl, -CF3, -CH2CH3, Cl, F, phenyl, -NH2, OCH3, NHCH3, andN(CH3)2.
- 20. The compound of claim 17 or 18, wherein R2 is optionally substituted on a carbon by a substitutent selected from the group consisting of fluorine, chlorine, phenyl, -NH2;NH Cj. 6alkyl, and N(Ci.6alkyl)2; C^alkyl, and Ci_6alkoxy.361
- 21. The compound of any one of claims 1-10, wherein R2 is a 4-6 membered heterocycloalkyl or C4_6cycloalkyl.
- 22. The compound of claim 21, wherein R2 is selected from the group of: tetrahydropyranyl, tetrahydrofuran, cyclopentane, cyclohexane, and cyclobutane.
- 23. The compound of claim 22, wherein R2 is selected from the group consisting of:
- 24. The compound of claim 1, represented by:Y is S(O)y, wherein y is 0, 1,2;L is a bond or Cy straight chain alkylene optionally substituted by one or two substituents each independently selected from the group consisting of methyl (optionally substituted by halogen or hydroxyl), hydroxyl and halogen;R2 is selected from phenyl optionally substituted with one, two , three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci_6alkyl, C2. ealkenyl, C2.6alkynyl, Ci.6alkoxy, NR’R”, -C(O)- NR’R”, -C(O)-Ci_6alkyl, -C(O)-Ci_6alkoxy, phenyl (optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Cj-ôalkyl, C2-6alkenyl, C2_6alkynyl, Ci-6alkoxy, NR’R”, C(O)- NR’R”, -C(O)-Ci.6alkyl, -C(O)-Ci_6alkoxy, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), NR’S(O)W, and -S(O)w-NR’R”(where w is 1, 2 or 3)), 5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from O, N and S (optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci_6alkyl, C2.6alkenyl, C2.6alkynyl, Ci.6alkoxy, NR’R”, C(O)- NR’R”, -C(O)-C!^alkyl, -C(O)-Cj.362 ôalkoxy, -S(O)w-Ci_ôalkyl (where w is 1, 2 or 3), -NR’-S(O)W, and -S(O)w-NR’R”(where w is 1, 2 or 3)), C3.6cycloalkyl, -S(O)w-Ci_ôalkyl (where w is 1, 2 or 3), S(O)W-NR’R” (where w is 1, 2 or 3),and -NR’-S(O)W, (where w is 1, 2 or 3)), and a 5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from O, N and S (wherein the 5-6 membered heteroaryl may be optionally substituted on a carbon with one, two , three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkoxy, phenyl (optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci^alkyl, C2-ealkenyl, C2-6alkynyl, Ci. ôalkoxy, NR’R”, C(O)- NR’R”, -C(O)-Ci.6alkyl, -C(O)-Cj.6alkoxy, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), S(O)W-NR’R” (where w is 1, 2 or 3),-NR’-S(O)w, and -S(O)W-NR’R”(where w is 1, 2 or 3)), heteroaryl, heterocycle, NR’R”, -C(O)-NR’R”, -C(O)-Ci.6alkyl, -C(O)-Ci.6alkoxy, -S(O)w-Ci_ ôalkyl (where w is 1, 2 or 3),-NR’-S(O)w, and -S(O)w-NR’R”(where w is 1, 2 or 3), and on a nitrogen by R’);R’ is selected, independently for each occurrence, from H, methyl, ethyl, and propyl,R” is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, — C(O)-methyl and -C(O)-ethyl, or R’ and R’ ’ taken together may form a 4-6 membered heterocycle;each of moieties R4, R5, R6, R7, R8, R9, R10, and R11 are independently selected for each occurrence from the group consisting of hydrogen, Ci-ôalkyl, C2-6alkenyl, C2-6alkynyl, halogen, hydroxyl, nitro, cyano, NR’R”, -C(O)- NR’R”, -S(O)w-Ci-ôalkyl (where w is 1, 2 or 3), NR’-S(O)Wj and S(O)w-NR’R”(where w is 0, 1 or 2), Cj.ôalkoxy,-C(O)-OH, -C(O)-Ci-6alkyl, and -C(O)-Ci_ ôalkoxy;wherein for each occurrence, Ci^alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C2-ôalkenyl, C2-ôalkynyl, Ci.6alkoxy, phenyl, NR’R”, -C(O)- NR’R”, S(O)w-methyl (where w is 1, 2 or 3), -NR’-S(O)W; and S(O)W-NR’R”(where w is 0, 1 or 2); Ci_ôalkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, phenyl, NR’R”, -C(O)- NR’R”, S(O)w-C1_6alkyl (where w is 1, 2 or 3), -NR’-S(O)Wj and S(O)W-NR’R” (where w is 0, 1 or 2); and C3.6cycloalkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of363 halogen, hydroxyl, nitro, cyano, carboxy, Cj-galkyl, Ci_6alkoxy, -C(O)-Ci_6aIkyl, -C(O)-Ci_6alkoxy, and NR’R”.
- 25. The compound of any one of daims 1-24, wherein R7 is selected from H and F.
- 26. The compound of any one of daims 1-25, wherein R6 is selected from H and F.
- 27. The compound of any one of daims 1-26, wherein R5 is selected from H and F.
- 28. The compound of any one of daims 1-27, wherein R10 is selected from the group consisting of H, methyl and F.
- 29. The compound of any one of daims 1-28, wherein each of R4, R5, R6, R7, R8, R9, R10, and R11 are H.
- 30. A compound represented by:whereinRm’ and Rm are each independently selected from the group consisting of H, halogen, Ci. galkyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), NR’R”, and hydroxyl;R22 is selected for each occurrence from the group consisting of H, halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, C2.6alkenyl, C2_6alkynyl, Ci.galkoxy, NR’R”, -C(O)-Cj^alkyl, -C(O)-Ci_ ôalkoxy, phenyl, heteroaryl, C3_6cycloalkyl, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -S(O)W-NR’R” (where w is 1, 2 or 3), and -NR’-S(O)W, (where w is 1, 2 or 3));R’ is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;R” is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, C(O)-methyl and -C(O)-ethyl, or R’ and R” taken together with the nitrogen to which they are attached may form a 4-6 membered heterocycle;364 each of moieties R4, R5, R6, R7, R8, R9, and R10 is independently selected for each occurrence from the group consisting ofhydrogen, Ci.6alkyl, C2-6alkynyl, C2.galkenyl, halogen, hydroxyl, nitro, cyano, andNR’R”;wherein for each occurrence, Ci-6alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C2.6alkenyl, C2.6alkynyl, Ci_6alkoxy, NR’R”, -NR’-S(O)W> and S(O)W-NR’R”; Ci_6alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci-ôalkyl, NR’R”, -NR’-S(O)W; and S(O)W-NR’R”; C3_ ôcycloalkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci.6alkyl, Cj.ôalkoxy, -C(O)-Ci_6alkyl, -C(O)-Ci_6alkoxy, and NR’R’ ’ ; phenyl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci^alkyl, C2.6alkenyl, C2.6alkynyl, Ci_6alkoxy, NR’R”, C(O)- NR’R”, -C(O)-Ci_6alkyl, -C(O)-Ci_6alkoxy, S(O)w-Ci_6alkyl (where w is 1, 2 or 3), NR’-S(O)W, and -S(O)W-NR’R”(where w is 1, 2 or 3), and heteroaryl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci-ôalkyl, C2_6alkenyl, C3_6cycloalkyl, C2. 6alkynyl, Ci.6alkoxy, NR’R”, C(O)- NR’R”, -C(O)-Ci_6alkyl, -C(O)-Cwalkoxy, -S(O)w-Cwalkyl (where w is 1, 2 or 3), NR’-S(O)W, and -S(O)W-NR’R”(where w is 1, 2 or 3)), C3_6cycloalkyl; and pharmaceutically acceptable salts thereof.
- 31. The compound of claim 30, wherein R7 is selected from H and F.
- 32. The compound of claim 30 and 31, wherein R6 is selected from H and F.
- 33. The compound of any one of claims 30-32, wherein R5 is selected from H and F.
- 34. The compound of any one of claims 30-33, wherein R10 is selected from the group consisting of H, methyl and F.
- 35. The compound of any one of claims 30-34 wherein each of R4, R5, R6, R7, R8, R9, R10, andR11 are H.
- 36. The compound of claim 30, wherein the compound is represented by:365
- 37. The compound of claim 30, wherein the compound is represented by:
- 38. The compound of any one of daims 30-37, wherein R22 is selected from the group consisting of:O>and
- 39. The compound of any one of daims 30-38, wherein R22 is phenyl.
- 40. A compound represented by:wherein366Y is C(RU)2 , S(O)y, NRy and O wherein y is 0, 1, or 2;Ry is selected from the group consisting of H, methyl, ethyl, propyl, phenyl and benzyl;Rm and Rm are each independently selected from the group consisting of H, halogen, Cjôalkyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), C2.6alkenyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), NR’R”, and hydroxyl;R is selected for each occurrence from the group consisting of H, halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, C2_6alkenyl, C2_6alkynyl, Ci_6alkoxy, NR’R”, -C(O)-Ci^alkyl, -C(O)-Cj. ôalkoxy, phenyl, heteroaryl, C3.gcycloalkyl, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -S(O)W-NR’R” (where w is 1, 2 or 3), and -NR’-S(O)W, (where w is 1, 2 or 3));R’ is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;R” is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, C(O)-methyl and -C(O)-ethyl, or R’ and R’ ’ taken together with the nitrogen to which they are attached may form a 4-6 membered heterocycle;each of moieties R4, R5, R6, R7, R8, R9, and R10 is independently selected for each occurrence from the group consisting of hydrogen, Ci^alkyl, C2_6alkynyl, CMalkenyl, halogen, hydroxyl, nitro, cyano, and NR’R’ ’ ;wherein for each occurrence, Ci^alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C2_6alkenyl, C2_6alkynyl, Ci-ôalkoxy, NR’R”, -NR’-S(O)W, and S(O)W-NR’R”; Ci.6alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, NR’R”, -NR’-S(O)W; and S(O)W-NR’R”; C3. ôcycloalkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, Ci_6alkoxy, -C(O)-Ci_6alkyl, -C(O)-Ci_6alkoxy, and NR’R”; phenyl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci-ôalkyl, C2.6alkenyl, C2_6alkynyl, Ci_6alkoxy, NR’R”, C(O)- NR’R”, -C(O)-Ci-6alkyl, -C(O)-Ci_6alkoxy, S(O)w-Ci_6alkyl (where w is 1, 2 or 3), NR’-S(O)W, and -S(O)W-NR’R”(where w is 1, 2 or 3), and367 heteroaryl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci^alkyl, C2.6alkenyl, C2.6alkynyl, Ci. ôalkoxy, NR’R”, C(O)- NR’R”, -C(O)-Ci_6alkyl, -C(O)-Ci_6alkoxy, -S(O)w-Ci-6alkyl (where w is 1, 2 or 3), NR’-S(O)W, and -S(O)w-NR’R”(where w is 1, 2 or 3)), and C3-6cycloalkyl; and pharmaceutically acceptable salts thereof.
- 41. The compound of claim 40, wherein R7 is selected from H and F.
- 42. The compound of claim 40 or 41, wherein R6 is selected from H and F.
- 43. The compound of any one of claims 40-42, wherein R5 is selected from H and F.
- 44. The compound of any one of claims 40-43, wherein R10 is selected from the group consisting of H, methyl and F.
- 45. The compound of any one of claims 40-44 wherein each of R4, R5, R6, R7, R8, R9, R10, and R11 are H.
- 46. The compound of any one of claims 40-45, wherein Y is S.
- 47. A compound represented by:whereinY is C(RU)2 , S(O)y, NRy and O wherein y is 0, 1, or 2;RY is selected from the group consisting of H, methyl, ethyl, propyl, phenyl and benzyl;Rm’ and Rm are each independently selected from the group consisting of H, halogen, Ci. ôalkyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), C2.6alkenyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), NR’R”, and hydroxyl;368Rc is H or Ci_6alkyl;R is selected for each occurrence from the group consisting of H, halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, C2-6alkenyl, C2_6alkynyl, Ci.6alkoxy, NR’R”, -C(O)-Ci^alkyl, -C(O)-Ci. ôalkoxy, phenyl, heteroaryl, C3_6cycloalkyl, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -S(O)W-NR’R” (where w is 1, 2 or 3), and -NR’-S(O)W, (where w is 1, 2 or 3));R’ is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;R” is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, C(O)-methyl and -C(O)-ethyl, or R’ and R” taken together with the nitrogen to which they are attached may form a 4-6 membered heterocycle;each of moieties R4, R5, R6, R7, R8, R9, and R10 is independently selected for each occurrence from the group consisting of hydrogen, Ci^alkyl, C2-6alkynyl, C2-6alkenyl, halogen, hydroxyl, nitro, cyano, and NR’R’ ’ ;wherein for each occurrence, Ci^alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C2_6alkenyl, C2-6alkynyl, Ci_6alkoxy, NR’R”, -NR’-S(O)W) and S(O)W-NR’R”; Ci_6alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci^alkyl, NR’R”, -NR’-S(O)W; and S(O)W-NR’R”; C3. ôcycloalkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Ci_6alkyl, Ci_6alkoxy, -C(O)-Ci_6alkyl, -C(O)-C!_6alkoxy, and NR’R”; phenyl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci^alkyl, C2.6alkenyl, C2.6alkynyl, Ci_6alkoxy, NR’R”, C(O)-NR’R”, -C(O)-Ci_6alkyl, -C(O)-Ci_6alkoxy, S(O)w-Ci_6alkyl (where w is 1, 2 or 3), NR’-S(O)W, and -S(O)w-NR’R”(where w is 1, 2 or 3), and heteroaryl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci^alkyl, C2-6alkenyl, C2-6alkynyl, Cj. ôalkoxy, NR’R”, C(O)- NR’R”, -C(O)-Ci_6alkyl, -C(O)-Cj.6alkoxy, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), NR’-S(O)W, -S(O)W-NR’R”(where w is 1, 2 or 3)), and C3_6cycloalkyl, and pharmaceutically acceptable salts thereof.369
- 48. The compound of claim 47, wherein Rc is H or methyl.
- 49. The compound of claim 47 or 48, wherein Rc is H.
- 50. The compound of any one of claims 47-49, wherein R7 is selected from H and F.
- 51. The compound of any one of claims 47-50, wherein R6 is selected from H and F.
- 52. The compound of any one of claims 47-51, wherein R5 is selected from H and F.
- 53. The compound of any one of claims 47-52, wherein R10 is selected from the group consisting of H, methyl and F.
- 54. The compound of any one of claims 47-53 wherein each of R4, R5, R6, R7, R8, R9, R10, and R11 are H.
- 55. The compound of any one of claims 47-54, wherein Y is S.
- 56. A compound represented by:whereinY is C(RH)2 , S(O)y, NRy and O wherein y is 0, 1, or 2;Ry is selected from the group consisting of H, methyl, ethyl, propyl, phenyl and benzyl;Rm’ and Rm are each independently selected from the group consisting of H, halogen, Ci_ ôalkyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), C2-6alkenyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), NR’R’ ’, and hydroxyl;Rc is H or Ci-6alkyl;R78 is selected from the group consisting of H, halogen, hydroxyl, nitro, cyano, carboxy, Ci. ôalkyl, C2.6alkenyl, C2.6alkynyl, Ci_6alkoxy, NR’R”, -C(O)-Ci.6alkyl, -C(O)-Ci.6alkoxy, phenyl,370 heteroaryl, C3_ôcycloalkyl, -S(O)w-Ci_6alkyl (where w is 1, 2 or 3), -S(O)W-NR’R” (where w is 1,2 or 3), and -NR’-S(O)W, (where w is 1, 2 or 3));R79 is selected from the group consisting of H, halogen, hydroxyl, nitro, cyano, carboxy, Cp ôalkyl, C2-ôalkenyl, C2-ôalkynyl, Cpôalkoxy, NR’R”, -C(O)-Cpôalkyl, -C(O)-Cpôalkoxy, phenyl, heteroaryl, C3.ôcycloalkyl, -S(O)w-Cpôalkyl (where w is 1, 2 or 3), -S(O)W-NR’R” (where w is 1,2 or 3), and -NR’-S(O)W, (where w is 1, 2 or 3));R’ is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;R’ ’ is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, C(O)-methyl and -C(O)-ethyl, or R’ and R” taken together with the nitrogen to which they are attached may form a 4-6 membered heterocycle;each of moieties R4, R5, R6, R7, R8, R9, and R10 is independently selected for each occurrence from the group consisting of hydrogen, Cpôalkyl, C2-ôalkynyl, C2.6alkenyl, halogen, hydroxyl, nitro, cyano, and NR’R”;wherein for each occurrence, Cpôalkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C2.6alkenyl, C2-6alkynyl, Cp6alkoxy, NR’R”, -NR’-S(O)W; and S(O)W-NR’R”; Cp6alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Cpôalkyl, NR’R”, -NR’-S(O)W; and S(O)W-NR’R”; C3. ôcycloalkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, Cp6alkyl, Ci.6alkoxy, -C(O)-Cpôalkyl, -C(O)-Ci-6alkoxy, and NR’R”; phenyl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Ci^alkyl, C2.6alkenyl, C2.6alkynyl, Cp6alkoxy, NR’R”, C(O)- NR’R”, -C(O)-Cp6alkyl, -C(O)-Cp6alkoxy, S(O)w-Ci-6alkyl (where w is 1, 2 or 3), NR’-S(O)W, and -S(O)w-NR’R”(where w is 1, 2 or 3), and heteroaryl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, Cpôalkyl, C2-6alkenyl, C2-ôalkynyl, C3. ôcycloalkyl, Cp6alkoxy, NR’R”, C(O)-NR’R”, -C(O)-Cp6alkyl, -C(O)-Cp6alkoxy, -S(O)w-Cp ôalkyl (where w is 1, 2 or 3), NR’-S(O)W, and -S(O)W-NR’R”(where w is 1, 2 or 3), and pharmaceutically acceptable salts thereof.371
- 57. The compound of claim 56, wherein R° is H or methyl.
- 58. The compound of claim 56 or 57, wherein Rc is H.
- 59. The compound of any one of daims 56-58, wherein R7 is selected from H and F.
- 60. The compound of any one of daims 56-59, wherein R6 is selected from H and F.
- 61. The compound of any one of daims 56-60, wherein R5 is selected from H and F.
- 62. The compound of any one of daims 56-61, wherein R10 is selected from the group consisting of H, methyl and F.
- 63. The compound of any one of daims 56-62 wherein each of R4, R5, R6, R7, R8, R9, R10, and R11 are H.
- 64. A compound selected from the group consisting of compounds in Table 1, 2, 3, 4, 5, and 6, and pharmaceutically acceptable salts thereof.
- 65. A pharmaceutically acceptable composition comprising a compound of any one of daims 164, and a pharmaceutically acceptable excipient.
- 66. A method of treating a hepatitis B infection in a patient in need thereof, comprising administering an effective amount of a compound of any one of daims 1-64.
- 67. A method of treating a hepatitis B infection in a patient in need thereof, comprising administering a first compound selected from a compound of daims 1-64, and optionally administering a one or more additional compounds each selected from a compound of daims 1-63.
- 68. A method of treating a hepatitis B infection in a patient in need thereof, comprising administering an amount of a compound of any one of daims 1-64, and administering another HBV capsid assembly promoter.
- 69. A method of treating a hepatitis B infection in a patient in need thereof, comprising administering a first compound selected from any one of daims 1-64, and one or more other HBV agent each selected from the group consisting of HBV capsid assembly promoters, HBF viral polymerase interfering nucleosides, viral entry inhibitors, HBsAg sécrétion inhibitors, disruptors of nucleocapsid formation, cccDNA formation inhibitors, antiviral core372 protein mutant, HBc directed transbodies, RNAi targeting HBV RNA, immunostimulants, TLR-7/9 agonists, cyclophilin inhibitors, HBV vaccines, SMAC mimetics, epigenetic modulators, kinase inhibitors, and STING agonists.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/952,467 | 2014-03-13 | ||
US62/010,025 | 2014-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA18052A true OA18052A (en) | 2018-04-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2015229174B2 (en) | Hepatitis B core protein allosteric modulators | |
ES2905950T3 (en) | Hepatitis B core protein modulators | |
CA2881057C (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b | |
AU2016231832B2 (en) | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use | |
US10987360B2 (en) | Hepatitis B core protein modulators | |
CA3232128A1 (en) | Pyridine derivative and use thereof | |
OA18052A (en) | Hepatitis B core protein allosteric modulators. | |
BR112016020895B1 (en) | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS, THEIR USES, AND PHARMACEUTICAL COMPOSITION | |
NZ723972B2 (en) | Hepatitis b core protein allosteric modulators | |
OA19643A (en) | Hepatitis B core protein modulators. | |
OA17199A (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B. |